

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2013258849 B2**

(54) Title  
**Rotavirus-like particle production in plants**

(51) International Patent Classification(s)  
**C12N 7/04** (2006.01) **C07K 14/14** (2006.01)  
**A61K 39/15** (2006.01) **C12N 7/01** (2006.01)  
**A61P 31/14** (2006.01) **C12N 15/46** (2006.01)  
**A61P 37/04** (2006.01) **C12N 15/82** (2006.01)

(21) Application No: **2013258849** (22) Date of Filing: **2013.05.10**

(87) WIPO No: **WO13/166609**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	<b>61/646,058</b>		<b>2012.05.11</b>		<b>US</b>

(43) Publication Date: **2013.11.14**

(44) Accepted Journal Date: **2018.12.13**

(71) Applicant(s)  
**Mitsubishi Tanabe Pharma Corporation;Medicago Inc.**

(72) Inventor(s)  
**D'aoust, Marc-Andre;Landry, Nathalie;Lavoie, Pierre-Olivier;Arai, Masaaki;Asahara, Naomi;Mutepfa, David Levi Rutendo;Hitzeroth, Inga Isabel;Rybicki, Edward Peter**

(74) Agent / Attorney  
**Adams Pluck, PO BOX 905, Hornsby, NSW, 2077, AU**

(56) Related Art  
**YANG, Y. M. ET AL., "Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants", SCIENCE CHINA LIFE SCIENCES., (2011-01), vol. 54, no. 1, pages 82 - 89**



## (51) International Patent Classification:

C12N 7/04 (2006.01) C07K 14/14 (2006.01)  
A61K 39/15 (2006.01) C12N 15/46 (2006.01)  
A61P 31/14 (2006.01) C12N 15/82 (2006.01)  
A61P 37/04 (2006.01) C12N 7/01 (2006.01)

## (21) International Application Number:

PCT/CA2013/050364

## (22) International Filing Date:

10 May 2013 (10.05.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/646,058 11 May 2012 (11.05.2012) US

(71) Applicants: **MEDICAGO INC.** [CA/CA]; 600 -1020  
Route de l'Eglise, Quebec, Québec G1V 3V9 (CA). **MIT-**  
**SUBISHI TANABE PHARMA CORPORATION**  
[JP/JP]; 2 - 6 - 18, Kitahama, Chuo-ku, Osaka-shi, Osaka  
541-8505 (JP).

(72) Inventors: **D'AOUST, Marc-Andre**; 3925 rue Louise-Fis-  
et, Quebec, Québec G1X 4N4 (CA). **LANDRY, Nathalie**;  
1060, rue de La Voie Ouest, St-Jean-Chrysostome, Québec  
G6Z 1K1 (CA). **LAVOIE, Pierre-Olivier**; 621 Franklin,  
Quebec, Québec G1N 2L7 (CA). **ARAI, Masaaki**; c/o  
Mitsubishi Tanabe Pharma Corporation, 2-6-18, Kitahama,  
Chuo-ku, Osaka-shi, Osaka 541-8505 (JP). **ASAHARA,**  
**Naomi**; c/o Mitsubishi Tanabe Pharma Corporation, 2 - 6 -  
18, Kitahama, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP).  
**MUTEPPA, David Levi Rutendo**; 26 Bonnington Cres-  
cent, Sherwood Nottingham N5G 3EY (GB). **HITZEROTH,**  
**Inga Isabel**; 11 Clifford Avenue, Vrede-  
hoek, Cape Town (ZA). **RYBICKI, Edward Peter**; 34  
Uitvlugt Road, Pinelands, 7405 Cape Town (ZA).


(74) Agents: **SECHLEY, Konrad A.** et al.; 2300 - 550 Burrard  
Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,

[Continued on next page]

## (54) Title: ROTAVIRUS-LIKE PARTICLE PRODUCTION IN PLANTS

Figure 47



VP2/VP4/VP6 /VP7 RLPs

(57) Abstract: A method of producing a virus-like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid into the plant, or portion of the plant. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein for example but not limited to rotavirus protein VP2. The nucleotide sequence may further comprise one or more than one amplification element and/or a compartment targeting sequence. A second nucleic acid might be introduced into the plant, or portion of the plant. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, for example but not limited to rotavirus protein VP6. Optionally, a third nucleic acid and/ or fourth nucleic acid might be introduced into the plant, or portion of the plant. The third nucleic acid comprises a third regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, for example but not limited to rotavirus protein VP4. The fourth nucleic acid comprises a fourth regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, for example but not limited to rotavirus protein VP7. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.



KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

**Published:**

- with international search report (*Art. 21(3)*)
- with sequence listing part of description (*Rule 5.2(a)*)

## ROTAVIRUS-LIKE PARTICLE PRODUCTION IN PLANTS

### FIELD OF INVENTION

5 [0001] This invention relates to producing rotavirus structural proteins in plants. More specifically, the present invention relates to producing virus-like particles comprising rotavirus structural protein in plants.

### BACKGROUND OF THE INVENTION

10 [0002] Rotavirus infection is a global problem mainly affecting children under the age of five. It results in severe gastroenteritis and in worst cases death.

[0003] Rotaviruses are members of the Reoviridae family of viruses (genus Rotavirus) that affect the gastrointestinal system and respiratory tract. The name is derived from the wheel like appearance of virions when viewed by negative contrast  
15 electron microscopy (Figure 1a; prior art). The rotavirus is usually globular shape and is named after the outer and inner shells or double-shelled capsid structure of the same. The outer capsid is about 70 nm, and inner capsid is about 55 nm in diameter, respectively. The double-shelled capsid of the rotavirus surrounds the core including the inner protein shell and genome. The genome of the rotavirus consists of double  
20 stranded RNA segments encoding at least 11 rotavirus proteins.

[0004] The dsRNA codes for six structural proteins (VP) and six non-structural proteins (NSP) (Figure 1c; prior art). The structural proteins comprise VP1, VP2, VP3, VP4, VP6 and VP7 (Figure 1b; prior art). Three concentric layers are formed by the assembly of VP2, VP6 and VP7 respectively, with VP4 forming “spikes” on the  
25 surface of the virus structure. The NSPs are synthesized in infected cells and function in various parts of the replication cycle or interact with some of the host proteins to influence pathogenesis or the immune response to infection (Greenberg and Estes, 2009).

[0005] VP2 is a 102 kDa protein and is the most abundant protein of the viral core. It  
30 forms the inner-most structural protein layer and provides a scaffold for the correct

assembly of the components and transcription enzymes of the viral core (Lawton, 2000). VP1, the largest viral protein at 125 kDa, acts as an RNA-dependent polymerase for rotavirus, creating a core replication intermediate, and associates with VP2 at its icosahedral vertices (Varani and Allain, 2002; Vende et al., 2002). VP3, a 98 kDa protein, is also directly associated with the viral genome, acting as an mRNA capping enzyme that adds a 5' cap structure to viral mRNAs. Together, VP1 and VP3 form a complex that is attached to the outer 5-fold vertices of the VP2 capsid layer (Angel, 2007). VP6 is a 42 kDa protein which forms the middle shell of the viral core, is the major capsid protein and accounts for more than 50% of the total protein mass of the virion (González et al., 2004; Estes, 1996). It is required for gene transcription and may have a role in encapsulation of the rotavirus RNA by anchoring VP1 to VP2 in the core, as seen in bluetongue virus, another member of the Reoviridae family. It also determines the classification of rotaviruses into five groups (A to E) with group A most commonly affecting humans (Palombo, 1999). VP6 in rotavirus group A has at least four subgroups (SG), which depend on the presence or absence of SG specific epitopes: SG I, SG II, SG (I+II) and SG non-(I+II). Groups B and C lack a common group A antigen but are also known to infect humans, while group D only affects animals e.g chickens and cows (Thongprachum, 2010).

[0006] The two outer capsid proteins VP7, a 37 kDa glycoprotein (G) and the 87 kDa protease sensitive VP4 (P), define the virus' serotypes. These two proteins induce neutralizing antibody responses and are thus used to classify rotavirus serotypes into a dual nomenclature system, depending on the G-P antigen combination (e.g. G1 P[8] or G2 P[4]) (Sanchez-Padilla et al., 2009). The VP4 protein dimerizes to form 60 spikes on the outer shell of the virus, which are directly involved in the initial stages of host cell entry. The spike protein contains a cleavage site at amino acid (aa) position 248. Upon infection, it is cleaved by the protease trypsin to produce VP5 (529 aa, 60 kDa) and VP8 (246 aa, 28 kDa) (Denisova et al., 1999). This process enhances virus infectivity (cell attachment and invasion of host cell) and stabilizes the spike structure (Glass, 2006). The VP7 glycoprotein forms the third or outside layer of the virus. At present, 27 G and 35 P genotypes are known (Greenberg and Estes, 2009). VP4 and VP7 are the major antigens involved in virus neutralization and are important targets for vaccine development (Dennehy, 2007).

[0007] In infected mammalian cells, rotaviruses undergo a unique mode of morphogenesis to form the complete triple-layered VP2/6/4/7 viral particles (Lopez et al., 2005). The triple-layer capsid is a very stable complex which enables faecal–oral transmission and delivery of the virus into the small intestine where it infects non-dividing differentiated enterocytes near the tips of the villi (Greenberg and Estes, 2009). Firstly, the intact virus attaches to sialic acid-independent receptors via 60 VP4 dimer spikes on the surface of the virus (Lundgren and Svensson, 2001). The 60 VP4 dimer spikes on the surface of the virus allow the virus to attach to these cell receptors. VP4 is susceptible to proteolytic cleavage by trypsin which results in a conformational change that exposes additional attachment sites on the surface of the glycoprotein for interaction with a series of co-receptors.

[0008] The multi-step attachment and entry process is, however, not clearly understood but the virus is delivered across the host's plasma membrane. The VP7 outer capsid shell which is also involved in the entry process, is removed in the process and double-layered particles (DLP) are delivered into the cell cytoplasm in vesicles (Figure 2; prior art). The DLP escapes from the vesicle and goes into non-membrane bound cytoplasmic inclusions. Early transcription of the genome by VP1 begins in particles so that dsRNA is never exposed to the cytoplasm. RNA replication and core formation takes place in these non-membrane-bound cytoplasmic inclusions. The nascent (+) RNAs are then transported into the cytoplasm and serve as templates for viral protein synthesis. VP4 is produced in the cytosol and transported to the rough endoplasmic reticulum (RER), and VP7 is secreted into the RER. VP2 and VP6 are produced and assemble in the cytosol in virosomes and subsequently bud into the RER compartments, receiving a transient membrane envelope in the process (Lopez et al., 2005; Tian et al., 1996). In the RER, the transient envelopes of the viral particles are removed and replaced by VP4 and VP7 protein monomers, with critical involvement of rotaviral glycoprotein NSP4 (Tian et al., 1996; Lopez et al., 2005; Gonzalez et al., 2000). NSP4 functions as an intracellular receptor in the ER membrane and binds newly made subviral particles and probably also the spike protein VP4 (Tian et al., 1996). NSP4 is also toxic to humans and is the causative agent of the diarrhea. The complete, mature particles are subsequently transferred from the RER through the Golgi apparatus to the plasma membrane for secretion (Lopez et al., 2005).

[0009] A variety of different approaches have been taken to generate a rotavirus vaccine suitable to protect human populations from the various serotypes of rotavirus. These approaches include various Jennerian approaches, use of live attenuated viruses, use of virus-like particles, nucleic acid vaccines and viral sub-units as immunogens. At present there are two oral vaccines available on the market, however, these have low efficacy in some developing countries due to strain variation and presence of other pathogens.

[0010] U.S. Pat. Nos. 4,624,850, 4,636,385, 4,704,275, 4,751,080, 4,927,628, 5,474,773, and 5,695,767, each describe a variety of rotavirus vaccines and/or methods of preparing the same. A commonality shared by the members of this group is that each of these vaccines relies on the use of whole viral particles to create the ultimate rotavirus vaccines. Given the long standing need for an effective, multivalent vaccine, it is clear that this body of work has been only partially successful in addressing the need for such a vaccine.

[0011] Departing from traditional methods of vaccine generation, advances in the field of molecular biology have permitted the expression of individual rotavirus proteins. Crawford et al. (J Virol. 1994 September; 68(9): 5945–5952) cloned VP2, VP4, VP6, and VP7 coding for the major capsid protein into the baculovirus expression system and expressed each protein in insect cells. Co-expression of different combinations of the rotavirus major structural proteins resulted in the formation of stable virus-like particles (VLPs). The co-expression of VP2 and VP6 alone or with VP4 resulted in the production of VP2/6 or VP2/4/6 VLPs, which were similar to double-layered rotavirus particles. Co-expression of VP2, VP6, and VP7, with or without VP4, produced triple-layered VP2/6/7 or VP2/4/6/7 VLPs, which were similar to native infectious rotavirus particles. The VLPs maintained the structural and functional characteristics of native particles, as determined by electron microscopic examination of the particles, the presence of non-neutralizing and neutralizing epitopes on VP4 and VP7, and hemagglutination activity of the VP2/4/6/7 VLPs.

[0012] Vaccine candidates generated from virus-like particles of different protein compositions have shown potential as subunit vaccines. O'Neal et al. ("Rotavirus Virus-like Particles Administered Mucosally Induce Protective Immunity," J. Virology, 71(11):8707-8717 (1997)) showed that VLPs containing VPs 2 and 6 or

VPs 2, 6, and 7 when administered to mice with and without the addition of cholera toxin induced protective immunity in immunized mice, although protection was more effective when the VLPs were administered with cholera toxin (CT).

[0013] Core-like particles (CLP) and VLPs have also been used to immunize cows  
5 Fernandez, et al., ("Passive Immunity to Bovine Rotavirus in Newborn Calves Fed Colostrum Supplements From Cows Immunized with Recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines," Vaccine, 16(5):507-516 (1998)). In this study the ability of CLPs and VLPs to create passive immunity was studied. This group concluded that VLPs were more effective than CLPs in  
10 inducing passive immunity.

[0014] Plants are increasingly being used for large-scale production of recombinant proteins. For example US 2003/0175303 discloses the expression of recombinant rotavirus structural protein VP6, VP2, VP4 or VP7 in stable transformed tomato plants.

[0015] Saldana et al. expressed VP2 and VP6 in the cytoplasm of tomato plants using a cauliflower mosaic virus (CaMV) 35S promoter and recombinant *A. tumefaciens* (Saldana et al., 2006). Electron microscopy studies showed that a small proportion of the particles had assembled into 2/6 VLPs. A protective immune response was detected in mice and this may have to some extent been contributed by the non-  
20 assembled VPs. Individual proteins have been shown to elicit immune responses in mice, as in the case of VP8 and VP6 (Zhou et al., 2010).

[0016] Matsumura et al., (2002) were first to report bovine rotavirus A VP6 expression and assembly in transgenic potato plants. In their study, they used transgenic potato plants regulated by a cauliflower mosaic virus (CaMV) 35S promoter and recombinant *Agrobacterium tumefaciens* carrying the VP6 gene. The protein was expressed, purified and immunogenic studies performed. Immune-  
25 response in adult mice showed presence of VP6 antibodies in the sera. However, they did not show evidence of assembled VP6 proteins. It may have been simple monomers or trimers that could elicit an immune response in mice. Another group's work showed VP6 assembly in *Nicotiana benthamiana* using a potato virus X (PVX) vector (O'Brien et al., 2000). When the VP6 protein was expressed in plants, it was  
30 discovered that it only assembled when fused to the PVX protein rods. Once cleavage



occurred, VP6 assembled into icosahedral VLPs as seen in a similar study of HIV-PVX by Marusic et al., (2001). This result probably suggests that rotavirus proteins may require an additional factor or enhancement in order to form VLPs.

[0017] Production of VLP is a challenging task, as both the synthesis and assembly of one or more recombinant proteins are required. This is the case for VLP of rotavirus which is an RNA virus with a capsid formed by 1860 monomers of four different proteins. For VLP production the simultaneous expression and assembly of two to three recombinant proteins is necessary. These comprise 120 molecules of VP2 (inner layer), 780 molecules of VP6 (middle layer) and 780 molecules of the glycoprotein VP7 (outer layer), ultimately forming a double or triple-layered particle. In addition, the production of most VLP requires the simultaneous expression and assembly of several recombinant proteins, which – for the case of rotavirus like particle (RLP) – needs to occur in a single host cell.

[0018] A more recent study showed the successful expression of codon-optimized human rotavirus VP6 in *Chenopodium amaranticolor* using a Beet black scorch virus (BBSV) mediated expression system. The protein was engineered as a replacement to the coat protein open reading frame of BBSV. Oral immunization of female BALB/c mice with the plant based VP6 protein induced high titers of anti-VP6 mucosal IgA and serum IgG (Zhou et al., 2010). The group, however, did not mention whether the VP6 proteins assembled into VLPs or particles.

[0019] Rotavirus VP7 has also been successfully expressed in tobacco plants and was shown to maintain its neutralizing immune response in mice (Yu and Langridge, 2001). Another study using transgenic potato plants to express VP7 showed that the VP7 gene was stable over 50 generations in the transformed plants. VP7 protein from the 50th generation induced both protective and neutralizing antibodies in adult mice (Li et al., 2006).

[0020] Yang et al. (Yang Y M, Li X, Yang H, et al. 2011) co-expressed three rotavirus capsid proteins VP2, VP6 and VP7 of group A RV (P[8]G1) in tobacco plants and expression levels of these proteins, as well as formation of rotavirus-like particles and immunogenicity were studied. VLPs were purified from transgenic tobacco plants and analyzed by electron microscopy and Western blot. Yang et al.

results indicate that the plant derived VP2, VP6 and VP7 protein self-assembled into 2/6 or 2/6/7 rotavirus like particle with a diameter of 60-80 nm.

## SUMMARY OF THE INVENTION

5 [0021] The present invention relates to producing rotavirus structural proteins in plants. More specifically, the present invention also relates to producing virus-like particles comprising rotavirus structural protein in plants.

[0022] Firstly, there is described herein a method (A) of producing a rotavirus-likeparticle (RLP) in a plant comprising:

10 a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the  
15 plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein into the plant, portion of a plant or plant cell,

b) incubating the plant, portion of a plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP.

20 [0023] Furthermore a fourth nucleic acid comprising a fourth regulatory region active in the plant and operatively linked to a fourth nucleotide sequence encoding a fourth rotavirus structural protein may be introduced into the plant, portion of a plant or plant cell in step a), and is expressed when incubating the plant, portion of a plant or plant cell in step b).

[0024] In the method (A) as described above the first rotavirus structural protein may be  
25 VP2, the second rotavirus structural protein may be VP6 and the third rotavirus structural protein may be VP4 or VP7. Furthermore, the fourth rotavirus structural protein may be VP7 or VP4. The VP4 may be processed or cleaved to produce VP5 and VP8. Cleavage of VP4 may be performed using a protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, or a subtilisin. The protease may be co-  
30 expressed within the plant.

[0025] There is also provided herein a method (B) of producing a rotavirus-like particle (RLP) comprising:

- a) introducing a nucleic acid comprising a regulatory region active in the plant operatively linked to a first nucleotide sequence encoding one or more rotavirus structural protein, into the plant, portion of a plant or plant cell,
- b) incubating the plant, portion of a plant or plant cell under conditions that permit the transient expression of the first nucleic acid, thereby producing the RLP.

[0026] The method (B) as described above may further comprise introducing in (step a) a second nucleic acid comprising a second regulatory region active in the plant and operatively linked to a second nucleotide sequence encoding one or more rotavirus structural protein and expressing the a second nucleic acid when incubating the plant, portion of a plant or plant cell in step b).

[0027] The method (B) as described above may further comprise introducing in (step a) a third nucleic acid comprising a third regulatory region active in the plant and operatively linked to a third nucleotide sequence encoding one or more rotavirus structural protein is introduced into the plant, portion of a plant or plant cell in step a), and expressing the third nucleic acid when incubating the plant, portion of a plant or plant cell in step b).

[0028] Furthermore, in method (A) or (B) an additional nucleic acid may be expressed in the plant, portion of a plant or plant cell, and wherein the additional nucleic acid comprises a regulatory region active in the plant operatively linked to a nucleotide sequence encoding a suppressor of silencing.

[0029] The codon usage of the nucleotide sequence may be adjusted to preferred human codon usage, increased GC content or a combination thereof.

[0030] The rotavirus structural protein may comprise a truncated, native or a non-native signal peptide. The non-native signal peptide may be a protein disulfide isomerase signal (PDI) peptide.

[0031] The first, second, third or fourth nucleotide sequence or a combination thereof may be operatively linked to a Cowpea Mosaic Virus (CPMV) regulatory region.

[0032] The method (A) or (B) as described above may further comprise the steps of:

- c) harvesting the plant, portion of a plant or plant cell, and

d) purifying the RLPs from the plant, portion of a plant or plant cell.

[0033] During the step of harvesting or purifying in method (A) or (B), VP4 may be processed or cleaved to produce VP5 and VP8 using trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[0034] The RLPs may range size from 70-100 nm and may purified in the presence of calcium.

[0035] There is further provided a RLP produced by a method as described herein, e.g., the methods (A) or (B) as described above. The RLP produced may comprise at least a VP4 rotavirus structural protein. The VP4 may be cleaved into VP5 and VP8 using a protease for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. The protease may be co-expressed within the plant or added during harvesting, purification, or both. Furthermore the RLP produced by the method (A) or (B) may be a double layered RLP and/or a triple layered RLP.

[0036] Furthermore, nucleotide sequences are provided. The nucleotide sequence encoding VP2 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 45. The nucleotide sequence encoding VP6 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:46. The nucleotide sequence encoding VP7 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 19, 20, 48, 49, 52, 53, 54 or 57. And the nucleotide sequence encoding VP4 may comprise from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 15, 16, 47, 50, or 51. In addition VP2 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO:1 or SEQ ID NO: 25. VP6 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO:3 or SEQ ID NO: 31. VP7 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO: 4, 39, 43 or 59. VP4 may be encoded by an amino acid sequence comprising from 80% to 100% identity with the amino acid sequence defined by SEQ ID NO: 2 or SEQ ID NO: 36. 33. The one or more rotavirus structural protein may be VP2, VP4, VP6 and/or VP7. The VP4 may be processed to VP5 and VP8. The one or more rotavirus structural protein may be selected

from rotavirus strain G9 P[6], rotavirus A WA strain, rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain, and rotavirus SA11 strain.

[0037] In method (A) as described above the first, second or third nucleic acid sequence or a combination thereof may comprise a regulatory region active in the plant operatively  
5 linked to one or more than one comovirus enhancer, to one or more than one amplification element and to a nucleotide sequence encoding a rotavirus structural protein, and wherein a fourth nucleic acid encoding a replicase may be introduced into the plant, portion of a plant or plant cell.

[0038] In method (B) as described above the first, second, third or fourth nucleic acid  
10 sequence or a combination thereof may comprise a regulatory region active in the plant operatively linked to one or more than one comovirus enhancer, to one or more than one amplification element and to a nucleotide sequence encoding a rotavirus structural protein, and wherein a fifth nucleic acid encoding a replicase may be introduced into the plant, portion of a plant or plant cell.

[0039] In addition, there is provided herein a method (C) of producing a rotavirus-likeparticle (RLP) in a plant comprising:

a) introducing a nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, into the plant, or portion of the plant,

20 b) incubating the plant, portion of the plant under conditions that permit the transient expression of the first nucleic acid, thereby producing the RLP.

[0040] Furthermore, a second nucleic acid may be introduced into the plant or portion of the plant, the second nucleic acid comprises a second regulatory region that is active in the plant and operatively linked to a second nucleotide sequence encoding one or more  
25 rotavirus structural protein and wherein the second nucleic acid is expressed when incubating the plant or portion of the plant in step b).

[0041] Furthermore a third nucleotide sequence may be introduced into the plant or portion of the plant, the third nucleic acid comprises a third regulatory region that is active in the plant and operatively linked to a third nucleotide sequence encoding one or more  
30 rotavirus structural protein and wherein the third nucleic acid is expressed when incubating the plant or portion of the plant in step b).

[0042] The method (C) as described above may further comprising a step of harvesting the plant and extracting the RLPs.

[0043] The one or more rotavirus structural protein of method (C) may be rotavirus protein VP2, VP4 or VP6. The one or more rotavirus structural protein encoded by the first or second nucleotides sequence may be VP2 or VP6. The one or more rotavirus structural protein encoded by the third nucleotides sequence may be VP4. The VP4 may be cleaved to produce VP5 and VP8.

[0044] The first, second or third nucleotide sequence may further encode, comprise, or encode and comprise, one or more than one compartment targeting sequence and/or an amplification element. The one or more compartment targeting sequence directs the one or more rotavirus structural protein to the endoplasmatic reticulum (ER), chloroplast, plastid or apoplast of the plant cell.

[0045] In addition, there is provided herein a method (D) of producing a rotavirus-likeparticle (RLP) comprising,

a) providing a plant or portion of a plant comprising a nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein;

b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the nucleic acid, thereby producing the RLP.

[0046] Furthermore the plant or portion of the plant of method (D) may further comprise;

i) a second nucleic acid comprising a second regulatory region active in the plant and operatively linked to a second nucleotide sequence encoding one or more rotavirus structural protein or,

ii) a second and third nucleic acid, wherein the second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a second nucleotide sequence encoding one or more rotavirus structural protein and the third nucleic acid comprises a third regulatory region active in the plant and operatively linked to a third nucleotide sequence encoding one or more rotavirus structural protein, wherein the second or the second and third nucleic acids are expressed when incubating the plant or portion of the plant in step b).

[0047] The one or more structural protein in method (D) may be rotavirus protein VP2, VP4 or VP6. The one or more rotavirus structural protein encoded by the first or second nucleotides sequence may be VP2 or VP6. The one or more rotavirus structural protein encoded by the third nucleotides sequence may be VP4. The VP4 may be cleaved into VP5 and VP8 using a protease for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. The protease may be co-expressed within the plant or added during harvesting, purification, or both.

[0048] There is further provided a RLP produced by a method as described herein, e.g., method (A), method (B), method (C), method (D), or a combination thereof, as described above. The RLP may comprise one or more rotavirus structural protein that may comprises comprise plant-specific N-glycans, or modified N-glycans.

[0049] There is further provided a composition comprising an effective dose of the RLP made by a method as described herein, e.g., method (A), method (B), method (C), method (D), or a combination thereof as just described, for inducing an immune response, and a pharmaceutically acceptable carrier.

[0050] There is also provided a method of inducing immunity to a rotavirus infection in a subject, comprising administering an RLP as described herein, to the subject. The RLP may be administered to a subject orally, intradermally, intranasally, intramuscularly, intraperitoneally, intravenously, or subcutaneously.

[0051] In addition, there is provided plant matter comprising a RLP produced by a method as described herein, e.g., method (A), method (B), method (C), method (D), or a combination thereof, as described above. The plant matter may be used in inducing immunity to a rotavirus virus infection in a subject. The plant matter may also be admixed as a food supplement.

[0052] In the methods as described herein (e.g., methods A, B, C or D) the plant or portion of the plant may further be administered with, or may further comprise, another nucleic acid sequence encoding a suppressor of silencing.

[0053] Furthermore, there is provided herein a method (E) of producing rotavirus structural protein in plant comprising

a) introducing a nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein, into the plant, or portion of the plant;

b) incubating the plant or portion of the plant under conditions that permit the transient expression of the nucleic acid, thereby producing the one or more rotavirus structural protein.

[0053a] In particular, in an aspect of the present invention there is provided a method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:

a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of the plant or plant cell,

wherein the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated native signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell, and

d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.

[0053b] In another aspect of the present invention there is provided a method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell comprising:

a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second



nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third  
5 rotavirus structural protein is VP7, and

wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

b) incubating the plant, portion of the plant or plant cell under conditions that permit the  
10 transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell, and

d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.

15 [0053c] In another aspect of the invention there is provided a method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:

a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second  
20 regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of a the plant or plant cell, wherein  
25 the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide, or

a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first  
30 nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid

comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

b) incubating the plant, portion of a the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell.

[0053d] In another aspect there is provided a rotavirus like particle (RLP) produced by a method embodied by the invention. Typically, the RLP is of a size from 70-100nm and generally wherein the RLP comprises one or more rotavirus structural protein that comprises plant-specific N-glycans, or plant-specific modified N-glycans.

[0053e] In another aspect there is provided a composition comprising an effective dose of a rotavirus like particle (RLP) embodied by the invention for inducing an immune response in a subject, and a pharmaceutically acceptable carrier.

[0053f] In another aspect there is provided a method of inducing immunity to a rotavirus infection in a subject, comprising administering a composition embodied by the invention comprising a rotavirus like particle (RLP).

[0053g] In another aspect there is provided the use of a composition embodied by the invention comprising a rotavirus like particle (RLP) in the manufacture of a medicament for inducing immunity to a rotavirus infection in a subject.

[0054] This summary of the invention does not necessarily describe all features of the invention.

[0054a] Throughout this specification, the word “comprise”, or variations thereof such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0054b] Any discussion of documents, acts, materials, devices, articles or the like which has been included in this specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters  
5 form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of this application.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

10 [0055] These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

[0056] **FIGURE 1** shows rotavirus structure and gene-protein assignment . (A) Transmission electron microscopy of rotavirus particles (bar represents 100nm). (B) Organization of the virus capsid proteins comprising inner, intermediate and outer. (C)  
15 Rotavirus dsRNA segments arranged as per size and function. The dsRNA can be separated by polyacrylamide gel electrophoresis (D). Proteins in (C) are indicated by dsRNA segments in (D). Images from Crawford et al.,1997 (A), Swiss Institute of Bioinformatics, 2008 (B) and Greenberg and Estes, 2009 (D).

[0057] **Figure 2** shows rotavirus cell entry and replication. When rotavirus enters a cell,  
20 VP4 and VP7 are lost, forming a double layered particle (DLP). Transcription of the dsRNA commences resulting in translation of VP2, VP4, VP6 and VP7. Progeny cores with replicase activity are produced in virus factories (also called viroplasms). Late transcription occurs in these progeny cores. At the periphery of virus factories, these core are coated with VP6, forming immature DLPs that bud across the membrane of the  
25 endoplasmic reticulum, acquiring a transient lipid membrane which is modified with the ER resident viral glycoproteins NSP4 and VP7; these enveloped particles also contain VP4. As the particles move towards the interior of the ER cisternae, the transient lipid membrane and the nonstructural protein NSP4 are lost, while the virus surface proteins VP4 and VP7 rearrange to form the outermost virus protein layer, yielding mature infectious triple-  
30 layered particles (see Swiss Institute of

Bioinformatics (ViralZone): [viralzone.expasy.org/viralzone/all\\_by\\_species/107.html](http://viralzone.expasy.org/viralzone/all_by_species/107.html))

[0058] **FIGURE 3** shows Agrobacterium vectors pTRAc, pTRAc-*rbcs1*-cTP and pTRAc-ERH. P35SS, CaMV 35S promoter with duplicated transcriptional enhancer;; CHS, chalcone synthase 5' untranslated region; pA35S, CaMV 35S polyadenylation signal; SAR, scaffold attachment region of the tobacco Rb7 gene; LB and RB, the left and right borders for T-DNA integration; ColE1ori, origin of replication for *E. coli*; RK2ori, origin of replication for Agrobacterium; bla, ampicillin/carbenicillin-resistance bla gene; LPH, signal-peptide sequence from the murine mAb24 heavy chain; his6, 6 × His tag sequence; SEKDEL, ER-retention signal sequence; *rbcs1*-cTP, chloroplast-transit peptide sequence of a Rubisco small-subunit gene (*rbcs1*) from *Solanum tuberosum*; npt II, kanamycin resistance npt II gene; Pnos and pAnos, promoter and polyadenylation signal of the nopaline synthase gene (Maclean et al., 2007).

[0059] **Figure 4** shows an overview of rotavirus cloning and infiltration procedure

[0060] **Figure 5** shows an apoplast protein extraction procedure. (A) Illustration of the plant cell and location of the apoplast. VP proteins are expressed in the cytosol and targeted to the apoplast (red arrow). (B) - After time trial, plant leaf is vacuum infiltrated with PBS (1) and placed in a perforated spin column (2) then centrifuged in a 2ml Eppendorf tube to collect sap (3).

[0061] **Figure 6** shows a western blots of expression of rotavirus VP6 protein in plant leaf cell compartments over 7 days. Mouse anti-rotavirus VP6 antibody (1:5000) was used to probe the membranes. (+) and (-) indicates expression with or without silencing suppressor respectively. The red lines indicate the position of VP6 proteins in the various samples analysed (~ 40 kDa). Expression and extraction efficiency of VP6 was best in the cytoplasm.

[0062] **Figure 7** shows a western blot showing the individual expression of his-tagged rotavirus proteins at day 3 in the cytoplasm of *N. benthamiana* plant leaves. +ve – bacterial expressed rotavirus VP2; M – molecular weight marker; VP – rotavirus capsid protein. VP7 infiltration resulted in yellowing of leaves (b).

[0063] **Figure 8** shows expression of rotavirus VP2 (a) and VP4 (b) targeted to various *N. benthamiana* plant leaf cell compartments at day 3. The respective chicken

anti-rotavirus serum (1:2000) for VP2 and VP4 were used for probing the proteins. cTp - chloroplasts; ER – endoplasmic reticulum; pTRAc – cytoplasm; A – apoplast; Negative control (-ve) – plants infiltrated with silencing suppressor only; Positive control (+ve) in (a) – bacterial expressed VP2, (b) – bacterial expressed VP4; (- and +) with or without silencing suppressor; M – molecular weight marker. The arrows indicate the position of the protein bands in question.

[0064] **Figure 9** shows western blot analysis of day 3 extracts of co-expressed VP2/6/4 in the cytoplasm of *N. benthamiana* leaves. Proteins were probed with a mixture of chicken anti-rotavirus serum (anti-VP2 (1/5000) and anti-VP4 (1/5000)) and mouse anti-VP6 antibody (1:5000). Infiltration of recombinant *Agrobacterium* was done with silencing suppressor. Negative control (-ve) – whole plants infiltrated with silencing suppressor only; M – molecular weight marker.

[0065] **Figure 10** shows electron micrographs of day 3 cytoplasm extracted rotavirus proteins stained with uranyl acetate. (a) Negative protein sample extract with silencing suppressor; (b) VP6 protein extract; (c) VP2/6 protein extract and (d) VP2/6/4 protein extract. Bars = 200 nm. All RLPs detected were between 70 - 100 nm in diameter. Arrow in (b) indicates VP6 sheath/mat. Arrow in (c) indicates an example of aRLP. All proteins were expressed in the presence of a silencing suppressor. All were captured with mouse-anti VP6 antibody (1:2000).

[0066] **Figure 11** shows sucrose gradient purification of co-expressed VP2/6 and VP2/6/4 (a). Dot blots of sucrose gradient purified VP2/6 (b) and VP2/6/4 (c). Protein extracts were loaded on a sucrose gradient (10 – 60 %) and ultracentrifuged. Fractions were analysed by probing with (b) mouse anti-VP6 antibody (1:5000) and (c) chicken anti-VP2 and VP4 serum (1:5000).

[0067] **Figure 12** shows western blot analysis of VP2/6 fractions (a), SDS-PAGE coomassie stained gel photograph of fractions VP2/6 fractions 16 and 17 (b), and western blot analysis of fractions 16 and 17 (c). Mouse anti-VP6 (1:5000) and chicken anti-VP2 serum (1:5000) was used in the western blot (a) and only mouse anti-VP6 (1:5000) in (c). Negative control (- ve) in (a) and (c) – bacterial expressed VP4, and in (b) – plants infiltrated with silencing suppressor and sucrose gradient purified; crude – non-purified VP2/6 extract; Positive control (+ve) in (a) – bacterial expressed VP2,

(b) and (c) – plant expressed VP6; VP6-SF9 – VP6 protein of known concentration expressed in SF9 insect cells. Arrows indicate protein bands of interest.

[0068] **Figure 13** shows total soluble protein assay on fractions of sucrose density gradient purified VP2/6. (a) – IgG standard curve, (b) - absorbance readings of fractions taken at 750 nm. Points of interest: fractions 16 to 19.

[0069] **Figure 14** shows sucrose density gradient analysis of cytoplasm co-expressed VP2/6/4 fractions. Raw absorbance readings at 750nm were taken to verify the protein peaks previously detected on the dot blot of VP2/6/4.

[0070] **Figure 15** shows transmission electron micrographs of sucrose density gradient purified VP2/6 particles. Both (a) and (b) show two different sections viewed on the copper grid. All RLPs detected were between 70 - 100 nm in diameter. Samples were captured with mouse-anti VP6 antibody (1:2000). Bars represent 200 nm.

[0071] **Figure 16a** shows amino acid sequence (SEQ ID NO:1) and nucleotide sequences of Rotavirus VP2 (SEQ ID NO:13 and 14). **Figure 16b** shows amino acid sequence (SEQ ID NO:2) and nucleotide sequences of Rotavirus VP4 (SEQ ID No: 15 and 16). **Figure 16c** shows amino acid sequence (SEQ ID NO: 3) and nucleotide sequences of Rotavirus VP6 (SEQ ID NO: 17 and 18). **Figure 16d** shows amino acid sequence (SEQ ID NO:4) and nucleotide sequences of Rotavirus VP7 (SEQ ID NO: 19 and 20).

[0072] **Figure 17A** shows nucleotide sequence of primer IF-WA\_VP2(opt).s1+3c (SEQ ID NO: 21). **Figure 17B** shows nucleotide sequence of primer IF-WA\_VP2(opt).s1-4r (SEQ ID NO: 22). **Figure 17C** shows a schematic representation of construct 1191. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation.

[0073] **Figure 18** shows nucleotide sequence (SEQ ID NO: 23) of construct 1191 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette.

[0074] **Figure 19** shows nucleotide sequence encoding VP2(opt) from Rotavirus A WA strain (SEQ ID NO:45).

[0075] **Figure 20** shows amino acid sequence of VP2 from Rotavirus A WA strain (SEQ ID NO: 25).

[0076] **Figure 21** shows a schematic representation of construct number 1710.

[0077] **Figure 22A** shows a schematic representation of construct 193. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation. **Figure 22B** shows nucleotide sequence of construct 193 (SEQ ID NO: 26). Construct 193 is shown from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS into BeYDV(m)+Replicase amplification system with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette.

[0078] **Figure 23** shows nucleotide sequence of expression cassette 1710 (SEQ ID NO: 27). Expression cassette number 1710 is shown from 2X35S promoter to NOS terminator. VP2(opt) from Rotavirus A WA strain is underlined.

[0079] **Figure 24** shows a schematic representation of construct number 1711.

[0080] **Figure 25A** shows nucleotide sequence of primer IF-WA\_VP6(opt).s1+3c (SEQ ID NO:28). **Figure 25B** shows nucleotide sequence of primer IF-WA\_VP6(opt).s1-4r (SEQ ID NO: 29). **Figure 25c** shows expression cassette number 1713 from 2X35S promoter to NOS terminator (SEQ ID NO: 30). VP6(opt) from Rotavirus A WA strain is underlined. Figure 25d shows nucleotide sequence encoding VP6(opt) from Rotavirus A WA strain (SEQ ID NO: 46)

[0081] **Figure 26** shows the amino acid sequence of VP6 from Rotavirus A WA strain (SEQ ID NO: 31).

[0082] **Figure 27** shows the schematic representation of construct number 1713.

[0083] **Figure 28** shows the nucleotide sequence of expression cassette number 1714 from 2X35S promoter to NOS terminator (SEQ ID NO:32). VP6(opt) from Rotavirus A WA strain is underlined.

[0084] **Figure 29** shows a schematic representation of construct number 1714.

[0085] **Figure 30A** shows the nucleotide sequence of primer IF-Rtx\_VP4(opt).s1+3c (SEQ ID NO: 33). **Figure 30B** shows the nucleotide sequence of primer IF-Rtx\_VP4(opt).s1-4r (SEQ ID NO: 34).

[0086] **Figure 31A** shows the nucleotide sequence of expression cassette number 1731 from 2X35S promoter to NOS terminator (SEQ ID NO: 35). VP4(opt) from Rotavirus A Rotarix strain is underlined. **Figure 31B** shows optimized coding sequence of Rotavirus A VP4 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO: 47). **Figure 31C** shows the nucleotide sequence of expression cassette number 1730 from 2X35S promoter to NOS terminator (SEQ ID NO: 44). VP4(opt) from Rotavirus A Rotarix strain is underlined.

[0087] **Figure 32** shows amino acid sequence of VP4 from Rotavirus A Rotarix strain (SEQ ID NO: 36).

[0088] **Figure 33A** shows a schematic representation of construct number 1730. **Figure 33B** shows a schematic representation of construct number 1731.

[0089] **Figure 34A** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s1+3c (SEQ ID NO: 37). **Figure 34B** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s1-4r (SEQ ID NO: 38). **Figure 34C** shows the nucleotide sequence of expression cassette number 1733 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined (SEQ ID NO: 24). **Figure 34D** shows nucleotide sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 48). **Figure 34E** shows the optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO 54).

[0090] **Figure 35** shows the amino acid sequence of VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 39).

[0091] **Figure 36** shows a schematic representation of construct number 1733.

[0092] **Figure 37** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s2+4c (SEQ ID NO: 40).

[0093] **Figure 38** shows a schematic representation of construct 1192. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation.

[0094] **Figure 39** shows the nucleotide sequence of construct 1192 from left to right t-DNA borders (underlined) (SEQ ID NO: 41). 2X35S/CPMV-HT/PDISP/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette are shown.



[0095] **Figure 40A** shows the nucleotide sequence of expression cassette number 1735 from 2X35S promoter to NOS terminator (SEQ ID NO: 42). PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined. **Figure 40B** Nucleotide sequence encoding PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 49).

[0096] **Figure 41** shows amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 43).

[0097] **Figure 42** shows a schematic representation of construct number 1735.

[0098] **Figure 43A** shows the coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO: 50). **Figure 43B** shows the optimized coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 51). **Figure 43C** shows the coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 52). **Figure 43D** shows optimized coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO :53).

[0099] **Figure 44A** shows the nucleotide sequence of primer IF-TrSp+Rtx\_VP7(opt).s1+3c (SEQ ID NP: 55). **Figure 44B** shows the nucleotide sequence of primer IF-Rtx\_VP7(opt).s1-4r (SEQ ID NO: 56). **Figure 44C** shows the nucleotide sequence of optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO: 57). **Figure 44D** shows the nucleotide sequence of expression cassette number 1734 from 2X35S promoter to NOS terminator (SEQ ID NO 58). VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined. **Figure 44E** shows the amino acid sequence of TrSp-VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 59). **Figure 44F** shows the schematic representation of construct number 1734.

[00100] **Figure 45** shows purification of rotavirus-like particles comprising VP2 and VP6 by iodixanol density gradient centrifugation. **Figure 45A** Coomassie-stained SDS-PAGE analysis of the load prior to centrifugation and fractions 1 to 10 (fraction 1 being at the bottom of the tube). Position of the rotavirus antigens are

shown by arrows. **Figure 45B** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-rotavirus antibody. **Figure 45C** Western blot analysis of the same fractions as in (A) using a rabbit polyclonal anti-VP2 antibody.

[00101] **Figure 46** shows purification of rotavirus-like particles comprising  
5 VP2, VP6 and VP7 by iodixanol density gradient centrifugation. **Figure 46A**  
Coomassie-stained SDS-PAGE analysis of the load prior to centrifugation and  
fractions 1 to 10 (fraction 1 being at the bottom of the tube). Position of the rotavirus  
antigens are shown by arrows. **Figure 46B** Western blot analysis of the same fractions  
as in (A) using a rabbit polyclonal anti-rotavirus antibody. **Figure 46C** Western blot  
10 analysis of the same fractions as in (A) using a rabbit polyclonal anti-VP7 antibody.

[00102] **Figure 47** shows purification of rotavirus-like particles comprising  
VP2, VP4, VP6 and VP7 by iodixanol density gradient centrifugation. **Figure 47A**  
Coomassie-stained SDS-PAGE analysis of the load prior to centrifugation and  
fractions 1 to 10 (fraction 1 being at the bottom of the tube). Position of the rotavirus  
15 antigens are shown by arrows. **Figure 47B** Western blot analysis of the same fractions  
as in (A) using a rabbit polyclonal anti-rotavirus antibody. **Figure 47C** Western blot  
analysis of the same fractions as in (A) using a rabbit polyclonal anti-VP7 antibody.

[00103] **Figure 48** shows assessment of VP4 content in purified rotavirus-like  
particles comprising VP2, VP4, VP6 and VP7 by anti-VP4 specific ELISA.

20 [00104] **Figure 49** shows cryo-electron microscopy image of purified  
rotavirus-like particles comprising VP2 and VP6 (left panel) and VP2, VP4, VP6 and  
VP7 (right panel).

## DETAILED DESCRIPTION

[00105] The following description is of a preferred embodiment.

25 [00106] The present invention relates to virus-like particles (VLPs) comprising  
one or more rotavirus structural protein (i.e. a rotavirus like particle, rotavirus VLP or  
RLP), and methods of producing rotavirus-like particle (RLPs) in plants. The  
rotavirus like particle (RLP) may therefore comprise one or more rotavirus structural  
protein. The RLP may be double layered or triple layered.

30 [00107] The present invention in part provides a method of producing a  
rotavirus-like particle (RLP) in a plant. The method may comprise introducing one or

more nucleic acid comprising a regulatory region active in the plant operatively linked to a nucleotide sequence encoding one or more rotavirus structural protein into the plant, or portion of the plant. Followed by incubating the plant or portion of the plant under conditions that permit the transient expression of the nucleic acids, thereby producing the RLP.

[00108] Furthermore, the present invention in part provides a method of producing a rotavirus-like particle (RLP) vaccine candidate in a plant. The method may comprise introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein into the plant, portion of the plant or plant cell. Followed by incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP. The RLP may be single, double or triple layered.

[00109] The “rotavirus structural protein” may refer to all or a portion of a rotavirus structural protein sequence isolated from rotavirus, present in any naturally occurring or variant rotavirus strain or isolate. Thus, the term rotavirus structural protein and the like include naturally occurring rotavirus structural protein sequence variants produced by mutation during the virus life-cycle or produced in response to selective pressure (e.g., drug therapy, expansion of host cell tropism or infectivity, etc.). As one of skill in the art appreciates, such rotavirus structural protein sequences and variants thereof may be also produced using recombinant techniques.

[00110] Furthermore, structural proteins may include capsid proteins such for example VP2 and VP6 and/or surface proteins such for example VP4. The structural protein may further include for example VP7.

[00111] Non-limiting examples of rotavirus structural protein are rotavirus protein VP2, VP4, VP6 and VP7, and a fragment of VP2, VP4, VP6 and VP7. Non-limiting examples of VP2, VP4, VP6 and VP7, or fragments of VP2, VP4, VP6 and VP7 protein that may be used according to the present invention include those VP2,

VP4 VP6 and VP7 protein from rotavirus strain G9 P[6], rotavirus A WA strain, rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain and rotavirus SA11 strain.

[00112] An example of a VP2 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO:25. Furthermore, the VP2 structural protein may comprise the sequence set forth in SEQ ID NO: 1, SEQ ID NO:25, or a sequence having at least about 90-100% sequence similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP2 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO:13, 14, 25, or 45 or a sequence having at least about 80-100% sequence similarity thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00113] An example of a VP4 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 2 and SEQ ID NO: 36. Furthermore, the VP4 structural protein may comprise the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 36 or a sequence having at least about 90-100% sequence similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP4 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO: 15, 16, 47, 50 or 51 or a sequence having at least about 80-100% sequence similarity thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00114] An example of a VP6 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 3 and SEQ ID NO: 31. Furthermore, the VP6 structural protein may comprise the sequence set forth in SEQ ID NO: 3, SEQ ID NO: 31 or a sequence having at least about 90-100% sequence similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP6 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO:17, 18, or 46 or a sequence having at least about 80-100% sequence similarity

thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00115] An example of a VP7 structural protein, which is not to be considered limiting, is set forth in the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 39, SEQ ID NO: 43, and SEQ ID NO: 47. Furthermore, the VP7 structural protein may comprise the sequence set forth in SEQ ID NO: 4, SEQ ID NO: 39 and SEQ ID NO: 43, or a sequence having at least about 90-100% similarity thereto, including any percent similarity within these ranges, such as 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto. In addition, a VP7 structural protein may be encoded by a nucleotide sequence as set forth in SEQ ID NO:19, 20, 48, 49, 52, 53 or 54 or a sequence having at least about 80-100% sequence similarity thereto, including any percent similarity within these ranges, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% sequence similarity thereto.

[00116] Amino acid sequence similarity or identity may be computed by using the BLASTP and TBLASTN programs which employ the BLAST (basic local alignment search tool) 2.0 algorithm. Techniques for computing amino acid sequence similarity or identity are well known to those skilled in the art, and the use of the BLAST algorithm is described in ALTSCHUL et al. (1990, J Mol. Biol. 215: 403-410) and ALTSCHUL et al. (1997, Nucleic Acids Res. 25: 3389-3402).

[00117] The term "virus-like particle" (VLP), or "virus-like particles" or "VLPs" refers to structures that self-assemble and comprise one or more structural proteins such as for example rotavirus structural protein, for example but not limited to VP2, VP4, VP6 and/or VP7 structural protein. VLPs comprising rotavirus structural protein maybe also be referred to "rotavirus VLP", "rotavirus -like particle (RVLP)", "rotavirus -like particle (RLP)" , "rotavirus -like particle", "RVLP" or "RLP" . VLPs or RLPs are generally morphologically and antigenically similar to virions produced in an infection, but lack genetic information sufficient to replicate and thus are non-infectious. VLPs may be produced in suitable host cells including plant host cells. Following extraction from the host cell and upon isolation and further purification under suitable conditions, VLPs may be purified as intact structures. The RLP may be a single-, double or triple-layered RLP. Single-layered RLPs may be obtained by expressing one rotavirus structural protein, such as VP2 or VP6. Double-layered RLPs may be obtained by expressing two rotavirus structural proteins, such as

for example by co-expressing both VP2 and VP6, with or without VP4. Triple-layered RLPs may be obtained by the simultaneous expression of at least three rotavirus structural proteins for example the co-expression of VP2, VP6 and VP7, with or without VP4. Co-expression of VP4 results in a particle with spikes that resembles native rotavirus. VP4 may be processed or cleaved to produce VP5 and VP8. This processing may take place within the host using endogenous proteases, or by co-expressing a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed to produce VP5 and VP8 by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin during any step of the RLP extraction procedure, or after RLP purification.

[00118] Each of the rotavirus structural proteins has different characteristics and size, and is required in different amounts for assembly into RLP. The term "rotavirus VLP", "rotavirus virus-like particle (RVLP)", "rotavirus virus-like particle (RLP)", "rotavirus virus-like particle", "RVLP" or "RLP" refers to a virus-like particle (VLP) comprising one or more rotavirus structural proteins. Example of rotavirus structural proteins may include, but are not limited to VP2, VP4 (or VP5 and VP8) VP6 and VP7 structural protein.

[00119] The present invention also provides for a method of producing RLPs in a plant, wherein a first nucleic acid (a first nucleic acid) encoding a first rotavirus structural protein, for example a VP2 or VP6 protein, is co-expressed with a second nucleic acid encoding a second rotavirus structural protein, for example a VP6 or VP2 protein. Furthermore, a third nucleic acid encoding a third rotavirus structural protein, for example VP4 or VP7 may be co-expressed with the first and second nucleic acid so that the first, the second nucleic acids and third nucleic acids are co-expressed in the plant. The first nucleic acid, second nucleic acid and third nucleic acid, may be introduced into the plant in the same step, or may be introduced to the plant sequentially. The VP4 may be processed or cleaved to produce VP5 and VP8 within the host by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00120] Furthermore, a plant that expresses a first nucleic acid encoding a first rotavirus structural protein, a second nucleic acid encoding a second rotavirus structural protein and a third nucleic acid encoding a third rotavirus structural protein may be further transformed with a fourth nucleic acid encoding a fourth rotavirus structural protein, for example a VP7 or VP4 protein, so that the first, the second nucleic acids, third and fourth nucleic acids are co-expressed in the plant. The VP4 may be processed or cleaved to produce VP5 and VP8 within the host by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00121] Furthermore, a first plant expressing the first nucleic acid encoding one or more rotavirus structural protein, for example a VP2 or VP6 protein, may be crossed with a second plant expressing the second nucleic acid encoding one or more rotavirus structural protein for example but not limited to VP6 or VP2 protein, to produce a progeny plant (third plant) that co-expresses the first and second nucleic acids encoding VP2 and VP6 or VP6 and VP2, respectively. Furthermore, the third plant expressing the first and second nucleic acids encoding VP2 and VP6 or VP6 and VP2, respectively, may be crossed with a fourth plant expressing the third nucleic acid encoding one or more rotavirus structural protein for example but not limited to VP4 or VP7, to produce a further progeny plant (fifth plant) that co-expresses the first, second and third nucleic acids encoding VP2, VP6, and VP4 or VP7 respectively. The VP4 may be processed or cleaved to produce VP5 and VP8 within the plant using host a protease, or by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin within one of the first, second, third or fourth plants. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00122] As described in more detail below, RLPs may be produced in a plant by expressing a nucleic acid (a first nucleic acid) encoding one or more rotavirus structural protein, for example but not limited to VP2, VP6 or VP7. A second nucleic

acid encoding a second rotavirus structural protein, for example but not limited to VP7, VP6 or VP2 might be co-expressed in the plant. Furthermore, a third nucleic acid encoding a third rotavirus structural protein, for example but not limited to VP6, VP7 or VP2 might be co-expressed in the plant. The nucleic acid, second nucleic acid and third nucleic acid may be introduced to the plant in the same step, or they may be introduced to the plant sequentially. The nucleic acid, second nucleic acid and third nucleic acid may be introduced in the plant in a transient manner, or in a stable manner.

[00123] Furthermore, a plant that expresses a first nucleic acid encoding a first rotavirus structural protein, for example a VP2 protein, may be transformed with a second nucleic acid encoding a second rotavirus structural protein, for example but not limited to VP6 or VP7 so that both the first and the second nucleic acids are co-expressed in the plant. The plant might be further transformed with a third nucleic acid encoding a third rotavirus structural protein, for example but not limited to VP7 or VP6.

[00124] Alternatively, a plant that expresses a VP6 or VP7 protein, (second nucleic acid) may be transformed with the first nucleic acid encoding the VP2 protein, so that both the first and the second nucleic acids are co-expressed in the plant. The plant might be further transformed with a third nucleic acid encoding a third rotavirus structural protein, for example but not limited to VP7 or VP6.

[00125] In addition, a plant expressing a first and second nucleic acid encoding a first and second rotavirus structural protein for example a VP2 and VP6 protein, may be transformed with a third nucleic acid encoding a third rotavirus structural protein example VP4 or VP7. The VP4 may be processed or cleaved to produce VP5 and VP8 by co-expressing a nucleic acid encoding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin. Alternatively, VP4 may be processed during any step of RLP extraction, or after RLP purification by adding a suitable protease, for example, trypsin, a trypsin-like protease, a serine protease, a chymotrypsin-like protease, subtilisin.

[00126] The present invention also provides a method of producing RLPs in a plant that involves introducing one or more nucleic acid encoding one or more rotavirus structural protein operatively linked to a regulatory region active in the



plant, and one or more than one compartment targeting sequence and/or an amplification elements, into the plant, portion of the plant or plant cell. The plant, portion of the plant or plant cell is then incubated under conditions that permit the expression of the one or more nucleic acid, thereby producing the RLPs. The one or more rotavirus structural protein may be VP2, VP4 (or VP5 and VP8), VP6, VP7 a fragment of the VP2, VP4 (or VP5 and VP8), VP6, VP7 or a combination thereof.

[00127] The present invention further provides for a RLP comprising one or more rotavirus structural protein for example but not limited to VP2, VP4 (or VP5 and VP8), VP6, VP7 or a combination thereof. The RLP may be produced by one or more of the methods as provided by the present invention.

[00128] The occurrence of RLPs may be detected using any suitable method for example density gradient centrifugation or size exclusion chromatography. RLPs may be assessed for structure and size by, for example electron microscopy, or by size exclusion chromatography.

[00129] For size exclusion chromatography, total soluble proteins may be extracted from plant tissue by homogenizing (Polytron) sample of frozen-crushed plant material in extraction buffer, and insoluble material removed by centrifugation. Precipitation with ice cold acetone or PEG may also be of benefit. The soluble protein is quantified, and the extract passed through a Sephacryl™ column, for example a Sephacryl™ S500 column. Blue Dextran 2000 may be used as a calibration standard. Following chromatography, fractions may be further analyzed by immunoblot to determine the protein complement of the fraction.

[00130] The separated fraction may be for example a supernatant (if centrifuged, sedimented, or precipitated), or a filtrate (if filtered), and is enriched for proteins, or suprastructure proteins, such as for example nanotubes, nanospheres or higher-order, higher molecular weight, particles such as single-layered (sl), double-layered (dl) or triple-layered (tl) RLPs.

[00131] The separated fraction may be further processed to isolate, purify, concentrate or a combination thereof, the proteins, suprastructure proteins or higher-order particles by, for example, additional centrifugation steps, precipitation, chromatographic steps (e.g. size exclusion, ion exchange, affinity chromatography), tangential flow filtration, or a combination thereof. The presence of purified proteins,

suprastructure proteins or higher-order particles such as RLPs, may be confirmed by, for example, native or SDS-PAGE, Western analysis using an appropriate detection antibody, capillary electrophoresis, electron microscopy, or any other method as would be evident to one of skill in the art.

5 [00132] The RLP's produced according to the present invention may be purified, partially purified from a plant, portion of a plant or plant matter, or may be administered as an oral vaccine, using methods as know to one of skill in the art.

[00133] RLP purification may involve gradient centrifugation, for example sucrose, iodixanol, OptiPrep™ or cesium chloride (CsCl) density gradients may be  
10 used to purify or partially purify the RLPs from transformed plant biomass. As shown for example in Figure 45, an iodixanol step gradient or iodixanol continuous gradient might be used to purify the RLP and/or expressed rotavirus structural proteins.

[00134] Calcium (Ca<sup>2+</sup>) concentration has been shown to be important for the triple-layer particle (TLP) to double layer particle (DLP) transformation and is strain  
15 dependent (see for example Martin et al. Journal of Virology, Jan 2002, which is incorporated herein by reference). Complete loss of the outer-capsid proteins from TLPs (TLP decapsidation) takes place in the nanomolar range of [Ca<sup>2+</sup>]. Therefore the purification and/or extraction of RLP may be performed in the presence of calcium, and the step of gradient centrifugation may be performed in the presence of  
20 calcium, for example in the present of CaCl<sub>2</sub>. The concentration of CaCl<sub>2</sub> maybe between for example, 1 mM and 1000 mM, or any amount there between, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 50, 600, 650, 700, 750, 800, 850, 900, 950 mM or any amount therebetween.

25 [00135] The plants, or plant fragments may be minimally processed. By the term "minimal processing" it is meant plant matter, for example, a plant or portion thereof comprising a protein of interest and /or the RLP which is partially purified to yield a plant extract, homogenate, fraction of plant homogenate or the like (i.e. minimally processed). Partial purification may comprise, but is not limited to  
30 disrupting plant cellular structures thereby creating a composition comprising soluble plant components, and insoluble plant components which may be separated for example, but not limited to, by centrifugation, filtration or a combination thereof. In

this regard, proteins secreted within the extracellular space of leaf or other tissues could be readily obtained using vacuum or centrifugal extraction, or tissues could be extracted under pressure by passage through rollers or grinding or the like to squeeze or liberate the protein free from within the extracellular space. Minimal processing could also involve preparation of crude extracts of soluble proteins, since these preparations would have negligible contamination from secondary plant products. Further, minimal processing may involve aqueous extraction of soluble protein from leaves, followed by precipitation with any suitable salt. Other methods may include large scale maceration and juice extraction in order to permit the direct use of the extract. The RLPs may be purified or extracted using any suitable method for example mechanical or biochemical extraction.

[00136] The one or more rotavirus structural protein may be synthesized at an amount up to 2 g per kilogram of plant fresh weight. For example, the amount of synthesized structural protein may be between 1 and 2 g per kilogram of fresh weight, or any amount there between, such as 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2 g per kilogram of fresh weight or any amount therebetween. For example, the structural protein may be synthesized at an amount up to 1.54 g per kilogram of plant fresh weight.

[00137] Furthermore, the RLP may be synthesized at an amount up to 1.5 g per kilogram of plant fresh weight. For example, the amount of synthesized RLP may be between 0.5 and 1.5 g per kilogram of fresh weight, or any amount there between, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5 g per kilogram of fresh weight. For example, the RLP may be synthesized at an amount of up to 1.1g per kilogram of plant fresh weight.

[00138] The size (i.e. the diameter) of the above-defined RLPs, maybe measures for example by dynamic light scattering (DLS) or electron microscope (EM) techniques, is usually between 50 to 110 nm, or any size therebetween. For example, the size of the intact RLP structure may range from about 70 nm to about 110 nm, or any size therebetween, such as 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm or any size therebetween.

[00139] The present invention further provides a nucleic acid comprising a nucleotide sequence encoding one or more rotavirus structural protein operatively

linked to a regulatory region active in a plant. The nucleotide sequence may be optimized for example for human codon usage or plant codon usage. Furthermore one or more rotavirus structural protein may be operatively linked to one or more than one amplification elements. In addition one or more rotavirus structural protein may be operatively linked to one or more than one compartment targeting sequence. The one or more rotavirus structural protein encoded by the nucleotide sequence may be for example VP2, VP4, VP6 or VP7. Furthermore the one or more rotavirus structural protein encoded by the nucleotide sequence may be for example from any rotavirus group A to G, but more preferably from rotavirus group A. Furthermore, the one or more rotavirus structural protein encoded by the nucleotide sequence maybe from any rotavirus strain having a genotype of any combinations of G- and P- types from G1 to G27 and from P1 to P34, and more preferably from G1 to G19 and from P1 to P27, including, but not limited to G1P[8], G2P[4], G2P[8], G3P[8], G4P[8], G9P[6], G9P[8], rotavirus A WA strain, rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain or rotavirus SA11 strain.

[00140] A nucleic acid sequence referred to in the present invention, may be “substantially homologous” , “substantially similar” or “substantially identical” to a sequence, or a compliment of the sequence if the nucleic acid sequence hybridise to one or more than one nucleotide sequence or a compliment of the nucleic acid sequence as defined herein under stringent hybridisation conditions. Sequences are “substantially homologous” “substantially similar” “substantially identical” when at least about 70%, or between 70 to 100%, or any amount therebetween, for example 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100%, or any amount therebetween, of the nucleotides match over a defined length of the nucleotide sequence providing that such homologous sequences exhibit one or more than one of the properties of the sequence, or the encoded product as described herein.

[00141] For example the present invention provides an isolated polynucleotide comprising a nucleic acid which encodes one or more rotavirus structural protein that is at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 100% or any amount therebetween identical to sequences as defines for example in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 45, 46, 47, 49, 50, 51, 52, 53, 54. The polynucleotide may be human codon optimized by any of the methods known in the art.

[00142] Furthermore, the present invention provides RLPS that comprise rotavirus structural proteins that are for example encoded by nucleic acids that are at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% 100% or any amount therebetween identical to sequences as defines for  
5 example in SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, 20, 45, 46, 47, 49, 50, 51, 52, 53, 54.

[00143] Such a sequence similarity or identity may be determined using a nucleotide sequence comparison program, such as that provided within DNASIS (using, for example but not limited to, the following parameters: GAP penalty 5, #of top diagonals 5, fixed GAP penalty 10, k tuple 2, floating gap 10, and window size 5). However, other methods  
10 of alignment of sequences for comparison are well-known in the art for example the algorithms of Smith & Waterman (1981, Adv. Appl. Math. 2:482), Needleman & Wunsch (J. Mol. Biol. 48:443, 1970), Pearson & Lipman (1988, Proc. Nat'l. Acad. Sci. USA 85:2444), and by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and BLAST, available through the NIH.), or by manual alignment and visual  
15 inspection (see, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds. 1995 supplement), or using Southern or Northern hybridization under stringent conditions (see Maniatis et al., in Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory, 1982). Preferably, sequences that are substantially homologous exhibit at least about 80% and most preferably at least about 90% sequence similarity over a defined  
20 length of the molecule.

[00144] An example of one such stringent hybridization conditions may be overnight (from about 16-20 hours) hybridization in 4 X SSC at 65°C, followed by washing in 0.1 X SSC at 65°C for an hour, or 2 washes in 0.1 X SSC at 65°C each for 20 or 30 minutes.  
Alternatively an exemplary stringent hybridization condition could be overnight (16-20  
25 hours) in 50% formamide, 4 X SSC at 42°C, followed by washing in 0.1 X SSC at 65°C for an hour, or 2 washes in 0.1 X SSC at 65°C each for 20 or 30 minutes, or overnight (16-20 hours), or hybridization in Church aqueous phosphate buffer (7% SDS; 0.5M NaPO<sub>4</sub> buffer pH 7.2; 10 mM EDTA) at 65°C, with 2 washes either at 50°C in 0.1 X SSC, 0.1% SDS for 20 or 30 minutes each, or 2 washes at 65°C in 2 X SSC, 0.1% SDS for 20 or 30 minutes  
30 each for unique sequence regions.

[00145] A nucleic acid encoding a rotavirus structural polypeptide may be described as a "rotavirus nucleic acid", a "rotavirus nucleotide sequence", a "rotavirus nucleic acid", or a "rotavirus nucleotide sequence". For example, which is not to be considered limiting, a virus-like particle comprising one or more rotavirus structural protein or rotavirus structural polypeptide, may be described as a "rotavirus VLP", "RVLP" or "RLP".

[00146] Many organisms display a bias for use of particular codons to code for insertion of a particular amino acid in a growing peptide chain. Codon preference or codon bias, differences in codon usage between organisms, is afforded by degeneracy of the genetic code, and is well documented among many organisms. Codon bias often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, inter alia, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. The process of optimizing the nucleotide sequence coding for a heterologously expressed protein can be an important step for improving expression yields. The optimization requirements may include steps to improve the ability of the host to produce the foreign protein.

[00147] "Codon optimization" is defined as modifying a nucleic acid sequence for enhanced expression in cells of interest by replacing at least one, more than one, or a significant number, of codons of the native sequence with codons that may be more frequently or most frequently used in the genes of another organism or species. Various species exhibit particular bias for certain codons of a particular amino acid.

[00148] The present invention includes synthetic polynucleotide sequences that have been codon optimized for example the sequences have been optimized for human codon usage or plant codon usage. The codon optimized polynucleotide sequences may then be expressed in plants. More specifically the sequences optimized for human codon usage or plant codon usage may be expressed in plants. Without wishing to be bound by theory, it is believed that the sequences optimized for human codon increases the guanine-cytosine content (GC content) of the sequence and improves expression yields in plants.

[00149] There are different codon-optimisation techniques known in the art for improving, the translational kinetics of translationally inefficient protein coding regions. These techniques mainly rely on identifying the codon usage for a certain host organism. If a certain gene or sequence should be expressed in this organism, the coding sequence of such genes and sequences will then be modified such that one will replace codons of the sequence of interest by more frequently used codons of the host organism.

[00150] The rotavirus structural protein or polypeptide may be expressed in an expression system comprising a viral based, DNA or RNA, expression system, for example but not limited to, a comovirus-based expression cassette and geminivirus-based amplification element.

[00151] The expression system as described herein may comprise an expression cassette based on a bipartite virus, or a virus with a bipartite genome. For example, the bipartite viruses may be of the Comoviridae family. Genera of the Comoviridae family include Comovirus, Nepovirus, Fabavirus, Cheravirus and Sadwavirus. Comoviruses include Cowpea mosaic virus (CPMV), Cowpea severe mosaic virus (CPSMV), Squash mosaic virus (SqMV), Red clover mottle virus (RCMV), Bean pod mottle virus (BPMV), Turnip ringspot virus (TuRSV), Broad bean true mosaic virus (BBtMV), Broad bean stain virus (BBSV), Radish mosaic virus (RaMV). Examples of comovirus RNA-2 sequences comprising enhancer elements that may be useful for various aspects of the invention include, but are not limited to: CPMV RNA-2 (GenBank Accession No. NC\_003550), RCMV RNA-2 (GenBank Accession No. NC\_003738), BPMV RNA-2 (GenBank Accession No. NC\_003495), CPSMV RNA-2 (GenBank Accession No. NC\_003544), SqMV RNA-2 (GenBank Accession No. NC\_003800), TuRSV RNA-2 (GenBank Accession No. NC\_013219.1), BBtMV RNA-2 (GenBank Accession No. GU810904), BBSV RNA2 (GenBank Accession No. FJ028650), RaMV (GenBank Accession No. NC\_003800).

[00152] Segments of the bipartite comoviral RNA genome are referred to as RNA-1 and RNA-2. RNA-1 encodes the proteins involved in replication while RNA-2 encodes the proteins necessary for cell-to-cell movement and the two capsid proteins. Any suitable comovirus-based cassette may be used including CPMV, CPSMV, SqMV, RCMV, or BPMV, for example, the expression cassette may be based on CPMV.

[00153] “Expression cassette” refers to a nucleotide sequence comprising a nucleic acid of interest under the control of, and operably (or operatively) linked to, an appropriate promoter or other regulatory elements for transcription of the nucleic acid of interest in a host cell.

5 [00154] The expression systems may also comprise amplification elements from a geminivirus for example, an amplification element from the bean yellow dwarf virus (BeYDV). BeYDV belongs to the Mastreviruses genus adapted to dicotyledonous plants. BeYDV is monopartite having a single-strand circular DNA genome and can replicate to very high copy numbers by a rolling circle mechanism.  
10 BeYDV-derived DNA replicon vector systems have been used for rapid high-yield protein production in plants.

[00155] As used herein, the phrase “amplification elements” refers to a nucleic acid segment comprising at least a portion of one or more long intergenic regions or long intergenic repeat (LIR) of a geminivirus genome. As used herein, “long  
15 intergenic region” or “long intergenic repeat” refers to a region of a long intergenic region that contains a rep binding site capable of mediating excision and replication by a geminivirus Rep protein. In some aspects, the nucleic acid segment comprising one or more LIRs, may further comprises a short intergenic region or small intergenic region (SIR) of a geminivirus genome. As used herein, “short intergenic region” or  
20 “small intergenic region” refers to the complementary strand (the short IR (SIR) of a Mastreviruses). Any suitable geminivirus-derived amplification element may be used herein. See, for example, WO2000/20557; WO2010/025285; Zhang X. et al. (2005, Biotechnology and Bioengineering, Vol. 93, 271-279), Huang Z. et al. (2009, Biotechnology and Bioengineering, Vol. 103, 706-714), Huang Z. et al.(2009,  
25 Biotechnology and Bioengineering, Vol. 106, 9-17); which are herein incorporated by reference). If more than one LIR is used in the construct, for example two LIRs, then the promoter, CMPV-HT regions and the nucleic acid sequence of interest and the terminator are bracketed by each of the two LIRs. Furthermore, the amplification element might for example originate from the sequence as disclosed in Halley-Stott  
30 et al. (2007) Archives of Virology 152: 1237-1240, deposited under Gen Bank accession number DQ458791, which are herein incorporated by reference. The nucleic acid segment comprising LIRs are joined nucleotides 2401 to 2566 and 1 to 128. The nucleic acid segment comprising SIRs are nucleotides 1154 to 1212.



[00156] As described herein, co-delivery of bean yellow dwarf virus (BeYDV)-derived vector and a Rep/RepA-supplying vector, by agroinfiltration of *Nicotiana benthamiana* leaves results in efficient replicon amplification and robust protein production.

5 [00157] A comovirus-based expression cassette and a geminivirus-derived amplification element may be comprised on separate vectors, or the component parts may be included in one vector. If two vectors are used, the first and second vectors may be introduced into a plant cell simultaneously, or separately.

10 [00158] A viral replicase may also be included in the expression system as described herein to increase expression of the nucleic acid of interest. An non-limiting example of a replicase is a BeYDV replicase (pREP110) encoding BeYDV Rep and RepA (C2/C1; Huang et al., 2009, *Biotechnol. Bioeng.* 103, 706-714; which is incorporated herein by reference). Another non-limiting example of a replicase is disclosed in Halley-Stott et al. (2007) *Archives of Virology* 152: 1237-1240,  
15 deposited under Gen Bank accession number DQ458791, which are herein incorporated by reference. The nucleic acid segment comprising C1:C2 gene are nucleotides 1310 to 2400.

[00159] By “co-expressed” it is meant that two or more than two nucleotide sequences are expressed at about the same time within the plant, and within the same  
20 tissue of the plant. However, the nucleotide sequences need not be expressed at exactly the same time. Rather, the two or more nucleotide sequences are expressed in a manner such that the encoded products have a chance to interact. The two or more than two nucleotide sequences can be co-expressed using a transient expression system, where the two or more sequences are introduced within the plant at about the  
25 same time under conditions that both sequences are expressed. Alternatively, a platform plant comprising one of the nucleotide sequences may be transformed in a stable manner, with an additional sequence encoding the protein of interest for example one or more rotavirus structural protein, introduced into the platform plant in a transient manner.

30 [00160] Correct folding of the protein may be important for stability of the protein, formation of multimers, formation of RLPs and function. Folding of a protein may be influenced by one or more factors, including, but not limited to, the

sequence of the protein, the relative abundance of the protein, the degree of intracellular crowding, the availability of cofactors that may bind or be transiently associated with the folded, partially folded or unfolded protein. Furthermore the compartment or sub-compartment within the plant where the protein is expressed may influence the expression levels and folding of the protein.

[00161] The expression of the one or more rotavirus structural protein may be targeted to specific plant cell compartment and/or sub-compartments by agroinfiltration in transgenic plants. The compartment or sub-compartments may be for example plastids, endoplasmic reticle (ER), chloroplast or apoplast. Without wishing to be bound by theory, compartment or sub-compartments targeting may increased protein accumulation into the targeted compartment or sub-compartments over cytoplasmic accumulation. Compartment or sub-compartment accumulation may protect protein from degradation by proteases present in the cytoplasm and/or allow it to accumulate to higher concentration without affecting the function of the plant cell.

[00162] Therefore, the expression cassette or vector may be adapted to direct the vector or rotavirus structural protein or polypeptide expressed from the vector to the desired compartment or sub-compartment in the plant.

[00163] For example the expression cassette or vector may be adapted to target plastids by causing an expressed rotavirus structural protein or polypeptide to include a portion capable of interacting with the thylakoid membranes of the plastids, in particular the transfer mechanism of the thylakoid membranes. This interaction may cause the rotavirus structural protein or polypeptide to be imported into the plastid from the cytoplasm where it is expressed. Without wishing to be bound by theory, the mechanism of importation from the cytoplasm may be important for proper folding of the proteins. It will be appreciated that the expression cassette or vector may be adapted to target the plastids themselves to become transformed and expression of the rotavirus structural protein or polypeptide may occur wholly within the plastid.

[00164] By the term "targeting sequence" it is meant that the targeting sequences may be included in the vector or expression cassette. Such targeting sequences may be translated into a peptide which directs the vector or product thereof to the desired compartment or sub-compartment in the plant, such as a plastid. For example, plastid signal peptides (also referred to as "plastid transit peptides" in the

art) for targeting proteins into plastids are known in the art. A non limiting example of a plastid transit peptide that may be used is that of rbcsl-cTP. As suitable example of a chloroplast-transit peptide sequence is the Rubisco small-subunit gene (rbcS1), for example, from *Solanum tuberosum*.

5 [00165] Therefore, the rotavirus structural protein or polypeptide may include a signal peptide that is the same as, or heterologous with, the remainder of the polypeptide or protein. The term "signal peptide" is well known in the art and refers generally to a short (about 5-30 amino acids) sequence of amino acids, found generally at the N-terminus of a polypeptide that may direct translocation of the  
10 newly-translated polypeptide to a particular organelle, or aid in positioning of specific domains of the polypeptide chain relative to others. As a non-limiting example, the signal peptide may target the translocation of the protein into the endoplasmic reticulum and/or aid in positioning of the N-terminus proximal domain relative to a membrane-anchor domain of the nascent polypeptide to aid in cleavage and folding of  
15 the mature protein, for example which is not to be considered limiting, a rotavirus structural protein.

[00166] A signal peptide (SP) may be native to the protein or virus protein, or a signal peptide may be heterologous with respect to the primary sequence of the protein or virus protein being expressed. For example the native signal peptide of  
20 rotavirus structural protein may be used to express the rotavirus structural protein in a plant system.

[00167] A signal peptide may also be non-native, for example, from a protein, viral protein or native structural protein of a virus other than rotavirus protein, or from a plant, animal or bacterial polypeptide. A non limiting example of a signal  
25 peptide that may be used is that of alfalfa protein disulfide isomerase (PDISP) (nucleotides 32-103 of Accession No. Z11499). Furthermore, the signal peptide may be completely deleted or truncated. By truncation or truncated it is meant that 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or any amount therebetween of amino acid residues are  
30 deleted from the signal peptide. Preferably, the truncated amino acid residues are continuous, and the truncation occurs from the second methionine onward

[00168] The present invention therefore provides for a rotavirus structural protein, such as for example VP2, VP4, VP6 and/or VP7, comprising a native, a non-native signal peptide or truncated signal peptide, and nucleic acids encoding such rotavirus structural proteins.

5 [00169] The one or more than one genetic constructs of the present invention may be expressed in any suitable plant host that is transformed by the nucleotide sequence, or constructs, or vectors of the present invention. Examples of suitable hosts include, but are not limited to, agricultural crops including alfalfa, canola, Brassica spp., maize, Nicotiana spp., potato, ginseng, pea, oat, rice, soybean, wheat,  
10 barley, sunflower, cotton and the like.

[00170] The nucleotide sequences encoding for the rotavirus structural proteins may be transferred into the plant host using 1, 2, 3, 4 or 5 binary plasmid vectors. Each binary plasmid vector may therefore contain 1, 2, 3, 4 or 5 nucleotide sequences encoding for a rotavirus structural protein.

15 [00171] The one or more genetic constructs of the present invention can further comprise a 3' untranslated region. A 3' untranslated region refers to that portion of a gene comprising a DNA segment that contains a polyadenylation signal and any other regulatory signals capable of effecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by effecting the addition of  
20 polyadenylic acid tracks to the 3' end of the mRNA precursor. Polyadenylation signals are commonly recognized by the presence of homology to the canonical form 5' AATAAA-3' although variations are not uncommon. Non-limiting examples of suitable 3' regions are the 3' transcribed nontranslated regions containing a polyadenylation signal of Agrobacterium tumor inducing (Ti) plasmid genes, such as  
25 the nopaline synthase (NOS) gene, plant genes such as the soybean storage protein genes, the small subunit of the ribulose-I, 5-bisphosphate carboxylase gene (ssRUBISCO; US 4,962,028; which is incorporated herein by reference), the promoter used in regulating plastocyanin expression, described in US 7,125,978 (which is incorporated herein by reference).

30 [00172] One or more of the genetic constructs of the present invention may also include further enhancers, either translation or transcription enhancers, as may be required. Enhancers may be located 5' or 3' to the sequence being transcribed.

Enhancer regions are well known to persons skilled in the art, and may include an ATG initiation codon, adjacent sequences or the like. The initiation codon, if present, may be in phase with the reading frame ("in frame") of the coding sequence to provide for correct translation of the transcribed sequence.

5 [00173] The constructs of the present invention can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, micro-injection, electroporation, etc. For reviews of such techniques see for example Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academy Press, New York VIII, pp. 421-463 (1988); Geierman and Corey, *Plant Molecular Biology*,  
10 2d Ed. (1988); and Miki and Iyer, *Fundamentals of Gene Transfer in Plants*. In *Plant Metabolism*, 2d Ed. DT. Dennis, DH Turpin, DD Lefebvre, DB Layzell (eds), Addison Wesley, Langmans Ltd. London, pp. 561-579 (1997). Other methods include direct DNA uptake, the use of liposomes, electroporation, for example using protoplasts, micro-injection, microprojectiles or whiskers, and vacuum infiltration.  
15 See, for example, Bilang, et al. (*Gene* 100: 247-250 (1991)), Scheid et al. (*Mol. Gen. Genet.* 228: 104-112, 1991), Guerche et al. (*Plant Science* 52: 111-116, 1987), Neuhauser et al. (*Theor. Appl Genet.* 75: 30-36, 1987), Klein et al., *Nature* 327: 70-73 (1987); Howell et al. (*Science* 208: 1265, 1980), Horsch et al. (*Science* 227: 1229-1231, 1985), DeBlock et al., *Plant Physiology* 91: 694-701, 1989), *Methods for Plant*  
20 *Molecular Biology* (Weissbach and Weissbach, eds., Academic Press Inc., 1988), *Methods in Plant Molecular Biology* (Schuler and Zielinski, eds., Academic Press Inc., 1989), Liu and Lomonosoff (*J Virol Meth*, 105:343-348, 2002,), U.S. Pat. Nos. 4,945,050; 5,036,006; and 5,100,792, U.S. patent application Ser. Nos. 08/438,666, filed May 10, 1995, and 07/951,715, filed Sep. 25, 1992, (all of which are hereby  
25 incorporated by reference).

#### Transient expression

[00174] Without wishing to be bound by theory, the protein concentration and ratio of the different rotavirus structural proteins may be important for the assembly efficiency of RLPs. Therefore multiplicity and time of infection, may be important to  
30 manipulate protein concentration and the overall assembly efficiency of RLPs in plants.

[00175] The construct of the present invention may be transiently expressed in a plants or portion of a plant. A transient expression system relying on the epichromosomal expression of recombinant *Agrobacterium tumefaciens* in a plant, portion of a plant or plant cell may be used to express the rotavirus structural protein, targeted to various cell compartments or sub-compartments. A transient expression system allows for a high production speed. Furthermore, large amounts of protein can be attained within a few days after infiltration of recombinant *Agrobacterium* in plants (Rybicki, 2010; Fischer et al., 1999). It is also possible to express long gene sequences and have more than one gene simultaneously expressed in the same cell, allowing for efficient assembly of multimeric proteins (Lombardi et al., 2009).

[00176] The nucleotide sequences encoding for the rotavirus structural proteins may be transferred into the plant host into 1, 2, 3, 4 or 5 transformed *Agrobacterium tumefaciens* strain.

[00177] However, during transient expression post-transcriptional gene silencing may limit the expression of the heterologous proteins in plants. The co-expression of a suppressor of silencing, for example, but not limited to Nss from Tomato spotted wilt virus may be used to counteract the specific degradation of transgene mRNAs (Brigneti et al., 1998). Alternate suppressors of silencing are well known in the art and may be used as described herein (Chiba et al., 2006, Virology 346:7-14; which is incorporated herein by reference), for example but not limited to HcPro, TEV -p1/HC-Pro (Tobacco etch virus-p1/HC-Pro), BYV -p21, p19 of Tomato bushy stunt virus (TBSV p19), capsid protein of Tomato crinkle virus (TCV -CP), 2b of Cucumber mosaic virus; CMV-2b), p25 of Potato virus X (PVX-p25), p11 of Potato virus M (PVM-p11), p11 of Potato virus S (PVS-p11), p16 of Blueberry scorch virus, (BScV -p16), p23 of Citrus tristexa virus (CTV-p23), p24 of Grapevine leafroll-associated virus-2, (GLRaV-2 p24), p10 of Grapevine virus A, (GVA-p10), p14 of Grapevine virus B (GVB-p14), p10 of Heracleum latent virus (HLV-p10), or p16 of Garlic common latent virus (GCLV-p16). Therefore, a suppressor of silencing, for example HcPro, TEV -p1/HC-Pro, BYV-p21, TBSV p19, TCV-CP, CMV-2b, PVX-p25, PVM-p11, PVS-p11, BScV-p16, CTV-p23, GLRaV-2 p24, GBV-p14, HLV-p10, GCLV-p16or GVA-p10, may be co-expressed along with one or more rotavirus structural protein for example VP2, VP4, VP6, or a combination

thereof, to further ensure high levels of protein production within a plant or portion of a plant.

[00178] The present invention also provides a methods as described above, wherein an additional (second, third, fourth, or fifth ) nucleotide sequence is expressed within the plant, the additional (second, third, fourth, or fifth) nucleotide sequence encoding a suppressor of silencing is operatively linked with an additional (second, third, fourth, or fifth) regulatory region that is active in the plant. The nucleotide sequence encoding a suppressor of silencing may be, for example Nss, HcPro, TEV -p1/HC-Pro, BYV-p21, TBSV p19, TCV-CP, CMV-2b, PVX-p25, PVM-p11, PVS-p11, BScV-p16, CTV-p23, GLRaV-2 p24, GBV-p14, HLV-p10, GCLV-p16 or GVA-p10.

[00179] As described below, transient expression methods may be used to express the constructs of the present invention (see Liu and Lomonossoff, 2002, Journal of Virological Methods, 105:343-348; which is incorporated herein by reference). Alternatively, a vacuum-based transient expression method, as described by Kapila et al., 1997, which is incorporated herein by reference) may be used. These methods may include, for example, but are not limited to, a method of Agro-inoculation or Agro-infiltration, syringe infiltration, however, other transient methods may also be used as noted above. With Agro-inoculation, Agro-infiltration, or syringe infiltration, a mixture of Agrobacteria comprising the desired nucleic acid enter the intercellular spaces of a tissue, for example the leaves, aerial portion of the plant (including stem, leaves and flower), other portion of the plant (stem, root, flower), or the whole plant. After crossing the epidermis the Agrobacteria infect and transfer t-DNA copies into the cells. The t-DNA is episomally transcribed and the mRNA translated, leading to the production of the protein of interest in infected cells, however, the passage of t-DNA inside the nucleus is transient.

[00180] To aid in identification of transformed plant cells, the constructs of this invention may be further manipulated to include plant selectable markers. Useful selectable markers include enzymes that provide for resistance to chemicals such as an antibiotic for example, gentamycin, hygromycin, kanamycin, or herbicides such as phosphinothrycin, glyphosate, chlorosulfuron, and the like. Similarly, enzymes providing for production of a compound identifiable by colour change such as GUS (beta-glucuronidase), or luminescence, such as luciferase or GFP, may be used.

[00181] Also considered part of this invention are transgenic plants, plant cells or seeds containing the gene construct of the present invention. Methods of regenerating whole plants from plant cells are also known in the art. In general, transformed plant cells are cultured in an appropriate medium, which may contain selective agents such as antibiotics, where selectable markers are used to facilitate identification of transformed plant cells. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be used to establish repetitive generations, either from seeds or using vegetative propagation techniques. Transgenic plants can also be generated without using tissue cultures.

[00182] The use of the terms "regulatory region", "regulatory element" or "promoter" in the present application is meant to reflect a portion of nucleic acid typically, but not always, upstream of the protein coding region of a gene, which may be comprised of either DNA or RNA, or both DNA and RNA. When a regulatory region is active, and in operative association, or operatively linked, with a gene of interest, this may result in expression of the gene of interest. A regulatory element may be capable of mediating organ specificity, or controlling developmental or temporal gene activation. A "regulatory region" may includes promoter elements, core promoter elements exhibiting a basal promoter activity, elements that are inducible in response to an external stimulus, elements that mediate promoter activity such as negative regulatory elements or transcriptional enhancers. "Regulatory region", as used herein, may also includes elements that are active following transcription, for example, regulatory elements that modulate gene expression such as translational and transcriptional enhancers, translational and transcriptional repressors, upstream activating sequences, and mRNA instability determinants. Several of these latter elements may be located proximal to the coding region.

[00183] In the context of this disclosure, the term "regulatory element" or "regulatory region" typically refers to a sequence of DNA, usually, but not always, upstream (5') to the coding sequence of a structural gene, which controls the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at a particular site. However, it is to be understood that other nucleotide sequences, located within introns, or 3' of the



sequence may also contribute to the regulation of expression of a coding region of interest. An example of a regulatory element that provides for the recognition for RNA polymerase or other transcriptional factors to ensure initiation at a particular site is a promoter element. Most, but not all, eukaryotic promoter elements contain a TATA box, a conserved nucleic acid sequence comprised of adenosine and thymidine nucleotide base pairs usually situated approximately 25 base pairs upstream of a transcriptional start site. A promoter element comprises a basal promoter element, responsible for the initiation of transcription, as well as other regulatory elements (as listed above) that modify gene expression.

[00184] There are several types of regulatory regions, including those that are developmentally regulated, inducible or constitutive. A regulatory region that is developmentally regulated, or controls the differential expression of a gene under its control, is activated within certain organs or tissues of an organ at specific times during the development of that organ or tissue. However, some regulatory regions that are developmentally regulated may preferentially be active within certain organs or tissues at specific developmental stages, they may also be active in a developmentally regulated manner, or at a basal level in other organs or tissues within the plant as well. Examples of tissue-specific regulatory regions, for example see-specific a regulatory region, include the napin promoter, and the cruciferin promoter (Rask et al., 1998, J. Plant Physiol. 152: 595-599; Bilodeau et al., 1994, Plant Cell 14: 125-130). An example of a leaf-specific promoter includes the plastocyanin promoter (see US 7,125,978, which is incorporated herein by reference).

[00185] An inducible regulatory region is one that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer the DNA sequences or genes will not be transcribed. Typically the protein factor that binds specifically to an inducible regulatory region to activate transcription may be present in an inactive form, which is then directly or indirectly converted to the active form by the inducer. However, the protein factor may also be absent. The inducer can be a chemical agent such as a protein, metabolite, growth regulator, herbicide or phenolic compound or a physiological stress imposed directly by heat, cold, salt, or toxic elements or indirectly through the action of a pathogen or disease agent such as a virus. A plant cell containing an inducible regulatory region may be exposed to an inducer by

externally applying the inducer to the cell or plant such as by spraying, watering, heating or similar methods. Inducible regulatory elements may be derived from either plant or non-plant genes (e.g. Gatz, C. and Lenk, L.R.P., 1998, Trends Plant Sci. 3, 352-358; which is incorporated by reference). Examples, of potential inducible promoters include, but not limited to, tetracycline-inducible promoter (Gatz, C., 1997, Ann. Rev. Plant Physiol. Plant Mol. Biol. 48, 89-108; which is incorporated by reference), steroid inducible promoter (Aoyama, T. and Chua, N.H., 1997, Plant 1. 2, 397-404; which is incorporated by reference) and ethanol-inducible promoter (Salter, M.G., et al, 1998, Plant Journal 16, 127-132; Caddick, M.X., et al, 1998, Nature Biotech. 16, 177-180, which are incorporated by reference) cytokinin inducible IB6 and CKI 1 genes (Brandstatter, I. and Kieber, J.J., 1998, Plant Cell 10, 1009-1019; Kakimoto, T., 1996, Science 274, 982-985; which are incorporated by reference) and the auxin inducible element, DR5 (Ulmasov, T., et al., 1997, Plant Cell 9, 1963-1971; which is incorporated by reference).

[00186] A constitutive regulatory region directs the expression of a gene throughout the various parts of a plant and continuously throughout plant development. Examples of known constitutive regulatory elements include promoters associated with the CaMV 35S transcript (Odell et al., 1985, Nature, 313: 810-812), the rice actin 1 (Zhang et al, 1991, Plant Cell, 3: 1155-1165), actin 2 (An et al., 1996, Plant J., 10: 107-121), or tms 2 (U.S. 5,428,147, which is incorporated herein by reference), and triosephosphate isomerase 1 (Xu et. al., 1994, Plant Physiol. 106: 459-467) genes, the maize ubiquitin 1 gene (Cornejo et al, 1993, Plant Mol. Biol. 29: 637-646), the Arabidopsis ubiquitin 1 and 6 genes (Holtorf et al, 1995, Plant Mol. Biol. 29: 637-646), and the tobacco translational initiation factor 4A gene (Mandel et al, 1995, Plant Mol. Biol. 29: 995-1004).

[00187] The term "constitutive" as used herein does not necessarily indicate that a gene under control of the constitutive regulatory region is expressed at the same level in all cell types, but that the gene is expressed in a wide range of cell types even though variation in abundance is often observed. Constitutive regulatory elements may be coupled with other sequences to further enhance the transcription and/or translation of the nucleotide sequence to which they are operatively linked. For example, the CPMV-HT system is derived from the untranslated regions of the Cowpea mosaic virus (CPMV) and demonstrates enhanced translation of the

associated coding sequence. By "native" it is meant that the nucleic acid or amino acid sequence is naturally occurring, or "wild type". By "operatively linked" it is meant that the particular sequences, for example a regulatory element and a coding region of interest, interact either directly or indirectly to carry out an intended function, such as mediation or modulation of gene expression. The interaction of operatively linked sequences may, for example, be mediated by proteins that interact with the operatively linked sequences.

[00188] The RLP produced within a plant may induce a rotavirus VP7 structural protein comprising plant-specific N-glycans. Therefore, this invention also provides for a RLP comprising VP7 having plant specific N-glycans.

[00189] Furthermore, modification of N-glycan in plants is known (see for example U.S. 60/944,344; which is incorporated herein by reference) and VP7 having modified N-glycans may be produced. VP7 comprising a modified glycosylation pattern, for example with reduced fucosylated, xylosylated, or both, fucosylated and xylosylated, N-glycans may be obtained, or VP7 having a modified glycosylation pattern may be obtained, wherein the protein lacks fucosylation, xylosylation, or both, and comprises increased galactosylation. Furthermore, modulation of post-translational modifications, for example, the addition of terminal galactose may result in a reduction of fucosylation and xylosylation of the expressed VP7 when compared to a wild-type plant expressing VP7.

[00190] For example, which is not to be considered limiting, the synthesis of VP7 having a modified glycosylation pattern may be achieved by co-expressing VP7 along with a nucleotide sequence encoding beta-1.4 galactosyltransferase (GalT), for example, but not limited to mammalian GalT, or human GalT however GalT from another sources may also be used. The catalytic domain of GalT may also be fused to a CTS domain (i.e. the cytoplasmic tail, transmembrane domain, stem region) of N-acetylglucosaminyl transferase (GNT1), to produce a GNT1-GalT hybrid enzyme, and the hybrid enzyme may be co-expressed with VP7. The VP7 may also be co-expressed along with a nucleotide sequence encoding N-acetylglucosaminyl transferase III (GnT-III), for example but not limited to mammalian GnT-III or human GnT-III, GnT-III from other sources may also be used. Additionally, a GNT1-GnT-III hybrid enzyme, comprising the CTS of GNT1 fused to GnT-III may also be used.

[00191] Therefore the present invention also provides RLPs comprising VP7 having modified N-glycans.

[00192] Without wishing to be bound by theory, the presence of plant N-glycans on VP7 may stimulate the immune response by promoting the binding of VP7 by antigen presenting cells. Stimulation of the immune response using plant N-glycan has been proposed by Saint-Jore-Dupas et al. (2007).

[00193] The present invention will be further illustrated in the following examples.

Examples

#### **Example 1**

#### **Expression of rotavirus proteins and production of VLPs in *N. benthamiana* plant leaves**

[00194] The following analysis utilized rotavirus capsid proteins from the G9P[6] rotavirus strain, and assessed whether rotavirus-like particles were formed in the various compartments of tobacco *N. benthamiana* leaf cells. Co-expression of VP2 and VP6 as well as various combinations of VP2, VP6, VP7 and VP4 in tobacco plant leaves were investigated.

#### **Materials and Methods**

##### Plasmid construction

[00195] Plant codon optimized rotavirus cDNAs for VP2, VP4, VP6 and VP7 were supplied by Geneart, Germany. The plasmid DNA was transformed into DH5- $\alpha$  chemically competent *E. coli* cells (*E. coli*<sup>TM</sup>, Lucigen) as per the manufacturer's instructions. Novel binary *Agrobacterium* vectors pTRAc (cytoplasm), pTRAc-rbcs1-cTP (chloroplast targeting) and pTRAc-ERH (endoplasmic reticulum targeting) supplied by Rainer Fischer (Fraunhofer Institute for Molecular Biology and Applied Ecology, IME, Germany) were used in this study. An additional vector, pTRAc-A (apoplast), was derived from the modification of pTRAc-ERH by restriction enzyme (RE) digestion at sites NcoI and XhoI in the multiple cloning site (Figure 3). This removes the histidine tag and KDEL sequence which retain proteins in the ER. The proteins are instead targeted to the apoplast.

[00196] VP2, VP4 and VP6 cDNA was restriction enzyme (RE) digested with NcoI/XhoI while VP7 was cut with AflIII/XhoI. Restriction enzymes AflIII, NcoI and MluI have compatible sticky ends. For direct cloning of the DNA into pTRAc, pTRAc-rcs-cTP and pTRAc-A, the vectors were each RE digested at sites AflIII/XhoI, MluI/XhoI and NcoI/XhoI, respectively. Cloning of DNA in the vectors was carried out as per standard protocol followed by transformation into chemically competent *E. coli* DH5- $\alpha$  cells (*E. cloni*<sup>TM</sup>, Lucigen). Selected recombinant colonies were verified by colony PCR. For cloning in pTRAc-ERH, a NotI restriction enzyme site was added to replace the stop codon of each the four rotavirus cDNA by PCR amplification. The cDNA was amplified with primers as detailed in Table 1. The PCR reaction conditions included denaturation at 95°C for 5 min, followed by five cycles of denaturation at 95°C for 30 sec, annealing at 52°C for 1 min, and elongation at 72°C for 1.5 min. A further 20 cycles were done as follows; 95°C for 30 sec, 57°C for 1 min, 72°C for 1.5 min and 72°C for 5 min. The amplified fragments were then cloned into pGEM-T-Easy (Promega) as per the manufacturer's instructions. Transformation was carried out in chemically competent *E. coli* DH5- $\alpha$  (*E. cloni*<sup>TM</sup>, Lucigen). Colony PCR was then carried out on selected colonies as done for the other three constructs.

Table 1: Rotavirus cDNA primers for ER vector cloning

Primer	Sequence	R.E site added	Orientation
VP2F	5'-TTCCATGGCTTACCGTAAAAGG-3'	-	SEQ ID NO: 5 Forward
VP2R	5'-ATGCGGCCGCAAGCTCGTTCATAATCCTCATG-3'	NotI	SEQ ID NO: 6 Reverse
VP4F	5'-TTCCATGGCTTCCCTCATCTAC-3'	-	SEQ ID NO: 7 Forward
VP4R	5'-ATGCGGCCGCAAGACGGCACTGGAGAATGAG-3'	NotI	SEQ ID NO: 8 Reverse
VP6F	5'-TTCCATGGATGTGCTCTACTC-3'	-	SEQ ID NO: 9 Forward
VP6R	5'-ATGCGGCCGCCCTTCACGAGCATGGAACG-3'	NotI	SEQ ID NO: 10 Reverse
VP7F	5'-GTACATGTACGGAATCGAGTAC-3'	-	SEQ ID NO: 11 Forward
VP7R	5'-ATGCGGCCGCCACACGGTAGTAGAAAGCAGC-3'	NotI	SEQ ID NO: 12 Reverse

[00197] The pGEM-VP DNAs from positive colonies were sequenced to verify fidelity of the PCR. DNA was digested with NcoI/NotI and the appropriate DNA fragment cloned into pTRAc-ERH at sites NcoI and NotI to form pTRAc-ERH-VP. Transformation was then carried out into *E. coli* DH5- $\alpha$  cells as previously done. Colony PCR was also performed to check for rotavirus DNA in selected colonies.

**Agrobacterium transformation**

[00198] Agrobacterium tumefaciens GV3101 strain was provided by Professor Rainer Fischer (Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany) and made electrocompetent as previously described (Shen and Forde, 1989). Three hundred nanograms of isolated rotavirus pTRA-VP constructs were mixed with 100 µl of electrocompetent GV3101 cells in a 0.1 cm electrogap cuvette (BioRad™) then electroporated in a GenePulser (BioRad) under the following settings: 1.8 kV, 25 µF and 200 Ω. Incubation was allowed for 1 hr at 27°C in 900 µl of LB before plating on LA plates containing 50 µg/ml carbenicillin (carb), 30 µg/ml kanamycin (kan) and 50 µg/ml rifampicin (rif). The plates were incubated at 27°C for 3 days. To check for positive transformants, plasmid DNA was isolated from the recombinant Agrobacterium colonies and back-transformed into E. coli competent DH5-α cells. These were then selected on 100 µg/ml ampicillin (amp) LA. Colony PCR and restriction enzyme digests on cDNA were done to verify successful transformants. Glycerol stocks of relevant recombinant Agrobacterium were made and stored at -70 °C.

**Recombinant Agrobacterium infiltration**

[00199] A. tumefaciens LBA 4404 (pBIN-NSs) used in this study was obtained from Marcel Prins (Laboratory of Virology, Wageningen University, Binnenhaven, Netherlands). It contains the NSs silencing suppressor found in Tomato spotted wilt virus (TSWV). Recombinant Agrobacterium (pTRA-VPs) from glycerol stocks were grown at 27 °C overnight in LB with 50 µg/ml carb, 30 µg/ml kan and 50 µg/ml rif. The recombinant Agrobacterium and LBA4404 (pBIN-NSs) were then each inoculated in induction medium (LB, 10 mM 2-(N-morpholino) ethanesulphonic acid MES, 2 mM MgSO<sub>4</sub>, 20 µM acetosyringone, 50 µg/ml carb, 30 µg/ml kan and 50 µg/ml rif, and pH 5.6).

[00200] Cultures were incubated at 27°C overnight. Agrobacterium cells were collected by centrifugation at 4000 rpm for 5 min at 4°C and then resuspended in 2 ml infiltration medium (10 mM MES, 10 mM MgCl<sub>2</sub>, 3 % sucrose, pH 5.6, 200 µM acetosyringone and sterile water). Optical density (OD<sub>600</sub>) of the cells was verified and diluted with infiltration medium to obtain an OD<sub>600</sub> of 0.25. For each pTRA-VP construct, LBA4404 was mixed with recombinant Agrobacterium to final OD<sub>600</sub> of

0.5. For co-expression studies, each construct was added to total an OD600 of 0.5, for example; VP2 – 0.25 and VP6 – 0.25, until the OD600 for mixture equalled 0.5. Acetosyringone used in the induction and infiltration medium helps in activation of vir genes in *Agrobacterium*.

5 [00201] Wounded plant cells release phenolic compounds which are detected by Vir A and Vir G genes in *Agrobacterium* subsequently leading to induction of protein expression in the host cells (Zupan, J. et al., 2000). The cells were then incubated at room temperature for 1 h to allow acetosyringone to induce vir genes. Three week old wild type *N. benthamiana* plants were infiltrated with recombinant  
10 *Agrobacterium* expressing the VP proteins. This involved either vacuum infiltration of whole plants or injection of recombinant *Agrobacterium* (pTRA-VP) into the abaxial air spaces on the ventral side of plant leaves. Recombinant *agrobacterium* was infiltrated either with or without the silencing suppressor LBA 4404 (pBIN-NSs).

15 [00202] Initially, 2 ml of *Agrobacterium* infiltration medium suspension was injected into each plant using a syringe per construct. One plant was used per construct over a seven day time trial. Co-expression of rotavirus proteins was also carried out in which VP2, VP6 and VP4 were simultaneously expressed in the cytoplasm of *N. benthamiana* plant leaves. Combinations investigated were VP2/6 and VP2/6/4. VP4 “spike” protein may bind to VP6, and thus there is a possibility that  
20 they could add to RLP structures. VP7 cloning was attempted but toxicity issues to host cells proved to be a problem. Recombinant VP7 *Agrobacterium* killed leaf cells within a day after infiltration. Several methods were tried to evade this such as infiltrating plants at a low temperature of 17° C and infiltrating after day 3 and/or day 5 of the time trials. As such, VP7 was omitted in the co-expression studies due to its  
25 toxic nature in the tobacco plants.

### Protein Extraction

30 [00203] Whole leaves or two leaf discs per construct were harvested and ground in liquid nitrogen. Ground leaf matter was resuspended in sterile PBS containing Complete Protease Inhibitor (EDTA-free; Roche). This was then centrifuged for 5 min at 13000 rpm and the pellets (plant leaf matter) discarded. 100 µl of each construct were then mixed with 5X SDS-PAGE loading buffer and boiled for 2 min at 95 °C, ready for further analysis on SDS-PAGE gels and western blots.

The rest of the samples were stored at -20 °C for future use. Figure 4 shows an overview of the cloning and infiltration procedure for the rotavirus cDNA.

#### **Apoplast protein extraction**

[00204] An additional extraction procedure was carried out on the pTRAc-A, apoplast constructs. The apoplast is the free diffusional space between the plasma membrane and cell walls of plant cells (Figure 5a). Proteins expressed in the cytoplasm have an export sequence that targets them to the apoplast hence they accumulate here. In the extraction procedure that followed, whole leaves from each extraction day were either vacuum or injection infiltrated with sterile PBS containing Complete Protease Inhibitor. For vacuum infiltration, individual plant leaves were suspended in PBS and put under a vacuum at 100 mbar for 10 min in a vacuum tank. The leaves were then rolled and gently placed in spin columns (similar to Qiagen spin columns) with a hole at the bottom (Figure 5b2). The holes allow easy passage of fluid from the leaves without allowing solid leaf matter to pass through. The spin columns were placed in 2 ml Eppendorf tubes and centrifugation carried out at 4000 rpm for 15 min (Figure 5 b3). The filtrate was collected and protein loading dye for SDS-PAGE gels and western blot analysis was added to 100 µl of each filtrate sample.

#### **Western Blots and Coomassie stains**

[00205] Western blots and Coomassie blue stained SDS-PAGE gels were used as previously described. Mouse anti-rotavirus VP6 antibody (US Biologicals) (1:5000), anti-mouse histidine tag antibody (Sigma®) (1:2000), chicken anti-VP2 and chicken anti-VP4 serum (1:2000) were used to probe each of the respective proteins in western blots. Coomassie blue stained SDS-PAGE gels were used to quantify proteins by density scanning of bands using a Syngene Gel Documentation System.

#### **Electron Microscopy**

[00206] To determine whether expressed proteins assembled into RLPs, transmission electron microscopy (TEM) of immuno-trapped particles was performed on day 3 of expression of cytoplasm expressed VP6, VP2/6 and VP2/6/4, all in the presence of a silencing suppressor Nss. Glow discharged carbon/copper grids were placed on 20 µl of mouse anti-rotavirus VP6 antibody (1:5000) for 5 min and then washed 3 times with sterile distilled water. The grids were then placed on 10 µl of the



protein extracts and left for 2 min before being washed 3 times again with sterile distilled water. Finally, the grids were floated on 20 µl of 2 % uranyl acetate for 1 min before viewing under a TEM (Zeiss 912 OMEGA Energy Filter Transmission Electron Microscope, University of Cape Town).

- 5 [00207] For samples isolated from sucrose gradients, the sucrose first had to be removed by dialysis before immune-trapping on the copper grids. If not removed, sucrose crystals inhibit definitive viewing of samples under the TEM as it forms crystals on the grids, disrupting the structure of bound carbon and material. The sucrose fractions were placed in 10 000 MW dialysis cassettes and dialyzed in sterile  
10 PBS containing 0.4 M NaCl for 4 hr before exchanging the buffer and leaving it overnight at 4 °C with stirring. Since volume increases with dialysis, the protein samples required concentrating. The samples were vacuum freeze dried for 3 hours and resuspended in 2 ml of sterile PBS, ready for further analysis.

#### **Sucrose gradient purification of RLPs**

- 15 [00208] Plant protein extracts were initially filtered through miracloth to remove solid plant matter. Sucrose gradients from 10 to 60 % sucrose were set up in 40ml tubes each by creating six layers of 5 ml of sucrose dissolved in sterile PBS (pH 7.4). Clarified protein samples in 5 to 10 ml volumes were then loaded on top of each gradient column.

- 20 [00209] Ultracentrifugation at 150 000 g (SWTi28 swinging bucket rotor, Beckman Coulter) was carried out at 4 °C for 1 h 30 min. At the end of the centrifugation, 2 ml fractions were collected from the bottom of each column by tube puncture. Dot blots were then performed to determine fractions with proteins of interest. For each fraction, 1 µl of sample was loaded in a grid on a nitrocellulose  
25 membrane, which was then blocked with BSA blocking buffer. Western blot analysis was then performed as usual. Proteins were probed with mouse anti-VP6 antibody (1:5000) for VP6 or chicken anti-VP2 and VP4 serum (1:5000) for the other two proteins.

#### **Total Soluble Protein Assay**

- 30 [00210] Total soluble protein (TSP) was determined by Bradford assays. This was carried out to compare the levels of accumulated proteins in cytoplasm co-expressed VP2/6. The protein IgG (1.43mg/ml stock) was used in a dilution series as a

standard. 5 µl of standard and samples were each added to a clean dry microtitre plate. Total Soluble Protein Reagents A and B were added as per manufacturer's instructions (Bio-Rad Dc Protein Assay). All experiments were done in triplicate. Absorbance readings were recorded at 750 nm using a microplate reader (Bio-tek PowerWave XS).

## Results

### Expression of VP6 in plant leaf cell compartments

[00211] VP6 was expressed and targeted to all cellular compartments (Figure 6; (the line marks VP6, at ~42 kDa)), with and without the silencing suppressor. In the cytoplasm, protein was expressed from day one of the time trial, with increasing protein accumulation in the cytoplasm during the week-long trial (Figure 6a). In the ER, protein accumulation was clearly seen at day 3 only (Figure 6b). The protein ran at a higher band size (approximately 11 kDa more) than the other proteins. This may be a result of the 6 histidine-tag added to the C-terminal end of the protein, as well as the cleavage site (refer to pProEx vector sequence)

[00212] Protein accumulation in the chloroplasts occurred between days 1 and 3 (Figure 6 "chloroplasts"). The silencing suppressor had an effect on the proteins as no proteins were detected in its absence. There was no protein expression at days 5 and 7. The apoplast, just as in the ER, had the best protein accumulation between days 3 and 5 of the time trial (Figure 6 "apoplast") and none at all at day 1 and day 7. The silencing suppressor had a positive effect especially on day 3, resulting in higher protein detection levels compared to when it was left out. It can also be seen that two bands are visible at the ~40 kDa mark probably as a result of cleavage of the signaling tag on the VP6 protein.

[00213] The ER, chloroplasts and apoplast all exhibited the highest protein expression on day 3, with the most protein accumulating in the presence of the silencing suppressor. The cytoplasm was the best in terms of protein accumulation as it exhibited high and increasing protein expression throughout the time-trial.

### Expression of histidine-tagged rotavirus proteins in the cytoplasm

[00214] The four rotavirus VPs were cloned into an additional vector, pTRAc-HT. This vector includes a 6-histidine tag to proteins targeted to the cytoplasm and makes detection easy by use of an anti-histidine tag antibody if the antibodies for the

proteins of interest are unavailable. In our case, only VP6 has a commercially available antibody and hence we tried this procedure for early detection of all proteins while awaiting serum. The cytoplasm also worked well for VP6 expression and motivated us to try the other proteins.

5 [00215] Western blot results of day 3 extracts from a 7 day time trial showed successful expression of VP2, VP4 and VP6 (Figure 7a). In order to obtain expression of VP7 in plants, various techniques were tried. However, plants infiltrated with VP7 exhibited yellowing leaves from day 1 and proceeded to wilt during the course of the time trial (Figure 7b). No expression of protein was detected under these conditions,  
10 even after day 1 of infiltration when the plant still looked reasonably good.

#### **Expression of VP2 and VP4 in plants**

[00216] VP2 and VP4 were infiltrated in *N. benthamiana* plant leaves and targeted to the ER, chloroplast, cytoplasm and apoplast. We were unable to express VP2 targeted to the apoplast vector as we could not get any positive clones in *E. coli*.  
15 However, the protein was successfully expressed and targeted to all other 3 compartments (Figure 8a). Chicken anti-VP2 and anti-VP4 serum (1:2000) was used in western blot analysis of extracts. VP2 and VP4 bands were visible just below the 100 kDa mark (protein band indicated by arrow) as seen in Figure 8a and 8b respectively. Expression appeared to be best in the cytoplasm and ER for VP2 while  
20 for VP4, in the cytoplasm and apoplast. The silencing suppressor did not have a significant effect on the expression of the proteins. It only slightly increased expression in the VP2 ER construct and not so much in the rest, as can be seen from the western blot. VP4 constructs were all expressed in the presence of the silencing suppressor.

#### **Co-expression of VP2/6 and VP2/6/4 in the cytoplasm**

[00217] The cytoplasm appeared to be best for rotavirus capsid protein expression and exhibited the highest extraction efficiencies. All further expression work was therefore done with proteins targeted to the cytoplasm.

[00218] VP2 and VP6 have been shown to form RLPs with protective  
30 immunogenic responses in mice and therefore co-expression of VP2/6 and VP2/6/4 in the cytoplasm was investigated. Day 3 extracts of co-expressed VP2/6/4 were detected by western blot with anti-VP2 and VP4 serum (1/5000) and mouse anti-VP6

antibody (1:5000) (Figure 9). VP6 expression was very high as previously determined, but expression of VP2 and VP4 was very low as can be seen from the very faint band at the 100 kDa mark. This may have been attributed by the co-expression which resulted in more host cell resources being utilized in the over-expression of VP6, leaving less for VP2 and/or VP4. It was also not easy to determine if the detected band was both VP2 and VP4 or either of the 2 proteins. The very visible band running above 130 kDa may be dimerized VP6 proteins. The band visible at the 55 kDa mark is most likely the abundant plant enzyme Rubisco.

[00219] Transmission electron microscopic analysis on the cytoplasm-expressed VP6 as well as on co-expressed VP2/6 and VP2/6/4, were carried out to check for protein particles and assembled RLPs (Figure 10). This also determined if VP2 and/or VP4 were indeed co-expressed successfully. VP6 when expressed alone assembled to form sheaths of protein as indicated by the arrow in Figure 10b. On addition of VP2, the particles assembled to form RLPs (Figure 10c). VP2 acts as scaffolding protein that enables other proteins to assemble and ultimately form a complete rotavirus structure. VP6 as such bound to VP2 but it was still not easy to determine VP4 structures in co-expressed VP2/6/4. The electron micrograph in Figure 10d may be purely assembled VP2/6 particles. It has been shown however that VP4 binds to VP6 during protein assembly, and this occurs before VP7 binds. It is likely that these VP4 structures are not stable and may fall off the RLP structure during preparation procedures for electronic microscopy.

#### **Sucrose gradient purification of VP2/6 and VP2/6/4**

[00220] VP2/6 and VP2/6/4 were purified on a sucrose gradient ranging from 10 to 60 % sucrose (Figure 11a). 2 ml fractions were collected from the bottom of each of the tubes and probed with mouse anti-VP6 antibody and/or chicken anti-VP2 and VP4 serum to determine which fractions contained the proteins. For VP2/6, proteins were found in fractions 16 and 17 as these were positive for VP6 protein on the blot (Figure 11b). VP2/6/4 blot analysis with chicken anti-VP2 and VP4 serum showed positive results throughout all the fractions. This may have been as a result of the high levels of background protein detection by the chicken serum. However, intensity of dots was highest in fractions 17 and 18 as seen in Figure 11c, possibly due to higher concentration of the proteins of interest in these fractions.

[00221] Putting these results together (Figure 11b and 11c), the rotavirus proteins were in fractions ranging from 16 to 20.

#### **Western Blot and Coomassie stains of fractions**

[00222] A western blot and SDS-PAGE of co-expressed VP2/6 were done to verify presence of VP2 and VP6 proteins in fractions 13 to 20. Western blot analysis for VP6 protein probed with mouse anti-VP6 antibody was positive in fractions 16 right through to 20 (Figure 12a, bottom arrow and Figure 12c). VP2 protein probed with chicken anti-VP2 serum was detected in fractions 17 to 20 (Figure 12a, top arrow). VP2 has been shown to express less than VP6 in past co-expression studies and this was also shown here Figure 12a in which VP2 protein bands have a lower intensity in comparison to VP6.

[00223] Fractions 16 and 17 of co-expressed VP2/6 previously determined to contain VP6 protein by dot blots (Figure 11b) were electrophoresed on an SDS-PAGE gel. A protein of known concentration, SF9 insect cell expressed VP6 (0.91  $\mu\text{g}/\mu\text{l}$ ) was included so as to determine the concentration of VP2/6 crude proteins (Figure 11b and c). This was done by density scanning of the crude protein band (lane labeled crude) using a Syngene Gel Documentation System and consequently allowed us to determine the amount of VP2/6 per kilogram of leaf matter. Protein yield was found to be approximately 1.54 g/kg fresh weight (FW). 1.1 mg of purified RLPs were obtained from 1 gram of plant material (1.1g/kg).

#### **Total Soluble Protein Assay of VP2/6**

[00224] Total soluble protein (TSP) was determined on co-expressed VP2/6 fractions to determine the relative amounts of VP2/6 protein (Figure 13). Protein concentrations were calculated as 0.538 mg/ml and 1.012 mg/ml for fractions 17 and 18 respectively with the use of an IgG standard (Figure 13a). The protein bands corresponding to VP2/6 in these fractions were calculated by density scanning on a Syngene Gel Documentation System and found to be approximately 0.108 mg/ml and 0.202 mg/ml, respectively.

[00225] Thus, the TSP for VP2/6 in fractions 17 and 18 were both approximately 20 % TSP. Most of the RLPs in the sucrose column were found to be between 15 and 25 % sucrose, corresponding with fractions 15 to approximately 20, where the graph is noted to suddenly peak and then subside. The differences in

density of the various materials in the extract allowed me to separate and thereby purify the proteins of interest. SDS-PAGE gels stained with Coomassie blue showed only one prominent band indicating that the proteins are relatively pure (Figure 12b).

#### **TEM of purified VP2/6**

[00226] Purified VP2/6 fractions were pooled together and dialyzed in high salt PBS to remove sucrose before viewing on a transmission electron microscope. The TEM was done to determine purity and check if RLPs remained intact after the purification procedure. As can be seen in Figure 15, most of the background material which mainly consisted of the host cell's products (Figure 10b, c and d) was removed, leaving behind RLPs. Most of the RLPs remained intact but some appeared to have lost shape probably as a result of deformation due to the conditions on the EM grid.

#### **Preliminary analysis of expression of rotavirus structural proteins in *N. benthamiana* leaves**

[00227] This preliminary analysis focused on the expression of rotavirus structural proteins VP2 (SEQ ID NO:1), VP4 (SEQ ID NO:2), VP6 (SEQ ID NO:3) and VP7 (SEQ ID NO:4) in *N. benthamiana* leaves as an example host expression system. The strain of rotavirus selected here was a G9 P[6] strain which circulates predominantly in South Africa and other sub-Saharan regions. A RLP vaccine targeting this strain would help in alleviating the burden of disease in sub-Saharan Africa.

[00228] A transient expression system mediated by *Agrobacterium* was used in this analysis. Transient expression, as opposed to transgenic expression, permits rapid expression of proteins in a relatively short time, without integration of the rotavirus capsid protein genes in the host's chromosome. Most proteins were expressed and accumulated to detectable amounts by day 3 of recombinant *Agrobacterium* infiltration in *N. benthamiana* leaves. As shown below successful expression of several rotavirus structural proteins was observed including VP2, VP4 and VP6 in plant leaf cell compartments as detailed in table 2:

#### **Table 2: Expression of rotavirus VP proteins in various leaf cell compartments**

Capisd Protein	Leaf Cell Compartment			
	Apoplast	Chloroplast	Cytoplasm	ER
VP2	0	1	1	1
VP4	1	0	1	1
VP6	1	1	1	1
VP7	0	0	0	0

0 = no expression  
1 = expressed

[00229] Expression of the glycoprotein VP7 was not observed possibly due to its toxic effects on plant cells. It is worth noting that for this preliminary study, a VP7 containing its native signal peptide had been used. Infiltrating at day 3 during co-expression trials was also tried. This was attempted to see if the protein was expressed and soon after assembled with VP2 and VP6 to form RLPs. The toxic nature of recombinant VP7 as observed in this study has been previously described (Williams et al., 1995; McCorquodale, 1987; Arias et al., 1986).

[00230] Past VP7 expression studies in transgenic potatoes has been reported (Li et al., 2006; Choi et al., 2005; Wu et al., 2003). Choi et. al. (2005) used a simian rotavirus VP7, and Li et. al. and Wu et. al. (Li et al., 2006; Wu et al., 2003) used human group A G1 VP7. The result described herein used human rotavirus G9 VP7.

[00231] VP2 was expressed and targeted to all compartments except the apoplast as we were unable to clone the appropriate cDNA, and time constraints only allowed us a few attempts before proceeding with the other constructs. Expression levels of VP2 were noted to be significantly low in all the compartments. In a past study quoted by Saldana et al. 2006, it was concluded that a VP2 having its sequence optimized for expression in the plant was impossible to express, despite mRNA being detected in the plant cells. They however managed to express it in tomato plant cells using synthetic DNA. The reason for the difficulty in VP2 expression is most likely as result of improper mRNA translation or that the mRNA contains some sequence motifs that destabilize the plant cells (Kawaguchi and Bailey-Serres, 2002). Evidence of low expression levels of VP2 in comparison to VP6 have been seen in both plant

and insect-cell expression studies by Mena et al. (2006), Saldana et al. (2006), Vieira et al. (2005), and Labbé et al. (1991).

[00232] The outer capsid protein, VP4, which forms spikes on the surface of the virion structure, was expressed and targeted for accumulation in the cytoplasm, ER and apoplast. No protein accumulation was detected in chloroplasts. As observed for VP2, protein expression levels for VP4 were lower than seen for VP6 on western blots. The protein has a trypsin cleavage site which results in two proteins, VP5 and VP8. It may be possible that local trypsin in *N. benthamiana* leaves cleaves some of the proteins as they are produced resulting in lower concentration levels of accumulated, intact VP4 in the designated compartments. The protein has been shown to be a major neutralizing antigen but there have been a few attempts to clone the whole protein for vaccine development (Khodabandehloo et al., 2009; Mahajan et al., 1995; Nishikawa et al., 1989). There have been, however, several studies in the insect-cell and yeast expression system showing expression of either the VP5 or VP8 subunits of VP4 (Andrés et al., 2006; Favacho et al., 2006; Kovacs-Nolan et al., 2001). To date, the present study represents the first study showing expression of the whole protein in a plant expression system.

[00233] VP6 was expressed in all compartments with over-expression being observed in the cytoplasm with protein accumulation observed from day 1 to day 7 in this compartment. This is contrary to some literature which suggests that protease activity and gene silencing reduce or hinder the accumulation of foreign protein in the cytoplasm (Fischer et al., 2004). In addition, given the right pH conditions, VP6 is known to self-assemble into tubular or helical particles, much like the particles seen in our study (Figure 9b) (Estes et al., 1987). VP6 makes up about 50 % of the viral core and therefore is a major antigen in the development of a rotavirus vaccine. The result attained above enabled us to further investigate the co-expression of VP2, VP6 and VP4 in the cytoplasm.

[00234] When co-expressed in the cytoplasm, VP2 and VP6 assembled to form RLPs. Very high protein yields from transient expression system of between 1.27 – 1.54 g/kg FW were observed. When purified on a sucrose column, the amount of VPs retained was 1.1 g/kg FW. This yield is comparable to that obtained for the production of an antibody, IgG, using a transient expression system in *N. benthamiana*, with a yield of up to 1.5 g/kg FW (Vézina et al., 2009). Saldana et al. (2006) were until now



the only group known to have successfully co-expressed rotavirus VP2 and VP6 in transgenic tomato plants and to levels of approximately 1 % total soluble protein. The assembly of VP2/6 in the insect-cell expression system has been well documented (Vieira et al., 2005;; O'Brien et al., 2000). These VP2/6 RLPs have also been shown to provide protective immunity against rotavirus infection (Zhou et al., 2011, Saldana et al., 2006). Thus the VP2/6 RLPs we produced in the plant expression system are suitable candidates for the development a subunit rotavirus vaccine.

[00235] VP2/6/4 were also co-expressed and detected. The first peak visible (Figure 14, fraction 16) in the total protein absorbance reading of the co-expressed proteins might be assembled VP2/6/4, but on examination of this fraction under a TEM, no RLPs were detected. The protein peak observed may result from an accumulation of VP4 monomers or its respective VP5 and VP8 subunits. The second peak (fraction 18), when examined under a TEM showed RLP structures very much similar to the ones seen in the VP2/6 sample. However, Crawford et al have previously reported that VP4 could not be seen under TEM, and that VP2/6/4 and VP2/6/4/7 particles had similar structure and diameter under TEM (Crawford 1994). We made the same observation for VP2/6/7 RLPs, VP 2/6/4/7 RLPs and VP2/6 RLPs, which all look similar under regular TEM.

## Example 2

### Constructs

#### A-2X35S/CPMV-HT/ RVA(WA) VP2(opt)/ NOS (Construct number 1710)

[00236] An optimized sequence encoding VP2 from Rotavirus A WA strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP2 coding sequence was amplified using primers IF-WA\_VP2(opt).s1+3c (Figure 17A, SEQ ID NO: 21) and IF-WA\_VP2(opt).s1-4r (Figure 17B, SEQ ID NO: 22), using optimized VP2 gene sequence (Figure 19, SEQ ID NO: 45) as template. For sequence optimization, VP2 protein sequence (Genbank accession number CAA33074) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17C) was digested

with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1710 (Figure 23, SEQ ID NO: 27). The amino acid sequence of VP2 from Rotavirus A strain WA is presented in Figure 20 (SEQ ID NO: 25). A representation of plasmid 1710 is presented in Figure 21.

B-2X35S/CPMV-HT/RVA(WA) VP2(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1711)

[00237] An optimized sequence encoding VP2 from Rotavirus A WA strain was cloned into 2X35S/CPMV-HT/NOS comprising the BeYDV(m)+replicase amplification system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP2 coding sequence was amplified using primers IF-WA\_VP2(opt).s1+3c (Figure 17A, SEQ ID NO: 21) and IF-WA\_VP2(opt).s1-4r (Figure 17B, SEQ ID NO: 22), using optimized VP2 gene sequence (SEQ ID NO: 45) as template. For sequence optimization, VP2 protein sequence (Genbank accession number CAA33074) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette into the BeYDV(m) amplification system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 193 (Figure 22A) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 193 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette into the BeYDV(m) amplification system. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 22B (SEQ ID NO: 26). The resulting construct was given number 1711 (Figure 23, SEQ ID NO: 27).

The amino acid sequence of VP2 from Rotavirus A strain WA is presented in Figure 20 (SEQ ID NO: 25). A representation of plasmid 1711 is presented in Figure 24.

C-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS (Construct number 1713)

[00238] An optimized sequence encoding VP6 from Rotavirus A WA strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP6 coding sequence was amplified using primers IF-WA\_VP6(opt).s1+3c (Figure 25a, SEQ ID NO: 28) and IF-WA\_VP6(opt).s1-4r (Figure 25b, SEQ ID NO: 29), using optimized VP6 gene sequence (SEQ ID NO: 46) as template. For sequence optimization, VP6 protein sequence (Genbank accession number AAA47311) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17c) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for "In Fusion" cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1713 (Figure 25c, SEQ ID NO: 30). The amino acid sequence of VP6 from Rotavirus A strain WA is presented in Figure 26 (SEQ ID NO: 31). A representation of plasmid 1713 is presented in Figure 27.

D-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1714)

[00239] An optimized sequence encoding VP6 from Rotavirus A WA strain was cloned into 2X35S/CPMV-HT/NOS comprising the BeYDV(m)+replicase amplification system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP6 coding sequence was amplified using primers IF-WA\_VP6(opt).s1+3c (Figure 25a, SEQ ID NO: 28) and IF-WA\_VP6(opt).s1-4r (Figure 25b, SEQ ID NO: 29), using

optimized VP6 gene sequence (SEQ ID NO: 46) as template. For sequence optimization, VP6 protein sequence (Genbank accession number AAA47311) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette into the BeYDV(m) amplification system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 193 (Figure 22A) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 193 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette into the BeYDV(m) amplification system. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 22B (SEQ ID NO: 26). The resulting construct was given number 1714 (Figure 28, SEQ ID NO: 32). The amino acid sequence of VP6 from Rotavirus A strain WA is presented in Figure 26 (SEQ ID NO: 31). A representation of plasmid 1714 is presented in Figure 29.

C-2X35S/CPMV-HT/RVA(Rtx) VP4(opt)/NOS (Construct number 1730)

[00240] An optimized sequence encoding VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S/CPMV-HT/NOS in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP4 coding sequence was amplified using primers IF-Rtx\_VP4(opt).s1+3c (Figure 30A, SEQ ID NO: 33) and IF-Rtx\_VP4(opt).s1-4r (Figure 30B, SEQ ID NO: 34), using optimized VP4 gene sequence (Figure 31B, (SEQ ID NO: 47) as template. For sequence optimization, VP4 protein sequence (Genbank accession number AEX30660) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 18, SEQ ID NO: 23) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin

gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in (Figure 18, SEQ ID NO: 23). The resulting construct was given number 1730 (Figure 31C, SEQ ID NO: 50). The amino acid sequence of VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] is presented in Figure 32 (SEQ ID NO: 36). A representation of plasmid 1730 is presented in Figure 33A.

E-2X35S/CPMV-HT/RVA(Rtx) VP4(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1731)

[00241] An optimized sequence encoding VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S/CPMV-HT/NOS comprising the BeYDV(m)+replicase amplification system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP4 coding sequence was amplified using primers IF-Rtx\_VP4(opt).s1+3c (Figure 30A, SEQ ID NO: 33) and IF-Rtx\_VP4(opt).s1-4r (Figure 30B, SEQ ID NO: 34), using optimized VP4 gene sequence (SEQ ID NO: 47) as template. For sequence optimization, VP4 protein sequence (Genbank accession number AEX30660) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression cassette into the BeYDV(m) amplification system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 193 (Figure 22A) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 193 is an acceptor plasmid intended for "In Fusion" cloning of genes of interest in a CPMV-HT-based expression cassette into the BeYDV(m) amplification system. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 22B (SEQ ID NO: 26). The resulting construct was given number 1731 (Figure 31, SEQ ID NO: 35). The amino acid sequence of VP4 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] is presented in Figure 32 (SEQ ID NO: 36). A representation of plasmid 1731 is presented in Figure 33B.

F-2X35S/CPMV-HT/RVA(Rtx) VP7(opt)/NOS (Construct number 1733)

[00242] An optimized sequence encoding VP7 with is native signal peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A  
 5 fragment containing the VP7 coding sequence was amplified using primers IF-Rtx\_VP7(opt).s1+3c (Figure 34A, SEQ ID NO: 37) and IF-Rtx\_VP7(opt).s1-4r (Figure 34B, SEQ ID NO: 38), using optimized VP7 gene sequence (SEQ ID NO: 54) as template. For sequence optimization, VP7 protein sequence (Genbank accession number AEX30682) was backtranslated and optimized for human codon usage, GC content and mRNA  
 10 structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17C) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression  
 15 cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1733 (Figure 34C, SEQ ID NO: 24). The amino acid sequence of VP7 with is native signal  
 20 peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is presented in Figure 35 (SEQ ID NO: 39). A representation of plasmid 1733 is presented in Figure 36.

D-2X35S/CPMV-HT/TrSp-RVA(Rtx) VP7(opt)/NOS (Construct number 1734)

[00243] An optimized sequence encoding VP7 with a truncated version of the native  
 25 signal peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S-CPMV-HT-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP7 coding sequence was amplified using primers IF-  
 TrSP+Rtx\_VP7(opt).s1+3c (Figure 44A, SEQ ID NO: 55) and IF-Rtx\_VP7(opt).s1-4r  
 30 (Figure 44B, SEQ ID NO: 56), using optimized VP7 gene sequence (corresponding to nt 88-981 from Figure 44C, SEQ ID NO: 57) as template. For sequence optimization, VP7 protein sequence

(Genbank accession number AEX30682) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct number 1191 (Figure 17C) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1191 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 18 (SEQ ID NO: 23). The resulting construct was given number 1734 (Figure 44D, SEQ ID NO: 58). The amino acid sequence of VP7 with truncated signal peptide from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is presented in Figure 44E (SEQ ID NO: 59). A representation of plasmid 1734 is presented in Figure 44F.

G-2X35S/CPMV-HT/PDISP/RVA(WA) VP7(opt)/NOS into BeYDV(m)+Replicase amplification system (Construct number 1735)

[00244] A sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain was cloned into 2X35S-CPMV-HT-PDISP-NOS expression system in a plasmid containing Plasto\_pro/P19/Plasto\_ter expression cassette using the following PCR-based method. A fragment containing the VP7 coding sequence without his wild type signal peptide was amplified using primers IF-Rtx\_VP7(opt).s2+4c (Figure 37A, SEQ ID NO: 40) and IF-Rtx\_VP7(opt).s1-4r (Figure 34B, SEQ ID NO: 38), using optimized VP7 gene sequence (SEQ ID NO: 54). For sequence optimization, VP7 protein sequence (Genbank accession number AEX30682) was backtranslated and optimized for human codon usage, GC content and mRNA structure. The PCR product was cloned in-frame with alfalfa PDI signal peptide in 2X35S/CPMV-HT/NOS expression system using In-Fusion cloning system (Clontech, Mountain View, CA). Construct 1192 (Figure 38) was digested with SacII and StuI restriction enzyme and the linearized plasmid was used for the In-Fusion assembly reaction. Construct number 1192 is an acceptor plasmid intended for “In Fusion” cloning of genes of interest in frame with an alfalfa PDI signal peptide in a CPMV-HT-based expression cassette. It also incorporates a gene construct for the co-

expression of the TBSV P19 suppressor of silencing under the alfalfa Plastocyanin gene promoter and terminator. The backbone is a pCAMBIA binary plasmid and the sequence from left to right t-DNA borders is presented in Figure 39 (SEQ ID NO: 41). The resulting construct was given number 1735 (Figure 40, SEQ ID NO: 42). The amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is presented in Figure 41 (SEQ ID NO: 43). A representation of plasmid 1735 is presented in Figure 42.

Table 3. Description of synthesized genes for the production of RLPS.

SEQ ID No	Antigen	Strain of origin	Sequence type*	Figure in disclosure
45	VP2	WA	Optimized	19B
46	VP6	WA	Optimized	25D
47	VP4	Rotarix	Optimized	31B
50	VP4	SA11	Wild-type	43A
51	VP4	SA11	Optimized	43B
54	VP7	Rotarix	Optimized	34E
53	VP7	SA11	Wild-type	43D
52	VP7	SA11	Optimized	43C

\* Optimized sequences were modified to favor the use of preferred human codons and increase GC content

Table 4. Description of assembled and tested construct for the production of RLPS.

Expression system	Amplification system	Signal peptide <sup>†</sup>	Antigen (strain) <sup>*,‡</sup>	Gene SEQ ID used for PCR	Construct number
CPMV HT	-	-	RVA(WA) VP2 [optimized]	SEQ ID NO: 45	1710
CPMV HT	BeYDV(m)+rep	-	RVA(WA) VP2 [optimized]	SEQ ID NO: 45	1711
CPMV HT	-	-	RVA(WA) VP6 [optimized]	SEQ ID NO: 46	1713
CPMV HT	BeYDV(m)+rep	-	RVA(WA) VP6 [optimized]	SEQ ID NO: 46	1714
CPMV HT	-	-	RVA(Rtx) VP4 [optimized]	SEQ ID NO: 47	1730
CPMV HT	BeYDV(m)+rep	-	RVA(Rtx) VP4 [optimized]	SEQ ID NO: 47	1731



CPMV HT	-	WtSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1733
CPMV HT	-	TrSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1734
CPMV HT	-	SpPDI	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1735
CPMV HT	BeYDV(m)+rep	WtSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1736
CPMV HT	BeYDV(m)+rep	TrSp	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1737
CPMV HT	BeYDV(m)+rep	SpPDI	RVA(Rtx) VP7 [optimized]	SEQ ID NO: 54	1738
CPMV HT	-	-	RVA(SA11) VP4	SEQ ID NO: 50	1760
CPMV HT	BeYDV(m)+rep	-	RVA(SA11) VP4	SEQ ID NO: 50	1761
CPMV HT	-	-	RVA(SA11) VP4 [optimized]	SEQ ID NO: 51	1770
CPMV HT	BeYDV(m)+rep	-	RVA(SA11) VP4 [optimized]	SEQ ID NO: 51	1771
CPMV HT	-	WtSp	RVA(SA11) VP7	SEQ ID NO: 53	1763
CPMV HT	-	TrSp	RVA(SA11) VP7	SEQ ID NO: 53	1764
CPMV HT	-	SpPDI	RVA(SA11) VP7	SEQ ID NO: 53	1765
CPMV HT	BeYDV(m)+rep	WtSp	RVA(SA11) VP7	SEQ ID NO: 53	1766
CPMV HT	BeYDV(m)+rep	TrSp	RVA(SA11) VP7	SEQ ID NO: 53	1767
CPMV HT	BeYDV(m)+rep	SpPDI	RVA(SA11) VP7	SEQ ID NO: 53	1768
CPMV HT	-	WtSp	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1773
CPMV HT	-	TrSp	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1774
CPMV HT	-	SpPDI	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1775
CPMV HT	BeYDV(m)+rep	WtSp	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1776
CPMV HT	BeYDV(m)+rep	TrSp	RVA(SA11) VP7[optimized]	SEQ ID NO: 52	1777
CPMV HT	BeYDV(m)+rep	SpPDI	RVA(SA11) VP7 [optimized]	SEQ ID NO: 52	1778

† WtSp: Wild type signal peptide, SpPDI: Signal peptide of plant origin, cloned from alfalfa protein disulfide isomerase gene, TrSp: truncated wild type signal peptide, TrSp start at 2nd Met in WtSp (M30).

\* [optimized] means that the sequence has been optimized based on codon usage, GC content and RNA structure.

### Example 3

#### Assembly of gene constructs and Agrobacterium transformation

5 [00245] All plasmids, including plasmids 1710, 1713, 1730 and 1734, were used to transform *Agrobacterium tumefaciens* (AGL1; ATCC, Manassas, VA 20108, USA) by electroporation (Mattanovich et al., 1989, Nucleic Acid Res. 17:6747) alternatively, heat shock using CaCl<sub>2</sub>-prepared competent cells (XU et al., 2008, Plant Methods 4) may be used. The integrity of the plasmids in the *A. tumefaciens* strains  
10 created was confirmed by restriction mapping. The *A. tumefaciens* strain transformed with a given binary plasmid is named AGL1/"plasmid number". For example, the *A. tumefaciens* strain transformed with construct number 1710 is termed "AGL1/1710".

#### Preparation of plant biomass, inoculum, agroinfiltration, and harvesting

15 [00246] *Nicotiana benthamiana* plants were grown from seeds in flats filled with a commercial peat moss substrate. The plants were allowed to grow in the greenhouse under a 16/8 photoperiod and a temperature regime of 25°C day/20°C night. Three weeks after seeding, individual plantlets were picked out, transplanted in pots and left to grow in the greenhouse for three additional weeks under the same environmental conditions.

20 [00247] Agrobacteria transfected with each construct were grown in a LB medium from vegetal origin and supplemented with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) and 50 µg/ml kanamycin pH5.6 until they reached an OD<sub>600</sub> between 0.6 and 2.5. Agrobacterium suspensions were mixed to reach appropriate ratio for each construct and brought to 2.5X OD<sub>600</sub> with infiltration  
25 medium (10 mM MgCl<sub>2</sub> and 10 mM MES pH 5.6). *A. tumefaciens* suspensions were stored overnight at 4°C. On the day of infiltration, culture batches were diluted with infiltration medium in 2.5 suspension volumes and allowed to warm before use. Whole plants of *N. benthamiana* were placed upside down in the bacterial suspension in an air-tight stainless steel tank under a vacuum of 20-40 Torr for 2-min. Following  
30 infiltration, plants were returned to the greenhouse for a 3-12 day incubation period until harvest. Harvested biomass was kept frozen (-80°C) until use for purification of particles.

### Extraction and purification of rotavirus-like particles

[00248] Proteins were extracted from frozen biomass by mechanical extraction in a blender with 3 volumes of extraction buffer (TNC: 10 mM Tris pH 7.4, 140 mM NaCl, 10 mM CaCl<sub>2</sub>). The slurry was filtered through a large pore nylon filter to remove large debris and centrifuged 5000 g for 5 min at 4°C. The supernatant was collected and centrifuged again at 5000 g for 30 min (4°C) to remove additional debris. The supernatant was depth-filtered and ultra-filtered and the filtrate was centrifuged at 75 000 g for 20 min (4°C) to concentrate the rotavirus-like particles. The pellet containing the particles was resuspended in 1/12 volume of TNC and the insoluble were remove with a centrifugation at 5000 g for 5 minutes. The supernatant was filtered on Miracloth before being loaded on iodixanol density gradients.

[00249] Density gradient centrifugation was performed as follows. Tubes containing step gradients from 5% to 45% of iodixanol were prepared and overlaid with the filtered extracts containing the rotavirus-like particles. The gradients were centrifuged at 120 000 g for 4 hours (4°C). After centrifugation, 1 ml fractions were collected from the bottom to the top and analysed by Coomassie-stained SDS-PAGE and Western blot. To remove iodixanol for the fractions selected for further analysis, selected fractions were centrifuged 75 000 g for 20 min (4°C) and the pelleted particles were resuspended in fresh TNC buffer.

### SDS-PAGE and immunoblotting

[00250] Protein concentrations were determined by the BCA protein assay (Pierce Biochemicals, Rockport IL). Proteins were separated by SDS-PAGE under reducing or non-reducing conditions and stained with Coomassie Blue. Stained gels were scanned and densitometry analysis performed using ImageJ Software (NIH).

[00251] For immunoblotting, electrophoresed proteins were electrotransferred onto polyvinylene difluoride (PVDF) membranes (Roche Diagnostics Corporation, Indianapolis, IN). Prior to immunoblotting, the membranes were blocked with 5% skim milk and 0.1% Tween-20 in Tris-buffered saline (TBS-T) for 16-18h at 4°C.

[00252] Immunoblotting was performed by incubation with a suitable antibody (Table 5), in 2 µg/ml in 2% skim milk in TBS-Tween 20 0.1%. Secondary antibodies used for chemiluminescence detection were as indicated in Table 5, diluted as indicated in 2% skim milk in TBS-Tween 20 0.1%. Immunoreactive complexes were

detected by chemiluminescence using luminol as the substrate (Roche Diagnostics Corporation). Horseradish peroxidase–enzyme conjugation of human IgG antibody was carried out by using the EZ-Link Plus® Activated Peroxidase conjugation kit (Pierce, Rockford, IL).

- 5 Table 5: Electrophoresis conditions, antibodies, and dilutions for immunoblotting of rotavirus antigens.

Rotavirus antigen	Electrophoresis condition	Primary antibody	Dilution	Secondary antibody	Dilution
VP2	Reducing	Rabbit polyclonal anti-VP2 (kindly provided by professor Koki Taniguchi)	1 µg/ml	Goat anti-rabbit (JIR 111-035-144)	1:10 000
VP6	Reducing	ABIN 308233	1:20000	Goat anti-rabbit (JIR 111-035-144)	1:10 000
VP7	Non-Reducing	Rabbit polyclonal anti-VP7 (kindly provided by professor Koki Taniguchi)	1:2000	Goat anti-rabbit (JIR 111-035-144)	1:10 000

#### Anti-VP4 Enzyme-linked immuno sorbent assay (ELISA)

- U-bottom 96-well microtiter plates were coated with a mouse monoclonal anti-VP4 (kindly provided by Professor Koki Taniguchi) diluted 1:100000 in 10 mM PBS pH7.4 (phosphate-buffered saline), 150 mM NaCl for 16-18 hours at 4°C. After incubation, plates were washed three times with 10 mM PBS pH7.4, 1 M NaCl containing 0.1% Tween-20 and blocked with 5% BSA in 10 mM PBS pH7.4, 150 mM NaCl containing 0.1% Tween-20 for 1 hour at 37°C. After the blocking step, plates were washed three times with 10 mM PBS pH7.4, 1 M NaCl containing 0.1% Tween-20. Samples were added and plates were incubated for 1 hour at 37°C. Plate were then washed 3 times with 10 mM PBS pH7.4, 1 M NaCl, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> containing 0.1% Tween-20. For all remaining wash steps, washing buffer remain the same and during the third wash, plates were incubated 10 minutes at room temperature before completely removing washing solution. Rabbit polyclonal

antibody raised against Rotavirus (kindly provided by Professor Koki Taniguchi) diluted 1:10000 with 3% BSA in 10 mM PBS pH7.4, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> containing 0.1% Tween-20 was added and plates were incubated for 1 hour at 37°C. Plates were then washed 3 times and horseradish peroxidase-conjugated goat anti-rabbit antibody (111-035-144, Jackson ImmunoResearch, West Grove, PA) diluted 1:5000 with 3% BSA in 10 mM PBS pH7.4, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub> containing 0.1% Tween-20 was added and plates were incubated for 1 hour at 37°C. Plates were washed 3 times. After final washes, plates were incubated with SureBlue TMB peroxidase substrate (KPL, Gaithersburg, MD) for 20 minutes at room temperature. Reaction was stopped by the addition of 1N HCl and A450 values were measured using a Multiskan Ascent plate reader (Thermo Scientific, Waltham, MA).

Production of rotavirus-like particles comprising VP2 and VP6.

[00253] Rotavirus-like particles comprising VP2 and VP6 were produced by transient expression in *Nicotiana benthamiana*. Plants were agro-infiltrated with an inoculum of *Agrobacteria* containing a mixture of AGL1/1710 and AGL1/1713 in a 1:1 proportion and incubated for 7 days before harvest. Rotavirus-like particles were purified from the biomass using the methodology described in the materials and methods section. After centrifugation of the clarified extracts on iodixanol density gradient, the first ten fractions from the bottom of the tube were analyzed by Coomassie-stained SDS-PAGE. As shown in Figure 45A, the rotavirus antigens (VP2 and VP6) were mainly found in fractions 2 and 3 of the density gradient where the concentration of iodixanol is approximately 35%, a concentration where rotavirus-like particles are expected to be found. Very little contamination by plant proteins was found in these fractions. Western blot analysis of the fractions with anti-rotavirus hyperimmune rabbit serum and polyclonal rabbit anti-VP2 antibodies confirmed the identity of VP2 and VP6 in the density gradient fractions (Figures 45B and 45C). Fractions 2 and 3 were pooled and iodixanol was removed by high speed centrifugation and resuspension, and the purified particles were sent for cryo-electron microscopy analysis (NanoImaging Services Inc., La Jolla, CA) to confirm the assembly of the VP2 and VP6 into particles resembling the rotavirus particle. As shown in Figure 49 (left panel) the cryoEM images of VP2/VP6 particles confirmed the correct assembly of the antigens into rotavirus-like particles.

Production of rotavirus-like particles comprising VP2, VP6 and VP7.

[00254] Rotavirus-like particles comprising VP2, VP6 and VP7 were produced by transient expression in *Nicotiana benthamiana*. Plants were agro-infiltrated with an inoculum of *Agrobacteria* containing a mixture of AGL1/1710, AGL1/1713, AGL1/1734 in a 1:1:1 proportion and incubated for 7 days before harvest. Rotavirus-like particles were purified from the biomass using the methodology described in the materials and methods section. After centrifugation of the clarified extracts on iodixanol density gradient, the first ten fractions from the bottom of the tube were analyzed by Coomassie-stained SDS-PAGE. As shown in Figure 46A, the rotavirus antigens (VP2, VP6 and VP7) were mainly found in fractions 2 and 3 of the density gradient where the concentration of iodixanol is approximately 35%, a concentration where rotavirus-like particles are expected to be found. Very little contamination by plant proteins was found in these fractions. Western blot analysis of the fractions with anti-rotavirus hyperimmune rabbit serum and polyclonal rabbit anti-VP7 antibodies confirmed the identity of VP6 and VP7 in the density gradient fractions (Figures 46B and 46C).

Production of rotavirus-like particles comprising VP2, VP4, VP6 and VP7.

[00255] Rotavirus-like particles comprising VP2, VP4, VP6 and VP7 were produced by transient expression in *Nicotiana benthamiana*. Plants were agro-infiltrated with an inoculum of *Agrobacteria* containing a mixture of AGL1/1710, AGL1/1730, AGL1/1713, AGL1/1734 in a 1:1:1:1 proportion and incubated for 7 days before harvest. Rotavirus-like particles were purified from the biomass using the methodology described in the materials and methods section. After centrifugation of the clarified extracts on iodixanol density gradient, the first ten fractions from the bottom of the tube were analyzed by Coomassie-stained SDS-PAGE. As shown in figure 47A, 3 of the 4 rotavirus antigens (VP2, VP6 and VP7) were visible and mainly found in fractions 3 of the density gradient where the concentration of iodixanol is approximately 35%, a concentration where rotavirus-like particles are expected to be found. Very little contamination by plant proteins was found in these fractions. The absence of detectable level of VP4 in the Coomassie-stained gel was expected since VP4 cannot be observed when the same analysis is performed on purified human rotavirus virion. Western blot analysis of the fractions with anti-rotavirus hyperimmune rabbit serum and polyclonal rabbit anti-VP7 antibodies confirmed the

identity of VP6 and VP7 in the density gradient fractions (Figures 47B and 47C). Iodixanol was removed from fraction 3 by high speed centrifugation and resuspension and the purified particles were analyzed by ELISA to confirm the presence of VP4. The results presented in Figure 48 clearly show that the ELISA specifically recognizes VP4 as the negative control particles comprising VP2/VP6 and VP7 only resulted in background signal level. In contrast, the analysis of 3 different lots of purified particles comprising VP2, VP4, VP6 and VP7 antigens showed strong and uniform signals when assayed under the same conditions. Purified VP2/VP4/VP6/VP7 RLPs were sent for cryo-electron microscopy analysis (NanoImaging Services Inc., La Jolla, CA) to confirm the assembly of the four antigens into particles resembling the rotavirus particle. As shown in Figure 49 (right panel) the cryoEM images of VP2/VP4/VP6/VP7 particles confirmed the correct assembly of the antigens into rotavirus-like particles.

[00256] Table 6 lists sequences provided in various embodiments of the invention.

Table 6: Sequence description for sequence identifiers.

SEQ ID NO	Description	Page/Figure
1	Amino acid sequence of optimized G9P6_VP2	Figure 16A
2	Amino acid sequence of optimized G9P6_VP4	Figure 16B
3	Amino acid sequence of optimized G9P6_VP6	Figure 16C
4	Amino acid of optimized G9P6_VP7	Figure 16D
5	Primer VP2F	Table 1
6	Primer VP2R	Table 1
7	Primer VP4F	Table 1
8	Primer VP4R	Table 1
9	Primer VP6F	Table 1
10	Primer VP6R	Table 1
11	Primer VP7F	Table 1
12	Primer VP7R	Table 1
13	Nucleotide sequence of G9P6_VP2	Figure 16A
14	Nucleotide sequence of optimized G9P6_VP2	Figure 16A
15	Nucleotide sequence of G9P6_VP4	Figure 16B
16	Nucleotide sequence of G9P6_VP4	Figure 16B
17	Nucleotide sequence of G9P6_VP6	Figure 16C
18	Nucleotide sequence of optimized G9P6_VP6	Figure 16C
19	Nucleotide sequence of G9P6_VP7	Figure 16D
20	Nucleotide sequence of G9P6_VP7	Figure 16D

21	Primer IF-WA_VP2(opt).s1+3c	Figure 17A
22	Primer IF-WA_VP2(opt).s1-4r	Figure 17B
23	Construct 1191 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette	Figure 18
24	Expression cassette number 1733 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.	Figure 34C
25	Amino acid sequence of VP2 from Rotavirus A WA strain	Figure 20
26	Construct 193 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS into BeYDV(m)+Replicase amplification system with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette	Figure 22B
27	Expression cassette number 1710 from 2X35S promoter to NOS terminator. VP2(opt) from Rotavirus A WA strain is underlined.	Figure 23
28	Primer IF-WA_VP6(opt).s1+3c	Figure 25a
29	Primer IF-WA_VP6(opt).s1-4r	Figure 25b
30	Expression cassette number 1713 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.	Figure 25c
31	Amino acid sequence of VP6 from Rotavirus A WA strain	Figure 26
32	Expression cassette number 1714 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.	Figure 28
33	Primer IF-Rtx_VP4(opt).s1+3c	Figure 30A
34	Primer IF-Rtx_VP4(opt).s1-4r	Figure 30B
35	Expression cassette number 1731 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.	Figure 31A
36	Amino acid sequence of VP4 from rotavirus A Rotarix strain	Figure 32
37	Primer IF-Rtx_VP7(opt).s1+3c	Figure 34A
38	Primer IF-Rtx_VP7(opt).s1-4r	Figure 34B
39	Amino acid sequence of VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Fig 35
40	Primer IF-Rtx_VP7(opt).s2+4c	Figure 37A
41	Construct 1192 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/PDISP/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette	Figure 39
42	Expression cassette number 1735 from 2X35S promoter to NOS terminator. PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.	Figure 40A
43	Amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	41



44	Expression cassette number 1730 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.	Figure 31C
45	Nucleotide sequence encoding VP2(opt) from Rotavirus A WA strain	Figure 19
46	Nucleotide sequence encoding VP6(opt) from Rotavirus A WA strain	Figure 25d
47	Optimized coding sequence of Rotavirus A VP4 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]	Figure 31B
48	Nucleotide sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Figure 34D
49	Nucleotide sequence encoding PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Figure 40B
50	Coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43A
51	Optimized coding sequence of Rotavirus A VP4 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43B
52	Optimized coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43C
53	Coding sequence of Rotavirus A VP7 from strain RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]	Figure 43D
54	Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]	Figure 34E
55	Primer IF-TrSP+Rtx VP7(opt).s1+3c	Figure 44A
56	Primer IF-Rtx VP7(opt).s1-4r	Figure 44B
57	Nucleotide sequence of Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]	Figure 44C
58	Expression cassette number 1734 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.	Figure 44D
59	Amino acid sequence of TrSp-VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain	Figure 44E

## References

Yang Y M, Li X, Yang H, et al. Immunogenicity and virus-like particle formation of rotavirus capsid produced in transgenic plants. *Sci China Life Sci*, 2011, 54: 82-89

Angel, J., Franco, M.A. and Greenberg, H.B. (2007). Rotavirus vaccines: recent developments and future considerations. *Nature reviews: Microbiology* 5, 529-539

Araujo, I.T., Ferreira, M.S.R. and Failho, A.M. (2001). Rotavirus genotypes [4]G9, P[6]G9, and P[8]G9 in hospitalized children with acute gastroenteritis in Rio de Janeiro, Brazil. *J Clin Microbiol* 39 1999–2001.

Arias, C.F., Ballado, T. and Plebafiski, M. (1986). Synthesis of the outer-capsid glycoprotein of the simian rotavirus SA11 in *Escherichia coli*. *Gene* 47, 211-219

Au K.S., Mattion N.M., Estes M.K., (1993). A Subviral Particle Binding Domain on the Rotavirus Nonstructural Glycoprotein NS28. *Virology* 194, 665-67

Balen B, Krsnik-Rasol M, (2007). N-glycosylation of recombinant therapeutic glycoproteins in plant systems. *Food Technology and Biotechnology* 45 1-10.

Bardor, M., Faveeuw, C., Fitchette, A.C., Gilbert, D., Galas, L., Trottein, F., Faye, L. and Lerouge P. (2003). Immunoreactivity in mammals of two typical plant glycoepitopes, core alpha (1,3)-fucose and core xylose. *Glycobiology* 13 427-434

Berois, M., Sapin, C., Erk, I., Poncet, D. and Cohen, J. (2003). Rotavirus Nonstructural Protein NSP5 Interacts with Major Core Protein VP2. *Journal of virology* 77, 1757

Bertolotti-Ciarlet, A., Ciarlet, M., Crawford, S.E., Conner, M.E. and Estes, M.K. (2003). Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. *Vaccine* 21, 3885-3900

Chen, J.Z., Settembre, E.C., Aoki, A.T., Zhang, X., Bellamy, A.R., Dormitzer, P.R., Harrison, S.C. and Grigorieff, N. (2009). Molecular interactions in rotavirus assembly and uncoating seen by high-resolution cryo-EM. *PNAS* 106, 10644-10648

Crawford, S.E., Estes, M.K., Ciarlet, M., Barone, C., O'Neal, C.M., Cohen, J. and Conner, M.E. (1999). Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. *Journal of Virology* 73, 4813- 4822

Crawford, S.E., Labbe, M., Cohen, J., Burroughs, M.H., Zhou, Y.J. and Estes, M.K. (1994). Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. *Journal of virology* 68, 5945-5952

Denisova, E.R., Dowling, W., LaMonica, R., Shaw, R., Scarlata, S., Ruggeri, F. and Mackow, E.R. (1999). Rotavirus Capsid Protein VP5\* Permeabilizes Membranes. *Journal of Virology* 73 3147-3153

Dennehy, P.H. (2007). Rotavirus vaccines - An update. *Vaccine* 25, 3137-3141

Estes M.K (1996). Rotavirus and their replication. *Fields Virology* 2, 1625-1655

Fabbretti, E., Afrikanova, I., Vascotto, F. and Burrone, O.R. (1999). Two nonstructural rotavirus proteins, NSP2 and NSP5, form viroplasm-like structures in vivo. *J Gen Virol* 80 333-9.

Favacho, A.R., Kurtenbach, E., Sardi, S.I. and Gouvea, V.S. (2006). Cloning, expression, and purification of recombinant bovine rotavirus hemagglutinin, VP8\*, in *Escherichia coli*. *Protein Expression and Purification* 46, 196-203

Gentsch, J.R., Laird, A.R., Bielfelt, B., Griffin, D.D., Bányai, K., Ramachandran, M., Jain, V., Cunliffe, N.A., Nakagomi, O., Kirkwood, C.D., Fischer, T.K., Parashar, U.D., Bresee, J.S., Jiang, B. and Glass, R.I. (2005). Serotype Diversity and Reassortment between Human and Animal Rotavirus Strains: Implications for Rotavirus Vaccine Programs *J Infect Dis.* 192 , S146-59

Glass, R.I., Parashar, U.D., Bresee, J.S., Turcios, R., Fischer, T.K., Widdowson, MA., Jiang, B. and Gentsch, J.R. (2006). Rotavirus vaccines: current prospects and future challenges. *Lancet* 368, 323–32

González, A.M., Nguyen, T.V., Azevedo, M.S. P., Jeong, K., Agarib, F., Iosef, C., Chang, K., Lovgren-Bengtsson, K., Morein, B. and Saif, L.J. (2004). Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. *Clinical & Experimental Immunology* 135 361–372

González, R.A., Espinosa, R., Romero, P., López, S. and Arias C.F. (2000). Relative localization of viroplasmic and endoplasmic reticulum-resident rotavirus proteins in infected cells. *Archives of Virology* 145, 1963–1973

Greenberg, H.B. and Estes, M.K. (2009). Rotaviruses: From Pathogenesis to Vaccination. *Gastroenterology* 136, 1939-1951

Hoshino, Y., Jones, R.W. and Kapikian, A.Z. (1998). Serotypic characterization of outer capsid spike protein VP4 of vervet monkey rotavirus SA11 strain. *Archives of Virology* 143, 1233-1244

Istrate, C., Hinkula, J., Charpilienne, A., Poncet, D., Cohen, J., Svensson, L. and Johansen, K. (2008). Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. *Vaccine* 26, 4594-4601

5 Khodabandehloo, M., Shamsi, S.M., Shahrabadi, Keyvani, H. and Bambai, B. (2009). Cloning and Expression of Simian Rotavirus Spike Protein (VP4) in Insect Cells by Baculovirus Expression System. *Iranian Biomedical Journal* 13 9-18

Kim, Y., Nielsen, P.R., Hodgins, D., Chang, K.O. and Saif, L.J. (2002). Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines. *Vaccine* 10 20, 1248–1258

Kovacs-Nolan J., Erika Sasaki, Dongwan Yoo, Yoshinori Mine, Cloning and Expression of Human Rotavirus Spike Protein, VP8\*, in *Escherichia coli*. *Biochemical and Biophysical Research Communications*, 282, 1183-1188

15 Lawton, J.A., Estes, M.K. and Venkataram, P.B.V. (2000). Mechanism of genome transcription in segmented dsRNA viruses. *Advances in Virus Research* 55, 185-214

Lopez, T., Camacho M., Zayas M., Najera R., Sanchez R., Arias C. F. and Lopez S. (2005). Silencing the Morphogenesis of Rotavirus. *Journal of Virology* 79, 184–92

Lundgren, O. and Svensson, L. (2001). Pathogenesis of Rotavirus diarrhoea. *Microbes and Infection* 3 1145-1156

20 Madore, H.P., Estes, M.K., Zarley, C.D., Hu, B., Parsons, S., Digravio, D., Greiner, S., Smith, R., Jiang, B., Corsaro, B., Barniak, V., Crawford, S. and Conner, M.E. (1999). Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. *Vaccine* 17, 2461-2471

25 Marusic, C., Rizza, P., Lattanzi, L., Mancini, C., Spada, M., Belardelli, F., Benvenuto, E. and Capone, I. (2001). Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. *Journal of Virology* 75, 8434–8439.

30 Matsumura, T., Itchoda, N. and Tsunemitsu, H. (2002). Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants. *Archives of Virology* 147, 1263-1270

Mena, J.A., Ramírez, O.T. and Palomares, L.A. (2006). Intracellular distribution of rotavirus structural proteins and virus-like particles expressed in the insect cellbaculovirus system. *Journal of Biotechnology* 122, 443-452

5 Meyer, J.C., Bergmann, C.C. and Bellamy, A.R. (1989). Interaction of rotavirus cores with the nonstructural glycoprotein NS28. *Virology* 171, 98-107

Molinari, P., Peralta, A. and Taboga, O. (2008). Production of rotavirus-like particles in *Spodoptera frugiperda* larvae. *Journal of Virological Methods* 147, 364-367

10 Nilsson, M., von Bonsdorff, C.H., Weclawicz, K., Cohen, J. and Svensson, L. (1998). Assembly of viroplasm and virus-like particles of rotavirus by a Semliki Forest virus replicon. *Virology* 242, 255-265

Nishikawa, K., Fukuhara, N., Liprandi, F., Green, K., Kapikian, A., Chanock, R. and Gorziglia, M. (1989). VP4 protein of porcine rotavirus strain OSU expressed by a baculovirus recombinant induces neutralizing antibodies. *Virology* 173, 631-637

15 O'Brien, G.J., Bryant, C.J., Voogd, C., Greenberg, H.B., Gardner, R.C. and Bellamy, A.R. (2000). Rotavirus VP6 expressed by PVX vectors in *Nicotiana benthamiana* coats PVX rods and also assembles into virus-like particles. *Virology* 270, 444-453

Palombo, E.A. (1999). Genetic and antigenic diversity of human rotaviruses: potential impact on the success of candidate vaccines. *FEMS Microbiology Letters* 181, 1-8

20 Palomares, L.A. and Ramirez, O.T. (2009). Challenges for the production of virus-like particles in insect cells: The case of rotavirus-like particles. *BiochemicalEngineering Journal* 45(3), 158-167

Peralta, A., Molinari, P. and Taboga, O. (2009). Chimeric recombinant rotavirus-like particles as a vehicle for the display of heterologous epitopes. *Virology Journal* 6, 192

25 Ramachandran, M., Kirkwood, C.D., Unicomb, L., Cunliffe, N.A., Ward, R.L., Bhan, M.K., Clark, H.F., Glass, R.I. and Gentsch, J.R. (2000). Molecular characterization of serotype G9 rotavirus strains from a global collection. *Virology* 278, 436-444

30 Ribes, J.M., Ortego, J., Ceriani, J., Montava, R., Enjuanes, L. and Buesa, J. (2011). Transmissible gastroenteritis virus (TGEV)-based vectors with engineered murine tropism express the rotavirus VP7 protein and immunize mice against rotavirus. *Virology* 410 107-118

Rodríguez-Limas, W.A., Tyo, K.E.J., Nielsen, J., Ramírez, O.T. and Palomares, L.A. (2011). Molecular and process design for rotavirus-like particle production in *Saccharomyces cerevisiae*. *Microb Cell Fact*. 10, 33

5 Saldana, S., Esquivel Guadarrama, F., Olivera Flores Tde, J., Arias, N., Lopez, S., Arias, C., Ruiz-Medrano, R., Mason, H., Mor, T., Richter, L., Arntzen, C.J. and Gomez Lim, M.A. (2006). Production of rotavirus-like particles in tomato (*Lycopersicon esculentum* L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. *Viral Immunology* 19, 42-53

10 Sanchez-Padilla, E., Grais, R.F., Guerin, P.J., Steele, A.D., Burny, M.E. and Luquero, F.J. (2009). Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. *Lancet Infectious Diseases* 9, 567-576.

15 Steele, A.D., Ivanoff, B. and African Rotavirus Network (2003). Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. *Vaccine* 21, 361-367

Tian, P., Ball, J.M., Zeng, C.Q.Y. and Estes, M.K. (1996). The Rotavirus Nonstructural Glycoprotein NSP4 Possesses Membrane Destabilization Activity. *Journal of Virology* 70, 6973-6981

20 Thongprachum, A., Chaimongkol, N., Khamrin, P., Pantip, C., Mizuguchi, M., Ushijima, H. and Maneekarn, N. (2010). A novel multiplex RT-PCR for identification of VP6 subgroups of human and porcine rotaviruses, *Journal of Virological Methods*, 168, 191-196

25 Trabelsi, A., Peenze, I., Pager, C., Jeddi, M. and Steele, D. (2000). Distribution of Rotavirus VP7 Serotypes and VP4 Genotypes Circulating in Sousse, Tunisia, from 1995 to 1999: Emergence of Natural Human Reassortants. *Journal of Clinical Microbiology* 38, 3415-3419

Varani, G. and Allain, F.H-T. (2002). How a rotavirus hijacks the human protein synthesis machinery. *Nature Structural Biology* 9, 158 – 160.

30 Vende, P., Taraporewala, Z.F. and Patton, J.T. (2002). RNA-Binding Activity of the Rotavirus Phosphoprotein NSP5 Includes Affinity for Double-Stranded RNA. *Journal of Virology* 76, 5291-5299.

Vesikari, T., Karvonen, A., Korhonen, T., Espo, M., Lebacqz, E., Forster, J., Zepp, F., Delem, A. and De Vos, B. (2004). Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. *Vaccine* 22, 2836-2842

5 Vézina, L.-P., Faye, L., Lerouge, P., D'Aoust, M.-A., Marquet-Blouin, E., Burel, C., Lavoie, P.-O., Bardor, M. and Gomord, V. (2009), Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. *Plant Biotechnology Journal* 7, 442-455.

10 Zhou, B., Zhang, Y., Wang, X., Dong, J., Wang, B., Han, C., Yu, J., Li, D. (2010). Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. *Vaccine* 28, 6021-6027

15 Zhou, H., Guo, L., Wang, M., Qu, J., Zhao, Z., Wang, J. and Hung, T. (2011). Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. *Virology Journal* 8, 3

[00257] All citations are hereby incorporated by reference.

[00258] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the  
20 invention as defined in the claims.

## CLAIMS

1. A method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:
- 5 a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the
- 10 plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of the plant or plant cell,
- wherein the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated native signal peptide, or comprises a
- 15 nucleotide sequence encoding a non-native signal peptide,
- b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,
- c) harvesting the plant, portion of the plant or plant cell, and
- 20 d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.
2. The method of claim 1, wherein a fourth nucleic acid comprising a fourth regulatory region active in the plant and operatively linked to a fourth nucleotide sequence encoding a fourth rotavirus structural protein is introduced into the plant,
- 25 portion of the plant or plant cell in step a), and is expressed when incubating the plant, portion of a plant or plant cell in step b), wherein the fourth rotavirus structural protein is VP4.



3. The method of claim 1, wherein the first, second, and third nucleic acid are introduced into the plant, portion of the plant or plant cell in a ratio of 1:1:1.
4. The method of claim 2, wherein the first, second, third and fourth nucleic acid are introduced into the plant, portion of the plant or plant cell in a ratio of 1:1:1:1.
- 5 5. The method of claim 1 or 2, wherein the codon usage of the nucleotide sequence is adjusted to preferred human codon usage, increased GC content, or a combination thereof.
6. The method of claim 1, wherein the non-native signal peptide is a protein disulfide isomerase signal peptide.
- 10 7. The method of claim 1, wherein the first, second and third nucleotide sequence is operatively linked to a translation enhancer element.
8. The method of claim 7, wherein the translation enhancer element comprises a Cowpea Mosaic Virus (CPMV) regulatory region.
9. The method of claim 1, wherein the first, second or third nucleotide sequence or a  
15 combination thereof is operatively linked to a Cowpea Mosaic Virus (CPMV) regulatory region.
10. The method of claim 2, wherein the first, second, third or fourth nucleotide sequence or a combination thereof is operatively linked to a Cowpea Mosaic Virus (CPMV) regulatory region.
- 20 11. An RLP produced by the method of any one of claims 1 to 10, wherein the RLP is of a size from 70-100.
12. A composition comprising an effective dose of the RLP of claim 11 for inducing an immune response in a subject, and a pharmaceutically acceptable carrier.
13. The method of claim 1 wherein the nucleotide sequence encoding VP2 comprises  
25 from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 45, the nucleotide sequence encoding VP6 comprises

from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:46, and the nucleotide sequence encoding VP7 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 19, 20, 48, 49, 52, 53, 54 or 57.

5 14. The method of claim 2 wherein the nucleotide sequence encoding VP2 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 45, the nucleotide sequence encoding VP6 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO:17, SEQ ID NO:18 or SEQ ID NO:46, the nucleotide sequence encoding VP7 comprises  
10 from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 19, 20, 48, 49, 52, 53, 54 or 57, and the nucleotide sequence encoding VP4 comprises from 80% to 100% identity with a nucleotide sequence as defined by SEQ ID NO: 15, 16, 47, 50, or 51.

15 15. A method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell comprising:

a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second  
20 nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and

25 wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,

b) incubating the plant, portion of the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the  
30 RLP, the RLP comprising VP2, VP6 and VP7,

c) harvesting the plant, portion of the plant or plant cell, and

d) extracting the RLPs from the plant, portion of the plant or plant cell in the presence of calcium and purifying the RLPs in the presence of calcium.

5 16. The method of claim 15, wherein the plant, portion of the plant or plant cell is provided with a fourth nucleic acid comprising a fourth regulatory region active in the plant and operatively linked to a fourth nucleotide sequence encoding a fourth rotavirus structural protein and the fourth rotavirus structural protein is expressed when incubating the plant, portion of the plant or plant cell in step b), wherein the fourth  
10 rotavirus structural protein is VP4.

17. The method of claim 15, wherein the non-native signal peptide is a protein disulfide isomerase signal peptide.

18. An RLP produced by the method of claim 15 or 16, wherein the RLP is of a size from 70-100.

15 19. A composition comprising an effective dose of the RLP of claim 18 for inducing an immune response in a subject, and a pharmaceutically acceptable carrier.

20. A method of inducing immunity to a rotavirus infection in a subject, comprising administering the composition of claim 19.

21. A method of inducing immunity to a rotavirus infection in a subject, comprising  
20 administering the composition of claim 12.

22. Use of the composition of claim 19 in the manufacture of a medicament for inducing immunity to a rotavirus infection in a subject.

23. Use of the composition of claim 12 in the manufacture of a medicament for inducing immunity to a rotavirus infection in a subject.

24. A method of producing a rotavirus like particle (RLP) in a plant, portion of a plant or plant cell, comprising:
- 5 a) introducing a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein selected from one of VP2, VP6 and VP7, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein selected from one of VP2, VP6 and VP7, and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein selected from one of VP2, VP6 and VP7, into the plant, portion of a the plant or plant cell, wherein the first, second or third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide, or
- 10 a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,
- 15 a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,
- 20 a) providing the plant, portion of the plant or plant cell comprising a first nucleic acid comprising a first regulatory region active in the plant operatively linked to a first nucleotide sequence encoding a first rotavirus structural protein, a second nucleic acid comprising a second regulatory region active in the plant operatively linked to a second nucleotide sequence encoding a second rotavirus structural protein and a third nucleic acid comprising a third regulatory region active in the plant operatively linked to a third nucleotide sequence encoding a third rotavirus structural protein, wherein the first rotavirus structural protein is VP2, the second rotavirus structural protein is VP6 and the third rotavirus structural protein is VP7, and wherein the third nucleotide sequence encoding VP7 comprises a nucleotide sequence encoding a truncated signal peptide, or comprises a nucleotide sequence encoding a non-native signal peptide,
- 25 b) incubating the plant, portion of a the plant or plant cell under conditions that permit the transient expression of the first, second and third nucleic acid, thereby producing the RLP, the RLP comprising VP2, VP6 and VP7,
- c) harvesting the plant, portion of the plant or plant cell.




Figure 1




Figure 2






Figure 3

**Figure 4**





**Figure 5**





Figure 6

**Figure 7**




Figure 8





Figure 9



**Figure 10**




Figure 11




Figure 12






Figure 13





Figure 14



**Figure 15**

**Figure 16A -1****Rotavirus VP2**Gene Name: **G9P6\_VP2**

Gene length: 2700 bp

Optimized for expression in:

*Nicotiana tabacum*

```

1      GGTACCGAATTCGGACGCGTTCGTTCCATGGCTTACCGTAAAAGGGTGCTAGGCGTGAA
-----+-----+-----+-----+-----+-----+
CCATGGCTTAAGCCTGCGCAAGCAAGGTACCGAATGGCATTTCACGATCCGCACTT
SEQ ID NO:1 G_R_V_R_S_M_A_Y_R_K_R_G_A_R_R_E_

61      GCTAACCTCAACAACAACGATAGGATGCAAGAGAAGATCGATGAGAAGCAGGATTCCAAC
-----+-----+-----+-----+-----+-----+
CGATTGGAGTTGTTGTTGCTATCCTACGTTCTCTTCTAGCTACTCTTCGTCCTAAGGTTG
A_N_L_N_N_N_D_R_M_Q_E_K_I_D_E_K_Q_D_S_N_

121     AAGATCCAGCTCTCCGATAAGGTGCTCTCCAAGAAAGAAGAGATCGTTACTGATTCCCAC
-----+-----+-----+-----+-----+-----+
TTCTAGGTCGAGAGGCTATTCCACGAGAGGTTCTTTCTTCTCTAGCAATGACTAAGGGTG
K_I_Q_L_S_D_K_V_L_S_K_K_E_E_I_V_T_D_S_H_

181     GAAGAGGTGAAGGTGACAGATGAGCTTAAGAAGTCCACAAAAGAAGAGTCCAAGCAGCTC
-----+-----+-----+-----+-----+-----+
CTTCTCCACTTCCACTGTCTACTCGAATTCTTCAGGTGTTTTCTTCTCAGGTTCTGTCGAG
E_E_V_K_V_T_D_E_L_K_K_S_T_K_E_E_S_K_Q_L_

241     CTTGAGGTGCTCAAGACAAAAGAGGAACACCAGAAAGAGATCCAGTACGAGATCCTCCAA
-----+-----+-----+-----+-----+-----+
GAACTCCACGAGTTCTGTTTTCTCTTGTGGTCTTTCTCTAGGTCATGCTCTAGGAGGTT
L_E_V_L_K_T_K_E_E_H_Q_K_E_I_Q_Y_E_I_L_Q_

```

Figure 16A -2

AAGACTATCCCAACTTTTCGAGCCAAAAGAGACTATCCTCAGGAAGCTTGAGGATATCCAG  
 301 -----+-----+-----+-----+-----+-----+  
 TTCTGATAGGGTTGAAAGCTCGGTTTCTCTGATAGGAGTCCTTCGAACTCCTATAGGTC  
 K \_ T \_ I \_ P \_ T \_ F \_ E \_ P \_ K \_ E \_ T \_ I \_ L \_ R \_ K \_ L \_ E \_ D \_ I \_ Q \_

CCAGAGCTTGCTAAGAAGCAGACTAAGCTCTTCAGGATCTTCGAGCCAAAGCAGCTCCCA  
 361 -----+-----+-----+-----+-----+-----+  
 GGTCTCGAACGATTCTTCGTCTGATTTCGAGAAGTCCTAGAAGCTCGGTTTCGTTCGAGGGT  
 P \_ E \_ L \_ A \_ K \_ K \_ Q \_ T \_ K \_ L \_ F \_ R \_ I \_ F \_ E \_ P \_ K \_ Q \_ L \_ P \_

ATCTACCGTGCTAACGGTGAAAGGGAACCTAGGAACAGGTGGTACTGGAAGCTCAAGAAG  
 421 -----+-----+-----+-----+-----+-----+  
 TAGATGGCACGATTGCCACTTTCCTTGAATCCTTGTCACCATGACCTTCGAGTTCTTC  
 I \_ Y \_ R \_ A \_ N \_ G \_ E \_ R \_ E \_ L \_ R \_ N \_ R \_ W \_ Y \_ W \_ K \_ L \_ K \_ K \_

GATACTCTCCCAGACGGTGATTACGATGTGAGAGAGTACTTCCTCAACCTCTACGATCAG  
 481 -----+-----+-----+-----+-----+-----+  
 CTATGAGAGGGTCTGCCACTAATGTACACTCTCTCATGAAGGAGTTGGAGATGCTAGTC  
 D \_ T \_ L \_ P \_ D \_ G \_ D \_ Y \_ D \_ V \_ R \_ E \_ Y \_ F \_ L \_ N \_ L \_ Y \_ D \_ Q \_

GTGCTCACTGAGATGCCAGATTACCTCCTCCTCAAGGATATGGCTGTGGAGAACAAGAAC  
 541 -----+-----+-----+-----+-----+-----+  
 CACGAGTGACTCTACGGTCTAATGGAGGAGGAGTTCTTATACCGACACCTCTTGTTCTTG  
 V \_ L \_ T \_ E \_ M \_ P \_ D \_ Y \_ L \_ L \_ L \_ K \_ D \_ M \_ A \_ V \_ E \_ N \_ K \_ N \_

TCCAGGGATGCTGGAAAGGTGGTGGATTCCGAGACTGCTTCCATCTGTGATGCTATCTTC  
 601 -----+-----+-----+-----+-----+-----+  
 AGGTCCCTACGACCTTTCACACCTTAAGGCTCTGACGAAGGTAGACACTACGATAGAAG  
 S \_ R \_ D \_ A \_ G \_ K \_ V \_ V \_ D \_ S \_ E \_ T \_ A \_ S \_ I \_ C \_ D \_ A \_ I \_ F \_

CAGGATGAAGAGACTGAGGGTGCTGTGAGGCGTTTCATTGCTGAGATGAGGCAGAGGGTT  
 661 -----+-----+-----+-----+-----+-----+  
 GTCCTACTTCTCTGACTCCACGACACTCCGCAAAGTAACGACTCTACTCCGTCTCCCAA  
 Q \_ D \_ E \_ E \_ T \_ E \_ G \_ A \_ V \_ R \_ R \_ F \_ I \_ A \_ E \_ M \_ R \_ Q \_ R \_ V \_

CAGGCTGATAGGAACGTGGTGAACCTACCCATCCATCCTCCACCCAATCGATTACGCTTTC  
 721 -----+-----+-----+-----+-----+-----+  
 GTCCGACTATCCTTGCACTTGTGAGGTTAGGTAGGAGGTGGGTTAGCTAATGCGAAAG  
 Q \_ A \_ D \_ R \_ N \_ V \_ V \_ N \_ Y \_ P \_ S \_ I \_ L \_ H \_ P \_ I \_ D \_ Y \_ A \_ F \_

AACGAGTACTTCTTCAGCACCAGCTTGTGGAGCCACTCAACAACGATATCATCTTCAAC  
 781 -----+-----+-----+-----+-----+-----+  
 TTGCTCATGAAGGAAGTCGTGGTCGAACACCTCGGTGAGTTGTTGCTATAGTAGAAGTTG  
 N \_ E \_ Y \_ F \_ L \_ Q \_ H \_ Q \_ L \_ V \_ E \_ P \_ L \_ N \_ N \_ D \_ I \_ I \_ F \_ N \_

Figure 16A -3

TACATCCCAGAGAGGATTAGGAACGACGTTAACTACATCCTCAACATGGATAGGAACCTC  
 841 -----+-----+-----+-----+-----+-----+  
 ATGTAGGGTCTCTCCTAATCCTTGCTGCAATTGATGTAGGAGTTGTACCTATCCTTGGAG  
Y\_I\_P\_E\_R\_I\_R\_N\_D\_V\_N\_Y\_I\_L\_N\_M\_D\_R\_N\_L

CCATCCACTGCTCGTTACATCAGGCCAAACCTCCTCCAGGATAGGCTCAACCTCCACGAT  
 901 -----+-----+-----+-----+-----+-----+  
 GGTAGGTGACGAGCAATGTAGTCCGGTTTGGAGGAGGTCCTATCCGAGTTGGAGGTGCTA  
P\_S\_T\_A\_R\_Y\_I\_R\_P\_N\_L\_L\_Q\_D\_R\_L\_N\_L\_H\_D

AACTTCGAGTCCCTCTGGGATACAATCACTACTTCCAACATACATTCTCGCTCGTTCCGTG  
 961 -----+-----+-----+-----+-----+-----+  
 TTGAAGCTCAGGGAGACCCTATGTTAGTGATGAAGGTTGATGTAAGAGCGAGCAAGGCAC  
N\_F\_E\_S\_L\_W\_D\_T\_I\_T\_T\_S\_N\_Y\_I\_L\_A\_R\_S\_V

GTGCCAGATCTCAAAGAACTCGTGTCCACTGAGGCTCAGATCCAGAAGATGTCCCAGGAT  
 1021 -----+-----+-----+-----+-----+-----+  
 CACGGTCTAGAGTTTCTTGAGCACAGGTGACTCCGAGTCTAGGTCTTCTACAGGGTCCTA  
V\_P\_D\_L\_K\_E\_L\_V\_S\_T\_E\_A\_Q\_I\_Q\_K\_M\_S\_Q\_D

CTCCAGCTTGAGGCTCTCACTATCCAGTCCGAGACTCAGTTCCTCACTGGTATCAACTCC  
 1081 -----+-----+-----+-----+-----+-----+  
 GAGGTGCAACTCCGAGAGTGATAGGTCAGGCTCTGAGTCAAGGAGTGACCATAGTTGAGG  
L\_Q\_L\_E\_A\_L\_T\_I\_Q\_S\_E\_T\_Q\_F\_L\_T\_G\_I\_N\_S

CAGGCTGCTAACGATTGCTTCAAGACTCTCATTGCTGCTATGCTCTCCCAGAGGACTATG  
 1141 -----+-----+-----+-----+-----+-----+  
 GTCCGACGATTGCTAACGAAGTTCTGAGAGTAACGACGATACGAGAGGGTCTCCTGATAC  
Q\_A\_A\_N\_D\_C\_F\_K\_T\_L\_I\_A\_A\_M\_L\_S\_Q\_R\_T\_M

TCCCTCGATTTTCGTGACTACTAACTATATGTCCCTCATCTCCGGAATGTGGCTCTTGACT  
 1201 -----+-----+-----+-----+-----+-----+  
 AGGGAGCTAAAGCACTGATGATTGATATACAGGGAGTAGAGGCCTTACACCGAGAACTGA  
S\_L\_D\_F\_V\_T\_T\_N\_Y\_M\_S\_L\_I\_S\_G\_M\_W\_L\_L\_T

GTGGTGCCAAACGATATGTTTCATCCGTGAGTCCCTTGTGGCTTGCCAGCTCGCTATCGTG  
 1261 -----+-----+-----+-----+-----+-----+  
 CACCACGGTTTGTATACAAGTAGGCACTCAGGGAACACCGAACGGTCGAGCGATAGCAC  
V\_V\_P\_N\_D\_M\_F\_I\_R\_E\_S\_L\_V\_A\_C\_Q\_L\_A\_I\_V

AACACTATCATCTACCCAGCTTTCGGAATGCAAAGGATGCACTACCGTAACGGTGATCCA  
 1321 -----+-----+-----+-----+-----+-----+  
 TTGTGATAGTAGATGGGTGAAAGCCTTACGTTTCCTACGTGATGGCATTGCCACTAGGT  
N\_T\_I\_I\_Y\_P\_A\_F\_G\_M\_Q\_R\_M\_H\_Y\_R\_N\_G\_D\_P

Figure 16A -4

```

CAGACTCCATTCCAGATCGCAGAGCAGCAGATCCAGAACTTCCAGGTGGCAAACCTGGCTC
1381 -----+-----+-----+-----+-----+-----+
GTCTGAGGTAAGGTCTAGCGTCTCGTCTAGGTCTTGAAGGTCCACCGTTTGACCGAG
Q T P F Q I A E Q Q I Q N F Q V A N W L

CACTTCGTGAACAACAACCAGTTCAGGCAGGCTGTGATCGATGGTGTGTTGAACCAGGTG
1441 -----+-----+-----+-----+-----+-----+
GTGAAGCACTTGTGTTGGTCAAGTCCGTCCGACACTAGCTACCACACAACCTTGGTCCAC
H F V N N N Q F R Q A V I D G V L N Q V

CTCAACGATAACATCCGTAACGGTCACGTGATCAACCAGCTCATGGAAGCTCTCATGCAA
1501 -----+-----+-----+-----+-----+-----+
GAGTTGCTATTGTAGGCATTGCCAGTGCCTAGTTGGTCGAGTACCTTCGAGAGTACGTT
L N D N I R N G H V I N Q L M E A L M Q

CTCTCCAGGCAGCAGTTCCTCAACTATGCCTATCGATTACAAGCGTTCCATCCAGAGGGGA
1561 -----+-----+-----+-----+-----+-----+
GAGAGGTCCGTCGTCAAGGTTGATACGGATAGCTAATGTTGCAAGGTAGGTCTCCCTT
L S R Q Q F P T M P I D Y K R S I Q R G

ATCCTCCTCCTTTCCAACAGGCTTGGACAGCTCGTGGATCTCACTAGGCTCCTCGCTTAC
1621 -----+-----+-----+-----+-----+-----+
TAGGAGGAGGAAAGGTTGTCCGAACCTGTCGAGCACCTAGAGTGATCCGAGGAGCGAATG
I L L L S N R L G Q L V D L T R L L A Y

AACTACGAGACTCTCATGGCTTGCATCACTATGAACATGCAGCACGTTTCAGACTCTCACT
1681 -----+-----+-----+-----+-----+-----+
TTGATGCTCTGAGAGTACCGAACGTAGTGATACTTGTACGTCGTGCAAGTCTGAGAGTGA
N Y E T L M A C I T M N M Q H V Q T L T

ACTGAGAAGCTCCAGCTCACTTCCGTGACTTCCCTCTGCATGCTCATCGGAAACGCTACT
1741 -----+-----+-----+-----+-----+-----+
TGACTCTTCGAGGTGAGTGAAGGCACTGAAGGGAGACGTACGAGTAGCCTTTGCGATGA
T E K L Q L T S V T S L C M L I G N A T

GTGATCCCATCCCCACAGACACTCTTCCACTACTACAACGTGAACGTGAACTTCCACTCC
1801 -----+-----+-----+-----+-----+-----+
CACTAGGGTAGGGGTGTCTGTGAGAAGGTGATGATGTTGCACTTGCCTTGAAGGTGAGG
V I P S P Q T L F H Y Y N V N V N F H S

AACTACAACGAGAGGATCAACGATGCTGTGGCTATCATCACTGCTGCTAACAGGCTTAAC
1861 -----+-----+-----+-----+-----+-----+
TTGATGTTGCTCTCCTAGTTGCTACGACACCGATAGTAGTGACGACGATTGTCCGAATTG
N Y N E R I N D A V A I I T A A N R L N

```

Figure 16A -5

```

CTCTACCAAAAGAAGATGAAGGCTATCGTTGAGGATTTCTCAAGAGGCTCTACATCTTC
1921 -----+-----+-----+-----+-----+-----+
GAGATGGTTTCTTCTACTTCCGATAGCAACTCCTAAAGGAGTTCTCCGAGATGTAGAAG
L_Y_Q_K_K_M_K_A_I_V_E_D_F_L_K_R_L_Y_I_F_

GATGTGTCCAGGGTGCCAGATGATCAGATGTACCGTCTTAGGGATAGGCTTAGGCTCCTC
1981 -----+-----+-----+-----+-----+-----+
CTACACAGGTCCCACGGTCTACTAGTCTACATGGCAGAATCCCTATCCGAATCCGAGGAG
D_V_S_R_V_P_D_D_Q_M_Y_R_L_R_D_R_L_R_L_L_

CCAGTGGAGATCAGAAGGCTCGATATCTTCAACCTCATCCTTATGAACATGGATCAGATC
2041 -----+-----+-----+-----+-----+-----+
GGTCACCTCTAGTCTTCCGAGCTATAGAAGTTGGAGTAGGAATACTTGTACCTAGTCTAG
P_V_E_I_R_R_L_D_I_F_N_L_I_L_M_N_M_D_Q_I_

GAGAGGGCTTCCGATAAGATCGCTCAGGGTGTTATTATCGCTTACCGTGATATGCACCTT
2101 -----+-----+-----+-----+-----+-----+
CTCTCCCGAAGGCTATTCTAGCGAGTCCCACAATAATAGCGAATGGCACTATACGTGGAA
E_R_A_S_D_K_I_A_Q_G_V_I_I_A_Y_R_D_M_H_L_

GAGAGGGATGAGATGTACGGATACGTGAACATTGCTAGGAACCTTGAGGGATTCCAGCAG
2161 -----+-----+-----+-----+-----+-----+
CTCTCCCTACTCTACATGCCTATGCACTTGTAACGATCCTTGGAACCTCCCTAAGGTCGTC
E_R_D_E_M_Y_G_Y_V_N_I_A_R_N_L_E_G_F_Q_Q_

ATCAACCTTGAAGAGCTTATGCGTTCCGGTGATTACGCTCAGATCACTAACATGCTCCTC
2221 -----+-----+-----+-----+-----+-----+
TAGTTGGAACCTCTCGAATACGCAAGGCCACTAATGCGAGTCTAGTGATTGTACGAGGAG
I_N_L_E_E_L_M_R_S_G_D_Y_A_Q_I_T_N_M_L_L_

AACAACCAGCCAGTGGCTCTTGTTGGTGCTCTCCCATTCATCACTGATTCCCTCCGTGATC
2281 -----+-----+-----+-----+-----+-----+
TTGTTGGTCGGTCACCGAGAACAACCACGAGAGGGTAAGTAGTGACTAAGGAGGCACTAG
N_N_Q_P_V_A_L_V_G_A_L_P_F_I_T_D_S_S_V_I_

TCCCTCATTGCTAAGTTGGATGCTACTGTGTTCGCTCAGATCGTGAAGCTCAGGAAAGTG
2341 -----+-----+-----+-----+-----+-----+
AGGGAGTAACGATTCAACCTACGATGACACAAGCGAGTCTAGCACTTCGAGTCCTTTTAC
S_L_I_A_K_L_D_A_T_V_F_A_Q_I_V_K_L_R_K_V_

GATACTCTCAAGCCAATCCTCTACAAGATCAACTCCGATTCCAACGATTTCTACCTCGTG
2401 -----+-----+-----+-----+-----+-----+
CTATGAGAGTTCGGTTAGGAGATGTTCTAGTTGAGGCTAAGGTTGCTAAAGATGGAGCAC
D_T_L_K_P_I_L_Y_K_I_N_S_D_S_N_D_F_Y_L_V_

```



**Figure 16A -6**

2461 GCTAACTACGATTGGGTGCCAACTTCCACTACAAAGGTGTACAAGCAGGTGCCACAGCAG  
-----+-----+-----+-----+-----+  
CGATTGATGCTAACCCACGGTTGAAGGTGATGTTTCCACATGTTTCGTCACGGTGTCGTC  
**A\_N\_Y\_D\_W\_V\_P\_T\_S\_T\_T\_K\_V\_Y\_K\_Q\_V\_P\_Q\_Q**

2521 TTCGATTTCGTAACCTCCATGCACATGCTCACTTCCAACCTCACTTTCCTGTGTACTCC  
-----+-----+-----+-----+-----+  
AAGCTAAAGGCATTGAGGTACGTGTACGAGTGAAGGTTGGAGTGAAAGTGACACATGAGG  
**F\_D\_F\_R\_N\_S\_M\_H\_M\_L\_T\_S\_N\_L\_T\_F\_T\_V\_Y\_S**

2581 GATCTCCTCGCTTTCGTGTCCGCTGATACTGTGGAGCCTATCAACGCTGTGGCTTTCGAT  
-----+-----+-----+-----+-----+  
CTAGAGGAGCGAAAGCACAGGCGACTATGACACCTCGGATAGTTGCGACACCGAAAGCTA  
**D\_L\_L\_A\_F\_V\_S\_A\_D\_T\_V\_E\_P\_I\_N\_A\_V\_A\_F\_D**

2641 AACATGAGGATTATGAACGAGCTTTGATGACTCGAGGGATCCTCTAGAGAA  
-----+-----+-----+-----+-----+  
TTGTACTCCTAATACTTGCTCGAACTACTGAGCTCCCTAGGAGATCTCTT  
**N\_M\_R\_I\_M\_N\_E\_L\_\*\_\*** SEQ ID NO: 1

TTCGAGCTC SEQ ID NO: 13  
-----+  
AAGCTCGAG SEQ ID NO: 14

**Figure 16B -1****Rotavirus VP4**

Gene name: **G9P6\_VP4**

Gene length: 2388 bp

Optimized for expression in: ***Nicotiana tabacum***

```

1  GGTACCGAATTCTGGACGCGTTTCGTTCCATGGCTTCCCTCATCTACCGTCAGTTGCTCACT
   -----+-----+-----+-----+-----+-----+
   CCATGGCTTAAGCCTGCGCAAGCAAGGTACCGAAGGGAGTAGATGGCAGTCAACGAGTGA
   SEQ ID NO 2 G_R_V_R_S_M_A_S_L_I_Y_R_Q_L_L_T_

61  AACTCCTACACTGTGGAGCTTTCGATGAGATCAACACTATCGGTTCCGAGAAGTCCCAG
   -----+-----+-----+-----+-----+-----+
   TTGAGGATGTGACACCTCGAAAGGCTACTCTAGTTGTGATAGCCAAGGCTCTTCAGGGTC
   N_S_Y_T_V_E_L_S_D_E_I_N_T_I_G_S_E_K_S_Q_

121 AACGTGACTATCAACCCAGGACCATTGCTCAGACTAACTACGCTCCAGTGACTTGGTCA
   -----+-----+-----+-----+-----+-----+
   TTGCACTGATAGTTGGGTCCTGGTAAGCGAGTCTGATTGATGCGAGGTCAGTGAACAGT
   N_V_T_I_N_P_G_P_F_A_Q_T_N_Y_A_P_V_T_W_S_

181 CACGGTGAAGTGAACGATTCCACTACTATCGAGCCAGTGCTCGATGGACCATAACAGCCA
   -----+-----+-----+-----+-----+-----+
   GTGCCACTTCACTTGCTAAGGTGATGATAGCTCGGTCACGAGCTACCTGGTATGGTCGGT
   H_G_E_V_N_D_S_T_T_I_E_P_V_L_D_G_P_Y_Q_P_

241 ACTAACTTCAAGCCACCAAACGATTACTGGATTCTCCTCAACCCAACTAACCAGCAGGTG
   -----+-----+-----+-----+-----+-----+
   TGATTGAAGTTCGGTGGTTTGCTAATGACCTAAGAGGAGTTGGGTTGATTGGTCGTCAC
   T_N_F_K_P_P_N_D_Y_W_I_L_L_N_P_T_N_Q_Q_V_

301 GTGCTTGAGGGAACATAACAAGACTGATATCTGGGTGGCACTCCTTCTGTGGAGCCAAAC
   -----+-----+-----+-----+-----+-----+
   CACGAACCTCCCTTGATTGTTCTGACTATAGACCCACCGTGAGGAAGAACACCTCGGTTTG
   V_L_E_G_T_N_K_T_D_I_W_V_A_L_L_L_V_E_P_N_

361 GTGACTAACCAGTCCAGGCAGTACACTCTCTCGGAGAGACTAAGCAGATCACTGTGGAG
   -----+-----+-----+-----+-----+-----+
   CACTGATTGGTCAGGTCCGTCATGTGAGAGAAGCCTCTCTGATTCTAGTGACACCTC
   V_T_N_Q_S_R_Q_Y_T_L_F_G_E_T_K_Q_I_T_V_E_

```

**Figure 16B -2**

```

AACAACACTAACAAGTGAAGTTCTTCGAGATGTTTCAGGTCCAACGTGAACGCTGAGTTC
421 -----+-----+-----+-----+-----+-----+
TTGTTGTGATTGTTTCACCTTCAAGAAGCTCTACAAGTCCAGGTGCACTTGCGACTCAAG
N__N__T__N__K__W__K__F__F__E__M__F__R__S__N__V__N__A__E__F__

CAGCACAAAGAGGACTCTCACTTCCGATACAAAGCTCGCTGGTTTTATGAAGTTCTACAAC
481 -----+-----+-----+-----+-----+-----+
GTCGTGTTCTCCTGAGAGTGAAGGCTATGTTTCGAGCGACCAAAATACTTCAAGATGTTG
Q__H__K__R__T__L__T__S__D__T__K__L__A__G__F__M__K__F__Y__N__

TCTGTGTGGACTTTCCACGGTGAAACTCCACACGCTACTACTGATTACTCCTCCACTTCC
541 -----+-----+-----+-----+-----+-----+
AGACACACCTGAAAGGTGCCACTTTGAGGTGTGCGATGATGACTAATGAGGAGGTGAAGG
S__V__W__T__F__H__G__E__T__P__H__A__T__T__D__Y__S__S__T__S__

AACCTTTCCGAGGTGGAGACTGTGATCCACGTGGAGTTCTACATCATCCCAAGGTCCCAA
601 -----+-----+-----+-----+-----+-----+
TTGGAAAGGCTCCACCTCTGACACTAGGTGCACCTCAAGATGTAGTAGGGTTCCAGGGTT
N__L__S__E__V__E__T__V__I__H__V__E__F__Y__I__I__P__R__S__Q__

GAGTCTAAGTGCTCCGAGTACATCAACACTGGACTCCCACCAATGCAAAACACTAGGAAC
661 -----+-----+-----+-----+-----+-----+
CTCAGATTACGAGGCTCATGTAGTTGTGACCTGAGGGTGGTTACGTTTGTGATCCTTG
E__S__K__C__S__E__Y__I__N__T__G__L__P__P__M__Q__N__T__R__N__

ATCGTGCCAGTGGCTTTGTCTCTCGTTCCGTGACTTACCAGAGGGCTCAGGTGAACGAG
721 -----+-----+-----+-----+-----+-----+
TAGCACGGTCAACGAAACAGGAGAGCAAGGCACTGAATGGTCTCCCGAGTCCACTTGCTC
I__V__P__V__A__L__S__S__R__S__V__T__Y__Q__R__A__Q__V__N__E__

GATATCATCATCTCCAAGACTTCCCTCTGGAAAGAGATGCAGTACAACAGGGATATTATC
781 -----+-----+-----+-----+-----+-----+
CTATAGTAGTAGAGGTTCTGAAGGGAGACCTTTCTCTACGTCATGTTGTCCCTATAATAG
D__I__I__I__S__K__T__S__L__W__K__E__M__Q__Y__N__R__D__I__I__

ATCAGGTTCAAGTTCAACAACCTCCATCGTGAAGCTCGGAGGACTCGGATACAAGTGGAGT
841 -----+-----+-----+-----+-----+-----+
TAGTCCAAGTTCAAGTTGTTGAGGTAGCACTTCGAGCCTCCTGAGCCTATGTTTCACCTCA
I__R__F__K__F__N__N__S__I__V__K__L__G__G__L__G__Y__K__W__S__

GAGATCTCCTTCAAGGCTGCTAACTACCAGTACTCCTACCTCAGGGATGGTGAACAGGTG
901 -----+-----+-----+-----+-----+-----+
CTCTAGAGGAAGTTCCGACGATTGATGGTCATGAGGATGGAGTCCCTACCACTTGTCAC
E__I__S__F__K__A__A__N__Y__Q__Y__S__Y__L__R__D__G__E__Q__V__

```

Figure 16B-3

ACAGCTCACACTACTTGCTCCGTGAACGGTGTTAACAACCTTCTCCTACAACGGTGGTTCC  
 961 -----+-----+-----+-----+-----+-----+  
 TGTCGAGTGTGATGAACGAGGCACTTGCCACAATTGTTGAAGAGGATGTTGCCACCAAGG  
 T \_ A \_ H \_ T \_ T \_ C \_ S \_ V \_ N \_ G \_ V \_ N \_ N \_ F \_ S \_ Y \_ N \_ G \_ G \_ S \_  
  
 CTCCCAACTGATTTCTCCGTGTCCCGTTACGAGGTGATCAAAGAGAACTCCTACGTTTAC  
 1021 -----+-----+-----+-----+-----+-----+  
 GAGGGTTGACTAAAGAGGCACAGGGCAATGCTCCACTAGTTTCTCTTGAGGATGCAAATG  
 L \_ P \_ T \_ D \_ F \_ S \_ V \_ S \_ R \_ Y \_ E \_ V \_ I \_ K \_ E \_ N \_ S \_ Y \_ V \_ Y \_  
  
 GTGGATTACTGGGATGATTCCCAGGCTTTCAGGAACATGGTGTATGTTAGATCCCTCGCT  
 1081 -----+-----+-----+-----+-----+-----+  
 CACCTAATGACCCTACTAAGGGTCCGAAAGTCCTTGTACCACATACAATCTAGGGAGCGA  
 V \_ D \_ Y \_ W \_ D \_ D \_ S \_ Q \_ A \_ F \_ R \_ N \_ M \_ V \_ Y \_ V \_ R \_ S \_ L \_ A \_  
  
 GCTAACCTCAACTCCGTGAAGTGCTCCGGTGGAACTACAACCTCCAGATCCCAGTGGGA  
 1141 -----+-----+-----+-----+-----+-----+  
 CGATTGGAGTTGAGGCACCTTACGAGGCCACCTTTGATGTTGAAGGTCTAGGGTCACCTT  
 A \_ N \_ L \_ N \_ S \_ V \_ K \_ C \_ S \_ G \_ G \_ N \_ Y \_ N \_ F \_ Q \_ I \_ P \_ V \_ G \_  
  
 GCTTGGCCAGTGATGTCTGGTGGAGCTGTGTCTCTCCACTTCGCTGGTGTACTACTCTCC  
 1201 -----+-----+-----+-----+-----+-----+  
 CGAACCGGTCACTACAGACCACCTCGACACAGAGAGGTGAAGCGACCACAATGTGAGAGG  
 A \_ W \_ P \_ V \_ M \_ S \_ G \_ G \_ A \_ V \_ S \_ L \_ H \_ F \_ A \_ G \_ V \_ T \_ L \_ S \_  
  
 ACTCAGTTCAGTGATTTCTGTGTCCTCAACTCCCTCAGGTTCCAGGTTCTCCCTCACTGTG  
 1261 -----+-----+-----+-----+-----+-----+  
 TGAGTCAAGTGACTAAAGCACAGGGAGTTGAGGGAGTCCAAGTCCAAGAGGGAGTGACAC  
 T \_ Q \_ F \_ T \_ D \_ F \_ V \_ S \_ L \_ N \_ S \_ L \_ R \_ F \_ R \_ F \_ S \_ L \_ T \_ V \_  
  
 GAAGAGCCACCATTCTCCATCCTCAGGACTAGGGTGTCCGGACTTTACGGACTCCCAGCT  
 1321 -----+-----+-----+-----+-----+-----+  
 CTTCTCGGTGGTAAGAGGTAGGAGTCCTGATCCCACAGGCCTGAAATGCCTGAGGGTCGA  
 E \_ E \_ P \_ P \_ F \_ S \_ I \_ L \_ R \_ T \_ R \_ V \_ S \_ G \_ L \_ Y \_ G \_ L \_ P \_ A \_  
  
 TTCAACCCAAACAACGGACACGAGTACTACGAGATCGCTGGACGTTTCTCCCTTATCTCC  
 1381 -----+-----+-----+-----+-----+-----+  
 AAGTTGGGTTTGTGCTGTGCTCATGATGCTCTAGCGACCTGCAAAGAGGGAATAGAGG  
 F \_ N \_ P \_ N \_ N \_ G \_ H \_ E \_ Y \_ Y \_ E \_ I \_ A \_ G \_ R \_ F \_ S \_ L \_ I \_ S \_  
  
 CTCGTGCCATCCAACGATGATTACCAGACTCCAATTATGAACTCCGTGACTGTGAGGCAG  
 1441 -----+-----+-----+-----+-----+-----+  
 GAGCACGGTAGGTTGCTACTAATGGTCTGAGGTTAATACTTGAGGCACTGACACTCCGTC  
 L \_ V \_ P \_ S \_ N \_ D \_ D \_ Y \_ Q \_ T \_ P \_ I \_ M \_ N \_ S \_ V \_ T \_ V \_ R \_ Q \_

**Figure 16B-4**

1501 **GATCTTGAGAGGCAGCTCGGAGATCTCAGGGAAGAGTTCAACTCCCTCTCCCAAGAGATC**  
 -----+-----+-----+-----+-----+-----+  
 CTAGAACTCTCCGTCGAGCCTCTAGAGTCCCTTCTCAAGTTGAGGGAGAGGGTTCTCTAG  
**D\_L\_E\_R\_Q\_L\_G\_D\_L\_R\_E\_E\_F\_N\_S\_L\_S\_Q\_E\_I\_**

1561 **GCTATGACTCAGCTCATCGATCTCGCTCTCCTCCCACTCGATATGTTCTCCATGTTCTCT**  
 -----+-----+-----+-----+-----+-----+  
 CGATACTGAGTCGAGTAGCTAGAGCGAGAGGGTGAGCTATACAAGAGGTACAAGAGA  
**A\_M\_T\_Q\_L\_I\_D\_L\_A\_L\_L\_P\_L\_D\_M\_F\_S\_M\_F\_S\_**

1621 **GGTATCAAGTCCACTATCGATGTGGCTAAGTCTATGGTGACTAAGGTGATGAAGAAGTTC**  
 -----+-----+-----+-----+-----+-----+  
 CCATAGTTCAGGTGATAGCTACACCGATTGAGATACCACTGATTCCACTACTTCTTCAAG  
**G\_I\_K\_S\_T\_I\_D\_V\_A\_K\_S\_M\_V\_T\_K\_V\_M\_K\_K\_F\_**

1681 **AAGAAGTCCGGAAGTCTGCTACTTCCATCTCCGAGCTTACTGGATCTCTCTCCAACGCTGCT**  
 -----+-----+-----+-----+-----+-----+  
 TTCTTCAGGCCTGAGCGATGAAGGTAGAGGCTCGAATGACCTAGAGAGAGGTTGCGACGA  
**K\_K\_S\_G\_L\_A\_T\_S\_I\_S\_E\_L\_T\_G\_S\_L\_S\_N\_A\_A\_**

1741 **TCTTCTGTGTCTAGGTCTCTCCATCAGGTCCAACATCTCCTCCATCTCAGTGTGGACT**  
 -----+-----+-----+-----+-----+-----+  
 AGAAGACACAGATCCAGGAGGAGGTAGTCCAGGTTGTAGAGGAGGTAGAGTACACCTGA  
**S\_S\_V\_S\_R\_S\_S\_S\_I\_R\_S\_N\_I\_S\_S\_I\_S\_V\_W\_T\_**

1801 **GATGTGTCCGAGCAGATCGCTGGATCTTCCGATTCCGTGCGTAACATCTCCACTCAGACT**  
 -----+-----+-----+-----+-----+-----+  
 CTACACAGGCTCGTCTAGCGACCTAGAAGGCTAAGGCACGCATTGTAGAGGTGAGTCTGA  
**D\_V\_S\_E\_Q\_I\_A\_G\_S\_S\_D\_S\_V\_R\_N\_I\_S\_T\_Q\_T\_**

1861 **TCCGCTATCTCCAAGAGGCTTAGGCTCAGAGAGATCACTACTCAGACTGAGGGAATGAAC**  
 -----+-----+-----+-----+-----+-----+  
 AGGCGATAGAGGTTCTCCGAATCCGAGTCTCTCTAGTGATGAGTCTGACTCCCTTACTTG  
**S\_A\_I\_S\_K\_R\_L\_R\_L\_R\_E\_I\_T\_T\_Q\_T\_E\_G\_M\_N\_**

1921 **TTCGATGATATCTCCGCTGCTGTGCTCAAGACTAAGATCGATAGGTCCACTCACATCTCC**  
 -----+-----+-----+-----+-----+-----+  
 AAGCTACTATAGAGGCGACGACACGAGTTCTGATTCTAGCTATCCAGGTGAGTGTAGAGG  
**F\_D\_D\_I\_S\_A\_A\_V\_L\_K\_T\_K\_I\_D\_R\_S\_T\_H\_I\_S\_**

1981 **CCAGATACTCTCCAGATATCATCACTGAGTCCTCCGAGAAGTTCATCCCAAGCGTGCT**  
 -----+-----+-----+-----+-----+-----+  
 GGTCTATGAGAGGGTCTATAGTAGTGACTCAGGAGGCTCTTCAAGTAGGGTTTCGCACGA  
**P\_D\_T\_L\_P\_D\_I\_I\_T\_E\_S\_S\_E\_K\_F\_I\_P\_K\_R\_A\_**

**Figure 16B-5**

2041 TACCGTGTTCTCAAGGATGATGAGGTGATGGAAGCTGATGTGGATGGAAAGTTCTTCGCT  
 -----+-----+-----+-----+-----+-----+  
 ATGGCACAAGAGTTTCCTACTACTCCACTACCTTCGACTACACCTACCTTTCAAGAAGCGA  
 Y\_R\_V\_L\_K\_D\_D\_E\_V\_M\_E\_A\_D\_V\_D\_G\_K\_F\_F\_A\_

2101 TACAAAGTGGGAACCTTTCGAAGAGGTGCCATTTCGATGTGGATAAGTTCGTGGATCTCGTG  
 -----+-----+-----+-----+-----+-----+  
 ATGTTTCACCCCTTGAAAGCTTCTCCACGGTAAGCTACACCTATTCAAGCACCTAGAGCAC  
 Y\_K\_V\_G\_T\_F\_E\_E\_V\_P\_F\_D\_V\_D\_K\_F\_V\_D\_L\_V\_

2161 ACTGATTCCCCAGTGATCTCCGCTATCATCGATTTCAAGACTCTCAAGAACCTCAACGAT  
 -----+-----+-----+-----+-----+-----+  
 TGACTAAGGGGTCAGTAGAGGCGATAGTAGCTAAAGTTCTGAGAGTTCTTGAGATTGCTA  
 T\_D\_S\_P\_V\_I\_S\_A\_I\_I\_D\_F\_K\_T\_L\_K\_N\_L\_N\_D\_

2221 AACTACGGAATCACTAGGTCCCAGGCTCTCGATCTCATCCGTTCCGATCCAAGGGTGCTC  
 -----+-----+-----+-----+-----+-----+  
 TTGATGCCTTAGTGATCCAGGGTCCGAGAGCTAGAGTAGGCAAGGCTAGGTTCCCACGAG  
 N\_Y\_G\_I\_T\_R\_S\_Q\_A\_L\_D\_L\_I\_R\_S\_D\_P\_R\_V\_L\_

2281 AGGGATTTTCATCAACCAGAACAACCCAATCATCAAGAACAGGATCGAGCAGCTCATTCTC  
 -----+-----+-----+-----+-----+-----+  
 TCCCTAAAGTAGTTGGTCTTGTGGGTTAGTAGTTCTTGTCTAGCTCGTCGAGTAAGAG  
 R\_D\_F\_I\_N\_Q\_N\_N\_P\_I\_I\_K\_N\_R\_I\_E\_Q\_L\_I\_L\_

2341 CAGTGCCGTCTTTGATGACTCGAGGGATCCTCTAGAGAATTCGAGCTC SEQ ID NO: 15  
 -----+-----+-----+-----+-----+  
 GTCACGGCAGAACTACTGAGCTCCCTAGGAGATCTCTTAAGCTCGAG SEQ ID NO: 16  
 Q\_C\_R\_L\_\*\_\*\_ SEQ ID NO: 2

**Figure 16C -1**  
**Rotavirus VP6**

Gene name: **G9P6\_VP6**

Gene length: 1254 bp

Optimized for expression in: ***Nicotiana tabacum***

```

1  GGTACCGAATTCGGACGCGTTCGTTCCATGGATGTGCTCTACTCCCTCTCCAAGACTCTC
   -----+-----+-----+-----+-----+-----+
   CCATGGCTTAAGCCTGCGCAAGCAAGGTACCTACACGAGATGAGGGAGAGGTTCTGAGAG
      G_R_V_R_S_M_D_V_L_Y_S_L_S_K_T_L_

61  AAGGATGCTAGGGATAAGATCGTGGAGGGAACCTCTCTACTCCAACGTTTCCGATCTCATC
   -----+-----+-----+-----+-----+-----+
   TTCCTACGATCCCTATTCTAGCACCTCCCTTGAGAGATGAGGTTGCAAAGGCTAGAGTAG
   K_D_A_R_D_K_I_V_E_G_T_L_Y_S_N_V_S_D_L_I_

121  CAGCAGTTCAACCAGATGATCATCACTATGAACGGAACGAGTTCCAGACTGGTGGAATC
   -----+-----+-----+-----+-----+-----+
   GTCGTCAAGTTGGTCTACTAGTAGTGATACTTGCCTTTGCTCAAGGTCTGACCACCTTAG
   Q_Q_F_N_Q_M_I_I_T_M_N_G_N_E_F_Q_T_G_G_I_

181  GGAAACCTCCCAATCAGGAAC TGGAAC TTCGAT TTCGGACT CCTCGGAAC TACTCTCCTC
   -----+-----+-----+-----+-----+-----+
   CCTTTGGAGGGTTAGTCCTTGACCTTGAAGCTAAAGCCTGAGGAGCCTTGATGAGAGGAG
   G_N_L_P_I_R_N_W_N_F_D_F_G_L_L_G_T_T_L_L_

241  AACCTCGATGCTAACTACGTGGAGACTGCTAGGAACACTATCGATTACTTTCGTTGATTTTC
   -----+-----+-----+-----+-----+-----+
   TTGGAGCTACGATTGATGCACCTCTGACGATCCTTGTGATAGCTAATGAAGCAACTAAAG
   N_L_D_A_N_Y_V_E_T_A_R_N_T_I_D_Y_F_V_D_F_

301  GTGGATAATGTGTGCATGGATGAGATGGTTCGTGAGTCCCAGAGGAACGGAATTGCTCCA
   -----+-----+-----+-----+-----+-----+
   CACCTATTACACACGTACCTACTCTACCAAGCACTCAGGGTCTCCTTGCCTTAACGAGGT
   V_D_N_V_C_M_D_E_M_V_R_E_S_Q_R_N_G_I_A_P_

361  CAGTCCGATTCCCTCAGGAAGCTCTCCGGTATCAAGTTCAAGAGGATCAACTTCGATAAC
   -----+-----+-----+-----+-----+-----+
   GTCAGGCTAAGGGAGTCCTTCGAGAGGCCATAGTTCAAGTTCTCCTAGTTGAAGCTATTG
   Q_S_D_S_L_R_K_L_S_G_I_K_F_K_R_I_N_F_D_N_

421  TCCTCCGAGTACATCGAGAAC TGGAAC TC CAGAAC AGGCAG AGGACT GGATTCACT
   -----+-----+-----+-----+-----+-----+
   AGGAGGCTCATGTAGCTCTTGACCTTGAGGTCTTGTCTCCGTCCTGACCTAAGTGA
   S_S_E_Y_I_E_N_W_N_L_Q_N_R_R_Q_R_T_G_F_T_

```

Figure 16C -2

TTCCACAAGCCAAACATCTTCCCATACTCCGCTTCCTTCACTCTCAACAGGTCCCAGCCA  
 481 -----+-----+-----+-----+-----+-----+  
 AAGGTGTTTCGGTTTGTAGAAGGGTATGAGGCGAAGGAAGTGAGAGTTGTCCAGGGTCGGT  
**F\_H\_K\_P\_N\_I\_F\_P\_Y\_S\_A\_S\_F\_T\_L\_N\_R\_S\_Q\_P\_**

GCTCACGATAACCTCATGGGAACATATGTGGCTCAACGCTGGTTCTGAGATCCAGGTGGCA  
 541 -----+-----+-----+-----+-----+-----+  
 CGAGTGCTATTGGAGTACCCTTGATACACCGAGTTGCGACCAAGACTCTAGGTCCACCGT  
**A\_H\_D\_N\_L\_M\_G\_T\_M\_W\_L\_N\_A\_G\_S\_E\_I\_Q\_V\_A\_**

GGATTCGATTACTCCTGCGCTATCAACGCTCCAGCTAACACTCAGCAGTTCGAGCACATC  
 601 -----+-----+-----+-----+-----+-----+  
 CCTAAGCTAATGAGGACGCGATAGTTGCGAGGTCGATTGTGAGTCGTCAAGCTCGTGTAG  
**G\_F\_D\_Y\_S\_C\_A\_I\_N\_A\_P\_A\_N\_T\_Q\_Q\_F\_E\_H\_I\_**

GTTCAGCTCAGAAGGGTGCTCACTACTGCTACTATCACTCTCCTCCCAGATGCTGAGAGG  
 661 -----+-----+-----+-----+-----+-----+  
 CAAGTCGAGTCTTCCCACGAGTGATGACGATGATAGTGAGAGGAGGGTCTACGACTCTCC  
**V\_Q\_L\_R\_R\_V\_L\_T\_T\_A\_T\_I\_T\_L\_L\_P\_D\_A\_E\_R\_**

TTCTCCTTCCCAAGGGTGATCAACTCCGCTGATGGTGCTACTACTTGGTACTTCAACCCA  
 721 -----+-----+-----+-----+-----+-----+  
 AAGAGGAAGGGTTCCTCACTAGTTGAGGCGACTACCACGATGATGAACCATGAAGTTGGGT  
**F\_S\_F\_P\_R\_V\_I\_N\_S\_A\_D\_G\_A\_T\_T\_W\_Y\_F\_N\_P\_**

GTGATCCTCAGGCCAAACAACGTGGAGGTGGAGTTCCTTCTCAACGGACAGATCATCAAC  
 781 -----+-----+-----+-----+-----+-----+  
 CACTAGGAGTCCGGTTTGTGTCACCTCCACCTCAAGGAAGAGTTGCCTGTCTAGTAGTTG  
**V\_I\_L\_R\_P\_N\_N\_V\_E\_V\_E\_F\_L\_L\_N\_G\_Q\_I\_I\_N\_**

ACTTACCAGGCTCGTTTCGGAACATATCGTGGCTAGGAACCTCGATACAATCAGGCTCTCC  
 841 -----+-----+-----+-----+-----+-----+  
 TGAATGGTCCGAGCAAAGCCTTGATAGCACCGATCCTTGAAGCTATGTTAGTCCGAGAGG  
**T\_Y\_Q\_A\_R\_F\_G\_T\_I\_V\_A\_R\_N\_F\_D\_T\_I\_R\_L\_S\_**

TTCCAGCTTATGAGGCCACCAAACATGACTCCATCCGTGGCTGCACTCTTCCCAAACGCA  
 901 -----+-----+-----+-----+-----+-----+  
 AAGGTCAATACTCCGGTGGTTTGTACTGAGGTAGGCACCGACGTGAGAAGGGTTTTCGT  
**F\_Q\_L\_M\_R\_P\_P\_N\_M\_T\_P\_S\_V\_A\_A\_L\_F\_P\_N\_A\_**

CAGCCATTCGAGCACACGCTACTGTGGGACTCACTCTCAAGATCGAGTCCGCTGTGTGC  
 961 -----+-----+-----+-----+-----+-----+  
 GTCGGTAAGCTCGTGGTGCGATGACACCTGAGTGAGAGTTCTAGCTCAGGCGACACACG  
**Q\_P\_F\_E\_H\_H\_A\_T\_V\_G\_L\_T\_L\_K\_I\_E\_S\_A\_V\_C\_**



**Figure 16C -3**

1021 GAGTCTGTGCTCGCTGATGCTTCCGAGACTATGCTCGCTAACGTGACTTCTGTGAGGCAA  
 -----+-----+-----+-----+-----+-----+  
 CTCAGACACGAGCGACTACGAAGGCTCTGATACGAGCGATTGCACTGAAGACACTCCGTT  
**E \_ S \_ V \_ L \_ A \_ D \_ A \_ S \_ E \_ T \_ M \_ L \_ A \_ N \_ V \_ T \_ S \_ V \_ R \_ Q \_**

1081 GAGTACGCTATCCCAGTGGGACCAGTGTTTCCACCAGGAATGAACTGGACTGATCTCATC  
 -----+-----+-----+-----+-----+-----+  
 CTCATGCGATAGGGTCACCCTGGTCACAAAGGTGGTCCTTACTTGACCTGACTAGAGTAG  
**E \_ Y \_ A \_ I \_ P \_ V \_ G \_ P \_ V \_ F \_ P \_ P \_ G \_ M \_ N \_ W \_ T \_ D \_ L \_ I \_**

1141 ACTAACTACTCCCCATCCAGAGAGGATAACCTCCAGAGGGTGTTCACTGTGGCTTCCATC  
 -----+-----+-----+-----+-----+-----+  
 TGATTGATGAGGGGTAGGTCTCTCCTATTGGAGGTCTCCACAAGTGACACCGAAGGTAG  
**T \_ N \_ Y \_ S \_ P \_ S \_ R \_ E \_ D \_ N \_ L \_ Q \_ R \_ V \_ F \_ T \_ V \_ A \_ S \_ I \_**

1201 CGTTCCATGCTCGTGAAGTGATGACTCGAGGGATCCTCTAGAGAA  
 -----+-----+-----+-----+-----+  
 GCAAGGTACGAGCACTTCACTACTGAGCTCCCTAGGAGATCTCTT  
**R \_ S \_ M \_ L \_ V \_ K \_ \* \_ \* \_** SEQ ID NO: 3

TTCGAGCTC SEQ ID NO: 17

-----+-----

AAGCTCGAG SEQ ID NO: 18

**Figure 16D -1**  
**Rotavirus VP 7**

Gene name: **G9P6\_VP7**

Gene length: 1041 bp

Optimized for expression in:

***Nicotiana tabacum***

```

1      GGTACCGAATTCGGACGCGTTCGTTGCATGTACGGAATCGAGTACACTACTATCCTCACT
      -----+-----+-----+-----+-----+-----+
      CCATGGCTTAAGCCTGCGCAAGCAACGTACATGCCTTAGCTCATGTGATGATAGGAGTGA
      SEQ ID NO: 4 G_R_V_R_C_M_Y_G_I_E_Y_T_T_I_L_T_

61      TTCCTCATCTCCATCGTGCTCCTCAACTACATCCTCAAGTCCCTCACTTCCGCTATGGAT
      -----+-----+-----+-----+-----+-----+
      AAGGAGTAGAGGTAGCACGAGGAGTTGATGTAGGAGTTCAGGGAGTGAAGGCGATACCTA
      F_L_I_S_I_V_L_L_N_Y_I_L_K_S_L_T_S_A_M_D_

121     TTCATCATCTACCGTTTCCTCCTCCTCATCGTGATCGCTTCCCCATTTCGTTAAGACTCAG
      -----+-----+-----+-----+-----+-----+
      AAGTAGTAGATGGCAAAGGAGGAGGAGTAGCACTAGCGAAGGGGTAAGCAATTCTGAGTC
      F_I_I_Y_R_F_L_L_L_I_V_I_A_S_P_F_V_K_T_Q_

181     AACTACGGTATCAACCTCCCAATCACTGGATCTATGGATACTGCTTACGCTAACTCCTCC
      -----+-----+-----+-----+-----+-----+
      TTGATGCCATAGTTGGAGGGTTAGTGACCTAGATACCTATGACGAATGCGATTGAGGAGG
      N_Y_G_I_N_L_P_I_T_G_S_M_D_T_A_Y_A_N_S_S_

241     CAGCAAGAGACTTTCCTCACTTCCACACTCTGCCTCTACTACCCAACTGAGGCATCCACA
      -----+-----+-----+-----+-----+-----+
      GTCGTTCTCTGAAAGGAGTGAAGGTGTGAGACGGAGATGATGGGTGACTCCGTAGGTGT
      Q_Q_E_T_F_L_T_S_T_L_C_L_Y_Y_P_T_E_A_S_T_

301     CAGATCGGAGATACAGAGTGAAGGATACTCTCTCCCAGCTCTTCCTCACTAAGGGATGG
      -----+-----+-----+-----+-----+-----+
      GTCTAGCCTCTATGTCTCACCTTCCTATGAGAGAGGGTCGAGAAGGAGTGATTCCCTACC
      Q_I_G_D_T_E_W_K_D_T_L_S_Q_L_F_L_T_K_G_W_

361     CCAACTGGTTCCGTGTACTTCAAAGAGTACACTGATATCGCTTCCTTCTCCATCGATCCA
      -----+-----+-----+-----+-----+-----+
      GGTTGACCAAGGCACATGAAGTTTCTCATGTGACTATAGCGAAGGAAGAGGTAGCTAGGT
      P_T_G_S_V_Y_F_K_E_Y_T_D_I_A_S_F_S_I_D_P_

```

**Figure 16D -2**

CAGCTCTACTGCGATTACAACGTGGTGCTTATGAAGTACGATTCCACTCTTGAGCTTGAT  
 421 -----+-----+-----+-----+-----+-----+  
 GTCGAGATGACGCTAATGTTGCACCACGAATACTTCATGCTAAGGTGAGAACTCGAACTA  
**Q \_ L \_ Y \_ C \_ D \_ Y \_ N \_ V \_ V \_ L \_ M \_ K \_ Y \_ D \_ S \_ T \_ L \_ E \_ L \_ D \_**  
  
 ATGTCCGAGCTTGCTGATCTCATCCTCAACGAGTGGCTCTGCAACCCAATGGATATCACT  
 481 -----+-----+-----+-----+-----+-----+  
 TACAGGCTCGAACGACTAGAGTAGGAGTTGCTCACCAGACGTTGGGTACCTATAGTGA  
**M \_ S \_ E \_ L \_ A \_ D \_ L \_ I \_ L \_ N \_ E \_ W \_ L \_ C \_ N \_ P \_ M \_ D \_ I \_ T \_**  
  
 CTCTACTACTACCAGCAGACTGATGAGGCTAACAAGTGGATCTCTATGGGACAGTCCTGC  
 541 -----+-----+-----+-----+-----+-----+  
 GAGATGATGATGGTCGTCTGACTACTCCGATTGTTACCTAGAGATACCCTGTCAGGACG  
**L \_ Y \_ Y \_ Y \_ Q \_ Q \_ T \_ D \_ E \_ A \_ N \_ K \_ W \_ I \_ S \_ M \_ G \_ Q \_ S \_ C \_**  
  
 ACTATCAAAGTGTGCCCCTCAACACTCAGACTCTCGGAATCGGATGCATCACTACTAAC  
 601 -----+-----+-----+-----+-----+-----+  
 TGATAGTTTCACACGGGTGAGTTGTGAGTCTGAGAGCCTTAGCCTACGTAGTGATGATTG  
**T \_ I \_ K \_ V \_ C \_ P \_ L \_ N \_ T \_ Q \_ T \_ L \_ G \_ I \_ G \_ C \_ I \_ T \_ T \_ N \_**  
  
 ACTGCTACTTTTCGAGGAAGTGGCTACTTCCGAGAAGCTCGTGATCACTGATGTGGTGGAT  
 661 -----+-----+-----+-----+-----+-----+  
 TGACGATGAAAGCTCCTTCACCGATGAAGGCTCTTCGAGCACTAGTGACTACACCACCTA  
**T \_ A \_ T \_ F \_ E \_ E \_ V \_ A \_ T \_ S \_ E \_ K \_ L \_ V \_ I \_ T \_ D \_ V \_ V \_ D \_**  
  
 GGTGTTAACCACAAGCTCGATGTGACTACTAACACATGCACAATCAGGAAGTGAAGAAG  
 721 -----+-----+-----+-----+-----+-----+  
 CCACAATTGGTGTTCGAGCTACACTGATGATTGTGTACGTGTTAGTCCTTGACGTTCTTC  
**G \_ V \_ N \_ H \_ K \_ L \_ D \_ V \_ T \_ T \_ N \_ T \_ C \_ T \_ I \_ R \_ N \_ C \_ K \_ K \_**  
  
 CTCGGACCAAGGAAAACGTGGCTATCATCCAAGTGGGAGGTTCCGATGTGCTCGATATC  
 781 -----+-----+-----+-----+-----+-----+  
 GAGCCTGGTTCCCTTTTGCACCGATAGTAGGTTACCCCTCCAAGGCTACACGAGCTATAG  
**L \_ G \_ P \_ R \_ E \_ N \_ V \_ A \_ I \_ I \_ Q \_ V \_ G \_ G \_ S \_ D \_ V \_ L \_ D \_ I \_**  
  
 ACTGCTGATCCAACACTACTGCTCCACAGACTGAGAGGATGATGAGGGTGAAGTGAAGAAG  
 841 -----+-----+-----+-----+-----+-----+  
 TGACGACTAGGTTGATGACGAGGTGTCTGACTCTCCTACTACTCCCACTTGACCTTCTTC  
**T \_ A \_ D \_ P \_ T \_ T \_ A \_ P \_ Q \_ T \_ E \_ R \_ M \_ M \_ R \_ V \_ N \_ W \_ K \_ K \_**  
  
 TGGTGGCAGGTTTTCTACACTGTGGTGGATTACATCAACCAGATCGTTCAGGTGATGTCC  
 901 -----+-----+-----+-----+-----+-----+  
 ACCACCGTCCAAAAGATGTGACACCACCTAATGTAGTTGGTCTAGCAAGTCCACTACAGG  
**W \_ W \_ Q \_ V \_ F \_ Y \_ T \_ V \_ V \_ D \_ Y \_ I \_ N \_ Q \_ I \_ V \_ Q \_ V \_ M \_ S \_**

**Figure 16D -3**

AAGAGGTCCCGTTCTCTCAACTCCGCTGCTTTCTACTACCGTGTGTGATGACTCGAGGGA  
961 -----+-----+-----+-----+-----+-----+  
TTCTCCAGGGCAAGAGAGTTGAGGCGACGAAAGATGATGGCACACACTACTGAGCTCCCT  
**K\_R\_S\_R\_S\_L\_N\_S\_A\_A\_F\_Y\_Y\_R\_V\_\*\_\*\_ SEQ ID NO: 4**

TCCTCTAGAGAATTCGAGCTC SEQ ID NO: 19  
1021 -----+-----+--  
AGGAGATCTCTTAAGCTCGAG SEQ ID NO: 20

**Figure 17**

A-2X35S/CPMV-HT/ RVA(WA) VP2(opt)/ NOS (Construct number 1710)

**Figure 17A, SEQ ID NO: 21**


IF-WA\_VP2(opt).s1+3c

AAATTTGTCGGGCCCATGGCATAACCGGAAGAGAGGAGCAAAGCGCGAA

**Figure 17B, SEQ ID NO: 22**

IF-WA\_VP2(opt).s1-4r

ACTAAAGAAAATAGGCCTTTAAAGCTCGTTCATTATTTCGCATATTGTCGA

**Figure 17C**

**Figure 18, SEQ ID NO: 23**

Construct 1191 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette

TGGCAGGATATATTGTGGTGTAAACAAATTGACGCTTAGACAACCTTAATAACACATTGCGGACGTTT  
TAAATGTACTGAATTAACGCCGAATCCCGGGCTGGTATATTTATATGTTGTCAAATAACTCAAAAACC  
ATAAAAGTTTAAAGTTAGCAAGTGTGTACATTTTACTTGAACAAAAATATTCACCTACTACTGTTATA  
AATCATTATTAACATTAGAGTAAAGAAATATGGATGATAAGAACAAGAGTAGTGATATTTTGACAA  
CAATTTTGTGCAACATTTGAGAAAAATTTGTTGTCTCTCTTTTCATTGGTCAAAAACAATAGAGAG  
AGAAAAAGGAAGAGGGAGAATAAAAAACATAATGTGAGTATGAGAGAGAAAGTTGTACAAAAGTTG  
TACCAAAATAGTTGTACAAATATCATTGAGGAATTTGACAAAAGCTACACAAATAAGGGTTAATTGC  
TGTAAATAAATAAGGATGACGCATTAGAGAGATGTACCATTAGAGAATTTTGGCAAGTCATTAAAA  
AGAAAGAATAAATTATTTTAAATTAAGTTGAGTCATTTGATTAAACATGTGATTATTTAATGAA  
TTGATGAAAGAGTTGGATTAAAGTTGTATTAGTAATTAGAATTTGGTGTCAAATTTAATTTGACATT  
GATCTTTTCTATATATTGCCCCATAGAGTCAGTTAACTCATTTTATATTTTCATAGATCAAATAAGA  
GAAATAACGGTATATTAATCCCTCCAAAAAAGCGGTATATTTACTAAAAATCTAAGCCACG  
TAGGAGGATAACAGGATCCCGTAGGAGGATAACATCCAATCCAACCAATCACAACAATCCTGATG  
AGATAACCCACTTTAAGCCACGCATCTGTGGCACATCTACATTATCTAAATCACACATTCTCCACA  
CATCTGAGCCACACAAAAACCAATCCACATCTTTACCCATTCTATAAAAAATCACACTTTGTGAG  
TCTACACTTTGATTTCCCTTCAAACACATACAAAGAGAAGAGACTAATTAATTAATTAATCATCTTGAG  
AGAAAAATGGAACGAGCTATACAAGGAAACGACGCTAGGGAACAAGCTAACAGTGAACGTTGGGATG  
GAGGATCAGGAGGTACCACTTCTCCCTTCAAACCTTCTGACGAAAGTCCGAGTTGGACTGAGTGGCG  
GCTACATAACGATGAGACGAATTCGAATCAAGATAATCCCTTGGTTTCAAGGAAAGCTGGGGTTTC  
GGGAAAGTTGTATTTAAGAGATATCTCAGATACGACAGGACGGAAGCTTCACTGCACAGAGTCCCTG  
GATCTTGGACGGGAGATTTCGGTTAACTATGCAGCATCTCGATTTTTCGGTTTCGACCAGATCGGATGT  
ACCTATAGTATTCGGTTTCGAGGAGTTAGTATCACCGTTTCTGGAGGGTCGCGAACTCTTCAGCATCT  
CTGTGAGATGGCAATTCGGTCTAAGCAAGAACTGCTACAGCTTGCCCCAATCGAAGTGGAAGTAAT  
GTATCAAGAGGATGCCCTGAAGGTACTCAAACCTTCGAAAAAGAAAGCGAGTAAGTTAAAAATGCTT  
CTTCGCTCTCTATTTATAATATGGTTTGTATTGTTAATTTTGTCTTGTAGAAGAGCTTAATTAATCG  
TTGTTGTTATGAAATACTATTTGTATGAGATGAAGTGGTGAATGTAATTCATTTACATAAGTGGAGT  
CAGAATCAGAATGTTTCTCCATAACTAAGTACATGAAGACCTGCCGCGTACAATTGCTTATATT  
TGAACAATAAAATTGAACATCTTTTGCCACAACCTTTATAAGTGGTTAATATAGCTCAAATATATGGT  
CAAGTTCAATAGATTAATAATGGAATATCAGTTATCGAAATTCATTAACAATCAACTTAACGTTATT  
AACTACTAATTTTATATCATCCCTTTGATAAATGATAGTACACCAATTAGGAAGGAGCATGCTCGCC  
TAGGAGATTGTCGTTTCCCGCCTTCAGTTTGCAAGCTGCTAGCCGTGAGCCAATACGCAAAACCGC  
CTCTCCCCGCGCGTTGGGAATTACTAGCGCGTGTGACAAGCTTGCATGCCGCTCAACATGGTGGAG  
CACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAATTGAG  
ACTTTTCAACAAAGGGTAATATCCGGAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTAT  
TGTGAAGATAGTGGAAGGAAGGTGGTCTCTACAAATGCCATCATTGCGATAAAGGAAAGGCCAT  
CGTTGAAGATGCCTTGCCGACAGTGGTCCCAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAGAA  
AAAGAAAGAGTTTCCAAACCGTCTTCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCACGAC  
ACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAATTGAGACTTTTC  
AACAAAGGGTAATATCCGGAACCTCCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGAAG  
ATAGTGGAAGGAAGGTGGTCTCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAA  
GATGCCTCTGCCGACAGTGGTCCCAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAGAAAGAA  
GACGTTCCAACCCAGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACG  
CACAATCCCACTATCCTTCGCAAGACCTTCTCTATATAAGGAAGTTTCATTTTCATTTGGAGAGGTAT  
TAAATCTTAATAGTTTTGATAAAAGCGAAGCTGGGGAACCCGAACCAACCTTCTTCTAAACTC  
TCTCTCATCTCTTAAAGCAAACCTTCTCTTGTCTTCTTGTGCTGAGCGATCTTCAACGTTGTCAGA  
TCGTGCTTCGGCACCAGTACAACGTTTCTTTCATGAAGCGAAATCAAAGATCTCTTTGTGGACACG  
TAGTGCGGCGCCATTAAATAACGTGTACTTGTCTATTCTTGTGCGGTGTGGTCTTGGGAAAAAGAAAG  
TTGCTGGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACTTTCGGCGGGTGCAA  
TATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTTCTTCTTCTGCTGATTGGTTCT  
ATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTCCCGTGGTTTTCGAACCTGGAGAAAGATTGTT  
AAGCTTCTGTATATTCTGCCAAATTTGTGCGGGCCCGCGGATGGCGAAAAACGTTGCGATTTTCGGCT  
TATTGTTTCTCTTGTGTTGTTGTTCTCAGATCTTCGCTGCAGGCTCCTCAGCCAAAACGACA  
CCCCATCTGTCTATCCACTGGCCCCCTGGATCTGCTGCCAAAATACTCCATGGTGACCTGGGATG  
CCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACCTCTGGATCCCTGTCCAGCGGT  
GTGCACACCTTCCCAGCTGTCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCCCCTC  
CAGCACCTGGCCAGCGAGACCGTCACCTGCAACGTTGCCACCCGGCCAGCAGCACCAAGGTGGA  
CAAGAAAAATTTGCCCAGGATTGTGGTTGTAAGCCTTGATATGTACAGTCCCAAGATATCATCT  
GTCTTCATCTTCCCCCAAGCCCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTTGT  
TGTGGTAGACATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTGTAGATGATGTGGAGGTG

CACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTCCGCTCAGTCAGTGAAC TTC  
CCATCATGCACCAGGACTGGCTCAATGGCAAGGAGCGATCGCTCACCATCACCATCACCATCACCAT  
CACCATTAAAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGTGA  
GCGGTTTTCTGTGCTCAGAGTGTGTTTATTTATGTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAG  
GTCGTCCCTTCAGCAAGGACACAAAAAGATTTTAATTTTATTAATAAAAAAAAAAAAAAAAAAGACCGG  
GAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAAAAGTTTCTTAAGATTG  
AATCCTGTTGCCGGTCTTGCGATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAAT  
TAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGCAATTATACATTT  
AATACGCGATAGAAAAAAAATATAGCGCGCAAACTAGGATAAATTATCGCGCGCGGTGTCATCTAT  
GTTACTAGATCTCTAGAGTCTCAAGCTTGGCGCGCCACGTGACTAGTGGCACTGGCCGTCGTTTTAC  
AACGTCGTGACTGGGAAAACCTGGCGTTACCCAACTTAATCGCCTTGACGACATCCCCCTTTCGCC  
AGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCG  
AATGCTAGAGCAGCTTGAGCTTGATCAGATTGTCGTTTCCCGCCTTCAGTTTAACTATCAGTGTTT  
GACAGGATATATTGGCGGTAAACCTAAGAGAAAAGAGCGTTTA

**Figure 19** nucleotide sequence encoding VP2(opt) from Rotavirus A WA strain (SEQ ID NO: 45).

ATGGCATAACCGGAAGAGAGGAGCAAAGCGCGAAAACCTGCCGCAACAGAACGAGAGA  
CTGCAAGAAAAAGAGATAGAGAAAGATGTCGACGTAACAATGGAAAACAAGAATAAC  
AATAGGAAACAACAGCTGTCCGACAAAGTTCTGTCCCAGAAGGAGGAAATTATCACT  
GACGCCCAGGACGATATTTAAATTTGCCGGAGAAATAAAGAAGAGCTCGAAAGAAGAA  
TCTAAACAGCTGCTCGAAATTCTGAAAACAAAAGAAGACCATCAGAAAGAGATTCAA  
TATGAAATTTTGCAAAAAACAATACCTACATTTGAGTCCAAAGAAAGTATCCTCAAG  
AAGCTTGAAGACATAAGACCGGAGCAGGCAAAAAACAGATGAAACTCTTTCGCATT  
TTCGAGCCAAAACAGCTCCCTATATATCGCGCCAATGGCGAGAAGGAGCTACGCAAC  
CGGTGGTACTGGAAGTTGAAAAAGACACCTTGCCAGATGGAGATTATGACGTCCGG  
GAGTATTTCTCAATCTCTATGATCAGATCCTCATCGAAATGCCGGACTATCTGCTC  
CTCAAGGACATGGCCGTGGAGAACAATAAGCAGAGACGCCGGCAAAGTTGTGAC  
TCTGAGACTGCCAATATTTGTGATGCCATCTTCCAGGATGAGGAGACCGAGGGAGTC  
GTCCGTAGATTTCATCGCTGATATGCGGCAACAGGTCCAGGCTGATCGTAACATTGTC  
AATTACCTTCCATCCTTCACCTATTGATCATGCATTCAATGAGTATTTTCTTAAC  
CACCAGTTGGTGGAGCCGCTGAACAATGAGATAATCTTCAATTACATACCAGAGAGG  
ATAAGGAATGACGTGAATTACATCCTGAACATGGATATGAATCTGCCATCTACAGCC  
AGGTATATCAGGCCAACTTGTTGCAGGATAGACTGAATCTTCACGATAATTTTGAG  
TCCCTGTGGGATACCATCACAACATCCAACCTACATTCTGGCCAGGTCCGTCGTTCCC  
GATTTGAAGGAGAAGGAGCTGGTCTCCACCGAAGCACAGATCCAGAAAATGAGCCAG  
GACCTGCAGCTGGAGGCCCTCACTATTCAGAGCGAGACACAGTTTTTAGCCGGGATT  
AACAGTCAGGCTGCCAATGATTGTTTCAAGACCCTCATAGCCGCCATGCTGTCTCAA  
AGAACCATGTCTTTGGACTTTGTGACCACGAACTATATGAGCCTAATCTCCGGAATG  
TGGCTACTTACAGTGATTCCCAACGATATGTTCTCCGGGAGTCACTAGTGGCCTGT  
GAGCTGGCGATCATCAACACCATCGTGTATCCAGCATTTCGGAATGCAGAGAATGCAT  
TACCGGAATGGCGACCCTCAGACACCCTTCCAGATCGCAGAACAGCAGATCCAGAAT  
TTCCAGGTGGCGAACTGGCTCCATTTTATTAACAATAACAGATTCAGGCAAGTTGTG  
ATTGATGGAGTTCTGAATCAGACTCTGAACGACAATATACGGAATGGACAGGTCATC  
AACCAGCTGATGGAAGCATTGATGCAACTCAGCAGACAGCAGTTCCCCACGATGCCT  
GTGGATTACAAACGGAGCATCCAACGGGGCATTTCTGCTTCTCTCCAATAGGCTGGGG  
CAGCTTGTCGACTTAACCCGACTGGTCTCCTATAACTACGAGACGCTAATGGCTTGT  
GTGACCATGAACATGCAGCACGTGCAAACCTGACAACTGAGAAGTTGCAGCTCACT  
TCTGTGACTTCGCTTTGTATGTTAATTGGTAACACAACCGTGATTCCGTCCCCACAG  
ACACTGTTCCACTACTACAACATCAACGTGAATTTCCACTCCAATTATAATGAGCGG  
ATCAACGACGCCGTCGCCATAATTACCGCAGCAAATAGGCTGAATCTTTATCAGAAA  
AAAATGAAGTCCATAGTGGAAGACTTTCTGAAACGGCTCCAGATTTTCGACGTACCA  
CGAGTGCCTGACGACCAAATGTACAGGCTGAGGGATCGCCTTCGGCTCTTACCCGTT  
GAACGGAGACGGCTTGACATATTCAACTTGATCCTGATGAATATGGAGCAGATCGAA  
CGCGCTTCTGATAAGATTGCTCAGGGGGTTATCATCGCATAACGAGATATGCAGCTG  
GAACGCGACGAGATGTACGGATATGTTAATATTGCACGGAATCTTGATGGCTACCAG  
CAAATTAACCTTGAGGAACTCATGCGCACCGGTGATTACGGACAAATTACGAACATG  
CTTCTCAACAATCAACCCGTTGCCCTTGTGGGTGCATTGCCCTTCGTTACGGACTCA  
TCCGTGATCAGTCTAATCGCCAAGCTCGACGCAACCGTCTTCGCTCAGATAGTGAAG  
CTCAGGAAAGTTGACACACTGAAGCCCATACTGTACAAAATAAACTCGGATTCCAAT  
GACTTTTACCTTGTGGCCAACTACGACTGGATCCCCACAAGTACAACCTAAGGTCTAC  
AAACAGGTGCCACAACCATTCGACTTTAGAGCCAGCATGCACATGCTGACTTCTAAC  
CTTACGTTTACCGTCTACTCTGACCTACTGTCATTTGTTTCAGCGGACACGGTAGAG  
CCCATTAAACGCAGTCGCATTCGACAATATGCGAATAATGAACGAGCTTTAA




**Figure 20**, SEQ ID NO: 25

Amino acid sequence of VP2 from Rotavirus A WA strain

MAYRKRGA KRENLPQQNERLQEKEIEKDVDVTMENKNNNRKQQLSDKVLSQKEEITDAQDDIKIAGEIK  
KSSKEESKQLLEILKTKEDHQKEIQYEILQKTIPTFESKESILKKLEDIRPEQAKKQMKLFRIPEPKQLPIYRA  
NGEKELRNRWYWKLLKDTLPDGDYDVREYFLNLYDQILIEMPDYLLLKDMAVENKNSRDAGKVVDSE  
TANICDAIFQDEETEGVRRFIADMRQQVQADRNVNYP SILHPIDHAFNEYFLNHQLVEPLNNEIIFNYIPE  
RIRNDVNYILNMDMNL PSTARYIRPNLLQDRLNLHDNFESLWD TITTSNYILARSVVPDLKEKELVSTEAQ  
IQKMSQDLQLEALTIQSETQFLAGINSQAANDCFKTLIAAMLSQRTMSLDFVTTNYMSLISGMWLLTVIPN  
DMFLRESLVACELAIINTIVYPAFGMQRMHYRNGDPQTPFQIAEQQIQNFQVANWLHFINNNRFRQVVID  
GVLNQTLNDNIRNGQVINQLMEALMQLSRQQFPTMPVDYKRSIQRGILL SNRLGQLVDLTRLVSYNYET  
LMACVTMNMQHVQTLTTEKLQLTSVTSLCMLIGNTTVIPSPQTLFHYYNINVNFHSNYNERINDAVAIITA  
ANRLNLYQKKMKSI VEDFLKRLQIFDVPRVPDDQMYRLRDRLRLLPVERRRLDIFNLILMNMEQIERASD  
KIAQGVIHAYRDMQLERDEMYGYVNIARNLDGYQQINLEELMRTGDYGGITNMLLNNQPVALVGALPFV  
TDSSVISLIAKL DATVFAQIVKLRKVDTLKPILYKINSDSNDFYLVANYDWIPTSTTKVYKQVPQPFDFRAS  
MHMLTSNLTFTVYSDDL SFVSADTVEPINAVAFDNMRIMNEL


**Figure 21**

Schematic representation of construct number 1710



B-2X35S/CPMV-HT/RVA(WA) VP2(opt)/NOS into BeYDV(m)+Replicase  
amplification system (Construct number 1711)

**Figure 22A**



**Figure 22B**, SEQ ID NO: 26

Construct 193 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/NOS into BeYDV(m)+Replicase amplification system with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette

TGGCAGGATATATTGTGGTGTAAACAAATTGACGCTTAGACAACCTTAATAACACATTGCGGACGTTT  
TAAATGTACTGAATTAACGCCGAATCCCGGGCTGGTATATTTATATGTTGTCAAATAACTCAAAAACC  
ATAAAAAGTTTAAAGTTAGCAAGTGTGTACATTTTACTTGAACAAAAATATTCACCTACTACTGTTATA  
AATCATTATTAACATTAGAGTAAAGAAATATGGATGATAAGAACAAGAGTAGTGATATTTTGACAA  
CAATTTTGTGCAACATTTGAGAAAAATTTGTTGTTCTCTCTTTTCATTGGTCAAAAACAATAGAGAG  
AGAAAAAGGAAGAGGGAGAATAAAAAACATAATGTGAGTATGAGAGAGAAAGTTGTACAAAAGTTG  
TACCAAAATAGTTGTACAAATATCATTGAGGAATTTGACAAAAGCTACACAAATAAGGGTTAATTGC  
TGTAAATAAATAAGGATGACGCATTAGAGAGATGTACCATTAGAGAATTTTGGCAAGTCATTAAAA  
AGAAAGAATAAATTATTTTAAAAATTAAGTTGAGTCATTTGATTAAACATGTGATTATTTAATGAA  
TTGATGAAAGGGTGGATTAAAGTTGTATTAGTAATTAGAATTTGGTGTCAAATTTTATTTGACATTT  
GATCTTTTCTATATATTGCCCCATAGAGTCAGTTAACTCATTTTATATTTTCATAGATCAAATAAGA  
GAAATAACGGTATATTAATCCCTCCAAAAAAGCGGTATATTTACTAAAAATCTAAGCCACG  
TAGGAGGATAACAGGATCCCGTAGGAGGATAACATCCAATCCAACCAATCACAACAATCCTGATG  
AGATAACCCACTTTAAGCCACGCATCTGTGGCACATCTACATTATCTAAATCACACATTCTCCACA  
CATCTGAGCCACACAAAAACCAATCCACATCTTTACCCATTCTATAAAAAATCACACTTTGTGAG  
TCTACACTTTGATTCCCTTCAAACACATACAAAGAGAAGAGACTAATTAATTAATTAATCATCTTGAG  
AGAAAAATGGAACGAGCTATACAAGGAAACGACGCTAGGGAACAAGCTAACAGTGAACGTTGGGATG  
GAGGATCAGGAGGTACCACTTCTCCCTTCAAACCTTCTGACGAAAGTCCGAGTTGGACTGAGTGGCG  
GCTACATAACGATGAGACGAATTCGAATCAAGATAATCCCTTGGTTTCAAGGAAAGCTGGGGTTTC  
GGGAAAGTTGTATTTAAGAGATATCTCAGATACGACAGGACGGAAGCTTCACTGCACAGAGTCCCTG  
GATCTTGGACGGGAGATTCCGTTAACTATGCAGCATCTCGATTTTCGGTTTCGACCAGATCGGATGT  
ACCTATAGTATTCGGTTTCGAGGAGTTAGTATCACCGTTTCTGGAGGGTCGCGAACTCTTCAGCATCT  
CTGTGAGATGGCAATTCGGTCTAAGCAAGAACTGCTACAGCTTGCCCCAATCGAAGTGGAAGTAAT  
GTATCAAGAGGATGCCCTGAAGGTACTCAAACCTTCGAAAAAGAAAGCGAGTAAGTTAAAAATGCTT  
CTTCGCTCTCTATTTATAATATGGTTTGTATTGTTAATTTTGTCTTGTAGAAGAGCTTAATTAATCG  
TTGTTGTTATGAAATACTATTTGTATGAGATGAAGTGGTGAATGTAATTCATTTACATAAGTGGAAT  
CAGAATCAGAATGTTTCTCCATAACTAAGTACATGAAGACCTGCCGCGTACAATTGCTTATATT  
TGAACAATAAAATTGAACATCTTTTGCCACAACCTTTATAAGTGGTTAATATAGCTCAAATATATGGT  
CAAGTTCAATAGATTAATAATGGAATATCAGTTATCGAAATTCATTAACAATCAACTTAACGTTATT  
AACTACTAATTTTATATCATCCCTTTGATAAATGATAGTACACCAATTAGGAAGGAGCATGCTCGCC  
TAGGAGATTGTCGTTTCCCGCTTCAGTTTGCAAGCTGCTAGCCGTGAGCCAATACGCAAAACCGC  
CTCTCCCCGCGCGTTGGGAATTACTAGCGCGTGTGAGACGCGTTGTTGTTGTGACTCCGAGGGGTTG  
CCTCAAACCTCTATCTTATAACCGGCGTGGAGGCATGGAGGCAGGGGTATTTTGGTCATTTTAATAGAT  
AGTGGAATAATGACGTGGAATTTACTTAAAGACGAAGTCTTTGCGACAAGGGGGGGCCACGCCGAA  
TTTAATATTACCGCGGTGGCCCCCTTATCGCGAGTGCTTTAGCACGAGCGGTCCAGATTTAAAGTA  
GAAAAATTTCCCGCCCACTAGGGTTAAAGGTGTTACACTATAAAAGCATATACGATGTGATGGTATT  
TGGTCGACAAGCTTGATGCCGGTCAACATGGTGGAGCAGACACACTTGCTACTCCAAAAATATC  
AAAGATACAGTCTCAGAAGACCAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAC  
CTCCTCGGATTCCATTGCCCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAGGAAGGTGGCTC  
CTACAAATGCCATCATTCGATAAAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCC  
AAAGATGGACCCCCACCCACGAGGAGCATCGTGAAAAAGAAGACGTTCCAACCACGCTTCAAAG  
CAAGTGGAATTGATGTGATAACATGGTGGAGCAGACACACTTGCTACTCCAAAAATATCAAAGATA  
CAGTCTCAGAAGACCAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAACCTCCTCGG  
ATTCCATTGCCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAGGAAGGTGGCTCCTACAAA  
TGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATG  
GACCCCCACCCACGAGGAGCATCGTGAAAAAGAAGACGTTCCAACCACGCTTCAAAGCAAGTG  
ATTGATGTGATATCTCCACTGACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCTTCC  
TCTATATAAGGAAGTTCAATTCATTTGGAGAGGTATTAATCTTAATAGGTTTTGATAAAAGCGAAC  
GTGGGGAAACCCGAACCAACCTTCTTCTAACTCTCTCTCATCTCTTAAAGCAAACCTTCTCTT  
GTCTTTCTTGCGTGAGCGATCTTCAACGTTGTGAGATCGTGCTTCGGCACCAGTACAACGTTTCTTTC  
ACTGAAGCGAAATCAAAGATCTCTTTGTGGACAGTAGTGCGGCGCCATTAAATAACGTTACTTGT  
CCTATTCTGCGGTGGTCTTGGGAAAAGAAAGCTTGTGAGGCTGCTGTTGAGGCTTCACTTGTG  
ACTTGTACGATTCTGTGACTTTTCGGCGGGTGAATATCTCTACTTCTGCTTGACGAGGTATTGTTGC  
CTGTAATCTTCTTCTTCTTCTTGTGCTGATTGGTTCTATAAGAAATCTAGTATTTTCTTGAACAGAG  
TTTTCCCGTGGTTTTCGAACTTGGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCAAATTTGTCCG  
GCCCCGCGGATGGCGAAAAACGTTGCGATTTTCGGCTTATTGTTTTCTTCTTGTGTTGGTTCCTTCTC  
AGATCTTCCCTGCAGGCTCCTCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCCTGGATC  
TGCTGCCAAAACCTCAATGGTGACCTGGGATGCCTGGTCAAGGGCTATTTCCTGAGCCAGTG  
ACAGTGACCTGGAACCTCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCTGCAGTCTGA

CCTCTACACTCTGAGCAGCTCAGTGACTGTCCCTCCAGCACCTGGCCCAGCGAGACCGTCACTGC  
AACGTTGCCACCCGGCCAGCAGCAACCAAGGTGGACAAGAAAATTGTGCCAGGGATTGTGGTTGTA  
AGCCTTGCATATGTACAGTCCCAGAAAGTATCATCTGTCTTCATCTTCCCCCAAAGCCCAAGGATGTG  
CTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGACATCAGCAAGGATGATCCCCGAGG  
TCCAGTTCAGCTGGTTGTAGATGATGTGGAGGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCA  
GTTCAACAGCACTTCCGCTCAGTCAGTGAACCTCCCATCATGCACCAGGACTGGCTCAATGGCAAG  
GAGCGATCGCTCACCATCACCATCACCATCACCATCACCATTAAAGGCCTATTTCTTTAGTTTGAAT  
TTACTGTTATTTCGGTGTGCATTTCTATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTATTTTA  
TGTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAGGTGCTCCCTTCAGCAAGGACACAAAAAGATTT  
TAATTTTATTAATAAAAAAAAAAAAAAAAAAGACCGGAATTCGATATCAAGCTTATCGACCTGCAGATC  
GTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTGCGGCTTTCGATGATTATCATA  
TAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATG  
GGTTTTTATGATTAGAGTCCCGCAATTATACATTTAATACGCGATAGAAAAACAAAATATAGCGCGCA  
AACTAGGATAAATTATCGCGCGCGGTGTCTATGTTACTAGATCTCTAGAGTCTCAAGCTTGGCGC  
GCCATAAAATGATTATTTTATGAATATATTTTCATTGTGCAAGTAGATAGAAATTACATATGTTACATA  
ACACACGAAATAAAACAAAAAAGACAATCCAAAAACAAACACCCCAAAAAAATAATCACTTTAGA  
TAAACTCGTATGAGGAGAGGCACGTTCACTGACTCGACGATTCCTCGAGCAAAAAAGTCTCCCCGTC  
ACACATATAGTGGGTGACGCAATTATCTTAAAGTAATCCTTCTGTTGACTTGTCATTGATAACATCC  
AGTCTTCGTCAGGATTGCAAAGAATTATAGAAGGGATCCCACCTTTTATTTCTTCTTTTCCATATT  
TAGGGTTGACAGTGAAATCAGACTGGCAACCTATTAATTGCTTCCACAATGGGACGAACCTGAAGGG  
GATGTCGTCGATGATATTATAGGTGGCGTGTTTCATCGTAGTTGGTGAAATCGATGGTACCGTTCCAAT  
AGTTGTGTCGTCGAGACTTCTAGCCCAGGTGGTCTTTCGGGTACGAGTTGGTCCGCAGATGTAGAG  
GCTGGGGTGTGCGATTCCATTCCCTTCCATTGTCCTGGTTAAATCGGCCATCCATTCAAGGTCAGATTG  
AGCTTGTGGTATGAGACAGGATGTATGTAAGTATAAGCGTCTATGCTTACATGGTATAGATGGGTTT  
CCCTCCAGGAGTGTAGATCTTCGTGGCAGCGAAGATCTGATTCTGTGAAGGGCGACACATACGGTTC  
AGGTTGTGGAGGGAATAATTTGTTGGCTGAATATTCCAGCCATTGAAGTTTGTGGCCATTCATGAG  
GGAATTCTTCTTGATCATGTCAAGATATTCCTCCTTAGACGTTGCAGTCTGGATAATAGTTCTCCAT  
CGTGCGTCAGATTTGCGAGGAGAGACCTTATGATCTCGGAAATCTCCTCTGGTTTTAATATCTCCGTC  
CTTTGATATGTAATCAAGGACTTGTTTAGAGTTTCTAGCTGGCTGGATATTAGGGTGATTTCCTTCAA  
AATCGAAAAAGAAGGATCCCTAATAACAAGGTTTTTATCAAGCTGGAGAAGAGCATGATAGTGGG  
TAGTGCCATCTTGATGAAGCTCAGAAGCAACACCAAGGAAGAAAATAAGAAAAGGTGTGAGTTTCT  
CCCAGAGAAACTGGAATAAATCATCTCTTTGAGATGAGCACTTGGGATAGGTAAGGAAAACATATTT  
AGATTGGAGTCTGAAGTTCTTACTAGCAGAAGGCATGTTGTTGTGACTCCGAGGGGTTGCCTCAAA  
TCTATCTTATAACCGCGTGGAGGCATGGAGGCAGGGGTATTTTGGTCATTTAATAGATAGTGGAA  
AATGACGTGGAATTTACTTAAAGACGAAGTCTTTGCGACAAGGGGGGGCCACGCCGAATTTAATAT  
TACCGGCGTGGCCCCCTTATCGCGAGTGCTTTAGCACGAGCGGTCCAGATTTAAAGTAGAAAAATT  
TCCCGCCCACTAGGGTTAAAGGTGTTCACTATAAAAGCATATACGATGTGATGGTATTTGACTAG  
TGGCACTGGCGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACCCAACCTAATCGCCTT  
GCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAAC  
AGTTGCGCAGCCTGAATGGCGAATGCTAGAGCAGCTTGAGCTTGGATCAGATTGTCGTTTCCCGCCTT  
CAGTTAAACTATCAGTGTTTGACAGGATATATTGGCGGGTAAACCTAAGAGAAAAGAGCGTTTA

**Figure 23**, SEQ ID NO: 27


Expression cassette number 1710 from 2X35S promoter to NOS terminator. VP2(opt) from Rotavirus A WA strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
 AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCACG  
 TATCTGTCACTTTATTGTGAAGATAGTGGAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
 AAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
 AGGAGCATCGTGGAAAAAGAACGCTTCCAACCACGCTTCAAAGCAAGTGGATTGATGTGATAAC  
 ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
 GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCCAGCTATCTG  
 TCACCTTATTGTGAAGATAGTGGAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGA  
 AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
 ATCGTGGAAAAAGAACGCTTCCAACCACGCTTCAAAGCAAGTGGATTGATGTGATAATGCCACTG  
 ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTCCTCTATATAAGGAAGTTCATTT  
 CATTTGGAGAGGTATTAATCTTAATAGGTTTGTATAAAGCGAACGTGGGGAAACCCGAACCAAA  
 CCTTCTTCTAACTCTCTCTCATCTCTTAAAGCAAACCTTCTCTTGTCTTCTTGTGCTGAGCGATCT  
 TCAACGTTGTCAGATCGTGTCTCGGCACCAAGTACAACGTTTCTTCTACTGAAGCGAAATCAAAGATC  
 TCTTGTGGACACGTAAGTGGCGGCCATTAAATAACGTGTACTTGTCTATTCTTGTGCGGTGTGGTCT  
 TGGGAAAAAGAAAGCTTGTGAGGCTGTGTTACGCCCCATACATTACTTGTACGATTCTGTGACT  
 TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTCTCTTC  
 TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTCCCGTGGTTTTCGAACTT  
 GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCAAATTTGTGCGGCCCATGGCATAACCGGAAGAG  
AGGAGCAAAGCGCGAAACCTGCCGCAACAGAACGAGAGACTGCAAGAAAAAGATAGAGAAAG  
ATGTGCGACGTAAACAATGGAAAAACAAGAATAACAATAGGAAACAACAGCTGTCCGACAAAGTCTGT  
CCCAGAAGGAGGAAATATCACTGACGCCCAGGACGATATTAATAATGCGGAGAAATAAAGAAAG  
GCTCGAAAGAAGAATCTAAACAGCTGCTCGAAATTTCTGAAAAACAAGAACCATCAGAAAGAGA  
TTCAATATGAAATTTGCAAAAAACAATACCTACATTTGAGTCCAAAGAAAGTATCCTCAAGAAAGCT  
TGAAGACATAAGACCGGAGCAGGCAAAAAACAGATGAAACTCTTTCGCATTTTCGAGCCAAAAACA  
GCTCCCTATATATCGCGCCAATGGCGAGAAGGAGCTACGCAACCGGTGGTACTGGAAGTTGAAAAA  
AGACACCCTGCCAGATGGAGATTATGACGTCCGGGAGTATTTCTCAATCTCTATGATCAGATCCTCA  
TCGAAATGCCGACTATCTGCTCCTCAAGGACATGGCCGTGGAGAACAATAATAGCAGAGACGCCG  
GCAAGTTGTGCACTCTGAGACTGCCAATATTTGTGATGCCATCTTCCAGGATGAGGAGACCGAGGG  
AGTCGTCCTGATATTCATCGCTGATATGCGGCAACAGGTCCAGGCTGATCGTAACATTGTCAATTAC  
CCTTCCATCCTTCAACCTATTGATCATGCAATCAATGAGTATTTTCTTAACCACCAAGTTGGTGAGCC  
GCTGAACAATGAGATAATCTTCAATTACATACCAGAGAGGATAAGGAATGACGTGAATTACATCCTG  
AACATGGATATGAATCTGCCATCTACAGCCAGGTATATCAGGCCAAACTTGTGTCAGGATAGACTGA  
ATCTTCACGATAATTTTGAAGTCCCTGTGGGATACCATCAACAATCCAACTACATTCTGGCCAGGTCC  
GTGCTTCCCGATTGTAAGGAGAAGGAGCTGGTCTCCACCGAAGCACAGATCCAGAAAAATGAGCCAG  
GACCTGCAGCTGGAGGCCCTCACTATTAGAGCGAGACACAGTATTTAGCCGGGATTAACAGTCAGG  
CTGCCAATGATTGTTTCAAGACCCTCATAGCCGCATGCTGTCTCAAGAACCATTGCTTTGGACTTT  
GTGACCACGAACTATATGAGCCTAATCTCCGGAATGTGGCTACTTACAGTGATTCCCAACGATATGTT  
CCTCCGGGAGTCACTAGTGGCCTGTGAGCTGGCGATCATCAACACCATCGTGTATCCAGCATTCCGA  
ATGCAGAGAATGCATTACCGGAATGGCGACCCCTCAGACACCCTTCCAGATCGCAGAACAGCAGATCC  
AGAATTTCCAGTGGCGAACTGGCTCCATTTTATTAACAATAACAGATTACGGCAAGTTGTGATTGA  
TGGAGTTCTGAATCAGACTCTGAACGACAATATACGGAATGGACAGGTTCATCAACCAGCTGATGGAA  
GCATTGATGCAACTCAGCAGACAGCAGTTCACACGATGCCTGTGGATTACAAACGGAGCATCCAAC  
GGGGCATTCTGCTTCTTCCAATAGGCTGGGGCAGCTTGTGCACTTAACCCGACTGGTCTCCTATAAC  
TACGAGACGCTAATGGCTTGTGTGACCATGAACATGCAGCACGTGCAAAACCTGACAACCTGAGAAGT  
TGCAGTCACTTCTGTGACTTCGCTTTGTATGTTAATTGGTAACACAACCGTGATTCCGTCCCCACAG  
ACACTGTTCCACTACTACAACATCAACGTGAATTTCCACTCCAATTATAATGAGCGGATCAACGACG  
CCGTGCCATAATTACCGCAGCAAATAGGCTGAATCTTTATCAGAAAAAATGAAGTCCATAGTGGA  
AGACTTTCTGAAACGGCTCCAGATTTTCGACGTACCACGAGTGCCTGACGACCAAAATGTACAGGCTG  
AGGGATCGCCTTCGGCTCTTACCCGTTGAACGGAGACGGCTTGACATATTCAACTTGATCCTGATGA  
ATATGGAGCAGATCGAACGCGCTTCTGATAAGATTGCTCAGGGGGTTATCATCGCATACCGAGATAT  
GCAGTGGAAACGCGACGAGATGTACGATATGTTAATATGACCGGAATCTTGACCGGATACCGCAAA  
ATTAACCTGGAGGAACCTCATGCGCACCGGTGATTACGGACAAATTACGAACATGCTTCTCAACAATC  
AACCCGTTGCCCTTGTGGGTGCATTGCCCTTCGTTACGGACTCATCCGTGATCAGTCTAATCGCCAAG  
CTCGACGCAACCGTCTTCGCTCAGATAGTGAAGCTCAGGAAAGTTGACACACTGAAGCCCATACTGT  
ACAAAATAAACTCGGATTCCAATGACTTTTACCTTGTGGCCAACTACGACTGGATCCCCACAAGTAC  
AATAAGGTCTACAAACAGGTGCCACAACCATTCGACTTTAGAGCCAGCATGCACATGCACTTCT  
AACCTTACGTTTACCGTCTACTCTGACCTACTGTCAATTTGTTTACGCGGACACGGTAGAGCCCATTA  
CGCAGTCGATTTCGACAATATGCGAATAATGAACGAGCTTTAAAGGCCTATTTTCTTTAGTTTGAATT  
TACTGTTATTCGGTGTGCATTTCTATGTTGGTGAGCGGTTTCTGTGCTCAGAGTGTGTTTATTTAT

GTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAGGTCGTCCCTTCAGCAAGGACACAAAAAGATTTT  
AATTTTATTAAGGACCGGGAATTCGATATCAAGCTTATCGACCTGCAGATC  
GTTCAAACATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCGATGATTATCATA  
TAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATG  
GGTTTTTATGATTAGAGTCCCGCAATTATACATTTAATACGCGATAGAAAACAAATATAGCGCGCA  
AACTAGGATAAATTATCGCGCGCGGTGTCATCTATGTTACTAGAT

**Figure 24**

Schematic representation of construct number 1711



C-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS (Construct number 1713)**Figure 25a**, SEQ ID NO: 28

IF-WA\_VP6(opt).s1+3c

AAATTTGTCGGGCCCATGGAGGTCCTTTATAGTCTCTCCAAAACGCTGA

**Figure 25b**, SEQ ID NO: 29

IF-WA\_VP6(opt).s1-4r

ACTAAAGAAAATAGGCCTCTACTTGATCAACATACTCCGGATAGAGGCCA  
CA**Figure 25c**, SEQ ID NO: 30

Expression cassette number 1713 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
 AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGC  
 TATCTGTCACTTTATTGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
 AAAGGAAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
 AGGAGCATCGTGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAAC  
 ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
 GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTG  
 TCACTTTATTGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGA  
 AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
 ATCGTGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
 ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTTCCTCTATATAAGGAAGTTCATTT  
 CATTGGAGAGGTATTAATCTTAATAGGTTTGTATAAAGCGAACGTGGGGAAACCCGAACCAAA  
 CCTTCTTCTAACTCTCTCATCTCTCTTAAAGCAAACCTCTCTCTTGTCTTTCTTGGCGTGAAGCATCT  
 TCAACGTTGTGATCGTGTCTCGGCACCACTACAACGTTTCTTTCACTGAAGCGAAATCAAAGATC  
 TCTTTGTGGACACGTAGTGCAGCGCCATTAAATAACGTGTACTTGTCTTCTTGTCTGCTGCTGCTG  
 TGGGAAAAGAAAGCTTGCTGGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACT  
 TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTTCTTCTC  
 TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTCCCGTGGTTTTCGAACCTT  
 GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCAAATTTGTGCGGGCCCATGGAGGTCCTTTATAGT  
CTCTCCAAAACGCTGAAGGACGCTAGGGACAAGATCGTGGAGGGTACACTTTATAGCAATGTCAGCG  
ACCTAATACAGCAGTTTAAATCAAATGATCGTTACAATGAATGGGAATGATTTCCAAACTGGCGGTAT  
TGGTAATCTGCCCGTGAGGAACTGGACATTCGATTTCCGGCCTGCTGGGCACGACTCTCCTTAATCTCG  
ATGCAAAATTATGTAGAAAACGCCAGAACGATTATCGAGTACTTTATCGATTTCATTGATAACGTTTGT  
ATGGATGAGATGGCCCGCGAGTCACAACGGAACGGAGTTGCTCCACAGTCCGAGGCCCTTCGGAAA  
CTCGCCGGCATTAAGTTCAAGCGTATTAATTTGACAACCTCCTCCGAATATATAGAGAACTGGAACCT  
GCAGAATCGTCGACAGAGAACCGGCTTCGTGTCCATAAACCTAATATCTTTCCGTATAGCGCCTCAT  
TCACCCTGAATAGGAGTCAGCCCCATGCACGACAACCTCATGGGTACAATGTGGCTGAATGCGGGGAG  
TGAAATACAGGTCGCCGGGTTGATTACTCCTGTGCCATTAATGCACCCGCAAAACATCCAGCAGTTC  
GAACATATCGTGCAACTAAGACGGGCTCTCACGACCGCGACAATTACACTCCTGCCGACGCCGAGC  
GCTTCTCCTTTCCCCGCGTAATCAACTCAGCTGATGGCGCCACCACTTGGTTCTTCAACCCTTTATAT  
TGCGCCCTAACAACGTAGAGGTGGAGTTTCTCTTAAACGGACAGATCATCAATACCTACCAAGCCAG  
GTTCCGGCACGATTATTGCAAGAAATTTGACGCTATCAGGCTGCTCTTCCAACCTGATGAGGCCCCCCA  
ATATGACTCCCGCTGTGAACGCTTTGTTTCCGCAGGCTCAGCCTTTCCAGCACACGCCACCGTCCGGC  
TTGACTCTTGAATAGAGAGCGCGGTCTGCGAATCAGTGTGCGAGACGCCAACGAGACGCTGCTGG  
CAAACGTTACCGCCGTGCGGCAAGAGTATGCCATCCCAGTAGGGCCTGTGTTTCCACCCGGCATGAA  
CTGGACTGAACTAATTACTAATATAGCCCATCCAGAGAAGACAACCTTGCAGCGGGTCTTCACTGTG  
GCCTCTATCCGGAGTATGTTGATCAAGTAGAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCCGT  
GTGCAATTTCTATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTATTTATGTAATTTAATTTCT  
 TTGTGAGCTCCTGTTTAGCAGGTGCTCCCTTCAGCAAGGACACAAAAAGATTTAATTTTATTAATAA  
 AAAAAAAAAAAAAAGACCGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGC  
 AATAAAGTTTCTTAAGATTGAATCCTGTTGCCGCTCTTGCATGATTATCATATAATTTCTGTTGAATT  
 ACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTTATGATTAGA  
 GTCCCGCAATTATACATTTAATACGCGATAGAAAAACAAATATAGCGCGCAAACTAGGATAAATTAT  
 CGCGCGCGGTGTATCTATGTTACTAGAT



**Figure 25d**

Nucleotide sequence encoding VP6(opt) from Rotavirus A WA strain (SEQ ID NO: 46)

ATGGAGGTCCTTTATAGTCTCTCCAAAACGCTGAAGGACGCTAGGGACAAGATCGTG  
GAGGGTACACTTTATAGCAATGTCAGCGACCTAATACAGCAGTTTAATCAAATGATC  
GTTACAATGAATGGGAATGATTTCCAAACTGGCGGTATTGGTAATCTGCCCCGTGAGG  
AACTGGACATTCGATTTTCGGCCTGCTGGGCACGACTCTCCTTAATCTCGATGCAAAT  
TATGTAGAAAACGCCAGAACGATTATCGAGTACTTTATCGATTTTCATTGATAACGTT  
TGTATGGATGAGATGGCCCGCGAGTCACAACGGAACGGAGTTGCTCCACAGTCCGAG  
GCCCTTCGGAAACTCGCCGGCATTAAAGTTCAAGCGTATTAATTTTCGACAACCTCCTCC  
GAATATATAGAGAACTGGAACCTTGCAGAATCGTCGACAGAGAACC GGCTTCGTGTTT  
CATAAACCTAATATCTTTCCGTATAGCGCCTCATTACCCCTGAATAGGAGTCAGCCC  
ATGCACGACAACCTCATGGGTACAATGTGGCTGAATGCGGGGAGTGAAATACAGGTC  
GCCGGGTTTCGATTACTCCTGTGCCATTAATGCACCCGCAAACATCCAGCAGTTCGAA  
CATATCGTGCAACTAAGACGGGCTCTCACGACCGCGACAATTACACTCCTGCCCCGAC  
GCCGAGCGCTTCTCCTTTCCCCGCGTAATCAACTCAGCTGATGGCGCCACCACTTGG  
TTCTTCAACCCTGTTATATTGCGCCCTAACAACGTAGAGGTGGAGTTTCTCTTAAAC  
GGACAGATCATCAATACCTACCAAGCCAGGTTTCGGCACGATTATTGCAAGAAATTTT  
GACGCTATCAGGCTGCTCTTCCAACTGATGAGGCCCCCAATATGACTCCCGCTGTG  
AACGCTTTGTTTCCGCAGGCTCAGCCTTTCCAGCACACGCCACCGTCGGCTTGACT  
CTTCGAATAGAGAGCGCGGTCTGCGAATCAGTGCTGGCAGACGCCAACGAGACGCTG  
CTGGCAAACGTTACCGCCGTGCGGCAAGAGTATGCCATCCCAGTAGGGCCTGTGTTT  
CCACCCGGCATGAACTGGACTGAACTAATTACTAACTATAGCCCATCCAGAGAAGAC  
AACTTGCAGCGGGTCTTCACTGTGGCCTCTATCCGGAGTATGTTGATCAAGTAG


**Figure 26, SEQ ID NO: 31**

Amino acid sequence of VP6 from Rotavirus A WA strain

MEVLYSLSKTLKDARDKIVEGTLYSNVSDLIQQFNQMIVTMNGNDFQTGGIGNLPVRNWTDFGLLGTTL  
LNLDANYVENARTHEYFIDFIDNVCMDMARESQRNGVAPQSEALRKLKAGIKFKRINFNSSEYIENWNL  
QNRRTQTGFVFHKNIFPYSASFTLNRSQPMHDNLMGMTMWLNAGSEIQVAGFDYSCAINAPANIQQFEHI  
VQLRRALTATITLLPDAERFSFPRVINSADGATTWFFNPVILRPNNVEVEFLNGQIINTYQARFGTHIARN  
FDAIRLLFQLMRPPNMTPAVNALFPQAQPFQHHATVGLTLRIESAVCESVLADANETLLANVTAVRQEYA  
IPVGPVFPPGMNWTTELITNYSRSDNLRVFTVASIRSMLIK

**Figure 27**

Schematic representation of construct number 1713



D-2X35S/CPMV-HT/RVA(WA) VP6(opt)/NOS into BeYDV(m)+Replicase  
amplification system (Construct number 1714)


**Figure 28, SEQ ID NO: 32**

Expression cassette number 1714 from 2X35S promoter to NOS terminator. VP6(opt) from Rotavirus A WA strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAACCTCCTCGGATTCCATTGCCAGC  
TATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
AAAGGAAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCCTCAAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAACCTCCTCGGATTCCATTGCCAGCTATCTG  
TCACCTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAAGGA  
AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
ATCGTGGAAAAAGAAGACGTTCCAACCACGTCCTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTTCTCTATATAAGGAAGTTCATTT  
CATTTGGAGAGGTATTAATCTTAATAGGTTTGTATAAAGCGAACGTGGGGAAACCCGAACCAAA  
CCTTCTCTAAACTCTCTCTCATCTCTTAAAGCAAACCTCTCTCTTGTCTTCTTGCCTGAGCGATCT  
TCAACGTTGTCAGATCGTGTCTCGGCACCAAGTACAACGTTTCTTCTACTGAAGCGAAATCAAAGATC  
TCTTTGTGGACACGTAAGTGGCGGCCATTAAATAACGTGTACTTGTCTATTCTTGTCTGGTGTGGTCT  
TGGGAAAAAGAAAGCTTGTGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACT  
TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTCTCTTC  
TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTCCCGTGGTTTTCGAACTT  
GGAGAAAAGATTGTTAAGCTTCTGTATATTCTGCCAAATTTGTCGGGCCCCATGGAGGTCCTTTATAGT  
CTCTCCAAAACGCTGAAGGACGCTAGGGACAAGATCGTGGAGGGTACACTTTATAGCAATGCTCAGCG  
ACCTAATACAGCAGTTTAAATCAAATGATCGTTACAATGAATGGGAATGATTTCCAAACTGGCGGTAT  
TGGTAATCTGCCCCGTGAGGAACCTGGACATTCGATTTCGGCCTGCTGGGCACGACTCTCCTTAATCTCG  
ATGCAAAATTATGTAGAAAACGCCAGAACGATTATCGAGTACTTTATCGATTTCATTGATAACGTTTGT  
ATGGATGAGATGGCCCGGAGTCACAACGGAACGGAGTTGCTCCACAGTCCGAGGCCCTTCGGAAA  
CTCGCCGGCATTAAAGTTCAAGCGTATTAATTTGACAACCTCCTCCGAATATATAGAGAACTGGAACCT  
GCAGAATCGTTCGACAGAGAACC GGCTTCGTGTTCCATAAAACCTAATATCTTTCCGTATAGCGCCTCAT  
TCACCCTGAATAGGAGTCAGCCCCATGCACGACAACCTCATGGGTACAATGTGGCTGAATGCGGGGAG  
TGAAATACAGGTCGCCGGGTTTCGATTACTCCTGTGCCATTAATGCACCCGCAAACATCCAGCAGTTC  
GAACATATCGTGCAACTAAGACGGGCTCTCAGCACC GCGACAATTACACTCCTGCCCGACGCCGAGC  
GCTTCTCCTTTCCCCGCGTAATCAACTCAGCTGATGGCGCCACCACTTGGTTCTCAACCCTGTTATAT  
TGCGCCCTAACAACGTAGAGGTGGAGTTTCTCTTAAACGGACAGATCATCAATACCTACCAAGCCAG  
GTTCCGGCACGATTATTGCAAGAAATTTTCGACGCTATCAGGCTGCTCTTCCAACCTGATGAGGCCCCCA  
ATATGACTCCCCTGTGAACGCTTTGTTTCCGAGGCTCAGCCTTTCCAGCACCAACGCCACCGTCGGC  
TTGACTCTTCGAATAGAGAGCGCGGTCTGCGAATCAGTGCTGGCAGACGCCAACGAGACGCTGCTGG  
CAAACGTTACCGCCGTGCGGCAAGAGTATGCCATCCAGTAGGGCCTGTGTTTCCACCCGGCATGAA  
CTGGACTGAACTAATTACTAATAAGCCCATCCAGAGAAGACAACCTTGACGCGGGTCTTCACTGTG  
GCCTCTATCCGGAGTATGTTGATCAAGTAGAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGT  
GTGCATTTCTATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTTATTTATGTAATTTAATTTCT  
TTGTGAGCTCCTGTTTAGCAGGTCGTCCCTTCAGCAAGGACACAAAAAGATTTAATTTTATTAATAA  
AAAAAAAAAAAAAAAAAGACCGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGC  
AATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGGCATGATTATCATATAATTTCTGTTGAATT  
ACGTTAAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTTATGATTAGA  
GTCCC GCAATTATACATTTAATACGCGATAGAAAAACAAATATAGCGCGCAAACCTAGGATAAATTAT  
CGCGCGCGGTGTCATCTATGTTACTAGAT

**Figure 29**

Schematic representation of construct number 1714



E-2X35S/CPMV-HT/ RVA(Rtx) VP4(opt)/ NOS (Construct number 1731)

**Figure 30A**, SEQ ID NO: 33

IF-Rtx\_VP4(opt).sl+3c

AAATTTGTCGGGCCCATGGCTAGCCTGATCTACAGACAACTCTTGACCAAT  
TC

**Figure 30B**, SEQ ID NO: 34

IF-Rtx\_VP4(opt).sl-4r

ACTAAAGAAAATAGGCCTTCAGAGTTTACATTGCAGGATTAATTGCTCAA  
TCCTA

**Figure 31A**, SEQ ID NO: 35

Expression cassette number 1731 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCCCAGC  
TATCTGTCACTTTATTGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
AAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
AGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCCAGCTATCTG  
TCACTTTATTGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGA  
AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
ATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTTCTCTATATAAGGAAGTTCATTT  
CATTTGGAGAGGTATTAATCTTAATAGGTTTGTATAAAGCGAACGTGGGGAAACCCGAACCAAAA  
CCTTCTTCTAACTCTCTCTCATCTCTCTTAAAGCAAACCTTCTCTTGTCTTTCTTGTGCGTGAGCGATCT  
TCAACGTTGTGAGATCGTGTCTCGGCACCAGTACAACGTTTTCTTCTACTGAAGCGAAATCAAAGATC  
TCTTTGTGGACACGTAGTGCAGCGCCATTAAATAACGTGTACTTGTCTTCTTGTGCGGTGTGGTCT  
TGGGAAAAAGAAAGCTTGTGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACT  
TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTCTCTTCT  
TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTTCCCGTGGTTTTCTGAACCT  
GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCCAAATTTGTGCGGGCCCATGGCTAGCCTGATCTAC  
AGACAACTCTTGACCAATTCATATTCTGTGGATCTTCATGACGAAATCGAGCAGATTGGGTCCGAGA  
AGACCCAGAACGTGACCATCAACCCTGGACCTTTGCTCAGACCCGCTATGCCCTGTGAATTGGGA  
TCACGGAGAAATCAACGACAGTACGACCGTCAACCCATTCTGGACGGGCCATACCAACCCACCACC  
TTACCCACCTAATGATTATTGGATTTTAATCAACTCCAACACAAACGGAGTGGTCTACGAGTCCAC  
TAATAACTCCGATTTTGGACCGCCGTTGTAGCCATCGAGCCACACGTCAATCCTGTGATCGCCAGT  
ATATGATATTTCGGCGAGTCCAAACAGTTTAACGTTTCCAATGACAGCAACAAATGGAAGTTTCTGGA  
GATGTTTCGAGCTCCTCTCAGAACGAATTCTATAATAGACGGACCCCTACCTCCGATACACGACTCG  
TGGGTATTTTAAGTACGGCGGCAGGGTGTGGACATTTACGGTGAAACCCCTCGAGCAACCACTGA  
CTCCAGTAGCACTGCAAACCTGAACAATATATCTATTACCATCCACAGCGAATTCTACATAATCCCA  
AGATCTCAGGAAAGTAAGTGTAACGAATATATCAACAACGGACTCCCCCAATTCAGAATACACGG  
AACGTGGTGCCTCTCCCACTCAGTTCTCGGTCTATCCAGTATAAGAGAGCACAAAGTGAATGAGGACA  
TTATTGTGAGCAAGACTAGCCTTTGGAAAGAAATGCAGTACAACAGAGACATTATCATCCGGTTTAA  
GTTTGGGAACCTCTATCGTGAAGATGGGCGGCCTGGGGTACAAATGGTCAGAAATCTCATATAAAGCC  
GCCAACTATCAGTATAACTACTTGAGAGACGGCGAGCAGGTAAACCGCCACACAACATGCTCTGTCA  
ACGGCGTTAATAACTTTAGTACAACGGAGGCTTCCTTCCACCGACTTCGGTATCAGCCGGTATGA  
AGTCATCAAGGAAAATTCTTATGTGTACGTAGATTACTGGGATGATAGCAAAGCGTTCCGCAACATG  
GTGTATGTTAGGAGCCTGGCTGCTAATCTCAATTCTGTGAAGTGTACTGGTGGATCATATTATTCTC  
AATTCCCGTGGGGCTTGGCCAGTCATGAATGGCGGGGCAGTCTCCCTCCATTTTGTGCGGTGACGT  
TGAGCACTCAGTTTACCGATTTCTGTCTCTGAACTCCCTGAGGTTCCGGTTTTCCCTTACTGTCGACG  
AGCCCCATTACGATTCTGCGTACAAGAAGTGTCAACCTCTACGGGTACCTGCCGGAATCCAAA  
CAACGGCAATGAATACTATGAAATTTCCGGCCGCTTCTCTTTGATAAGTCTGGTACCAACTATGAC  
GACTATCAGACACCCATCATGAACAGCGTGACTGTCTCAGACAGGACCTGGAAAGACAACTATAGAT  
CTGCGGGAAGAATTCAATTCTCTCAGTCAGGAGATTGCAATGGCCCAATTGATAGATCTTGCCCTACT  
GCCTCTCGATATGTTTAGTATGTTCTCCGGCATCAATCAACTATAGATCTGACAAAGAGCATGGCTA  
CTTCTGTGATGAAGAAGTTCAGGAAATCAAAAATTTGCCACGAGCATATCAGAAATGACGAACTCTCT  
GAGTGATGCAGCATCATCAGCGTCACGCAACGTTTCATTCCGTCGAATCTCAGCGCCATCAGCAAC  
TGGACAAACGTGTCCAAACGACGTGACGCAACGTTACCAACTCCTTGAACGATATTTTCAACGACGT  
CAACGATCAGTAAGAAACTCCGCTTGAAAGAAATGATCACCAGACTGAGGGAATGTCTTTCGACGA

CATTTCGCCGCCGTGCTAAAAACAAAATCGATATGTCTACTCAGATCGGCAAGAACACTCTGCCG  
GATATCGTAACCGAAGCCTCCGAAAAGTTTATCCCTAAGCGCAGCTACAGAATATTGAAAAGATGACG  
AGGTCATGGAGATCAACACAGAAGGGAAAGTTCTTCGCTTATAAGATCAACACCTTTGACGAGGTTCC  
GTTTGACGTCAATAAGTTTGCAGAGCTCGTGACAGATAGTCCAGTGATTCTGCCATCATTGACTTTA  
AGACTTTGAAGAACCTGAACGACAACCTATGGAATAACACGACCGAAGCGTTGAACCTCATTAAGTC  
CAATCCCAATATGTTGCGCAATTTTCAATTAACCAGAACAAATCCAATCATAAGAAATAGGATTGAGCAA  
TTAATCCTGCAATGTAACTCTGAAGGCCTATTTTCTTTAGTTTGAATTTACTGTTATTCCGGTGTGCAT  
TTCTATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTTATTTTATGTAATTTAATTTCTTTGTGA  
GCTCCTGTTTAGCAGGTCTGCCCTTCAGCAAGGACACAAAAAGATTTTAATTTTATTAATAAAAAA  
AAAAAAAAGACCGGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAA  
AGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCAGTATTATCATATAATTTCTGTTGAATTACGTT  
AAGCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCC  
GCAATTATACATTTAATACGCGATAGAAAACAAAATATAGCGCGCAAACTAGGATAAATTATCGCGC  
GCGGTGTCATCTATGTTACTAGAT

### Figure 31B

Optimized coding sequence of Rotavirus A VP4 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO: 47)

ATGGCTAGCCTGATCTACAGACAACTCTTGACCAATTCATATTCTGTGGATCTTCATGACGAAATCGA  
 GCAGATTGGGTCCGAGAAGACCCAGAACGTGACCATCAACCTGGACCTTTTGCTCAGACCCGCTAT  
 GCCCCTGTGAATTGGGATCACGGAGAAATCAACGACAGTACGACCGTCGAACCCATTCTGGACGGGC  
 CATACCAACCCACCACCTTCACCCCACCTAATGATTATTGGATTTTAATCAACTCCAACACAAACGGA  
 GTGGTCTACGAGTCCACTAATAACTCCGATTTTGGACCGCGGTTGTAGCCATCGAGCCACACGTCAA  
 TCCTGTGATCGCCAGTATATGATATTCCGGCAGTCCAAACAGTTTAACGTTTCCAATGACAGCAAC  
 AAATGGAAGTTTCTGGAGATGTTTCGAGCTCCTCTCAGAACGAATTCATAATAGACGGACCCCTTA  
 CCTCCGATACACGACTCGTGGGTATTTTAAGTACGGCGGCAGGGTGTGGACATTTACGGTGAAC  
 CCTCGAGCAACCCTGACTCCAGTAGCACTGCAAACTGAACAATATATCTATTACCATCCACAGC  
 GAATTCTACATAATCCCAAGATCTCAGGAAAAGTAAGTGAACGAATATATCAACAACGGACTCCCC  
 CAATTCAGAATACACGGAACGTGGTGCCTCTCCCACTCAGTTCTCGGTCTATCCAGTATAAGAGAGC  
 ACAAGTGAATGAGGACATTATTGTGAGCAAGACTAGCCTTTGGAAGAAATGCAGTACAACAGAGA  
 CATTATCATCCGGTTTAAAGTTTGGGAACCTCTATCGTGAAGATGGGCGGCCTGGGGTACAAATGGTCA  
 GAAATCTCATATAAAGCCGCAACTATCAGTATAACTACTTGAGAGACGGCGAGCAGTAACCGCCC  
 ACACAACATGCTCTGTCAACGGCGTTAATAACTTTAGCTACAACGGAGGCTTCTCTCCACCGACTTC  
 GGTATCAGCCGGTATGAAGTCATCAAGGAAAATTCTTATGTGTACGTAGATTACTGGGATGATAGCA  
 AAGCGTTCGCAACATGGTGTATGTTAGGAGCCTGGCTGCTAATCTCAATTCTGTGAAGTGTACTGGT  
 GGATCATATTATTTCTCAATTCCCGTGGGGGCTTGGCCAGTCATGAATGGCGGGGCAGTCTCCCTCCA  
 TTTTGTGGCGTGACGTTGAGCACTCAGTTTACCGATTTCGTGTCTCTGAACTCCCTGAGGTTCCGGTT  
 TTCCCTTACTGTGACGAGCCCCCATTACGCAATTCTGCGTACAAGAACTGTCAACCTCTACGGGTTAC  
 CTGCCGGAATCCAAACAACGGCAATGAATACTATGAAATTTCCGGCCGCTTCTCTTTGATAAGTCT  
 GGTACCAACTAATGACGACTATCAGACACCCATCATGAACAGCGTGACTGTCAGACAGGACCTGGA  
 AAGACAACCTTACAGATCTGCGGGAAGAATTCAATTCTCTCAGTCAGGAGATTGCAATGGCCCAATTG  
 ATAGATCTTGCCCTACTGCCTCTCGATATGTTTAGTATGTTCTCCGGCATCAATCAACTATAGATCT  
 GACAAAGAGCATGGCTACTTCTGTGATGAAGAAGTTCAGGAAATCAAACTTGCCACGAGCATATCA  
 GAAATGACGAACTCTCTGAGTGATGCAGCATCATCAGCGTCACGCAACGTTTCCATTCCGGTCAATC  
 TCAGCGCCATCAGCAACTGGACAAACGTGTCCAACGACGTCAGCAACGTGACCAACTCCTTGAACGA  
 TATTTCTACCCAGACGTCAACGATCAGTAAGAAACTCCGCTTGAAAGAAATGATCACCAGACTGAG  
 GGAATGTCTTTGACGACATTTCCGCCGCCGTGCTAAAAACAAAATCGATATGTCTACTCAGATCG  
 GCAAGAACACTCTGCCGATATCGTAACCGAAGCCTCCGAAAAGTTTATCCCTAAGCGCAGTACAG  
 AATATTGAAAGATGACGAGGTGATGAGATCAACACAGAAGGGAAGTTCTTCGCTTATAAGATCAA  
 CACCTTTGACGAGGTTCCGTTTACGTCATAAAGTTTGCAGAGCTCGTGACAGATAGTCCAGTGATTT  
 CTGCCATCATTGACTTTAAGACTTTGAAGAACCTGAACGACAACCTATGGAATAACACGACCGAAGC  
 GTTGAACCTCATTAAGTCCAATCCCAATATGTTGCGCAATTTCAATTAACCAGAACAAATCCAATCATAA  
 GAAATAGGATTGAGCAATTAATCTGCAATGTAACTCTGA

**Figure 31C** (SEQ ID NO: 44)

Expression cassette number 1730 from 2X35S promoter to NOS terminator. VP4(opt) from Rotavirus A Rotarix strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
 AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGC  
 TATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
 AAAGGAAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
 AGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAAGTGGATTGATGTGATAAC  
 ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
 GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTG  
 TCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGA  
 AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
 ATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAAGTGGATTGATGTGATATCTCCACTG  
 ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTTCTCTATATAAGGAAGTTCATTT  
 CATTGGAGAGGTATTAATCTTAATAGGTTTTGATAAAGCGAACGTGGGGAAACCCGAACCAAA  
 CCTTCTTCTAACTCTCTCTCATCTCTCTTAAAGCAAACCTTCTCTTGTCTTTCTTGGCGTGAAGCATCT  
 TCAACGTTGTGATGCTGCTTCCGACCAAGTACAAACGTTTTCTTTCACTGAAGCGAAATCAAAGATC  
 TCTTTGTGGACACGTAGTGGCGGCCATTAAATAACGTGTACTTGTCTTCTTGTCTGCTGCTGCTGCT  
 TGGGAAAAGAAAGCTTGTGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACT  
 TTCGGCGGGTGCAATATCTTACTTCTGCTTGACGAGGTATGTTGCCTGTACTTCTTCTTCTTCTTCT  
 TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTTCCCGTGGTTTTCGAACTT  
 GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCCAAATTTGTGCGGCCCATGGCTAGCCTGATCTAC  
 AGACAACCTTTGACCAATTCATATTCTGTGGATCTTCATGACGAAATCGAGCAGATTGGGTCCGAGA  
 AGACCCAGAACGTGACCATCAACCCCTGGACCTTTTGTCTCAGACCCGCTATGCCCTGTGAATTGGGA  
 TCACGGAGAAATCAACGACAGTACGACCGTGAACCCATTCTGGACGGGCCATACCAACCCACCACC  
 TTACCCCCACCTAATGATTATTGGATTTTAATCAACTCCAACACAAACGGAGTGGTCTACGAGTCCAC  
 TAATAACTCCGATTTTGGACCGCGCTTGTAGCCATCGAGCCACACGTCAATCTGTGCTGATCGCCAGT  
 ATATGATATTCGGCGAGTCCAAACAGTTTAACGTTTCCAATGACAGCAACAAATGGAAGTTTCTGGA  
 GATGTTTTCGAGCTCCTCTCAGAACGAATTCTATAATAGACGGACCCCTACCTCCGATACACGACTCG  
 TGGGTATTTTAAAGTACGGCGGCAGGGTGTGGACATTTACGGTGAAACCCCTCGAGCAACCACTGA  
 CTCCAGTAGCACTGCAAACCTGAACAATATATCTATTACCATCCACAGCGAATTCTACATAATCCCA  
 AGATCTCAGGAAGTAAGTGAACGAATATATCAACAACGGACTCCCCCAATTGAGAATACACGG  
 AACGTGGTGCCTCTCCCACTCAGTTCTCGGTCTATCCAGTATAAGAGAGCACAAGTGAATGAGGACA  
 TTATTGTGAGCAAGACTAGCCTTTGGAAGAAATGCAGTACAACAGAGACATTATCATCCGGTTTAA  
 GTTTGGGAACCTCTATCGTGAAGATGGGCGGCCTGGGGTACAAATGGTCAGAAATCTCATATAAAGCC  
 GCCAACTATCAGTATAACTACTTGAGAGACGGCGAGCAGGTAAACCGCCACACAACATGCTCTGTCA  
 ACGGCGTTAATAACTTTAGCTACAACGGAGGCTTCTTCCACCGACTTCGGTATCAGCCGGTATGA  
 AGTCATCAAGGAAAATTCTTATGTGTACGTAGATTACTGGGATGATAGCAAAGCGTTCGCAACATG  
 GTGTATGTTAGGAGCCTGGCTGCTAATCTCAATTCTGTGAAGTGTACTGGTGGATCATATTATTTCTC  
 AATTCCCGTGGGGGCTTGGCCAGTCATGAATGGCGGGGCAGTCTCCCTCCATTTTGTGCGGTGACGT  
 TGAGCACTCAGTTTACCGATTTCGTGTCTCTGAACTCCCTGAGGTTCCGGTTTTCCCTTACTGTGACG  
 AGCCCCATTGACATTCTGCGTACAAGAACTGTCAACCTCTACGGGTTACCTGCCGCAATCCAA  
 CAACGGCAATGAATACTATGAAATTTCCGGCCGCTTCTCTTTGATAAGTCTGGTACCAACTAAGAC  
 GACTATCAGACACCCATCATGAACAGCGTGACTGTGACAGACAGGACCTGGAAAAGACAACCTTACAGAT  
 CTGCGGGAAGAATTCAATTCTCTCAGTCAGGAGATTGCAATGGCCCAATTGATAGATCTTGCCCTACT  
 GCCTCTCGATATGTTTAGTATGTTCTCCGGCATCAATCAACTATAGATCTGACAAAGAGCATGGCTA  
 CTTCTGTGATGAAGAAGTTCAGGAAATCAAAACTTGCCACGAGCATATCAGAAATGACGAACTCTCT  
 GAGTGATGCAGCATCATCAGCGTCACGCAACGTTTCCATTCCGGTCAATCTCAGCGCCATCAGCAAC  
 TGGACAAACGTGTCCAACGACGTGACGAACGTGACCAACTCCTTGAACGATATTTCTACCCAGACGT  
 CAACGATCAGTAAGAAACTCCGCTTGAAGAAATGATCACCAGACTGAGGGAATGTCTTTCGACGA  
 CATTTCGCCCGCCGTGCTAAAAACCAAAATCGATATGTCTACTCAGATCGGCAAGAACACTCTGCCG  
 GATATCGTAACCGAAGCCTCCGAAAAGTTTATCCCTAAGCGCAGCTACAGAATATTGAAAGATGACG  
 AGGTGATGGAGATCAACACAGAAGGGAAGTTCTTCGCTTATAAGATCAACACCTTTGACGAGGTTCC  
 GTTTGACGTCAATAAGTTTGCAGAGCTCGTACAGATAGTCCAGTGATTCTGCCATCATTGACTTAA  
 AGACTTTGAAGAACCTGAACGACAACCTATGGAATAACACGGACCGAAGCGTTGAACCTCATTAAGTC  
 CAATCCCAATATGTTGCGCAATTTCAATTAACCAGAACAAATCCAATCATAAGAAATAGGATTGAGCAA  
 TTAATCCTGCAATGTAACCTCTGAAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCAT  
 TTCTATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTATTTTATGTAATTTAATTTCTTTGTGA  
 GCTCCTGTTTACGAGGTCTCCCTTCAGCAAGGACACAAAAAGATTTAATTTTATTAATAAAAAA  
 AAAAAAAGACCGGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAA  
 AGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCATGATTATCATATAATTTCTGTTGAATTACGTT  
 AAGCATGTAATAATTAACATGTAATGCATGACGTATTTATGAGATGGGTTTTATGATTAGAGTCCC  
 GCAATTATACATTTAATACGCGATAGAAAAACAAATATAGCGCGCAAACTAGGATAAATTATCGCGC  
 GCGGTGTCATCTATGTTACTAGAT

**Figure 32, SEQ ID NO: 36**


Amino acid sequence of VP4 from Rotavirus A Rotarix strain

MASLIYRQLLTNSYSVDLHDEIEQIGSEKTQNVNTINPGPFAQTRYAPVNWDHGEINDSTTVEPILDGPYQPT  
TFTPPNDYWILINSNTNGVVYESTNNSDFWTAVVAIEPHVNPVDRQYMIFGESKQFNVSNDSENKWKFLE  
MFRSSSQNEFYNNRRTLTSDTRLVGIFKYGGRVWTFHGETPRATTDSSSTANLNNISITIHSEFYIIPRSQESK  
CNEYINNGLPPIQNTRNVVPLPLSSRSIQYKRAQVNEDIIVSKTSLWKEMQYNRDIIIRFKFGNSIVKMGGGL  
GYKWSEISYKAANYQYNYLRDGEQVTAHTTCSVNGVNNFSYNGGFLPTDFGISRYEVIKENSYYVYVDY  
WDDSKAFRNMVYVRSLAANLNSVKCTGGSYYFSIPVGAWPVMNGGAVSLHFAGVTLSTQFTDFVSLNS  
LRFRLSLTVDEPPFSILRTRTVNLYGLPAANPNNGNEYEISGRFSLISLVPTNDDYQTPIMNSVTVRQDLE  
RQLTDLREEFNLSQEIAMAQIDLALLPLDMFSMFSGIKSTIDLTSMATSVMKKFRKSKLATSISEMTNS  
LSDAASSARNVSIRSNLSAISNWTNVSNDVSNVTNSLNDISTQTSTISKKLRLKEMITQTEGMSFDDISAA  
VLKTKIDMSTQIGKNTLPDIVTEASEKFIPKRSYRILKDDEVMEINTEGKFFAYKINTFDEVFPDVNKFAL  
VTDSPVISAIDFKTLKLNLDNYGITRTEALNLIKSNPNMLRNFINQNNPIIRNRIEQLILQCKL




**Figure 33A**

Schematic representation of construct number 1730



**Figure 33B**

Schematic representation of construct number 1731



F-2X35S/CPMV-HT/RVA(Rtx) VP7(Opt)/NOS (Construct number 1733)

**Figure 34A**, SEQ ID NO: 37

IF-Rtx\_VP7(opt).s1+3c

AAATTTGTCGGGCCCCATGTACGGCATCGAGTATACAACAATTTTAATTTTC

**Figure 34B**, SEQ ID NO: 38

IF-Rtx\_VP7(opt).s1-4r

ACTAAAGAAAATAGGCCTCTAAACGCGATAATAGAAGGCTGCTGAGTTCA  
GGGA

**Figure 34C**, SEQ ID NO: 24

Expression cassette number 1733 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGC  
TATCTGTCTACTTTATTGTGAAGATAGTGGAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
AAAGGAAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
AGGAGCATCGTGGAAGAAAGAACGTTCCAAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAAC  
ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTG  
TCACTTTATTGTGAAGATAGTGGAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGA  
AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
ATCGTGGAAGAAAGAACGTTCCAAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTTCCTCTATATAAGGAAGTTCATTT  
CATTTGGAGAGGTATTAATCTTAATAGGTTTTGATAAAGCGAACGTGGGGAAACCCGAACCAAA  
CCTTCTTCTAACTCTCTCTCATCTCTCTTAAAGCAAACTTCTCTTGTCTTTCTTGGCGTGAAGCATCT  
TCAACGTTGTCAGATCGTCTCGGCACCAAGTACAACGTTTTCTTTCACTGAAGCGAAATCAAAGATC  
TCTTTGTGGACACGTAGTGCAGGCCATTAAATAACGTGTACTTGTCTTCTTGTCTGCTGCTGCTGCT  
TGGGAAAAGAAAGCTTGCTGGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACT  
TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTTCTTCTT  
TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTCCCGTGGTTTTCGAACCTT  
GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCAAATTTGTCGGGCCCATGTACGGCATCGAGTAT  
ACAACAATTTTAATTTTCTGATTTCCATCATCTGTAAACTACATCCTTAAGTCCGTGACCAGAAAT  
ATGGATTATATTATCTATCGTAGCCTCCTCATCTACGTGGCCCTTTTGGCCCTGACCAGGGCCCCAGAA  
CTATGGCCTGAACCTTACCAATCACCGGTTCAATGGATACCGTTTACGCTAATTCCTCAAGAGGGG  
ATATTTCTGACAAGTACCCTGTGCCTGTATTATCCAACAGAAGCCTCTACCCAGATCAATGATGGGG  
AGTGGAAGGATAGTCTCTCACAGATGTTCTTAACCAAGGGCTGGCCACCGGTTCCGTCTACTTCAA  
GGAATACTCTAGTATTGTCGACTTCTCAGTTGACCCCAAGCTTTATTGCGACTACAACCTGGTACTTA  
TGAAATACGACCAGAACCTGGAGCTGGATATGTCCGAGCTGGCTGACCTGATCCTCAATGAGTGGCT  
GTGCAACCCCATGGACATCACATTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTGGATCAGT  
ATGGGCTCAAGTTGCACCGTGAAGGTGTGTCCCTTGAACACCCAAATGCTGGGCATTGGTTGTCAGA  
CAACTAATGTGGATTCTGTTGAAATGGTAGCCGAAAACGAGAAGCTGGCTATAGTGGACGTAGTCGA  
TGGGATTAACCACAAGATCAATCTGACTACCAACCACTTGTACCATCAGAACTGTAAAAAGCTCGGC  
CCCCGGGAGAACGTCGCCGTGATCCAGGTGGGGGGGAGCAATGTGCTCGACATTACTGCCGACCCTA  
CCACCAATCCACAGACGGAACGGATGATGAGAGTCAACTGGAAGAAATGGTGGCAGGTCTTTTATA  
CCATTGTGGACTACATTAACCAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAACTCAGC  
AGCCTTCTATTATCGCGTTTAGAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTT  
CTATGTTTGGTGAGCGGTTTTCTGTGCTCAGAGTGTGTTTATTTTATGTAATTTAATTTCTTTGTGAGC  
TCCTGTTTAGCAGGTGCTCCCTTCAGCAAGGACACAAAAAGATTTTAAATTTTATTAATAAAAAAAAAA  
AAAAAAGACCGGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAAAG  
TTTCTTAAGATTGAATCCTGTTGCCGCTTGTGCGATGATTATCATATAATTTCTGTTGAATTACGTTAA  
GCATGTAATAATTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGC  
AATTATACATTTAATACGCGATAGAAAACAAAAATATAGCGCGCAAACTAGGATAAATTATCGCGCGC  
GGTGTCTATGTTACTAGAT

**Figure 34D**

Nucleotide sequence encoding VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 48)

ATGTACGGCATCGAGTATACAACAATTTTAATTTTCCTGATTTCCATCATTCTGTAAACTACATCCTT  
AAGTCCGTGACCAGAATTATGGATTATATTATCTATCGTAGCCTCCTCATCTACGTGGCCCTTTTTC  
CCTGACCAGGGCCCAGAACTATGGCCTGAACCTACCAATCACCAGTTCAATGGATACCGTTTACGCT  
AATTCCACTCAAGAGGGGATATTTCTGACAAGTACCCTGTGCCTGTATTATCCAACAGAAAGCCTCTAC  
CCAGATCAATGATGGGGAGTGGAAGGATAGTCTCTCACAGATGTTCTTAACCAAGGGCTGGCCCACC  
GGTTCCGTCTACTTCAAGGAATACTCTAGTATTGTGCGACTTCTCAGTTGACCCCCAGCTTATTGCGA  
CTACAACCTGGTACTTATGAAATACGACCAGAACCTGGAGCTGGATATGTCCGAGCTGGCTGACCTG  
ATCCTCAATGAGTGGCTGTGCAACCCCATGGACATCACATTATATTACTACCAGCAGTCTGGAGAAT  
CCAACAAGTGGATCAGTATGGGCTCAAGTTGCACCGTGAAGGTGTGTCCCTTGAACACCCAAATGCT  
GGGCATTGGTTGTGACACAATAATGTGGATTTCGTTTGAATGGTAGCCGAAAACGAGAAGCTGGCT  
ATAGTGGACGTAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCACTTGTACCATCAGAA  
ACTGTAAAAAGCTCGGCCCCCGGGAGAACGTCGCCGTGATCCAGGTGGGGGGGAGCAATGTGCTCG  
ACATTACTGCCGACCCTACCACCAATCCACAGACGGAACGGATGATGAGAGTCAACTGGAAGAAAT  
GGTGGCAGGTCTTTTATACCATTGTGGACTACATTAACCAGATTGTGCAAGTCATGAGTAAACGGTC  
CAGATCCCTGAACTCAGCAGCCTTCTATTATCGCGTTTAG

**Figure 34E**

Optimized coding sequence of Rotavirus A VP7 from strain  
RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8] (SEQ ID NO 54)

ATGTACGGCATCGAGTATACAACAATTTTAATTTTCCTGATTTCCATCATTCTGTAA  
AACTACATCCTTAAGTCCGTGACCAGAATTATGGATTATATTATCTATCGTAGCCTC  
CTCATCTACGTGGCCCTTTTTCGCCCTGACCAGGGCCCAGAACTATGGCCTGAACCTTA  
CCAATCACCAGTTCAATGGATACCGTTTACGCTAATTCCACTCAAGAGGGGATATTT  
CTGACAAGTACCCTGTGCCTGTATTATCCAACAGAAAGCCTCTACCCAGATCAATGAT  
GGGGAGTGGAAGGATAGTCTCTCACAGATGTTCTTAACCAAGGGCTGGCCCACCGGT  
TCCGTCTACTTCAAGGAATACTCTAGTATTGTGCGACTTCTCAGTTGACCCCCAGCTT  
TATTGCGACTACAACCTGGTACTTATGAAATACGACCAGAACCTGGAGCTGGATATG  
TCCGAGCTGGCTGACCTGATCCTCAATGAGTGGCTGTGCAACCCCATGGACATCACA  
TTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTGGATCAGTATGGGCTCAAGT  
TGCACCGTGAAGGTGTGTCCCTTGAACACCCAAATGCTGGGCATTGGTTGTGACACA  
ACTAATGTGGATTTCGTTTGAATGGTAGCCGAAAACGAGAAGCTGGCTATAGTGGAC  
GTAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCACTTGTACCATCAGA  
AACTGTAAAAAGCTCGGCCCCCGGGAGAACGTCGCCGTGATCCAGGTGGGGGGGAGC  
AATGTGCTCGACATTACTGCCGACCCTACCACCAATCCACAGACGGAACGGATGATG  
AGAGTCAACTGGAAGAAATGGTGGCAGGTCTTTTATACCATTGTGGACTACATTAAC  
CAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAACTCAGCAGCCTTCTAT  
TATCGCGTTTAG


**Figure 35**, SEQ ID NO: 39

Amino acid sequence of VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain

MYGIEYTTILIFLISHILLNYILKSVTRIMDYIYRSLIYVALFALTRAQNYGLNLPITGSMDTVYANSTQEGI  
 FLTSTLCLYYPTEASTQINDGEWKDSLQMFLLTKGWPTGSVYFKEYSSIVDFSVDPQLYCDYNLVLMKYD  
 QNLELDMSELADLILNEWLCNPMIDITLYYYQQSGESNKWISMGSSCTVKVCPLNTQMLGIGCQTTNVDS  
 FEMVAENEKLAIVDVVDGINHKINLTTTCTIRNCKKLGPRENVAVIQVGGSNVLDITADPTTNPQTERM  
 MRVNWKKWWQVFYTIVDYINQIVQVMSKRSRSLNSAAFYRV

**Figure 36**

Schematic representation of construct number 1733



G-2X35S/CPMV-HT/ RVA(Rtx) VP7(opt)/NOS (Construct number 1735)


**Figure 37**, SEQ ID NO: 40

IF-Rtx\_VP7(opt).s2+4c

TCTCAGATCTTCGCCCAGAACTATGGCCTGAACTTACCAATCACCGGTTCA  
ATGGATACC

**Figure 38**

Schematic representation of construct 1192. SacII and StuI restriction enzyme sites used for plasmid linearization are annotated on the representation.



**Figure 39**, SEQ ID NO: 41

Construct 1192 from left to right t-DNA borders (underlined). 2X35S/CPMV-HT/PDISP/NOS with Plastocyanine-P19-Plastocyanine silencing inhibitor expression cassette

TGGCAGGATATATTGTGGTGTAAACAAATTGACGCTTAGACAACTTAATAACACATTGCGGACGTTT  
 TTAATGTACTGAATTAACGCCGAATCCCCGGGCTGGTATATTTATATGTTGTCAAATAACTCAAAAACC  
 AAAAAAGTTTAAAGTTAGCAAGTGTGTACATTTTACTTGAACAAAAATATTCACCTACTACTGTTATA  
 AATCATTATTAACATTAGAGTAAAGAAATATGGATGATAAGAACAAGAGTAGTGATATTTTGACAA  
 CAATTTTGTGCAACATTTGAGAAAAATTTGTTGTCTCTCTTTTCATTGGTCAAAAACAATAGAGAG  
 AGAAAAAGGAAGAGGGAGAATAAAAAACATAATGTGAGTATGAGAGAGAAAGTTGTACAAAAGTTG  
 TACCAAAATAGTTGTACAAATATCATTGAGGAATTTGACAAAAGCTACACAAATAAGGGTTAATTGC  
 TGTAATAATAAAGGATGACGCATTAGAGAGATGTACCATTAGAGAATTTTGGCAAGTCATTAAAA  
 AGAAAGAATAAATTATTTTAAAAATTTAAAGTTGAGTCATTGATTAAACATGTGATTATTTAATGAA  
 TTGATGAAAAGAGTTGGATTAAAGTTGTATTAGTAATTAGAATTTGGTGTCAAATTTAATTTGACATTT  
 GATCTTTTCTATATATTGCCCATAGAGTCAGTTAACTCATTTTATATTTTCATAGATCAAATAAGA  
 GAAATAACGGTATATTAATCCCTCCAAAAAACCGGTATATTTACTAAAAAATCTAAGCCACG  
 TAGGAGGATAACAGGATCCCCGTAGGAGGATAACATCCAATCCAACCAATCACAACAATCCTGATG  
 AGATAACCCACTTTAAGCCACGCATCTGTGGCAGTCTACATTATCTAAATCACACATTCTCCACA  
 CATCTGAGCCACACAAAAACCAATCCACATCTTTATACCCATTCTATAAAAAATCACACTTTGTGAG  
 TCTACACTTTGATTCCCTTCAAACACATACAAAGAGAAGAGACTAATTAATTAATCATCTTGAG  
 AGAAAAATGGAACGAGCTATACAAGGAAACGACGCTAGGGAACAAGCTAACAGTGAACGTTGGGATG  
 GAGGATCAGGAGGTACCACTTCTCCCTTCAAACCTTCTGACGAAAGTCCGAGTTGGACTGAGTGGCG  
 GCTACATAACGATGAGACGAATTCGAATCAAGATAATCCCTTGGTTTCAAGGAAAGCTGGGGTTTC  
 GGGAAAGTTGTATTTAAGAGATATCTCAGATACGACAGGACGGAAGCTTCACTGCACAGATCTCTG  
 GATCTTGGACGGGAGATTCCGTTAACTATGACAGCATCTCGATTTCGGTTTCGAGCAGGATCGGATGT  
 ACCTATAGTATTCGGTTTCGAGGAGTTAGTATCACCGTTTCTGGAGGGTCGCGAAGTCTTCAGCATCT  
 CTGTGAGATGGCAATTCGGTCTAAGCAAGAACTGCTACAGCTTGCCCAATCGAAGTGAAAGTAAT  
 GTATCAAGAGGATGCCCTGAAGGTACTCAAACCTTCGAAAAAGAAAGCGAGTAAGTTAAAAATGCTT  
 CTTCTCTCTCTATTTATAATATGGTTTGTATTGTTAATTTTGTCTTGTAGAAGAGCTTAATTAATCG  
 TTGTTGTTATGAAATACTATTTGTATGAGATGAACCTGGTGAATGTAATTCATTTACATAAGTGGAGT  
 CAGAATCAGAATGTTTCTCCATAACTAAGTACATGAAGACCTGCCGCGTACAATGTCTTATATT  
 TGAACAATAAAATTGAACATCTTTTGCCACAACCTTTATAAGTGGTTAATATAGCTCAAATATATGGT  
 CAAGTTCAATAGATTAATAATGGAAATATCAGTTATCGAAATTCATTAACAATCAACTTAACGTTATT  
 AACTACTAATTTTATATCATCCCTTTTGATAAATGATAGTACACCAATTAGGAAGGAGCATGCTCGCC  
 TAGGAGATTGTCTGTTTCCCGCCTTCAGTTTGCAAGCTGCTCTAGCCGTGTAGCCAAATACGCAAAACCGC  
 CTCTCCCCGCGCGTTGGGAATTACTAGCGCGTGTGACAAAGCTTGCATGCCGCTCAACATGGTGGAG  
 CACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAATTGAG  
 ACTTTTCAACAAAGGGTAATATCCGGAACCTCTCGGATTCCATTGCCAGCTATCTGTCACTTTAT  
 TGTGAAGATAGTGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCAT  
 CGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAGATGGACCCCAACCCACGAGGAGCATCGTGGAA  
 AAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAACATGGTGGAGCAGAC  
 ACATTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGGGCAATTGAGACTTTTC  
 AACAAAGGGTAATATCCGGAACCTCTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGAAG  
 ATAGTGGAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAA  
 GATGCCTCTGCCGACAGTGGTCCCAAGATGGACCCCAACCCACGAGGAGCATCGTGGAAAAAGAA  
 GACGTTCCAACCCAGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACG  
 CACAATCCCACTATCCTTCGCAAGACCTTCTCTATATAAGGAAGTTTCATTTTCAATTTGGAGAGGTAT  
 TAAAACTTAATAGGTTTGTATAAAGCGAAGCTGGGGAAACCCGAACCAACCTTCTCTAACTC  
 TCTCTCATCTCTTAAAGCAAACCTTCTCTTGTCTTCTTGTGCGTGAGCGATCTTCAACGTTGTGAGA  
 TCGTGTCTCGGCACCAGTACAACGTTTCTTCTACTGAAGCGAAATCAAAGATCTCTTTGTGGACAG  
 TAGTGCGGCGCCATTAAATAACGTGTACTGTCTATTCTTGTGCGGTGTGGTCTTGGGAAAAAGAAAGC  
 TTGCTGGAGGCTGCTGTTACGCCCCATACATTACTTGTACGATTCTGCTGACTTTCGGCGGGTGCAA  
 TATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTCTTCTTCTTCTGCTGATTGGTTCT  
 ATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTCCCGTGGTTTTCGAACTTGGAGAAAGATTGTT  
 AAGCTTCTGTATATTCTGCCAAATTTGTGCGGCCATGGCGAAAAACGTTGCGATTTTCGGCTTATT  
 GTTTTCTTCTTGTGTTGGTTCTTCTCAGATCTTCGCGCGGCTCTCAGCCAAAAACGACACCCCA  
 TCTGTCTATCCACTGGCCCTGGATCTGCTGCCAACTAACTCCATGGTGACCCTGGGATGCCTGGT  
 CAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACCTCTGGATCCCTGTCCAGCGGTGTGCAC  
 ACCTTCCCAGCTGTCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCCCTCCAGCAC  
 CTGGCCCGCAGGACCGTCACCTGCAACGTTGCCACCCGCGCCAGCAGCACCAGGTGGACAAGAA  
 AATTGTGCCAGGGATTGTGGTTGTAAGCCTTGATATGTACAGTCCAGAGTATCATCTGTCTCTCA  
 TCTTCCCCCAAGGCCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTA  
 GACATCAGCAAGGATGATCCCAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAG  
 CTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTCCGCTCAGTCAGTGAACCTCCCATCAT

GCACCAGGACTGGCTCAATGGCAAGGAGCGATCGCTCACCATCACCATCACCATCACCATT  
 AAAGGCCTATTTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGTGAGCGGTTT  
 TCTGTGCTCAGAGTGTGTTTATTTTATGTAAATTTAATTTCTTTGTGAGCTCCTGTTTAGCAGGTGCTCC  
 CTTTCAGCAAGGACACAAAAAGATTTTAAATTTATTAATAAAAAAAAAAAAAAAAAAGACCGGAATTCG  
 ATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAAAGTTCTTAAGATTGAATCCTG  
 TTGCCGGTCTTGCGATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATG  
 TAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGCAATTATACATTTAATACGC  
 GATAGAAAAACAAAATATAGCGCGCAAACTAGGATAAATTATCGCGCGCGGTGTCATCTATGTTACTA  
 GATCTCTAGAGTCTCAAGCTTGCGCGCGCCACGTGACTAGTGGCACTGGCCGTCGTTTTACAACGTCG  
 TGACTGGGAAAAACCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTCGCCAGCTGGC  
 GTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGCTA  
 GAGCAGCTTGAGCTTGGATCAGATTGTCGTTTCCCGCCTCAGTTTAACTATCAGTGTGACAGGA  
 TATATTGGCGGGTAAACCTAAGAGAAAAGAGCGTTTA

**Figure 40A**, SEQ ID NO:42

Expression cassette number 1735 from 2X35S promoter to NOS terminator.  
 PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-  
 A41CB052A/1988/G1P1A[8] strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACC  
 AAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGC  
 TATCTGTCACCTTATTGTGAAGATAGTGGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGAT  
 AAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACG  
 AGGAGCATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAAC  
 ATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
 GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGCCAGCTATCTG  
 TCACCTTATTGTGAAGATAGTGGAAAAAGGAAGGTGGCTCCTACAAATGCCATCATTGCGATAAAGGA  
 AAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGC  
 ATCGTGGAAAAAGAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTG  
 ACGTAAGGGATGACGCACAATCCCACTATCCTTCGCAAGACCCCTTCTCTATATAAGGAAGTTCATTT  
 CATTGGAGAGGTATTAATATCTTAATAGGTTTGTATAAAGCGAACGTGGGGAAACCCGAACCAAA  
 CCTTCTTCTAAACTCTCTCTCATCTCTCTTAAAGCAAACTTCTCTTGTCTTTCTTGCCTGAGCGATCT  
 TCAACGTTGTCAGATCGTGCTTCGGCACCAGTACAACGTTTTCTTTCACTGAAGCGAAATCAAAGATC  
 TCTTTGTGGACACGTAGTGCAGCGCCATTAAATAACGTGTACTTGTCTTATTCTTGTGCGTGTGGTCT  
 TGGGAAAAAGAAAGCTTGCTGGAGGCTGCTGTTACGCCCCATACATTACTTGTTACGATTCTGCTGACT  
 TTCGGCGGGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTTCTTCTTCTT  
 TTGCTGATTGGTTCTATAAGAAATCTAGTATTTCTTTGAAACAGAGTTTTCCCGTGGTTTTCAAGATT  
 GGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCAAATTTGTCGGGCCCCATGGCGGAAAAACGTTGC  
GATTTTCGGCTTATTGTTTTCTTCTTGTGTTGGTTCCTTCTCAGATCTTCGCCAGAACTATGGCCT  
GAACTTACCAATCACCGGTTCAATGGATACCGTTTACGCTAATTCCACTCAAGAGGGGATATTTCTGA  
CAAGTACCCTGTGCCTGTATTATCCAACAGAAAGCCTCTACCCAGATCAATGATGGGGAGTGGAAAGGA  
TAGTCTCTCACAGATGTTCTTAACCAAGGGCTGGCCACCGGTTCCGTCTACTTCAAGGAATACTCTA  
GTATTGTCGACTTCTCAGTTGACCCCGAGCTTTATTGCGACTACAACCTGGTACTTATGAAATACGAC  
CAGAACCTGGAGCTGGATATGTCCGAGCTGGCTGACCTGATCCTCAATGAGTGGCTGTGCAACCCCA  
TGGACATCACATTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTGGATCAGTATGGGCTCAAG  
TGACACCGTGAAGGTGTGTCCTTGAACACCCAAATGCTGGGCATTGGTTGTCAGACAACCTAATGTG  
GATTGTTTTGAAATGGTAGCCGAAAAACGAGAAGCTGGCTATAGTGGACGTAGTCGATGGGATTAACC  
ACAAGATCAATCTGACTACCACCACTGTACCATCAGAACTGTAAAAAGCTCGGCCCCCGGGAGAA  
CGTCGCCGTGATCCAGGTGGGGGGGAGCAATGTGCTCGACATTACTGCCGACCCTACCACCAATCCA  
CAGACGGAACGGATGATGAGAGTCAACTGGAAGAAATGGTGGCAGGTCTTTATACCATTTGTGGACT  
ACATTAACCAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAAGTACAGCAGCCTTCTATTA  
TCGCGTTTTAGAGGCCTATTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGTG  
 AGCGGTTTTCTGTGCTCAGAGTGTGTTATTTTATGTAATTTAATTTCTTTGTGAGCTCCTGTTTAGCA  
 GGTCGTCCCTTCAGCAAGGACACAAAAAGATTTTAAATTTATTAATAAAAAAAAAAAAAAAAAAGACCG  
 GGAATTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAACATTTGGCAATAAAGTTTCTTAAGATT  
 GAATCCTGTTGCCGGTCTGCGATGATTATCATATAATTTCTGTTGAATTACGTTAAGCATGTAATAA  
 TTAACATGTAATGCATGACGTTATTTATGAGATGGGTTTTATGATTAGAGTCCCGCAATTATACATT  
 TAATACGCGATAGAAAACAAAATATAGCGCGCAAACTAGGATAAATTATCGCGCGCGGTGTCATCTA  
 TGTTACTAGAT



**Figure 40B**

Nucleotide sequence encoding PDISP/VP7(opt) from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain (SEQ ID NO: 62)

```
ATGGCGAAAAACGTTGCGATTTTCGGCTTATTGTTTTCTTCTTGTGTTGGTTCCTTCTCAGATCTTC
GCCCAGAACTATGGCCTGAACCTACCAATCACCGTTCAATGGATACCGTTTACGCTAATTCCACTCA
AGAGGGGATATTTCTGACAAGTACCCTGTGCCTGTATTATCCAACAGAAGCCTCTACCCAGATCAAT
GATGGGGAGTGGAAGGATAGTCTCTCACAGATGTTCCCTAACCAAGGGCTGGCCACCGGTTCCGTCT
ACTTCAAGGAATACTCTAGTATTGTGCGACTTCTCAGTTGACCCCCAGCTTTATTGCGACTACAACCTG
GTACTTATGAAATACGACCAGAACCTGGAGCTGGATATGTCCGAGCTGGCTGACCTGATCCTCAATG
AGTGGCTGTGCAACCCCATGGACATCACATTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTG
GATCAGTATGGGCTCAAGTTGCACCGTGAAAGGTGTGTCCCTTGAACACCCAAATGCTGGGCATTGGT
TGTCAGACAACTAATGTGGATTTCGTTTGAAATGGTAGCCGAAAACGAGAAGCTGGCTATAGTGGACG
TAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCACTTGTACCATCAGAAACTGTAAAAA
GCTCGGCCCCCGGGAGAACGTCGCCGTGATCCAGGTGGGGGGGAGCAATGTGCTCGACATTACTGCC
GACCCTACCACCAATCCACAGACGGAACGGATGATGAGAGTCAACTGGAAGAAATGGTGGCAGGTC
TTTTATACCATTGTGGACTACATTAACCAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAA
CTCAGCAGCCTTCTATTATCGCGTTTAG
```


**Figure 41, SEQ ID NO: 43**

Amino acid sequence of PDISP/VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain

```
MAKNVAIFGLLFSLVLVPSQIFAQNYGLNLPITGSMDTVYANSTQEGIFLTSTLCLYYPTEASTQINDGE
WKDSLSQMFLTKGWPTGSVYFKEYSSIVDFSVDPLQYCDYNLVLWKYDQNLLELDMSSELADLILNEWLC
NPMDITLYYYQQSGESNKWISMGSCTVKVCPLNTQMLGIGCQTTNVDSFEMVAENEKLAIVDVVDGIN
HKINLTTTCTIRNCKKLGPRENVAVIQVGGSNVLDITADPTTNPQTERMMRVNWKKWWQVFYTIVDYI
NQIVQVMSKRSLNSAAFYYRV
```

**Figure 42**

Schematic representation of construct number 1735



**Figure 43A**

Coding sequence of Rotavirus A VP4 from strain  
RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO: 50)

```
ATGGCTTCGCTCATT TATAGACAATTGCTCACGAATTCTTATACAGTAGATTTATCC
GATGAGATACAAGAGATTGGATCAACTAAATCACAAAATGTCACAATTAATCCTGGA
CCATTTGCGCAAACAGGTTATGCTCCAGTTAACTGGGGACCTGGAGAAATTAATGAT
TCTACGACAGTTGAACCATTGCTGGATGGGCCTTATCAACCAACGACATTCAATCCA
CCAGTCGATTATTGGATGTTACTGGCTCCAACGACACCTGGCGTAATTGTTGAAGGT
ACAAATAATACAGATAGATGGTTAGCCACAATTTTAATCGAGCCAAATGTTCAAGTCT
GAAAATAGAACTTACACTATATTTGGTATTCAAGAACAATTAACGGTATCCAATACT
TCACAAGACCAGTGGAAATTTATTGATGTCGTAAAAACAACCTGCAAATGGAAGTATA
GGACAATATGGACCATTACTATCCAGTCCGAAATTATATGCAGTTATGAAGCATAAT
GAAAAATTATATACATATGAAGGACAGACACCTAACGCTAGGACAGCACATTATTCA
ACAACGAATTATGATTCTGTTAATATGACTGCTTTTTGTGACTTTTATATAATTCCT
AGATCTGAAGAGTCTAAATGTACGGAATACATTAATAATGGATTACCACCAATACAA
AATACTAGAAATGTTGTACCATTATCGTTGACTGCTAGAGATGTAATACACTATAGA
GCTCAAGCTAATGAAGATATTGTGATATCCAAGACATCATTGTGGAAAGAAATGCAA
TATAATAGAGATATAACTATTAGATTTAAATTTGCAAATACAATTATAAAATCAGGA
GGGCTGGGATATAAGTGGTCAGAAATATCATTTAAGCCAGCGAATTATCAATACACA
TATACTCGTGATGGTGAAGAAGTTACCGCACATACTACTTGTTCAGTGAATGGCGTT
AATGACTTCAGTTTTAATGGAGGATATTTACCAACTGATTTTGTGTATCTAAATTT
GAAGTAATTAAAGAGAATTCATACGTCTATATCGATTACTGGGATGATTACAAAGCA
TTTCGTAACGTGGTGTATGTCCGATCGTTAGCAGCAAACCTGAATTCAGTTATGTGT
ACTGGAGGCAGCTATAATTTTAGTCTACCAGTTGGACAATGGCCTGTTTTAACTGGG
GGAGCAGTTTCTTTACATTACAGCTGGTGTAACTATCTACTCAATTTACAGATTTT
GTATCATTAATTCATTAAGATTTAGATTTAGACTAGCTGTCGAAGAACCACACTTT
AACTGACTAGAACTAGATTAGATAGATTGTATGGTCTGCCTGCTGCAGATCCAAAT
AATGGTAAAGAATATTATGAAATTGCTGGACGATTTTCACTTATATCATTAGTGCCA
TCAAATGATGACTATCAGACTCCTATAGCAAACCTCAGTTACTGTACGACAAGATTTA
GAAAGGCAGTTAGGAGAACTAAGAGAAGAGTTTAAACGCTTTGTCTCAAGAAATTGCA
ATGTCGCAGTTAATCGATTTAGCGCTTCTACCATTAGATATGTTCTCAATGTTTTCT
GGCATTAAAGTACTATTGATGCTGCAAAATCAATGGCTACTAATGTTATGAAAAAA
TTCAAAAAGTCAGGATTAGCGAATTCAGTTTCAACACTGACAGATTCTTTATCAGAC
GCAGCATCATCAATATCAAGAGGTTCTATCTATACGTTTCGATTGGATCTTCAGCATCA
GCATGGACGGATGTATCAACACAAATAACTGATATATCGTCATCAGTAAGTTCAGTT
TCGACACAAACGTCAACTATCAGTAGAAGATTGAGACTAAAGGAAATGGCAACACAA
ACTGAGGGTATGAATTTTGATGATATATCAGCGGCTGTTTTGAAGACTAAGATAGAT
AAATCGACTCAAATATCACCAAACACAATACCTGACATTGTTACTGAAGCATCGGAA
AAATTCATACCAAATAGGGCTTACCGTGTTATAAACAACGATGATGTGTTTGAAGCT
GGAATTGATGGAAAATTTTTTGCTTATAAAGTGGATACATTTGAGGAAATACCATTT
GATGTACAAAAATTCGCTGACTTAGTTACAGATTCTCCAGTAATATCCGCTATAATT
GATTTTAAACACTTAAAAATTTGAACGATAATTACGGCATTACTAAGCAACAAGCA
TTTAATCTTTTAAGATCTGACCCAAGAGTTTTACGTGAATTCATTAATCAGGACAAT
CCTATAATTAGAAATAGAATTGAACAACCTGATTATGCAATGCAGGTTGTGA
```

**Figure 43B**

Optimized coding sequence of Rotavirus A VP4 from strain  
RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 51)

ATGGCTTCATTGATATATCGCCAGTTGCTGACTAATAGCTATACTGTGGATTTGTCA  
 GACGAAATCCAGGAAATAGGATCCACAAAGAGTCAGAACGTGACCATAAACCCCGGA  
 CCGTTTCGCCCAGACTGGGTATGCCCCCGTAAACTGGGGCCCCGGCGAGATTAACGAC  
 AGCACCACCGTGGAGCCACTGCTGGATGGACCCTACCAACCCACTACTTTTAATCCT  
 CCAGTGGACTACTGGATGTTGTTGGCTCCACGACACCTGGTGTAATTGTAGAGGGC  
 ACCAACAATACCGATCGCTGGCTGGCGACAATACTGATAGAACCCAACGTGCAGTCC  
 GAGAACAGAACCTATAACCATTTTCGGCATCCAGGAACAGCTAACCGTGAGCAATACG  
 AGCCAGGACCAGTGGAAGTTTATCGATGTAGTGAAAACCTACGGCCAATGGATCTATC  
 GGGCAATACGGGCGCTGCTGTCTCACCTAAGCTCTACGCCGTGATGAAACATAAT  
 GAGAACTGTACACTTACGAGGGCCAAACCCCAATGCCAGAACTGCCACTACAGT  
 ACAACCAACTATGACTCGGTGAACATGACAGCGTTCTGTGATTTTTATATTATCCA  
 AGATCAGAAGAATCCAAGTGTACTGAGTACATCAACAATGGACTTCCACCCATCCAG  
 AACACTCGAAATGTCTGCCACTGTCTCTAACTGCTCGGGATGTGATCCACTATCGC  
 GCCAAGCTAATGAGGATATAGTCATTTCAAAGACGAGCTTATGGAAGGAAATGCAG  
 TATAACAGAGACATCACAATCAGGTTCAAGTTCGCCAATACTATTATTAAGTCCGGG  
 GGAAGTGGGTACAAATGGAGTGAGATCAGTTTTAAGCCCGCTAACTATCAGTACACC  
 TATACTCGCGACGGCGAAGAGGTAACCGCCACACAACCTTGCTCGGTAAATGGCGTG  
 AACGATTTTAGCTTCAACGGGGGCTACCTGCCTACTGATTTCTGTGGTGAGCAAGTTT  
 GAAGTCATCAAGGAAAATTCCCTACGTGTATATTGACTACTGGGATGATAGCCAGGCC  
 TTCCGAAATGTTGTGTATGTTAGATCACTGGCCGCAAACCTTAATTCAGTCATGTGC  
 ACAGGAGGTTCTTACAATTTTAGTCTTCCCGTCGGGCAGTGGCCAGTGCTCACAGGG  
 GGCCTGTGAGCTTGCAATCCGCCGGAGTCACCTTGAGTACTCAGTTCACAGACTTT  
 GTGTCTCTGAATAGCCTAAGGTTTCAAGTTCAGGTTTAGACTTGCAAGTAGAAGAGCCTCACTTT  
 AAGCTCACTCGTACGAGGCTGGATCGGCTGTACGGCCTGCCGGCCGCTGATCCCAAT  
 AACGGCAAGGAATATTACGAGATAGCCGGGAGATTTTCGCTGATCAGTCTGGTGCCG  
 TCAAACGATGATTACCAGACCCCAATTGCCAACAGTGTCACTGTCAGGCAAGATCTG  
 GAGAGACAACTTGGCGAGCTGAGAGAGGAGTTCAACGCCCTGTCTCAAGAGATCGCA  
 ATGTCTCAGCTCATTGACCTGGCCCTGTTACCCCTCGACATGTTCTCAATGTTCTCC  
 GGCATAAAATCCACTATCGACGCTGCAAAGTCCATGGCCACAAATGTGATGAAGAAG  
 TTTAAGAAGAGCGGTCTGGCAAATAGCGTGTCTACGCTGACCGATAGTTTGTGGAT  
 GCCGCCAGTTCATTAGCCGTGGATCCAGCATTAGGTCCATTGGCTCTTCCGCCCTCT  
 GCTTGGACTGACGTGAGTACACAGATAACTGACATTTCTCTGTCTCCAGTGTG  
 AGCACACAACTTCCACGATATCAAGACGACTGAGGCTCAAAGAGATGGCAACGCAA  
 ACGGAAGGTATGAATTTTGATGACATCAGCGCCGAGTTTTGAAGACAAAGATCGAT  
 AAAAGCACTCAAATTAGCCCCAATACGATCCCTGACATTGTGACTGAGGCATCTGAA  
 AAGTTCATTCCCAACCGTGCTTATCGGGTCATTAACAATGATGATGTCTTCGAGGCC  
 GGCATCGATGGCAAGTTTTTTGCTTATAAAGTGGATACCTTCGAGGAGATTCTTTTC  
 GATGTACAGAAGTTTGCTGACCTCGTAACGGATAGCCCAGTGATAAGCGCCATTATA  
 GACTTCAAACATTGAAAAATTTGAACGATAATTATGGTATTACCAAGCAGCAGGCT  
 TTTAACTTGTTAAGATCTGACCCTCGCGTGCTCAGAGAGTTTATTAACCAGGACAAC  
 CCCATCATCAGAAACAGGATCGAGCAGCTGATTATGCAGTGTGCCTGTAA

### Figure 43C

Coding sequence of Rotavirus A VP7 from strain  
 RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO : 52)

ATGTATGGTATTGAATATACCACAGTTCTAACCTTTCTGATATCGATTATTCTACTA  
 AATTACATACTTAAATCATTAAGTAGAATAATGGACTTTATAATTTATAGATTTCTT  
 TTTATAATTGTGATATTGTCACCATTTCTCAGAGCACAAAATTATGGTATTAACTCTT  
 CCAATCACAGGCTCCATGGACACTGCATACGCTAATTCAACGCAAGAAGAAACATTC

CTCACTTCTACACTTTGCCTATATTATCCGACTGAGGCTGCGACTGAAATAAACGAT  
 AATTCATGGAAAGACACACTGTCACAACATTTCTTACGAAAGGGTGGCCAACTGGA  
 TCCGTATATTTTAAAGAATATACTAACATTGCATCGTTTCTGTTGATCCGCAGTTG  
 TATTGTGATTATAACGTAGTACTAATGAAATATGACGCGACGTTGCAATTGGATATG  
 TCAGAACTTGCGGATCTAATATTAAACGAATGGTTGTGTAATCCAATGGATATTACT  
 CTGTATTATTATCAGCAAACCTGACGAAGCGAATAAATGGATATCAATGGGCTCATCA  
 TGTACAATTAAAGTATGTCCACTTAATACACAAACTCTTGGAATTGGATGCTTGACA  
 ACTGATGCTACAACCTTTTGAAGAAGTTGCGACAGCTGAAAAGTTGGTAATTACTGAC  
 GTGGTTGATGGCGTTAATCATAAGCTGGATGTCACAACAGCAACGTGTACTATTAGA  
 AACTGTAAGAAATTGGGACCAAGAGAAAACGTAGCCGTTATACAAGTTGGTGGTTCT  
 GACATCCTCGATATAACTGCTGATCCAACCTACTGCACCACAGACAGAACGGATGATG  
 CGAATTAACCTGGAAAAAATGGTGGCAAGTTTTTTATACTGTAGTAGACTATGTAGAT  
 CAGATAATACAAGTTATGTCCAAAAGATCAAGATCACTAAATTCAGCAGCATTTTAT  
 TACAGAGTGTAG

### Figure 43D

Optimized coding sequence of Rotavirus A VP7 from strain  
 RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2] (SEQ ID NO :53)

ATGTACGGAATCGAGTATACCACCGTTCTGACATTTCTTATTAGTATTATCCTCTTG  
 AACTATATTCTGAAGTCACCTACCCGGATAATGGATTTTATTATATATAGGTTTCTG  
 TTCATCATTGTAATTCTGAGCCCTTTCCTGAGGGCCAGAAATTACGGCATAAACCTA  
 CCAATCACCGGTTCTATGGATACCGCTTATGCTAACTCTACACAAGAGGAGACATTC  
 CTCACATCAACCCTATGCCTGTACTATCCGACTGAAGCAGCCACAGAGATAAACGAT  
 AACTCTTGAAAGATACATTGAGCCAGCTCTTCCTGACTAAGGGATGGCCACCGGA  
 TCGGTCTACTTTAAGGAGTACACAAACATCGCAAGTTTCAGCGTGGATCCCCAGCTG  
 TATTGTGATTATAACGTTGTGCTGATGAAATACGACGCAACCCTCCAGCTTGACATG  
 AGCGAGTTGGCAGACCTAATCCTCAATGAGTGGCTGTGTAACCCAATGGATATAACA  
 CTGTACTATTATCAGCAGACCGATGAAGCAAACAAATGGATTTCAATGGGAAGCAGC  
 TGTACCATCAAAGTTTGTCTCTCAACACCCAACTCTCGGCATAGGGTGTCTGACC  
 ACAGACGCTACTACCTTTGAAGAAGTTGCGACCGCGGAAAAGCTGGTTATCACAGAT  
 GTGGTAGATGGCGTTAACCACAAATTTGGACGTAACCACAGCAACATGCACAATTAGG  
 AACTGCAAGAAGCTAGGACCCAGGGAAAACGTAGCCGTCATCCAAGTGGGCGGCAGT  
 GACATCCTAGACATCACCGCAGACCCAACAACAGCACCACAAACCGAGAGGATGATG  
 CGCATTAATTGGAAGAAATGGTGGCAGGTGTTTTACTGTGCTGACTATGTGGAC  
 CAGATCATTCAGGTGATGAGCAAGCGGAGTCGCTCATTGAATAGTGCTGCCTTTTAT  
 TACAGAGTCTAA

### D-2X35S/CPMV-HT/RVA(Rtx) VP7(Opt)/NOS (Construct number 1734)

#### Figure 44A (SEQ ID NO: 55)

IF-TrSP+Rtx\_VP7(opt).s1+3c

AAATTTGTCGGGCCCATGGATTATATTATCTATCGTAGCCTCCTCATCTA

#### Figure 44B, (SEQ ID NO: 56)

IF-Rtx\_VP7(opt).s1-4r

ACTAAAGAAAATAGGCCTCTAAACGCGATAATAGAAGGCTGCTGAGTTCAGGGA

**Figure 44C, (SEQ ID NO: 57)**

Optimized coding sequence of Rotavirus A VP7 from strain RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]

ATGTACGGCATCGAGTATACAACAATTTTAATTTTCCTGATTTCCATCATTCTGTTA  
AACTACATCCTTAAGTCCGTGACCAGAATTATGGATTATATTATCTATCGTAGCCTC  
CTCATCTACGTGGCCCTTTTTGCCCTGACCAGGGCCCAGAACTATGGCCTGAACCTA  
CCAATCACCGGTTCAATGGATACCGTTTACGCTAATTCCACTCAAGAGGGGATATTT  
CTGACAAGTACCCTGTGCCTGTATTATCCAACAGAAGCCTCTACCCAGATCAATGAT  
GGGGAGTGGAAGGATAGTCTCTCACAGATGTTCCCTAACCAAGGGCTGGCCACCGGT  
TCCGTCTACTTCAAGGAATACTCTAGTATTGTGCGACTTCTCAGTTGACCCCCAGCTT  
TATTGCGACTACAACCTGGTACTTATGAAATACGACCAGAACCTGGAGCTGGATATG  
TCCGAGCTGGCTGACCTGATCCTCAATGAGTGGCTGTGCAACCCCATGGACATCACA  
TTATATTACTACCAGCAGTCTGGAGAATCCAACAAGTGGATCAGTATGGGCTCAAGT  
TGCACCGTGAAGGTGTGTCCCTTGAACACCCAAATGCTGGGCATTGGTTGTCAGACA  
ACTAATGTGGATTTCGTTTGAATGGTAGCCGAAAACGAGAAGCTGGCTATAGTGGAC  
GTAGTCGATGGGATTAACCACAAGATCAATCTGACTACCACCACTTGTACCATCAGA  
AACTGTAAAAAGCTCGGCCCCCGGGAGAACGTCGCCGTGATCCAGGTGGGGGGGAGC  
AATGTGCTCGACATTACTGCCGACCCTACCACCAATCCACAGACGGAACGGATGATG  
AGAGTCAACTGGAAGAAATGGTGGCAGGTCTTTTATAACCATTGTGGACTACATTAAC  
CAGATTGTGCAAGTCATGAGTAAACGGTCCAGATCCCTGAACTCAGCAGCCTTCTAT  
TATCGCGTTTAG

**Figure 44D, (SEQ ID NO: 58)**

Expression cassette number 1734 from 2X35S promoter to NOS terminator. VP7 from Rotavirus A vaccine USA/Rotarix-A41CB052A/1988/G1P1A[8] strain is underlined.

GTCAACATGGTGGAGCACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTC  
TCAGAAGACCAAAGGGCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTC  
CTCGGATTCCATTGCCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAA  
GGTGGCTCCTACAAATGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCC  
TCTGCCGACAGTGGTCCCAAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAAAA  
GAAGACGTTCCAACCACGTCTTCAAAGCAAGTGGATTGATGTGATAACATGGTGGAG  
CACGACACACTTGTCTACTCCAAAAATATCAAAGATACAGTCTCAGAAGACCAAAGG  
GCAATTGAGACTTTTCAACAAAGGGTAATATCCGGAAACCTCCTCGGATTCCATTGC  
CCAGCTATCTGTCACTTTATTGTGAAGATAGTGGAAAAGGAAGGTGGCTCCTACAAA  
TGCCATCATTGCGATAAAGGAAAGGCCATCGTTGAAGATGCCTCTGCCGACAGTGGT  
CCCAAAGATGGACCCCCACCCACGAGGAGCATCGTGGAAAAAGAAGACGTTCCAACC  
ACGTCTTCAAAGCAAGTGGATTGATGTGATATCTCCACTGACGTAAGGGATGACGCA  
CAATCCCCTATCCTTCGCAAGACCCTTCCTCTATATAAGGAAGTTCATTTTCATTTG  
GAGAGGTATTAAAATCTTAATAGGTTTTGATAAAAGCGAACGTGGGGAAACCCGAAC  
CAAACCTTCTTCTAAACTCTCTCTCATCTCTCTTAAAGCAAACCTTCTCTTGTCTT  
TCTTGCGTGAGCGATCTTCAACGTTGTCAGATCGTGCTTCGGCACCAGTACAACGTT

TTCTTTCACTGAAGCGAAATCAAAGATCTCTTTGTGGACACGTAGTGCGGCGCCATT  
AAATAACGTGTACTTGTCTATTCTTGTGCGGTGTGGTCTTGGGAAAAGAAAGCTTGC  
TGGAGGCTGCTGTTTACGCCCCATACATTACTTGTACGATTCTGCTGACTTTCGGCG  
GGTGCAATATCTCTACTTCTGCTTGACGAGGTATTGTTGCCTGTACTTCTTTCTTCT  
TCTTCTTGCTGATTGGTTCTATAAGAAATCTAGTATTTTCTTTGAAACAGAGTTTTTC  
CCGTGGTTTTTCGAACTTGGAGAAAGATTGTTAAGCTTCTGTATATTCTGCCCCAATT  
TGTCGGGCCCCATGGATTATATTATCTATCGTAGCCTCCTCATCTACGTGGCCCTTTT  
TGCCCTGACCAGGGCCCAGAACTATGGCCTGAACTTACCAATCACCGGTTCAATGGA  
TACCGTTTACGCTAATTCCACTCAAGAGGGGATATTTCTGACAAGTACCCTGTGCCT  
GTATTATCCAACAGAAGCCTCTACCCAGATCAATGATGGGGAGTGGAAGGATAGTCT  
CTCACAGATGTTTCTAACCAAGGGCTGGCCCACCGGTTCCGTCTACTTCAAGGAATA  
CTCTAGTATTGTGCACTTCTCAGTTGACCCCCAGCTTTATTGCGACTACAACCTGGT  
ACTTATGAAATACGACCAGAACCTGGAGCTGGATATGTCCGAGCTGGCTGACCTGAT  
CCTCAATGAGTGGCTGTGCAACCCCATGGACATCACATTATATTACTACCAGCAGTC  
TGGAGAATCCAACAAGTGGATCAGTATGGGCTCAAGTTGCACCGTGAAGGTGTGTCC  
CTTGAACACCCAAATGCTGGGCATTGGTTGTCAGACAACATAATGTGGATTTCGTTTGA  
AATGGTAGCCGAAAACGAGAAGCTGGCTATAGTGGACGTAGTCGATGGGATTAACCA  
CAAGATCAATCTGACTACCACCCTTGTACCATCAGAACTGTAAAAAGCTCGGCCC  
CCGGGAGAACGTGCGCGTGATCCAGGTGGGGGGGAGCAATGTGCTCGACATTACTGC  
CGACCCTACCACCAATCCACAGACGGAACGGATGATGAGAGTCAACTGGAAGAAATG  
GTGGCAGGTCTTTTATACCATTGTGGACTACATTAACCAGATTGTGCAAGTCATGAG  
TAAACGGTCCAGATCCCTGAACTCAGCAGCCTTCTATTATCGCGTTTAGAGGCCTAT  
TTTCTTTAGTTTGAATTTACTGTTATTCGGTGTGCATTTCTATGTTTGGTGAGCGGT  
TTTCTGTGCTCAGAGTGTGTTTATTTTATGTAATTTAATTTCTTTGTGAGCTCCTGT  
TTAGCAGGTCGTCCCTTCAGCAAGGACACAAAAAGATTTTAATTTTATTAAAAAAAA  
AAAAAAAAGACCGGAATTTCGATATCAAGCTTATCGACCTGCAGATCGTTCAAAC  
ATTTGGCAATAAAGTTTCTTAAGATTGAATCCTGTTGCCGGTCTTGCGATGATTATC  
ATATAATTTCTGTTGAATTACGTTAAGCATGTAATAATTAACATGTAATGCATGACG  
TTATTTATGAGATGGGTTTTTATGATTAGAGTCCCGCAATTATACATTTAATACGCG  
ATAGAAAACAAAATATAGCGCGCAAACTAGGATAAATTATCGCGCGCGGTGTCTATCT  
ATGTTACTAGAT

**Figure 44E**, SEQ ID NO: 59

Amino acid sequence of TrSp-VP7 from Rotavirus A vaccine  
USA/Rotarix-A41CB052A/1988/G1P1A[8] strain

MDYIIYRSLLIYVALFALTRAQNYGLNLPITGSMDTVYANSTQEGIFLTSTLCLYYP  
TEASTQINDGEWKDSLSQMFLTKGWPTGSVYFKEYSSIVDFSVDLPQLYCDYNLVLK  
YDQNLELDMSELADLILNEWLCNPMDITLYYYQQSGESNKWISMGSSCTVKVCPLNT  
QMLGIGCQTTNVDSFEMVAENEKLAIVDVVDGINHKINLTTTCTIRNCKKLGPEN  
VAVIQVGGSNVLDTADPTTNPQTERMMRVNWKKWQVFYTIVDYINQIVQVMSKRS  
RSLNSAAFYYRV

**Figure 44F**

Schematic representation of construct number 1734







Figure 45



**Figure 46**




Figure 47






Figure 48




**Figure 49**

**VP2/VP6**



**VP2/VP6/VP4/VP7**



pctca2013050364-seq1.txt  
SEQUENCE LISTING

<110> Medicago Inc.  
Mitsubishi Tanabe Pharma Corporation  
<120> Rotavirus-like Particle Production in Plants  
<130> V84653WO  
<150> US 61/646,058  
<151> 2012-05-11  
<160> 59  
<170> PatentIn version 3.5  
<210> 1  
<211> 884  
<212> PRT  
<213> Nicotiana tabacum  
<400> 1

Gly Arg Val Arg Ser Met Ala Tyr Arg Lys Arg Gly Ala Arg Arg Glu  
1 5 10 15

Ala Asn Leu Asn Asn Asn Asp Arg Met Gln Glu Lys Ile Asp Glu Lys  
20 25 30

Gln Asp Ser Asn Lys Ile Gln Leu Ser Asp Lys Val Leu Ser Lys Lys  
35 40 45

Glu Glu Ile Val Thr Asp Ser His Glu Glu Val Lys Val Thr Asp Glu  
50 55 60

Leu Lys Lys Ser Thr Lys Glu Glu Ser Lys Gln Leu Leu Glu Val Leu  
65 70 75 80

Lys Thr Lys Glu Glu His Gln Lys Glu Ile Gln Tyr Glu Ile Leu Gln  
85 90 95

Lys Thr Ile Pro Thr Phe Glu Pro Lys Glu Thr Ile Leu Arg Lys Leu  
100 105 110

Glu Asp Ile Gln Pro Glu Leu Ala Lys Lys Gln Thr Lys Leu Phe Arg  
115 120 125

Ile Phe Glu Pro Lys Gln Leu Pro Ile Tyr Arg Ala Asn Gly Glu Arg  
130 135 140

Glu Leu Arg Asn Arg Trp Tyr Trp Lys Leu Lys Lys Asp Thr Leu Pro  
145 150 155 160

Asp Gly Asp Tyr Asp Val Arg Glu Tyr Phe Leu Asn Leu Tyr Asp Gln  
165 170 175

Val Leu Thr Glu Met Pro Asp Tyr Leu Leu Leu Lys Asp Met Ala Val  
Page 1

180

185

190

Glu Asn Lys Asn Ser Arg Asp Ala Gly Lys Val Val Asp Ser Glu Thr  
           195                                  200                                  205

Ala Ser Ile Cys Asp Ala Ile Phe Gln Asp Glu Glu Thr Glu Gly Ala  
           210                                  215                                  220

Val Arg Arg Phe Ile Ala Glu Met Arg Gln Arg Val Gln Ala Asp Arg  
           225                                  230                                  235                                  240

Asn Val Val Asn Tyr Pro Ser Ile Leu His Pro Ile Asp Tyr Ala Phe  
                                   245                                  250                                  255

Asn Glu Tyr Phe Leu Gln His Gln Leu Val Glu Pro Leu Asn Asn Asp  
                                   260                                  265                                  270

Ile Ile Phe Asn Tyr Ile Pro Glu Arg Ile Arg Asn Asp Val Asn Tyr  
           275                                  280                                  285

Ile Leu Asn Met Asp Arg Asn Leu Pro Ser Thr Ala Arg Tyr Ile Arg  
           290                                  295                                  300

Pro Asn Leu Leu Gln Asp Arg Leu Asn Leu His Asp Asn Phe Glu Ser  
           305                                  310                                  315                                  320

Leu Trp Asp Thr Ile Thr Thr Ser Asn Tyr Ile Leu Ala Arg Ser Val  
                                   325                                  330                                  335

Val Pro Asp Leu Lys Glu Leu Val Ser Thr Glu Ala Gln Ile Gln Lys  
                                   340                                  345                                  350

Met Ser Gln Asp Leu Gln Leu Glu Ala Leu Thr Ile Gln Ser Glu Thr  
           355                                  360                                  365

Gln Phe Leu Thr Gly Ile Asn Ser Gln Ala Ala Asn Asp Cys Phe Lys  
           370                                  375                                  380

Thr Leu Ile Ala Ala Met Leu Ser Gln Arg Thr Met Ser Leu Asp Phe  
           385                                  390                                  395                                  400

Val Thr Thr Asn Tyr Met Ser Leu Ile Ser Gly Met Trp Leu Leu Thr  
                                   405                                  410                                  415

Val Val Pro Asn Asp Met Phe Ile Arg Glu Ser Leu Val Ala Cys Gln  
                                   420                                  425                                  430

Leu Ala Ile Val Asn Thr Ile Ile Tyr Pro Ala Phe Gly Met Gln Arg  
           435                                  440                                  445

Met His Tyr Arg Asn Gly Asp Pro Gln Thr Pro Phe Gln Ile Ala Glu

450

455

460

Gln Gln Ile Gln Asn Phe Gln Val Ala Asn Trp Leu His Phe Val Asn  
 465 470 475 480

Asn Asn Gln Phe Arg Gln Ala Val Ile Asp Gly Val Leu Asn Gln Val  
 485 490 495

Leu Asn Asp Asn Ile Arg Asn Gly His Val Ile Asn Gln Leu Met Glu  
 500 505 510

Ala Leu Met Gln Leu Ser Arg Gln Gln Phe Pro Thr Met Pro Ile Asp  
 515 520 525

Tyr Lys Arg Ser Ile Gln Arg Gly Ile Leu Leu Leu Ser Asn Arg Leu  
 530 535 540

Gly Gln Leu Val Asp Leu Thr Arg Leu Leu Ala Tyr Asn Tyr Glu Thr  
 545 550 555 560

Leu Met Ala Cys Ile Thr Met Asn Met Gln His Val Gln Thr Leu Thr  
 565 570 575

Thr Glu Lys Leu Gln Leu Thr Ser Val Thr Ser Leu Cys Met Leu Ile  
 580 585 590

Gly Asn Ala Thr Val Ile Pro Ser Pro Gln Thr Leu Phe His Tyr Tyr  
 595 600 605

Asn Val Asn Val Asn Phe His Ser Asn Tyr Asn Glu Arg Ile Asn Asp  
 610 615 620

Ala Val Ala Ile Ile Thr Ala Ala Asn Arg Leu Asn Leu Tyr Gln Lys  
 625 630 635 640

Lys Met Lys Ala Ile Val Glu Asp Phe Leu Lys Arg Leu Tyr Ile Phe  
 645 650 655

Asp Val Ser Arg Val Pro Asp Asp Gln Met Tyr Arg Leu Arg Asp Arg  
 660 665 670

Leu Arg Leu Leu Pro Val Glu Ile Arg Arg Leu Asp Ile Phe Asn Leu  
 675 680 685

Ile Leu Met Asn Met Asp Gln Ile Glu Arg Ala Ser Asp Lys Ile Ala  
 690 695 700

Gln Gly Val Ile Ile Ala Tyr Arg Asp Met His Leu Glu Arg Asp Glu  
 705 710 715 720

Met Tyr Gly Tyr Val Asn Ile Ala Arg Asn Leu Glu Gly Phe Gln Gln



725

730

735

Ile Asn Leu Glu Glu Leu Met Arg Ser Gly Asp Tyr Ala Gln Ile Thr  
 740 745 750

Asn Met Leu Leu Asn Asn Gln Pro Val Ala Leu Val Gly Ala Leu Pro  
 755 760 765

Phe Ile Thr Asp Ser Ser Val Ile Ser Leu Ile Ala Lys Leu Asp Ala  
 770 775 780

Thr Val Phe Ala Gln Ile Val Lys Leu Arg Lys Val Asp Thr Leu Lys  
 785 790 795 800

Pro Ile Leu Tyr Lys Ile Asn Ser Asp Ser Asn Asp Phe Tyr Leu Val  
 805 810 815

Ala Asn Tyr Asp Trp Val Pro Thr Ser Thr Thr Lys Val Tyr Lys Gln  
 820 825 830

Val Pro Gln Gln Phe Asp Phe Arg Asn Ser Met His Met Leu Thr Ser  
 835 840 845

Asn Leu Thr Phe Thr Val Tyr Ser Asp Leu Leu Ala Phe Val Ser Ala  
 850 855 860

Asp Thr Val Glu Pro Ile Asn Ala Val Ala Phe Asp Asn Met Arg Ile  
 865 870 875 880

Met Asn Glu Leu

<210> 2

<211> 380

<212> PRT

<213> Nicotiana tabacum

<400> 2

Gly Arg Val Arg Ser Met Ala Ser Leu Ile Tyr Arg Gln Leu Leu Thr  
 1 5 10 15

Asn Ser Tyr Thr Val Glu Leu Ser Asp Glu Ile Asn Thr Ile Gly Ser  
 20 25 30

Glu Lys Ser Gln Asn Val Thr Ile Asn Pro Gly Pro Phe Ala Gln Thr  
 35 40 45

Asn Tyr Ala Pro Val Thr Trp Ser His Gly Glu Val Asn Asp Ser Thr  
 50 55 60

Thr Ile Glu Pro Val Leu Asp Gly Pro Tyr Gln Pro Thr Asn Phe Lys  
 65 70 75 80

pctca2013050364-seql.txt

Pro Pro Asn Asp Tyr Trp Ile Leu Leu Asn Pro Thr Asn Gln Gln Val  
85 90 95

Val Leu Glu Gly Thr Asn Lys Thr Asp Ile Trp Val Ala Leu Leu Leu  
100 105 110

Val Glu Pro Asn Val Thr Asn Gln Ser Arg Gln Tyr Thr Leu Phe Gly  
115 120 125

Glu Thr Lys Gln Ile Thr Val Glu Leu Pro Thr Asp Phe Ser Val Ser  
130 135 140

Arg Tyr Glu Val Ile Lys Glu Asn Ser Tyr Val Tyr Val Asp Tyr Trp  
145 150 155 160

Asp Asp Ser Gln Ala Phe Arg Asn Met Val Tyr Val Arg Ser Leu Ala  
165 170 175

Ala Asn Leu Asn Ser Val Lys Cys Ser Gly Gly Asn Tyr Asn Phe Gln  
180 185 190

Ile Pro Val Gly Ala Trp Pro Val Met Ser Gly Gly Ala Val Ser Leu  
195 200 205

His Phe Ala Gly Val Thr Leu Ser Thr Gln Phe Thr Asp Phe Val Ser  
210 215 220

Leu Asn Ser Leu Arg Phe Arg Phe Ser Leu Thr Val Glu Glu Pro Pro  
225 230 235 240

Phe Ser Ile Leu Arg Thr Arg Val Ser Gly Leu Tyr Gly Leu Pro Ala  
245 250 255

Phe Asn Pro Asn Asn Gly His Glu Tyr Tyr Glu Ile Ala Gly Arg Phe  
260 265 270

Ser Leu Ile Ser Leu Val Pro Ser Asn Asp Asp Tyr Gln Thr Pro Ile  
275 280 285

Met Asn Ser Val Thr Val Arg Gln Asp Leu Glu Arg Gln Leu Gly Asp  
290 295 300

Leu Arg Glu Glu Phe Asn Ser Leu Ser Gln Glu Ile Ala Met Thr Gln  
305 310 315 320

Leu Ile Asp Leu Ala Leu Leu Pro Leu Asp Met Phe Ser Met Phe Ser  
325 330 335

Asn Tyr Gly Ile Thr Arg Ser Gln Ala Leu Asp Leu Ile Arg Ser Asp  
340 345 350

pctca2013050364-seq1.txt

Pro Arg Val<sub>355</sub> Leu Arg Asp Phe Ile<sub>360</sub> Asn Gln Asn Asn Pro<sub>365</sub> Ile Ile Lys

Asn Arg Ile Glu Gln Leu Ile<sub>375</sub> Leu Gln Cys Arg Leu<sub>380</sub>

<210> 3

<211> 402

<212> PRT

<213> Nicotiana tabacum

<400> 3

Gly Arg Val Arg Ser<sub>5</sub> Met Asp Val Leu Tyr<sub>10</sub> Ser Leu Ser Lys Thr<sub>15</sub> Leu

Lys Asp Ala Arg<sub>20</sub> Asp Lys Ile Val Glu<sub>25</sub> Gly Thr Leu Tyr Ser<sub>30</sub> Asn Val

Ser Asp Leu<sub>35</sub> Ile Gln Gln Phe Asn<sub>40</sub> Gln Met Ile Ile Thr<sub>45</sub> Met Asn Gly

Asn Glu Phe Gln Thr Gly Gly<sub>55</sub> Ile Gly Asn Leu Pro<sub>60</sub> Ile Arg Asn Trp

Asn Phe Asp Phe Gly Leu<sub>70</sub> Leu Gly Thr Thr Leu<sub>75</sub> Leu Asn Leu Asp Ala<sub>80</sub>

Asn Tyr Val Glu Thr<sub>85</sub> Ala Arg Asn Thr Ile<sub>90</sub> Asp Tyr Phe Val Asp<sub>95</sub> Phe

Val Asp Asn Val<sub>100</sub> Cys Met Asp Glu Met<sub>105</sub> Val Arg Glu Ser Gln<sub>110</sub> Arg Asn

Gly Ile Ala<sub>115</sub> Pro Gln Ser Asp Ser<sub>120</sub> Leu Arg Lys Leu Ser<sub>125</sub> Gly Ile Lys

Phe Lys<sub>130</sub> Arg Ile Asn Phe Asp<sub>135</sub> Asn Ser Ser Glu Tyr<sub>140</sub> Ile Glu Asn Trp

Asn Leu Gln Asn Arg Arg<sub>150</sub> Gln Arg Thr Gly Phe<sub>155</sub> Thr Phe His Lys Pro<sub>160</sub>

Asn Ile Phe Pro Tyr<sub>165</sub> Ser Ala Ser Phe Thr<sub>170</sub> Leu Asn Arg Ser Gln<sub>175</sub> Pro

Ala His Asp Asn<sub>180</sub> Leu Met Gly Thr Met<sub>185</sub> Trp Leu Asn Ala Gly<sub>190</sub> Ser Glu

Ile Gln Val<sub>195</sub> Ala Gly Phe Asp Tyr<sub>200</sub> Ser Cys Ala Ile Asn<sub>205</sub> Ala Pro Ala

pctca2013050364-seql.txt

Asn Thr Gln Gln Phe Glu His Ile Val Gln Leu Arg Arg Val Leu Thr  
210 215 220

Thr Ala Thr Ile Thr Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro  
225 230 235 240

Arg Val Ile Asn Ser Ala Asp Gly Ala Thr Thr Trp Tyr Phe Asn Pro  
245 250 255

Val Ile Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly  
260 265 270

Gln Ile Ile Asn Thr Tyr Gln Ala Arg Phe Gly Thr Ile Val Ala Arg  
275 280 285

Asn Phe Asp Thr Ile Arg Leu Ser Phe Gln Leu Met Arg Pro Pro Asn  
290 295 300

Met Thr Pro Ser Val Ala Ala Leu Phe Pro Asn Ala Gln Pro Phe Glu  
305 310 315 320

His His Ala Thr Val Gly Leu Thr Leu Lys Ile Glu Ser Ala Val Cys  
325 330 335

Glu Ser Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr  
340 345 350

Ser Val Arg Gln Glu Tyr Ala Ile Pro Val Gly Pro Val Phe Pro Pro  
355 360 365

Gly Met Asn Trp Thr Asp Leu Ile Thr Asn Tyr Ser Pro Ser Arg Glu  
370 375 380

Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser Ile Arg Ser Met Leu  
385 390 395 400

Val Lys

<210> 4  
<211> 331  
<212> PRT  
<213> Nicotiana tabacum

<400> 4

Gly Arg Val Arg Cys Met Tyr Gly Ile Glu Tyr Thr Thr Ile Leu Thr  
1 5 10 15

Phe Leu Ile Ser Ile Val Leu Leu Asn Tyr Ile Leu Lys Ser Leu Thr  
20 25 30

Ser Ala Met Asp Phe Ile Ile Tyr Arg Phe Leu Leu Leu Ile Val Ile  
 35 40 45  
 Ala Ser Pro Phe Val Lys Thr Gln Asn Tyr Gly Ile Asn Leu Pro Ile  
 50 55 60  
 Thr Gly Ser Met Asp Thr Ala Tyr Ala Asn Ser Ser Gln Gln Glu Thr  
 65 70 75 80  
 Phe Leu Thr Ser Thr Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr  
 85 90 95  
 Gln Ile Gly Asp Thr Glu Trp Lys Asp Thr Leu Ser Gln Leu Phe Leu  
 100 105 110  
 Thr Lys Gly Trp Pro Thr Gly Ser Val Tyr Phe Lys Glu Tyr Thr Asp  
 115 120 125  
 Ile Ala Ser Phe Ser Ile Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Val  
 130 135 140  
 Val Leu Met Lys Tyr Asp Ser Thr Leu Glu Leu Asp Met Ser Glu Leu  
 145 150 155 160  
 Ala Asp Leu Ile Leu Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr  
 165 170 175  
 Leu Tyr Tyr Tyr Gln Gln Thr Asp Glu Ala Asn Lys Trp Ile Ser Met  
 180 185 190  
 Gly Gln Ser Cys Thr Ile Lys Val Cys Pro Leu Asn Thr Gln Thr Leu  
 195 200 205  
 Gly Ile Gly Cys Ile Thr Thr Asn Thr Ala Thr Phe Glu Glu Val Ala  
 210 215 220  
 Thr Ser Glu Lys Leu Val Ile Thr Asp Val Val Asp Gly Val Asn His  
 225 230 235 240  
 Lys Leu Asp Val Thr Thr Asn Thr Cys Thr Ile Arg Asn Cys Lys Lys  
 245 250 255  
 Leu Gly Pro Arg Glu Asn Val Ala Ile Ile Gln Val Gly Gly Ser Asp  
 260 265 270  
 Val Leu Asp Ile Thr Ala Asp Pro Thr Thr Ala Pro Gln Thr Glu Arg  
 275 280 285  
 Met Met Arg Val Asn Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Val  
 290 295 300

Val Asp Tyr Ile Asn Gln Ile Val Gln Val Met Ser Lys Arg Ser Arg  
 305 310 315 320

Ser Leu Asn Ser Ala Ala Phe Tyr Tyr Arg Val  
 325 330

<210> 5  
 <211> 22  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer VP2F

<400> 5  
 ttccatggct taccgtaaaa gg 22

<210> 6  
 <211> 32  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer VP2R

<400> 6  
 atgcggccgc aagctcggtc ataatcctca tg 32

<210> 7  
 <211> 22  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer VP4F

<400> 7  
 ttccatggct tccctcatct ac 22

<210> 8  
 <211> 31  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer VP4R

<400> 8  
 atgcggccgc aagacggcac tggagaatga g 31

<210> 9  
 <211> 21  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer VP6F

<400> 9  
 ttccatggat gtgctctact c 21

<210> 10  
 <211> 28  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> Primer VP6R  
  
 <400> 10  
 atgcggccgc cttcacgagc atggaacg 28

<210> 11  
 <211> 22  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> Primer VP7F  
  
 <400> 11  
 gtacatgtac ggaatcgagt ac 22

<210> 12  
 <211> 31  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 <223> Primer VP7R  
  
 <400> 12  
 atgcggccgc cacacggtag tagaaagcag c 31

<210> 13  
 <211> 2700  
 <212> DNA  
 <213> Nicotiana tabacum  
  
 <400> 13  
 ggtaccgaat tcggacgcgt tcgttccatg gcttaccgta aaaggggtgc taggcgtgaa 60  
 gctaacctca acaacaacga taggatgcaa gagaagatcg atgagaagca ggattccaac 120  
 aagatccagc tctccgataa ggtgctctcc aagaaagaag agatcgttac tgattcccac 180  
 gaagaggtga aggtgacaga tgagcttaag aagtccacaa aagaagagtc caagcagctc 240  
 cttgaggtgc tcaagacaaa agaggaacac cagaaagaga tccagtacga gatcctccaa 300  
 aagactatcc caactttcga gccaaaagag actatcctca ggaagcttga ggatatccag 360  
 ccagagcttg ctaagaagca gactaagctc ttcaggatct tcgagccaaa gcagctccca 420  
 atctaccgtg ctaacggtga aagggaactt aggaacaggt ggtactggaa gctcaagaag 480  
 gatactctcc cagacggtga ttacgatgtg agagagtact tcctcaacct ctacgatcag 540  
 gtgctcactg agatgccaga ttacctctc ctcaaggata tggctgtgga gaacaagaac 600  
 tccagggatg ctggaaaggt ggtggattcc gagactgctt ccatctgtga tgctatcttc 660  
 caggatgaag agactgaggg tgctgtgagg cgtttcattg ctgagatgag gcagaggggtt 720  
 caggctgata ggaacgtggt gaactacca tccatcctcc acccaatcga ttacgctttc 780

pctca2013050364-seq1.txt

aacgagtact	tccttcagca	ccagcttgtg	gagccactca	acaacgatat	catcttcaac	840
tacatcccag	agaggattag	gaacgacgtt	aactacatcc	tcaacatgga	taggaacctc	900
ccatccactg	ctcgttacat	caggccaaac	ctcctccagg	atagggtcaa	cctccacgat	960
aacttcgagt	ccctctggga	tacaatcact	acttccaact	acattctcgc	tcgttccgtg	1020
gtgccagatc	tcaaagaact	cgtgtccact	gaggctcaga	tccagaagat	gtcccaggat	1080
ctccagcttg	aggtctctac	tatccagtcc	gagactcagt	tcctcactgg	tatcaactcc	1140
caggctgcta	acgattgctt	caagactctc	attgctgcta	tgctctccca	gaggactatg	1200
tccctcgatt	tcgtgactac	taactatatg	tccctcatct	cgggaatgtg	gctcttgact	1260
gtggtgccaa	acgatatggt	catccgtgag	tcccttgtgg	cttgccagct	cgctatcgtg	1320
aacactatca	tctaccagc	tttcggaatg	caaaggatgc	actaccgtaa	cggtgatcca	1380
cagactccat	tccagatcgc	agagcagcag	atccagaact	tccaggtggc	aaactggctc	1440
cacttcgtga	acaacaacca	gttcaggcag	gctgtgatcg	atggtgtggt	gaaccagggtg	1500
ctcaacgata	acatccgtaa	cggtcacgtg	atcaaccagc	tcatggaagc	tctcatgcaa	1560
ctctccaggc	agcagttccc	aactatgcct	atcgattaca	agcgttccat	ccagagggga	1620
atcctcctcc	tttccaacag	gcttggacag	ctcgtggatc	tcactagggt	cctcgcttac	1680
aactacgaga	ctctcatggc	ttgcatcact	atgaacatgc	agcacgttca	gactctcact	1740
actgagaagc	tccagctcac	ttccgtgact	tccctctgca	tgctcatcgg	aaacgctact	1800
gtgatcccat	ccccacagac	actcttccac	tactacaacg	tgaacgtgaa	cttccactcc	1860
aactacaacg	agaggatcaa	cgatgctgtg	gctatcatca	ctgctgctaa	caggcttaac	1920
ctctaccaa	agaagatgaa	ggctatcggt	gaggatttcc	tcaagagggt	ctacatcttc	1980
gatgtgtcca	gggtgccaga	tgatcagatg	taccgtctta	gggatagggt	taggctcctc	2040
ccagtggaga	tcagaagggt	cgatatcttc	aacctcatcc	ttatgaacat	ggatcagatc	2100
gagagggctt	ccgataagat	cgctcagggt	gttattatcg	cttaccgtga	tatgcacctt	2160
gagaggggatg	agatgtacgg	atacgtgaac	attgctagga	accttgaggg	attccagcag	2220
atcaaccttg	aagagcttat	gcgttccggt	gattacgctc	agatcactaa	catgctcctc	2280
aacaaccagc	cagtggctct	tgttgggtgct	ctcccattca	tcactgattc	ctccgtgatc	2340
tccctcattg	ctaagttgga	tgctactgtg	ttcgtcaga	tcgtgaagct	caggaaagtg	2400
gatactctca	agccaatcct	ctacaagatc	aactccgatt	ccaacgattt	ctacctcgtg	2460
gctaactacg	attgggtgcc	aacttccact	aaaagggtgt	acaagcaggt	gccacagcag	2520
ttcgatttcc	gtaactccat	gcacatgctc	acttccaacc	tcactttcac	tgtgtactcc	2580
gatctcctcg	ctttcgtgtc	cgctgatact	gtggagccta	tcaacgctgt	ggctttcgat	2640
aacatgagga	ttatgaacga	gctttgatga	ctcgagggat	cctctagaga	attcgagctc	2700

<210> 14  
 <211> 2700  
 <212> DNA



&lt;213&gt; Nicotiana tabacum

&lt;400&gt; 14

ccatggctta agcctgcgca agcaaggtac cgaatggcat tttccccacg atccgcactt	60
cgattggagt tgttgttgct atcctacgtt ctcttctagc tactcttcgt cctaagggtg	120
ttctaggtcg agaggctatt ccacgagagg ttctttcttc tctagcaatg actaagggtg	180
cttctccact tccactgtct actcgaattc ttcaggtgtt ttcttctcag gttcgtcgag	240
gaactccacg agttctgttt tctccttggt gtctttctct aggtcatgct ctaggaggtt	300
ttctgatagg gttgaaagct cggttttctc tgataggagt ccttcgaact cctataggtc	360
ggtctcgaac gattcttcgt ctgattcgag aagtcctaga agctcggttt cgtcgagggt	420
tagatggcac gattgccact ttcccttgaa tccttggtcca ccatgacctt cgagttcttc	480
ctatgagagg gtctgccact aatgctacac tctctcatga aggagttgga gatgctagtc	540
cacgagtgc tctacggtct aatggaggag gaggttctat accgacacct cttgttcttg	600
aggtccctac gacctttcca ccacctaagg ctctgacgaa ggtagacact acgatagaag	660
gtcctacttc tctgactccc acgacactcc gcaaagtaac gactctactc cgtctcccaa	720
gtccgactat ccttgacca cttgatgggt aggtaggagg tgggttagct aatgcgaaag	780
ttgctcatga aggaagtcgt ggtcgaacac ctcggtgagt tgttgctata gtagaagttg	840
atgtagggtc tctcctaadc cttgctgcaa ttgatgtagg agttgtacct atccttgag	900
ggtaggtgac gagcaatgta gtccggtttg gaggagggtc tatccgagtt ggaggtgcta	960
ttgaagctca gggagacctt atgttagtga tgaaggttga tgtaagagcg agcaaggcac	1020
cacggtctag agtttcttga gcacagggtga ctccgagttt aggtcttcta cagggtccta	1080
gaggtcgaac tccgagagt ataggtcagg ctctgagtca aggagtgacc atagttgagg	1140
gtccgacgat tgctaacgaa gttctgagag taacgacgat acgagaggggt ctctgatac	1200
agggagctaa agcactgatg attgatatac agggagtaga ggccttacac cgagaactga	1260
caccacggtt tgctatacaa gtaggcactc agggaaacacc gaacggtcga gcgatagcac	1320
ttgtgatagt agatgggtcg aaagccttac gtttcctacg tgatggcatt gccactaggt	1380
gtctgaggta aggtctagcg tctcgtcgtc taggtcttga aggtccaccg tttgaccgag	1440
gtgaagcact tgttgttggt caagtccgtc cgacactagc taccacacaa cttggtccac	1500
gagttgctat tgtaggcatt gccagtgcac tagttggtcg agtaccttcg agagtacgtt	1560
gagaggtccg tcgtcaagggt ttgatacgga tagctaattgt tcgcaaggta ggtctcccct	1620
taggaggagg aaagggtgtc cgaacctgtc gagcacctag agtgatccga ggagcgaatg	1680
ttgatgctct gagagtaccg aacgtagtga tacttgtagc tcgtgcaagt ctgagagtga	1740
tgactcttcg aggtcgagtg aaggcactga agggagacgt acgagtagcc tttgcatga	1800
cactagggtg ggggtgtctg tgagaagggt atgatgttgc acttgacctt gaagggtgagg	1860
ttgatgttgc tctcctagtt gctacgacac cgatagtagt gacgacgatt gtccgaattg	1920
gagatgggtt tcttctactt ccgatagcaa ctctaaagg agttctccga gatgtagaag	1980

## pctca2013050364-seq1.txt

ctacacaggt	cccacggtct	actagtctac	atggcagaat	ccctatccga	atccgaggag	2040
ggtcacctct	agtcttccga	gctatagaag	ttggagtagg	aatacttgta	cctagtctag	2100
ctctcccgaa	ggctatttcta	gcgagtccca	caataatagc	gaatggcact	atacgtggaa	2160
ctctccctac	tctacatgcc	tatgcacttg	taacgatcct	tggaactccc	taaggctcgtc	2220
tagttggaac	ttctcgaata	cgcaaggcca	ctaattgcgag	tctagtgatt	gtacgaggag	2280
ttgttggtcg	gtcaccgaga	acaaccacga	gagggtaagt	agtgactaag	gaggcactag	2340
agggagtaac	gattcaacct	acgatgacac	aagcgagtct	agcacttcga	gtcctttcac	2400
ctatgagagt	tcggttagga	gatgttctag	ttgaggctaa	ggttgctaaa	gatggagcac	2460
cgattgatgc	taaccacagg	ttgaagggtga	tgtttccaca	tgttcgtcca	cggtgtcgtc	2520
aagctaaagg	cattgaggta	cgtgtacgag	tgaaggttgg	agtgaaagtg	acacatgagg	2580
ctagaggagc	gaaagcacag	gcgactatga	cacctcggat	agttgcgaca	ccgaaagcta	2640
ttgtactcct	aatacttgct	cgaaactact	gagctcccta	ggagatctct	taagctcgag	2700

<210> 15  
 <211> 2388  
 <212> DNA  
 <213> Rotavirus

<400> 15	
ggtagcgaat	tcggacgcgt
tcgttccatg	gcttccctca
tctaccgtca	gttgctcact
aactcctaca	ctgtggagct
ttccgatgag	atcaacacta
tcggttccga	gaagtcccag
aacgtgacta	tcaaccacag
accattcgct	cagactaact
acgctccagt	gacttggtca
cacggtgaag	tgaacgattc
cactactatc	gagccagtgc
tcgatggacc	ataccagcca
actaacttca	agccacaaaa
cgattactgg	attctcctca
acccaactaa	ccagcaggtg
gtgcttgagg	gaactaacia
gactgatatc	tggttggtgc
tccttcttgt	ggagccaaac
gtgactaacc	agtccaggca
gtacactctc	ttcggagaga
ctaagcagat	cactgtggag
aacaacacta	acaagtggaa
gttcttcgag	atgttcaggt
ccaacgtgaa	cgctgagttc
cagcacaaga	ggactctcac
ttccgataca	aagctcgctg
gttttatgaa	gttctacaac
tctgtgtgga	ctttccacgg
tgaaactcca	cacgctacta
ctgattactc	ctccacttcc
aacctttccg	aggtggagac
tgtgatccac	gtggagttct
acatcatccc	aaggtcccaa
gagtctaagt	gctccgagta
catcaacact	ggactcccac
caatgcaaaa	cactaggaac
atcgtgccag	tggttttgtc
ctctcgttcc	gtgacttacc
agaggggtca	ggtgaacgag
gatatcatca	tctccaagac
ttccctctgg	aaagagatgc
agtacaacag	ggatattatc
atcaggttca	agttcaacia
ctccatcgctg	aagctcggag
gactcggata	caagtggagt
gagatctcct	tcaaggctgc
taactaccag	tactcctacc
tcagggatgg	tgaacaggtg
acagctcaca	ctacttgctc
cgtgaacggg	gttaacaact
tctcctacaa	cggtgggttcc
ctcccaactg	atttctccgt
gtcccgttac	gaggtgatca
aagagaactc	ctacgtttac

pctca2013050364-seq1.txt

gtggattact gggatgattc ccaggctttc aggaacatgg tgtatgttag atccctcgct	1140
gctaacctca actccgtgaa gtgctccggg ggaaactaca acttccagat cccagtggga	1200
gcttggccag tgatgtctgg tggagctgtg tctctccact tcgctggtgt tacactctcc	1260
actcagttca ctgatttcgt gtccctcaac tccctcaggt tcaggttctc cctcactgtg	1320
gaagagccac cattctccat cctcaggact aggggtgtccg gacttttacgg actcccagct	1380
ttcaacccaa acaacggaca cgagtactac gagatcgctg gacgtttctc ccttatctcc	1440
ctcgtgccat ccaacgatga ttaccagact ccaattatga actccgtgac tgtgaggcag	1500
gatcttgaga ggcagctcgg agatctcagg gaagagttca actccctctc ccaagagatc	1560
gctatgactc agctcatcga tctcgctctc ctccactcg atatgttctc catgttctct	1620
ggtatcaagt ccactatcga tgtggctaag tctatggtga ctaaggatgat gaagaagttc	1680
aagaagtccg gactcgctac ttccatctcc gagcttactg gatctctctc caacgctgct	1740
tcttctgtgt ctaggtcctc ctccatcagg tccaacatct cctccatctc agtgtggact	1800
gatgtgtccg agcagatcgc tggatcttcc gattccgtgc gtaacatctc cactcagact	1860
tccgctatct ccaagaggct taggctcaga gagatcacta ctcagactga gggaatgaac	1920
ttcgatgata tctccgctgc tgtgctcaag actaagatcg atagggtccac tcacatctcc	1980
ccagatactc tcccagatat catcactgag tcctccgaga agttcatccc aaagcgtgct	2040
taccgtgttc tcaaggatga tgagggtgatg gaagctgatg tggatggaaa gttcttcgct	2100
tacaaagtgg gaactttcga agagggtgcca ttcgatgtgg ataagttcgt ggatctcgtg	2160
actgattccc cagtgatctc cgctatcatc gatttcaaga ctctcaagaa cctcaacgat	2220
aactacggaa tctactaggtc ccaggctctc gatctcatcc gttccgatcc aagggtgctc	2280
agggatttca tcaaccagaa caacccaatc atcaagaaca ggatcgagca gctcattctc	2340
cagtgccgtc tttgatgact cgagggatcc tctagagaat tcgagctc	2388

<210> 16  
 <211> 2388  
 <212> DNA  
 <213> Rotavirus

<400> 16	
ccatggctta agcctgcgca agcaaggtag cgaagggagt agatggcagt caacgagtga	60
ttgaggatgt gacacctcga aaggctactc tagttgtgat agccaaggct cttcagggtc	120
ttgactgat agttgggtcc tggtaagcga gtctgattga tgcgagggtca ctgaaccagt	180
gtgccacttc acttgctaag gtgatgatag ctcggtcacg agctacctgg tatggtcggt	240
tgattgaagt tcggtggttt gctaataacc taagaggagt tgggttgatt ggtcgtccac	300
cacgaactcc cttgattggt ctgactatag acccaccgtg aggaagaaca cctcggtttg	360
cactgattgg tcagggtccgt catgtgagag aagcctctct gattcgtcta gtgacacctc	420
ttgttgatgat tgttcacctt caagaagctc tacaagtcca ggttgactt gcgactcaag	480
gtcgtgttct cctgagagtg aaggctatgt ttcgagcgac caaaatactt caagatgttg	540

pctca2013050364-seq1.txt

agacacacct	gaaaggtgcc	actttgaggt	gtgcatgat	gactaatgag	gaggtgaagg	600
ttggaaaggc	tccacctctg	acactaggtg	cacctcaaga	tgtagtaggg	ttccagggtt	660
ctcagattca	cgaggctcat	gtagttgtga	cctgaggggtg	gttacgtttt	gtgatccttg	720
tagcacggtc	accgaaacag	gagagcaagg	cactgaatgg	tctcccgagt	ccacttgctc	780
ctatagtagt	agaggttctg	aaggagagacc	tttctctacg	tcatgttgtc	cctataatag	840
tagtccaagt	tcaagttggt	gaggtagcac	ttcgagcctc	ctgagcctat	gttcacctca	900
ctctagagga	agttccgacg	attgatggtc	atgaggatgg	agtccctacc	acttggtccac	960
tgtcgagtgt	gatgaacgag	gcacttgcca	caattgttga	agaggatggt	gccaccaagg	1020
gagggttgac	taaagaggca	cagggaatg	ctccactagt	ttctcttgag	gatgcaaagt	1080
cacctaata	ccctactaag	gggccgaaag	tccttggtacc	acatacaatc	tagggagcga	1140
cgattggagt	tgaggcactt	cacgaggcca	cctttgatgt	tgaagggtcta	gggtcacctt	1200
cgaaccggtc	actacagacc	acctcgacac	agagaggtga	agcgaccaca	atgtgagagg	1260
tgagtcaagt	gactaaagca	caggaggttg	aggaggtcca	agtccaagag	ggagtgcacac	1320
cttctcggtg	gtaagaggta	ggagtcctga	ttccacaggc	ctgaaatgcc	tgagggtcga	1380
aagttgggtt	tggtgcctgt	gctcatgatg	ctctagcgac	ctgcaaagag	ggaatagagg	1440
gagcacggta	ggttgctact	aatggtctga	ggttaatact	tgaggcactg	acactccgtc	1500
ctagaactct	ccgtcgagcc	tctagagtcc	cttctcaagt	tgaggggagag	ggttctctag	1560
cgatactgag	tcgagtagct	agagcgagag	gaggggtgagc	tatacaagag	gtacaagaga	1620
ccatagttca	ggtgatagct	acaccgattc	agataccact	gattccacta	cttcttcaag	1680
ttcttcaggc	ctgagcgatg	aaggtagagg	ctcgaatgac	ctagagagag	gttgcgacga	1740
agaagacaca	gatccaggag	gaggtagtcc	aggttgtaga	ggaggtagag	tcacacctga	1800
ctacacaggc	tcgtctagcg	acctagaagg	ctaaggcacg	cattgtagag	gtgagtctga	1860
aggcgataga	ggttctccga	atccgagtct	ctctagtgat	gagtctgact	cccttacttg	1920
aagctactat	agaggcgacg	acacgagttc	tgattctagc	tatccagggtg	agtgtagagg	1980
ggtctatgag	agggtctata	gtagtgactc	aggaggctct	tcaagtaggg	tttcgcacga	2040
atggcacaag	agttcctact	actccactac	cttcgactac	acctaccttt	caagaagcga	2100
atgtttcacc	cttgaaagct	tctccacggc	aagctacacc	tattcaagca	cctagagcac	2160
tgactaaggg	gtcactagag	gcgatagtag	ctaaagttct	gagagttctt	ggagttgcta	2220
ttgatgcctt	agtgatccag	ggccgagag	ctagagtagg	caaggctagg	ttcccacgag	2280
tccctaaagt	agttggtctt	gttgggttag	tagttcttgt	cctagctcgt	cgagtaagag	2340
gtcacggcag	aaactactga	gctccctagg	agatctctta	agctcgag		2388

<210> 17  
 <211> 1254  
 <212> DNA  
 <213> Nicotiana tabacum

pctca2013050364-seq1.txt

```

<400> 17
ggtagcgaat tcggacgcgt tcgttccatg gatgtgctct actccctctc caagactctc      60
aaggatgcta gggataagat cgtggaggga actctctact ccaacgtttc cgatctcatc      120
cagcagttca accagatgat catcactatg aacggaaacg agttccagac tggtggaatc      180
ggaaacctcc caatcaggaa ctggaacttc gatttcggac tcctcggaac tactctcctc      240
aacctcgatg ctaactacgt ggagactgct aggaacacta tcgattactt cgttgatttc      300
gtggataatg tgtgcatgga tgagatgggt cgtgagtcct agaggaaacg aattgctcca      360
cagtccgatt ccctcaggaa gctctccggt atcaagttca agaggatcaa cttcgataac      420
tcctccgagt acatcgagaa ctggaacctc cagaacagaa ggcagaggac tggattcact      480
ttccacaagc caaacatctt cccatactcc gtttccttca ctctcaacag gtcccagcca      540
gctcacgata acctcatggg aactatgtgg ctcaacgctg gttctgagat ccagggtggca      600
ggattcgatt actcctgcgc tatcaacgct ccagctaaca ctacgagctt cgagcacatc      660
gttcagctca gaagggtgct cactactgct actatcactc tcctcccaga tgctgagagg      720
ttctccttcc caagggtgat caactccgct gatggtgcta ctacttggtt cttcaaccca      780
gtgatcctca ggccaaacaa cgtggagggt gagttccttc tcaacggaca gatcatcaac      840
acttaccagg ctcgtttcgg aactatcgtg gctaggaact tcgatacaat caggctctcc      900
ttccagctta tgaggccacc aaacatgact ccattccgtg ctgcactctt cccaaacgca      960
cagccattcg agcaccacgc tactgtggga ctactctca agatcgagtc cgctgtgtgc     1020
gagtctgtgc tcgctgatgc ttccgagact atgctcgcta acgtgacttc tgtgaggcaa     1080
gagtacgcta tcccagtggt accagtgttt ccaccaggaa tgaactggac tgatctcatc     1140
actaactact ccccatccag agaggataac ctccagaggg tgttcaactgt ggcttccatc     1200
cgttccatgc tcgtgaagtg atgactcgag ggatcctcta gagaattcga gctc          1254

```

```

<210> 18
<211> 1254
<212> DNA
<213> Nicotiana tabacum

```

```

<400> 18
ccatggctta agcctgcgca agcaaggtag ctacacgaga tgaggagag gttctgagag      60
ttcctacgat ccctattcta gcacctcctt tgagagatga ggttgcaaag gctagagtag      120
gtcgtcaagt tgggttacta gtagtgatac ttgcctttgc tcaagggtctg accaccttag      180
cctttggagg gttagtcctt gaccttgaag ctaaagcctg aggagccttg atgagaggag      240
ttggagctac gattgatgca cctctgacga tccttgatga agctaataaa gcaactaaag      300
cacctattac acacgtacct actctaccaa gcactcaggg tctccttgcc ttaacgagg      360
gtcaggctaa gggagtcctt cgagaggcca tagttcaagt tctcctagtt gaagctattg      420
aggaggctca ttagctctt gaccttgag gtcttgctt cgtctcctg acctaagtga      480
aagggtgttc gttttagaa gggtagagg cgaaggaggt gagagttgtc cagggtcgg      540

```

pctca2013050364-seq1.txt

cgagtgc	tat	tggagta	cccc	ttgatac	acc	gagttgc	gac	caagact	cta	gggccac	cgt	600
cctaagc	taa	tgaggac	gcg	atagttg	cga	ggtcgatt	gt	gagtcgt	caa	gctcgtg	tag	660
caagtcg	agt	cttcccc	acga	gtgatga	cga	tgatagt	gag	aggaggg	tct	acgactc	tcc	720
aagagga	aagg	gttcccc	acta	gttgagg	cga	ctaccac	gat	gatgaac	cat	gaagttg	gggt	780
cactagg	agt	ccggttt	gtt	gcacctc	cac	ctcaagg	aag	agttgc	cctgt	ctagtag	ttg	840
tgaatgg	tcc	gagcaa	aagcc	ttgatag	cac	cgatc	cctga	agctat	gtta	gtccgag	agg	900
aaggtcg	aat	actccg	gttg	tttgta	ctga	ggtaggc	cacc	gacgtga	gaa	gggtttg	cgt	960
gtcggta	aagc	tcgtgg	tgcg	atgacac	cct	gagtgag	agt	tctag	ctcag	gcgacac	acg	1020
ctcagac	acg	agcgact	acg	aaggctc	tga	tacgag	cgat	tgcact	gaag	acactcc	ggt	1080
ctcatgc	gat	agggtc	accc	tggtcaca	aaa	gggtg	tcctt	acttgac	ctg	actagag	tag	1140
tgattga	tga	ggggtag	gtc	tctccta	tattg	gaggtc	tccc	acaagt	gaca	ccgaagg	tag	1200
gcaaggt	acg	agcactt	cac	tactgag	ctc	cctagg	agat	ctctta	agct	cgag		1254

<210> 19  
 <211> 1041  
 <212> DNA  
 <213> Nicotiana tabacum

<400> 19												
ggtagcc	aat	tcggacg	cgt	tcgttgc	atg	tacgga	atcg	agtacac	tac	tatcctc	act	60
ttcctca	tct	ccatcgt	gct	cctcaac	tac	atcctca	agt	ccctcac	ttc	cgctatg	gat	120
ttcatca	tct	accgttt	cct	cctcctc	atc	gtgatcg	ctt	ccccatt	cgt	taagact	cag	180
aactacg	gta	tcaacct	ccc	aatcact	gga	tctatgg	ata	ctgctta	cgc	taactc	tcc	240
cagcaag	aga	ctttcct	cac	ttccacac	t	tgctctac	t	acccaac	tga	ggcatcc	aca	300
cagatcg	gag	atacaga	gtg	gaaggata	ct	ctctccc	agc	tcttcct	cac	taaggga	tgg	360
ccaactg	ggt	ccgtgtac	tt	caaagagt	ac	actgat	atcg	cttcctt	ctc	catcgat	cca	420
cagctct	act	gcgattac	aa	cgtgggt	gctt	atgaagt	acg	attccac	tct	tgagctt	gat	480
atgtccg	agc	ttgctgat	ct	catcctca	ac	gagtggt	ctct	gcaaccca	aat	ggatatc	act	540
ctctact	act	accagcag	ac	tgatgagg	ct	aacaagt	gga	tctctat	ggg	acagtc	ctgc	600
actatca	aag	tgtgccc	act	caacact	cag	actctcg	gaa	tcggatg	cat	cactact	aac	660
actgcta	ctt	tcgagga	agt	ggctact	tcc	gagaagc	tcg	tgatcact	ga	tgtggtg	gat	720
gggtgta	aacc	acaagct	cga	tgtgact	act	aacacat	gca	caatcagg	aa	ctgcaaga	ag	780
ctcggac	caa	gggaaa	acgt	ggctatc	atc	caagtgg	gag	gttccga	tgt	gctcgat	atc	840
actgctg	atc	caactact	gc	tccacaga	ct	gagaggat	ga	tgagggt	gaa	ctggaaga	ag	900
tggtggc	agg	ttttctac	ac	tgtggtg	gat	tacatca	aacc	agatcgt	tca	ggatgat	tcc	960
aagaggt	ccc	gttctct	caa	ctccgct	gct	ttctact	acc	gtgtgtg	atg	actcgagg	ga	1020
tcctcta	gag	aattcg	agct	c								1041

pctca2013050364-seq1.txt

<210> 20  
 <211> 1041  
 <212> DNA  
 <213> Nicotiana tabacum

<400> 20  
 ccatggctta agcctgcgca agcaacgtac atgccttagc tcatgtgatg ataggagtga 60  
 aaggagtaga ggtagcacga ggagttgatg taggagttca gggagtgaag gcgataccta 120  
 aagtagtaga tggcaaagga ggaggagtag cactagcgaa ggggtaagca attctgagtc 180  
 ttgatgccat agttggaggg ttagtgacct agatacctat gacgaatgcg attgaggagg 240  
 gtcgttctct gaaaggagtg aaggtgtgag acggagatga tgggttgact ccgtaggtgt 300  
 gtctagcctc tatgtctcac cttcctatga gagagggctc agaaggagtg attccctacc 360  
 ggttgaccaa ggcacatgaa gtttctcatg tgactatagc gaaggaagag gtagctaggt 420  
 gtcgagatga cgctaattgt gcaccacgaa tacttcatgc taaggtgaga actcgaacta 480  
 tacaggctcg aacgactaga gtaggagttg ctcaccgaga cgttgggtta cctatagtga 540  
 gagatgatga tggtcgtctg actactccga ttgttcacct agagataccc tgtcaggacg 600  
 tgatagtttc acacgggtga gttgtgagtc tgagagcctt agcctacgta gtgatgattg 660  
 tgacgatgaa agctccttca ccgatgaagg ctcttcgagc actagtgact acaccaccta 720  
 ccacaattgg tgttcgagct aactgatga ttgtgtacgt gttagtcctt gacgttcttc 780  
 gagcctgggt cccttttgca ccgatagtag gttcaccctc caaggctaca cgagctatag 840  
 tgacgactag gttgatgacg aggtgtctga ctctcctact actcccactt gaccttcttc 900  
 accaccgtcc aaaagatgtg acaccaccta atgtagttgg tctagcaagt cactacagg 960  
 ttctccagg caagagagtt gaggcgacga aagatgatgg cacacactac tgagctcctt 1020  
 aggagatctc ttaagctcga g 1041

<210> 21  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-WA\_VP2(opt).s1+3c

<400> 21  
 aaatttgtcg ggcccatggc ataccggaag agaggagcaa agcgcgaa 48

<210> 22  
 <211> 50  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-WA\_VP2(opt).s1-4r

<400> 22  
 actaaagaaa ataggccttt aaagctcggt cattattcgc atattgtcga 50

<210> 23  
 <211> 4903  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Construct 1191

<400> 23  
 tggcaggata tattgtggtg taaacaaatt gacgcttaga caacttaata acacattgcg 60  
 gacgttttta atgtactgaa ttaacgccga atcccgggct ggtatattta tatgtttgtca 120  
 aataactcaa aaaccataaa agtttaagtt agcaagtgtg tacattttta cttgaacaaa 180  
 aatattcacc tactactggt ataatcatt attaaacatt agagtaaaga aatatggatg 240  
 ataagaacaa gagtagtgat attttgacaa caattttggt gcaacatttg agaaaatttt 300  
 gttgttctct cttttcattg gtcaaaaaca atagagagag aaaaaggaag agggagaata 360  
 aaaacataat gtgagtatga gagagaaagt tgtacaaaag ttgtaccaa atagttgtac 420  
 aaatatcatt gaggaatttg acaaaagcta cacaataag ggttaattgc tgtaaataaa 480  
 taaggatgac gcattagaga gatgtaccat tagagaattt ttggcaagtc attaaaaaga 540  
 aagaataaat tattttttaa attaaaagtt gagtcatttg attaaacatg tgattattta 600  
 atgaattgat gaaagagttg gattaaagtt gtattagtaa ttagaatttg gtgtcaaatt 660  
 taatttgaca ttgatcttt tcctatatat tgcccatag agtcagttaa ctcatTTTTA 720  
 tatttcatag atcaaataag agaaataacg gtatattaat ccctccaaaa aaaaaaacg 780  
 gtatatttac taaaaaatct aagccacgta ggaggataac aggatccccg taggaggata 840  
 acatccaatc caaccaatca caacaatcct gatgagataa cccacttta gcccacgcat 900  
 ctgtggcaca tctacattat ctaaatacaca cattcttcca cacatctgag ccacacaaaa 960  
 accaatccac atctttatca cccattctat aaaaaatcac actttgtgag tctacacttt 1020  
 gattcccttc aaacacatac aaagagaaga gactaattaa ttaattaatc atcttgagag 1080  
 aaaatggaac gagctataca aggaaacgac gctagggaac aagctaacag tgaacgttgg 1140  
 gatggaggat caggaggtac cacttctccc ttcaaacttc ctgacgaaag tccgagttgg 1200  
 actgagtggc ggctacataa cgatgagacg aattcgaatc aagataatcc ccttggtttc 1260  
 aaggaaagct ggggtttcgg gaaagttgta tttaagagat atctcagata cgacaggacg 1320  
 gaagcttcac tgcacagagt ccttggtatc ttggacgggag attcgggtta ctatgcagca 1380  
 tctcgatttt tcggtttcga ccagatcgga tgtacctata gtattcgggt tcgaggagtt 1440  
 agtatcaccg tttctggagg gtcgcaact cttcagcatc tctgtgagat ggcaattcgg 1500  
 tctaagcaag aactgctaca gcttgcccca atcgaagtgg aaagtaatgt atcaagagga 1560  
 tgccctgaag gtactcaaac cttcgaaaaa gaaagcgagt aagttaaaat gcttcttcgt 1620  
 ctctatttta taatatggtt tgttattgtt aattttgttc ttgtagaaga gcttaattaa 1680  
 tcgttggtgt tatgaaatac tatttgatg agatgaactg gtgtaatgta attcatttac 1740  
 ataagtggag tcagaatcag aatgtttcct ccataactaa ctagacatga agacctgccg 1800



## pctca2013050364-seq1.txt

cgtacaattg	tcttatat	gaacaactaa	aattgaacat	cttttgccac	aactttataa	1860
gtgggttaata	tagctcaaat	atatgggtcaa	gttcaataga	ttaataatgg	aaatatcagt	1920
tatcgaaatt	cattaacaat	caacttaacg	ttattaacta	ctaattttat	atcatcccct	1980
ttgataaatg	atagtacacc	aattaggaag	gagcatgctc	gcctaggaga	ttgtcgtttc	2040
ccgccttcag	tttgcaagct	gctctagccg	tgtagccaat	acgcaaaccg	cctctccccg	2100
cgcgttggga	attactagcg	cgtgtcgaca	agcttgcatt	ccggtcaaca	tggtggagca	2160
cgacacactt	gtctactcca	aaaatatcaa	agatacagtc	tcagaagacc	aaagggcaat	2220
tgagactttt	caacaaaggg	taatattccg	aaacctcttc	ggattccatt	gcccagctat	2280
ctgtcacttt	attgtgaaga	tagtggaata	ggaaggtggc	tcctacaaat	gccatcattg	2340
cgataaagga	aaggccatcg	ttgaagatgc	ctctgccgac	agtgggtcca	aagatggacc	2400
cccacccacg	aggagcatcg	tggaaaaaga	agacgttcca	accacgtctt	caaagcaagt	2460
ggattgatgt	gataacatgg	tggagcacga	cacacttgct	tactccaaaa	atatcaaaga	2520
tacagtctca	gaagaccaa	gggcaattga	gacttttcaa	caaagggtaa	tatccgga	2580
cctcctcgga	ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tggaaaagga	2640
aggtggctcc	tacaaatgcc	atcattgcga	taaaggaaag	gccatcgttg	aagatgcctc	2700
tgccgacagt	ggccccaaag	atggaccccc	accacgagg	agcatcgtag	aaaaagaaga	2760
cgttccaacc	acgtcttcaa	agcaagtggg	ttgatgtgat	atctccactg	acgtaagggg	2820
tgacgcacaa	tcccactatc	cttcgcaaga	cccttctctt	atataaggaa	gttcattttca	2880
tttgagagag	tattaaaatc	ttaatagggt	ttgataaaag	cgaacgtggg	gaaacccgaa	2940
ccaaaccttc	ttctaaactc	tctctcatct	ctcttaaagc	aaacttctct	cttgtctttc	3000
ttgcgtgagc	gatcttcaac	gttgtcagat	cgtgcttcgg	caccagtaca	acgttttctt	3060
tcactgaagc	gaaatcaaag	atctctttgt	ggacacgtag	tgcggcgcca	ttaaataacg	3120
tgtacttgct	ctattcttgt	cggtgtgggc	ttgggaaaag	aaagcttgct	ggaggctgct	3180
gttcagcccc	atacattact	tgttacgatt	ctgctgactt	tcggcgggtg	caatatctct	3240
acttctgctt	gacgaggtat	tgttgccctg	acttctttct	tcttcttctt	gctgattggg	3300
tctataagaa	atctagtatt	ttctttgaaa	cagagttttc	ccgtgggttt	cgaacttgga	3360
gaaagattgt	taagcttctg	tatattctgc	ccaaatttgt	cgggcccgcg	gatggcgaaa	3420
aacgttgcca	ttttcggttc	attgttttct	cttcttggtg	tggttccttc	tcagatcttc	3480
gcctgcaggc	tcctcagcca	aaacgacacc	cccattctgt	tatccactgg	cccctggatc	3540
tgctgcccac	actaactcca	tggtgaccct	gggatgcctg	gtcaagggct	atttccttga	3600
gccagtgcac	gtgacctgga	actctggatc	cctgtccagc	gggtgtgcac	ccttcccagc	3660
tgtcctgcag	tctgacctct	acactctgag	cagctcagtg	actgtcccct	ccagcacctg	3720
gcccagcgag	accgtcacct	gcaacgttgc	ccaccgggcc	agcagcacca	aggtggacaa	3780
gaaaattgtg	cccagggatt	gtgggttgtaa	gccttgcata	tgtacagtcc	cagaagtatc	3840

pctca2013050364-seq1.txt

atctgtcttc atcttcccc caaagcccaa ggatgtgctc accattactc tgactcctaa	3900
ggtcacgtgt gttgtggtag acatcagcaa ggatgatccc gaggtccagt tcagctgggt	3960
tgtagatgat gtggagggtgc acacagctca gacgcaaccc cgggaggagc agttcaacag	4020
cactttccgc tcagtcagtg aacttcccat catgcaccag gactggctca atggcaagga	4080
gcgatcgctc accatcacca tcaccatcac catcaccatt aaaggcctat tttctttagt	4140
ttgaatttac tgttattcgg tgtgcatttc tatgtttggt gagcggtttt ctgtgctcag	4200
agtgtgttta ttttatgtaa ttttaatttct ttgtgagctc ctgttttagca ggtcgtccct	4260
tcagcaagga cacaaaaaga ttttaatttt attaaaaaaa aaaaaaaaaa agaccgggaa	4320
ttcgatatca agcttatcga cctgcagatc gttcaaacat ttggcaataa agtttcttaa	4380
gattgaatcc tgttgccggt cttgcgatga ttatcatata atttctgttg aattacgtta	4440
agcatgtaat aattaacatg taatgcatga cgttatttat gagatgggtt tttatgatta	4500
gagtcccgca attatacatt taatacgcg tagaaaacaa aatatagcgc gcaaactagg	4560
ataaattatc gcgcgcggtg tcatctatgt tactagatct ctagagtctc aagcttggcg	4620
cgcccacgtg actagtggca ctggccgtcg ttttacaacg tcgtgactgg gaaaaccctg	4680
gcgttaccca acttaatcgc cttgcagcac atcccccttt cgccagctgg cgtaatagcg	4740
aagaggcccg caccgatcgc cttcccaac agttgcgcag cctgaatggc gaatgctaga	4800
gcagcttgag cttggatcag attgtcgttt cccgccttca gtttaaacta tcagtgtttg	4860
acaggatata ttggcgggta aacctaagag aaaagagcgt tta	4903

<210> 24  
 <211> 2721  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Expression cassette number 1733

<400> 24	
gtcaacatgg tggagcacga cacacttgtc tactccaaaa atatcaaaga tacagtctca	60
gaagaccaaa gggcaattga gacttttcaa caaagggtaa tatccggaaa cctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcgttg aagatgcctc tgccgacagt	240
gggtcccaaag atggaccccc acccacgagg agcatcgttg aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggttg agcacgacac acttgctctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc	540
atcgttgaag atgcctctgc cgacagtggc cccaaagatg gacccccacc cacgaggagc	600
atcgtggaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660

## pctca2013050364-seq1.txt

tccactgacg taagggatga cgcacaatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcactcttc ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacggt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgctcta ttcttgctcg tgtggtcttg ggaaaagaaa	1020
gcttgctgga ggctgctggt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgcctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaa agattgttaa gcttctgtat attctgcca aatttgctcg	1260
gccatgtac ggcacgagt atacaacaat tttaattttc ctgattttca tcattctggt	1320
aaactacatc cttagtcg tgaccagaat tatggattat attatctatc gtagcctcct	1380
catctacgtg gccctttttg ccctgaccag ggcccagaac tatggcctga acttaccaat	1440
caccggttca atggataccg tttacgctaa ttccactcaa gaggggatat ttctgacaag	1500
taccctgtgc ctgtattatc caacagaagc ctctaccag atcaatgatg gggagtggaa	1560
ggatagtctc tcacagatgt tcctaaccaa gggctggccc accggttccg tctacttcaa	1620
ggaatactct agtattgtcg acttctcagt tgacccccag ctttattgcg actacaacct	1680
ggtacttatg aaatacgacc agaacctgga gctggatatg tccgagctgg ctgacctgat	1740
cctcaatgag tggctgtgca accccatgga catcacatta tattactacc agcagtctgg	1800
agaatccaac aagtggatca gtatgggctc aagttgcacc gtgaaggtgt gtcccttgaa	1860
cacccaaatg ctgggcattg gttgtcagac aactaatgtg gattcgtttg aaatggtagc	1920
cgaaaacgag aagctggcta tagtggacgt agtcgatggg attaaccaca agatcaatct	1980
gactaccacc acttgtagca tcagaaactg taaaagctc ggcccccgga agaacgtcgc	2040
cgtgatccag gtggggggga gcaatgtgct cgacattact gccgacccta ccaccaatcc	2100
acagacggaa cggatgatga gagtcaactg gaagaaatgg tggcaggtct ttataacat	2160
tgtggactac attaaccaga ttgtgcaagt catgagtaaa cgggccagat ccctgaactc	2220
agcagccttc tattatcgcg tttagaggcc tattttcttt agtttgaatt tactgttatt	2280
cgggtgtgcat ttctatgttt ggtgagcggg tttctgtgct cagagtgtgt ttattttatg	2340
taatttaatt tctttgtgag ctctgtttta gcaggtcgtc ccttcagcaa ggacacaaaa	2400
agattttaat ttatttaaaa aaaaaaaaaa aaaagaccgg gaattcgata tcaagcttat	2460
cgacctgcag atcgttcaaa ctttggcaa taaagtttct taagattgaa tcctgttgcc	2520
ggtcttgca tgattatcat ataatttctg ttgaattacg ttaagcatgt aataattaac	2580
atgtaatgca tgacgttatt tatgagatgg gtttttatga ttagagtccc gcaattatac	2640
atttaatacg cgatagaaaa caaatatag cgcgcaaact aggataaatt atcgcgcgcg	2700

gtgtcatcta tggtactaga t

<210> 25  
 <211> 890  
 <212> PRT  
 <213> Rotavirus

<400> 25

Met Ala Tyr Arg Lys Arg Gly Ala Lys Arg Glu Asn Leu Pro Gln Gln  
 1 5 10 15

Asn Glu Arg Leu Gln Glu Lys Glu Ile Glu Lys Asp Val Asp Val Thr  
 20 25 30

Met Glu Asn Lys Asn Asn Asn Arg Lys Gln Gln Leu Ser Asp Lys Val  
 35 40 45

Leu Ser Gln Lys Glu Glu Ile Ile Thr Asp Ala Gln Asp Asp Ile Lys  
 50 55 60

Ile Ala Gly Glu Ile Lys Lys Ser Ser Lys Glu Glu Ser Lys Gln Leu  
 65 70 75 80

Leu Glu Ile Leu Lys Thr Lys Glu Asp His Gln Lys Glu Ile Gln Tyr  
 85 90 95

Glu Ile Leu Gln Lys Thr Ile Pro Thr Phe Glu Ser Lys Glu Ser Ile  
 100 105 110

Leu Lys Lys Leu Glu Asp Ile Arg Pro Glu Gln Ala Lys Lys Gln Met  
 115 120 125

Lys Leu Phe Arg Ile Phe Glu Pro Lys Gln Leu Pro Ile Tyr Arg Ala  
 130 135 140

Asn Gly Glu Lys Glu Leu Arg Asn Arg Trp Tyr Trp Lys Leu Lys Lys  
 145 150 155 160

Asp Thr Leu Pro Asp Gly Asp Tyr Asp Val Arg Glu Tyr Phe Leu Asn  
 165 170 175

Leu Tyr Asp Gln Ile Leu Ile Glu Met Pro Asp Tyr Leu Leu Leu Lys  
 180 185 190

Asp Met Ala Val Glu Asn Lys Asn Ser Arg Asp Ala Gly Lys Val Val  
 195 200 205

Asp Ser Glu Thr Ala Asn Ile Cys Asp Ala Ile Phe Gln Asp Glu Glu  
 210 215 220

Thr Glu Gly Val Val Arg Arg Phe Ile Ala Asp Met Arg Gln Gln Val  
 Page 23

225                      230                      235                      240  
 Gln Ala Asp Arg Asn<sub>245</sub> Ile Val Asn Tyr Pro<sub>250</sub> Ser Ile Leu His Pro<sub>255</sub> Ile  
 Asp His Ala Phe<sub>260</sub> Asn Glu Tyr Phe<sub>265</sub> Leu Asn His Gln Leu Val<sub>270</sub> Glu Pro  
 Leu Asn Asn<sub>275</sub> Glu Ile Ile Phe Asn<sub>280</sub> Tyr Ile Pro Glu Arg<sub>285</sub> Ile Arg Asn  
 Asp Val<sub>290</sub> Asn Tyr Ile Leu Asn<sub>295</sub> Met Asp Met Asn Leu<sub>300</sub> Pro Ser Thr Ala  
 Arg Tyr Ile Arg Pro Asn<sub>310</sub> Leu Leu Gln Asp Arg<sub>315</sub> Leu Asn Leu His Asp<sub>320</sub>  
 Asn Phe Glu Ser<sub>325</sub> Leu Trp Asp Thr Ile Thr<sub>330</sub> Thr Ser Asn Tyr Ile<sub>335</sub> Leu  
 Ala Arg Ser Val<sub>340</sub> Val Pro Asp Leu Lys<sub>345</sub> Glu Lys Glu Leu Val<sub>350</sub> Ser Thr  
 Glu Ala Gln<sub>355</sub> Ile Gln Lys Met Ser<sub>360</sub> Gln Asp Leu Gln<sub>365</sub> Leu Glu Ala Leu  
 Thr Ile<sub>370</sub> Gln Ser Glu Thr Gln<sub>375</sub> Phe Leu Ala Gly Ile<sub>380</sub> Asn Ser Gln Ala  
 Ala Asn Asp Cys Phe<sub>390</sub> Lys Thr Leu Ile Ala Ala<sub>395</sub> Met Leu Ser Gln Arg<sub>400</sub>  
 Thr Met Ser Leu Asp<sub>405</sub> Phe Val Thr Thr Asn<sub>410</sub> Tyr Met Ser Leu Ile<sub>415</sub> Ser  
 Gly Met Trp Leu<sub>420</sub> Leu Thr Val Ile<sub>425</sub> Pro Asn Asp Met Phe<sub>430</sub> Leu Arg Glu  
 Ser Leu Val<sub>435</sub> Ala Cys Glu Leu Ala<sub>440</sub> Ile Ile Asn Thr Ile<sub>445</sub> Val Tyr Pro  
 Ala Phe<sub>450</sub> Gly Met Gln Arg Met<sub>455</sub> His Tyr Arg Asn Gly<sub>460</sub> Asp Pro Gln Thr  
 Pro Phe Gln Ile Ala Glu<sub>470</sub> Gln Gln Ile Gln Asn<sub>475</sub> Phe Gln Val Ala Asn<sub>480</sub>  
 Trp Leu His Phe Ile<sub>485</sub> Asn Asn Asn Arg Phe<sub>490</sub> Arg Gln Val Val Ile<sub>495</sub> Asp  
 Gly Val Leu Asn Gln Thr Leu Asn Asp Asn Ile Arg Asn Gly Gln Val

500

505

510

Ile Asn Gln Leu Met Glu Ala Leu Met Gln Leu Ser Arg Gln Gln Phe  
 515 520 525

Pro Thr Met Pro Val Asp Tyr Lys Arg Ser Ile Gln Arg Gly Ile Leu  
 530 535 540

Leu Leu Ser Asn Arg Leu Gly Gln Leu Val Asp Leu Thr Arg Leu Val  
 545 550 555 560

Ser Tyr Asn Tyr Glu Thr Leu Met Ala Cys Val Thr Met Asn Met Gln  
 565 570 575

His Val Gln Thr Leu Thr Thr Glu Lys Leu Gln Leu Thr Ser Val Thr  
 580 585 590

Ser Leu Cys Met Leu Ile Gly Asn Thr Thr Val Ile Pro Ser Pro Gln  
 595 600 605

Thr Leu Phe His Tyr Tyr Asn Ile Asn Val Asn Phe His Ser Asn Tyr  
 610 615 620

Asn Glu Arg Ile Asn Asp Ala Val Ala Ile Ile Thr Ala Ala Asn Arg  
 625 630 635 640

Leu Asn Leu Tyr Gln Lys Lys Met Lys Ser Ile Val Glu Asp Phe Leu  
 645 650 655

Lys Arg Leu Gln Ile Phe Asp Val Pro Arg Val Pro Asp Asp Gln Met  
 660 665 670

Tyr Arg Leu Arg Asp Arg Leu Arg Leu Leu Pro Val Glu Arg Arg Arg  
 675 680 685

Leu Asp Ile Phe Asn Leu Ile Leu Met Asn Met Glu Gln Ile Glu Arg  
 690 695 700

Ala Ser Asp Lys Ile Ala Gln Gly Val Ile Ile Ala Tyr Arg Asp Met  
 705 710 715 720

Gln Leu Glu Arg Asp Glu Met Tyr Gly Tyr Val Asn Ile Ala Arg Asn  
 725 730 735

Leu Asp Gly Tyr Gln Gln Ile Asn Leu Glu Glu Leu Met Arg Thr Gly  
 740 745 750

Asp Tyr Gly Gln Ile Thr Asn Met Leu Leu Asn Asn Gln Pro Val Ala  
 755 760 765

Leu Val Gly Ala Leu Pro Phe Val Thr Asp Ser Ser Val Ile Ser Leu  
 Page 25

770

775

780

Ile Ala Lys Leu Asp Ala Thr Val Phe Ala Gln Ile Val Lys Leu Arg  
 785 790 795 800

Lys Val Asp Thr Leu Lys Pro Ile Leu Tyr Lys Ile Asn Ser Asp Ser  
 805 810 815

Asn Asp Phe Tyr Leu Val Ala Asn Tyr Asp Trp Ile Pro Thr Ser Thr  
 820 825 830

Thr Lys Val Tyr Lys Gln Val Pro Gln Pro Phe Asp Phe Arg Ala Ser  
 835 840 845

Met His Met Leu Thr Ser Asn Leu Thr Phe Thr Val Tyr Ser Asp Leu  
 850 855 860

Leu Ser Phe Val Ser Ala Asp Thr Val Glu Pro Ile Asn Ala Val Ala  
 865 870 875 880

Phe Asp Asn Met Arg Ile Met Asn Glu Leu  
 885 890

&lt;210&gt; 26

&lt;211&gt; 6745

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Construct 193

&lt;400&gt; 26

tggcaggata tattgtggtg taaacaaatt gacgcttaga caacttaata acacattgcg	60
gacgttttta atgtactgaa ttaacgccga atcccgggct ggtatatatta tatgttgtca	120
aataactcaa aaaccataaa agtttaagtt agcaagtgtg tacatatttta cttgaacaaa	180
aatattcacc tactactggt ataatcatt attaaacatt agagtaaaga aatatggatg	240
ataagaacaa gagtagtgat attttgacaa caattttgtt gcaacatttg agaaaatttt	300
gttgttctct cttttcattg gtcaaaaaca atagagagag aaaaaggaag agggagaata	360
aaaacataat gtgagtatga gagagaaagt tgtacaaaag ttgtacaaa atagttgtac	420
aaatatcatt gaggaatttg acaaaagcta cacaaataag ggttaattgc tgtaaataaa	480
taaggatgac gcattagaga gatgtacat tagagaattt ttggcaagtc attaaaaaga	540
aagaataaat tatttttaaa attaaaagtt gagtcatttg attaaacatg tgattattta	600
atgaattgat gaaagagttg gattaaagtt gtattagtaa ttagaatttg gtgtcaaatt	660
taatttgaca ttgatcttt tcctatatat tgcccatag agtcagttaa ctcattttta	720
tatttcatag atcaaataag agaaataacg gtatattaat ccctccaaaa aaaaaaacg	780
gtatatttac taaaaaatct aagccacgta ggaggataac aggatccccg taggaggata	840

## pctca2013050364-seq1.txt

acatccaatc	caaccaatca	caacaatcct	gatgagataa	cccactttta	gcccacgcat	900
ctgtggcaca	tctacattat	ctaaatcaca	catttctcca	cacatctgag	ccacacaaaa	960
accaatccac	atcttttatca	cccatttctat	aaaaaatcac	actttgtgag	tctacacttt	1020
gattcccctc	aaacacatac	aaagagaaga	gactaattaa	ttaattaatc	atcttgagag	1080
aaaatggaac	gagctataca	aggaaacgac	gctaggggaa	aagctaacag	tgaacggttg	1140
gatggaggat	caggaggtac	cacttctccc	ttcaaacttc	ctgacgaaag	tccgaggttg	1200
actgagtggc	ggctacataa	cgatgagacg	aattcgaatc	aagataatcc	ccttggtttc	1260
aaggaaagct	ggggtttcgg	gaaagttgta	tttaagagat	atctcagata	cgacaggacg	1320
gaagcttcac	tgcacagagt	ccttggtatc	tggacgggag	attcggttaa	ctatgcagca	1380
tctcgatttt	tcggtttcga	ccagatcgga	tgtacctata	gtattcggtt	tcgaggagtt	1440
agtatcaccg	tttctggagg	gtcgcgaact	cttcagcatc	tctgtgagat	ggcaattcgg	1500
tctaagcaag	aactgctaca	gcttgcccca	atcgaagtgg	aaagtaatgt	atcaagagga	1560
tgccctgaag	gtactcaaac	cttcgaaaaa	gaaagcgagt	aagttaaaat	gcttcttcgt	1620
ctcctattta	taatattggt	tgttattgtt	aattttgttc	ttgtagaaga	gcttaattaa	1680
tcgttggtgt	tatgaaatac	tatttgatg	agatgaactg	gtgtaatgta	attcatttac	1740
ataagtggag	tcagaatcag	aatgtttcct	ccataactaa	ctagacatga	agacctgccg	1800
cgtacaattg	tcttatattt	gaacaactaa	aattgaacat	cttttgccac	aactttataa	1860
gtggttaata	tagctcaaat	atatggtcaa	gttcaataga	ttaataatgg	aaatatcagt	1920
tatcgaaatt	cattaacaat	caacttaacg	ttattaacta	ctaattttat	atcatcccct	1980
ttgataaatg	atagtacacc	aattaggaag	gagcatgctc	gcctaggaga	ttgtcgtttc	2040
ccgccttcag	tttgcaagct	gctctagccg	tgtagccaat	acgcaaaccg	cctctccccg	2100
cgcgttggga	attactagcg	cgtgtcgaga	cgcgttgttg	ttgtgactcc	gaggggttgc	2160
ctcaaactct	atcttataac	cggcgtggag	gcatggaggc	aggggtatct	tggtcatttt	2220
aatagatagt	ggaaaatgac	gtggaattta	cttaaagacg	aagtctttgc	gacaaggggg	2280
ggcccacgcc	gaatttaata	ttaccggcgt	ggccccccct	tatcgcgagt	gcttttagcac	2340
gagcgggtcca	gatttaaagt	agaaaatttc	ccgcccacta	gggttaaagg	tgttcacact	2400
ataaaagcat	atacgatgtg	atggtatttg	gtcgacaagc	ttgcatgccg	gtcaacatgg	2460
tggagcacga	cacacttgct	tactccaaaa	atatcaaaga	tacagtctca	gaagacccaa	2520
gggcaattga	gacttttcaa	caaagggtaa	tatccggaaa	cctcctcgga	ttccattgcc	2580
cagctatctg	tcactttatt	gtgaagatag	tggaaaagga	aggtggctcc	tacaaatgcc	2640
atcattgcga	taaaggaaag	gccatcgttg	aagatgcctc	tgccgacagt	ggtcccaaag	2700
atggaccccc	accacgagg	agcatcgtgg	aaaaagaaga	cgttccaacc	acgtcttcaa	2760
agcaagtgga	ttgatgtgat	aacatggtgg	agcacgacac	acttgtctac	tccaaaaata	2820
tcaaagatac	agtctcagaa	gaccaaaggg	caattgagac	ttttcaacaa	agggtaatat	2880



pctca2013050364-seq1.txt

ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg aagatagtgg	2940
aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc atcgttgaag	3000
atgcctctgc cgacagtggc cccaaagatg gacccccacc cacgaggagc atcgtggaaa	3060
aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc tccactgacg	3120
taagggatga cgcacaatcc cactatcctt cgcaagaccc ttcctctata taaggaagtt	3180
catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga acgtggggaa	3240
acccgaacca aaccttcttc taaactctct ctcatctctc ttaaagcaaa cttctctctt	3300
gtctttcttg cgtgagcgat cttcaacggt gtcagatcgt gcttcggcac cagtacaacg	3360
ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc ggcgccatta	3420
aataacgtgt acttgctcta ttcttgtcgg tgtggtcttg ggaaaagaaa gcttgctgga	3480
ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg gcgggtgcaa	3540
tatctctact tctgcttgac gaggtattgt tgcctgtact tctttcttct tcttcttgct	3600
gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg tggttttcga	3660
acttgagaaa agattgttaa gcttctgtat attctgcccc aatttgctcg gccgcggat	3720
ggcgaaaaac gttgcgattt tcgggttatt gttttctctt cttgtgttgg ttccttctca	3780
gatcttcgcc tgcaggtccc tcagccaaaa cgacaccccc atctgtctat ccaactggccc	3840
ctggatctgc tgcccaaact aactccatgg tgaccctggg atgcctgggc aagggctatt	3900
tccctgagcc agtgacagt acctggaact ctggatccct gtccagcggg gtgcacacct	3960
tcccagctgt cctgcagtct gacctctaca ctctgagcag ctcaagtact gtccccctca	4020
gcacctggcc cagcgagacc gtcacctgca acgttgcccc cccggccagc agcaccaagg	4080
tggacaagaa aatttggtccc agggattgtg gttgtaagcc ttgcatatgt acagtcccag	4140
aagtatcatc tgtcttcac tttcccccaa agcccaagga tgtgctcacc attactctga	4200
ctcctaaggt cacgtgtgtt gtggtagaca tcagcaagga tgatcccgag gtccagttca	4260
gctggtttgt agatgatgtg gaggtgcaca cagctcagac gcaaccccgg gaggagcagt	4320
tcaacagcac tttccgctca gtcagtgaac ttcccatcat gcaccaggac tggctcaatg	4380
gcaaggagcg atcgctcacc atcaccatca ccatcaccat caccattaaa ggcctatttt	4440
ctttagtttg aatttactgt tattcgggtg gcatttctat gtttggtgag cggttttctg	4500
tgctcagagt gtgtttattt tatgtaattt aatttctttg tgagctcctg tttagcaggt	4560
cgtcccttca gcaaggacac aaaaagattt taattttatt aaaaaaaaaa aaaaaaaga	4620
ccgggaattc gatatcaagc ttatcgacct gcagatcggt caaacatttg gcaataaagt	4680
ttcttaagat tgaatcctgt tgccggtctt gcgatgatta tcatataatt tctgttgaat	4740
tacgttaagc atgtaataat taacatgtaa tgcagtacgt tttttatgag atgggttttt	4800
atgattagag tcccgaatt atacatttaa tacgcgatag aaaacaaaat atagcgcgca	4860
aactaggata aattatcgcg cgcggtgtca tctatgttac tagatctcta gagtctcaag	4920

pctca2013050364-seq1.txt

cttggcgcgc	cataaaatga	ttatTTTTatg	aatatatTTTc	attgtgcaag	tagatagaaa	4980
ttacatatgt	tacataacac	acgaaataaa	caaaaaaaga	caatccaaaa	acaaacaccc	5040
caaaaaaaat	aatcactTTa	gataaaactg	tatgaggaga	ggcacgttca	gtgactcgac	5100
gattccccgag	caaaaaaagt	ctccccgtca	cacatatagt	gggtgacgca	attatctTTa	5160
aagtaatcct	tctgttgact	tgtcattgat	aacatccagt	cttcgtcagg	attgcaaaga	5220
attatagaag	ggatcccacc	TTTTatTTTc	ttctTTTTTc	catatTTtagg	gttgacagtg	5280
aaatcagact	ggcaacctat	taattgcttc	cacaatggga	cgaacttgaa	ggggatgtcg	5340
tcgatgatat	tataggtggc	gtgttcacg	tagttggtga	aatcgatggg	accgttccaa	5400
tagttgtgtc	gtccgagact	tctagcccag	gtggctctTc	cggtagcagt	tggtcccgag	5460
atgtagaggc	tgggggtgtcg	gattccattc	cttccattgt	cctggTTaaa	tcggccatcc	5520
attcaagggtc	agattgagct	tgttggtatg	agacaggatg	tatgtaagta	taagcgtcta	5580
tgcttacatg	gtatagatgg	gtttccctcc	aggagtgtag	atcttcgtgg	cagcgaagat	5640
ctgattctgt	gaagggcgac	acatacggtt	caggttgtgg	agggataaat	ttgttggtcg	5700
aatattccag	ccattgaagt	tttgttgccc	attcatgagg	gaattctTcc	ttgatcatgt	5760
caagatattc	ctccttagac	gttgacgtct	ggataatagt	tctccatcgt	gcgtcagatt	5820
tgcgaggaga	gaccttatga	tctcgaaaat	ctcctctggg	TTaatatct	ccgtcctTtg	5880
atatgtaatc	aaggacttgt	ttagagttTc	tagctggctg	gatattaggg	tgattTcctt	5940
caaaatcgaa	aaaagaagga	tccctaatac	aaggTTTTTt	atcaagctgg	agaagagcat	6000
gatagtgggt	agtgccatct	tgatgaagct	cagaagcaac	accaaggaag	aaaataagaa	6060
aagggtgtgag	tttctccag	agaaactgga	ataaatcatc	tctttgagat	gagcactTgg	6120
gataggtgaag	gaaaacatat	ttagattgga	gtctgaagtt	cttactagca	gaaggcatgt	6180
tgttggtgact	ccgaggggtt	gcctcaaact	ctatcttata	accggcgtgg	aggcatggag	6240
gcaggggtat	tttggtcatt	ttaatagata	gtggaaaatg	acgtggaatt	tactTaaaga	6300
cgaagtcttt	gcgacaaggg	ggggcccacg	ccgaattTaa	tattaccggc	gtggcccccc	6360
cttatcgca	gtgctTtagc	acgagcggtc	cagattTaaa	gtagaaaatt	tcccggccac	6420
tagggTaaa	gggtgtcaca	ctataaaagc	atatacgatg	tgatggtatt	tgactagtgg	6480
cactggccgt	cgTTTTaaca	cgtcgtgact	gggaaaaccc	tggcgTtacc	caactTaatc	6540
gccttgacg	acatccccct	ttcgccagct	ggcgtaatag	cgaagaggcc	cgcaccgatc	6600
gccctTccca	acagttgcgc	agcctgaatg	gcgaatgcta	gagcagcttg	agcttggtatc	6660
agattgtcgt	ttccgcctt	cagttTaaac	tatcagtgtt	tgacaggata	tattggcggg	6720
taaacctaag	agaaaagagc	gttta				6745

<210> 27  
 <211> 4413  
 <212> DNA  
 <213> Artificial sequence

&lt;220&gt;

&lt;223&gt; Expression cassette number 1710

&lt;400&gt; 27

gtcaacatgg tggagcacga cacacttgtc tactccaaaa atatcaaaga tacagtctca	60
gaagacccaaa gggcaattga gacttttcaa caaagggtaa tatccggaaa cctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaaag gccatcggtg aagatgcctc tgccgacagt	240
ggccccaaag atggaccccc acccacgagg agcatcggtg aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatgggtg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc	540
atcgttgaag atgcctctgc cgacagtggg cccaaagatg gacccccacc cacgaggagc	600
atcgtggaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgcacaatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta atagggtttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcatctctc ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacggt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgtccta ttcttgtcgg tgtggctctg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgcctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaaa agattgttaa gcttctgtat attctgcca aatttgtcgg	1260
gcccatggca taccggaaga gaggagcaaa gcgcgaaaac ctgccgcaac agaacgagag	1320
actgcaagaa aaagagatag agaaagatgt cgacgtaaca atggaaaaca agaataacaa	1380
taggaaacaa cagctgtccg acaaagttct gtcccagaag gaggaaatta tcactgacgc	1440
ccaggacgat attaaaattg ccggagaaat aaagaagagc tcgaaagaag aatctaaaca	1500
gctgctcgaa attctgaaaa caaaagaaga ccatcagaaa gagattcaat atgaaatttt	1560
gcaaaaaaca atacctacat ttgagtccaa agaaagtatc ctcaagaagc ttgaagacat	1620
aagaccggag caggcaaaaa aacagatgaa actctttcgc attttcgagc caaaacagct	1680
ccctatatat cgcgccaatg gcgagaagga gctacgcaac cgggtgtact ggaagttgaa	1740
aaaagacacc ctgccagatg gagattatga cgtccgggag tatttcctca atctctatga	1800
tcagatcctc atcgaaatgc cggactatct gctcctcaag gacatggccg tggagaacaa	1860
aaatagcaga gacgccggca aagttgtcga ctctgagact gccaatatth gtgatgccat	1920

pctca2013050364-seq1.txt

cttccaggat	gaggagaccg	agggagtcgt	ccgtagattc	atcgctgata	tgcggaaca	1980
ggtccaggct	gatcgtaaca	ttgtcaatta	cccttccatc	cttcacccta	ttgatcatgc	2040
attcaatgag	tattttctta	accaccagtt	ggtggagccg	ctgaacaatg	agataatctt	2100
caattacata	ccagagagga	taaggaatga	cgtgaattac	atcctgaaca	tggatatgaa	2160
tctgccatct	acagccaggt	atatcaggcc	aaacttggtg	caggatagac	tgaatcttca	2220
cgataatfff	gagtcctgt	gggataccat	cacaacatcc	aactacattc	tggccagggtc	2280
cgtcgttccc	gatttgaagg	agaaggagct	ggtctccacc	gaagcacaga	tccagaaaat	2340
gagccaggac	ctgcagctgg	aggccctcac	tattcagagc	gagacacagt	ttttagccgg	2400
gattaacagt	caggctgcc	atgattgttt	caagaccctc	atagccgcca	tgctgtctca	2460
aagaaccatg	tctttggact	ttgtgaccac	gaactatatg	agcctaattc	ccggaatgtg	2520
gctacttaca	gtgattccca	acgatatgtt	cctccgggag	tcactagtgg	cctgtgagct	2580
ggcgatcatc	aacaccatcg	tgtatccagc	attcggaatg	cagagaatgc	attaccggaa	2640
tggcgaccct	cagacaccct	tccagatcgc	agaacagcag	atccagaatt	tccaggtggc	2700
gaactggctc	cattttatta	acaataacag	attcaggcaa	gttgtgattg	atggagttct	2760
gaatcagact	ctgaacgaca	atatacgga	tggaacaggtc	atcaaccagc	tgatggaagc	2820
attgatgcaa	ctcagcagac	agcagttccc	cacgatgcct	gtggattaca	aacggagcat	2880
ccaacggggc	attctgcttc	tctccaatag	gctggggcag	cttgtcgact	taacccgact	2940
ggtctcctat	aactacgaga	cgctaattgg	ttgtgtgacc	atgaacatgc	agcacgtgca	3000
aaccctgaca	actgagaagt	tgcagctcac	ttctgtgact	tcgctttgta	tgtaatttg	3060
taacacaacc	gtgattccgt	ccccacagac	actgttccac	tactacaaca	tcaacgtgaa	3120
tttccactcc	aattataatg	agcggatcaa	cgacgccgtc	gccataatta	ccgcagcaaa	3180
taggctgaat	ctttatcaga	aaaaaatgaa	gtccatagt	gaagactttc	tgaaacggct	3240
ccagattttc	gacgtaccac	gagtgccctga	cgaccaaagt	tacaggctga	gggatcgctt	3300
tcggctctta	cccgttgaac	ggagacggct	tgacatattc	aacttgatcc	tgatgaatat	3360
ggagcagatc	gaacgcgctt	ctgataagat	tgctcagggg	gttatcatcg	cataccgaga	3420
tatgcagctg	gaacgcgacg	agatgtacgg	atatgttaat	attgcacgga	atcttgatgg	3480
ctaccagcaa	attaacttgg	aggaactcat	gcgcaccggg	gattacggac	aaattacgaa	3540
catgcttctc	aacaatcaac	ccgttgccct	tgtgggtgca	ttgcccttcg	ttacggactc	3600
atccgtgatc	agtctaatac	ccaagctcga	cgcaaccgtc	ttcgctcaga	tagtgaagct	3660
caggaaagtt	gacacactga	agccataact	gtacaaaata	aactcggatt	ccaatgactt	3720
ttaccttgtg	gccaactacg	actggatccc	cacaagtaca	actaaggctc	acaaacaggt	3780
gccacaacca	ttcgacttta	gagccagcat	gcacatgctg	acttctaacc	ttacgtttac	3840
cgtctactct	gacctactgt	catttgtttc	agcggacacg	gtagagccca	ttaacgcagt	3900
cgatttcgac	aatatgcgaa	taatgaacga	gctttaaagg	cctattttct	ttagtttgaa	3960

pctca2013050364-seq1.txt

tttactgtta ttcggtgtgc atttctatgt ttggtgagcg gttttctgtg ctcagagtgt	4020
gtttatttta tgtaatttaa tttctttgtg agctcctgtt tagcagggtcg tcccttcagc	4080
aaggacacaa aaagatttta attttattaa aaaaaaaaaa aaaaaagacc gggaattcga	4140
tatcaagctt atcgacctgc agatcgttca aacatttggc aataaagttt ctttaagattg	4200
aatcctgttg ccggtcttgc gatgattatc atataatttc tgttgaatta cgттаagcat	4260
gtaataatta acatgtaatg catgacgtta tttatgagat gggtttttat gattagagtc	4320
ccgcaattat acatttaata cgcgatagaa aacaaaatat agcgcgcaaa ctaggataaa	4380
ttatcgcgcg cgggtgtcatc tatgttacta gat	4413

<210> 28  
 <211> 49  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-WA\_VP6(opt).s1+3c

<400> 28	
aaatttgtcg ggcccatgga ggtcctttat agtctctcca aaacgtga	49

<210> 29  
 <211> 52  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-WA\_VP6(opt).s1-4r

<400> 29	
actaaagaaa ataggcctct acttgatcaa catactccgg atagaggcca ca	52

<210> 30  
 <211> 2934  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Expression cassette number 1713

<400> 30	
gtcaacatgg tggagcacga cacacttgtc tactccaaaa atatcaaaga tacagtctca	60
gaagaccaa gggcaattga gacttttcaa caaagggtaa tatccggaaa ctcctcggga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcgttg aagatgcctc tgccgacagt	240
ggtcccaaag atggaccccc acccacgagg agcatcgtag aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggtgg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc	540

pctca2013050364-seq1.txt

atcgttgaag atgcctctgc cgacagtggg cccaaagatg gacccccacc cacgaggagc	600
atcgtggaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgcacaatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcactctctc ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacggt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgctcta ttcttgctcg tgtgggtcttg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtatcttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaa agattgttaa gcttctgtat attctgcca aatttgctcg	1260
gcccattggag gtcctttata gtctctccaa aacgctgaag gacgctaggg acaagatcgt	1320
ggagggtaga ctttatagca atgtcagcga cctaatacag cagtttaatc aaatgatcgt	1380
tacaatgaat gggaatgatt tccaaactgg cggattgggt aatctgcccg tgaggaactg	1440
gacattcgat ttcggcctgc tgggcacgac tctccttaat ctcgatgcaa attatgtaga	1500
aaacgccaga acgattatcg agtactttat cgatttcatt gataacgttt gtatggatga	1560
gatggccgc gagtcacaac ggaacggagt tgctccacag tccgaggccc ttcggaaact	1620
cgccggcatt aagttcaagc gtattaattt cgacaactcc tccgaatata tagagaactg	1680
gaacttgtag aatcgtagc agagaaccgg cttcgtgttc cataaaccta atatctttcc	1740
gtatagcgcc tcattcaccc tgaataggag tcagcccatg cagcacaacc tcatgggtac	1800
aatgtggctg aatgcgggga gtgaaataca ggtcgccggg ttcgattact cctgtgccat	1860
taatgcaccc gcaaacatcc agcagttcga acatatcgtg caactaagac gggctctcac	1920
gaccgcgaca attacactcc tgcccgcgc cgagcgcttc tcctttcccc gcgtaatcaa	1980
ctcagctgat ggccgacca cttggttctt caaccctgtt atattgcgcc ctaacaacgt	2040
agaggtggag tttctcttaa acggacagat catcaatacc taccaagcca ggttcggcac	2100
gattattgca agaaatttcg acgctatcag gctgctcttc caactgatga ggcccccaa	2160
tatgactccc gctgtgaacg ctttgtttcc gcaggctcag cctttccagc accacgccac	2220
cgtcggcttg actcttcgaa tagagagcgc ggtctgcgaa tcagtgtgg cagacgcaa	2280
cgagacgctg ctggcaaacg ttaccgccgt gcggcaagag tatgccatcc cagtagggcc	2340
tgtgtttcca cccggcatga actggactga actaattact aactatagcc catccagaga	2400
agacaacttg cagcgggtct tctactgtgg ctctatccgg agtatgttga tcaagtagag	2460
gcctatcttc tttagtttga atttactgtt attcgggtgt ctttctatg tttggtgagc	2520
ggttttctgt gctcagagtg tgtttatttt atgtaattta atttctttgt gagctcctgt	2580

## pctca2013050364-seq1.txt

ttagcaggtc gtcccttcag caaggacaca aaaagatttt aattttatta aaaaaaaaaa 2640  
 aaaaaaagac cgggaattcg atatcaagct tatcgacctg cagatcgttc aaacatttgg 2700  
 caataaagtt tcttaagatt gaatcctggt gccggtcttg cgatgattat catataattt 2760  
 ctgttgaatt acgttaagca tgtaataatt aacatgtaat gcatgacgtt atttatgaga 2820  
 tgggttttta tgattagagt cccgcaatta tacatttaac acgcgataga aaacaaaata 2880  
 tagcgcgcaa actaggataa attatcgcgc gcggtgtcat ctatgttact agat 2934

<210> 31  
 <211> 397  
 <212> PRT  
 <213> Rotavirus

<400> 31

Met Glu Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp  
1 5 10 15

Lys Ile Val Glu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu Ile Gln  
20 25 30

Gln Phe Asn Gln Met Ile Val Thr Met Asn Gly Asn Asp Phe Gln Thr  
35 40 45

Gly Gly Ile Gly Asn Leu Pro Val Arg Asn Trp Thr Phe Asp Phe Gly  
50 55 60

Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val Glu Asn  
65 70 75 80

Ala Arg Thr Ile Ile Glu Tyr Phe Ile Asp Phe Ile Asp Asn Val Cys  
85 90 95

Met Asp Glu Met Ala Arg Glu Ser Gln Arg Asn Gly Val Ala Pro Gln  
100 105 110

Ser Glu Ala Leu Arg Lys Leu Ala Gly Ile Lys Phe Lys Arg Ile Asn  
115 120 125

Phe Asp Asn Ser Ser Glu Tyr Ile Glu Asn Trp Asn Leu Gln Asn Arg  
130 135 140

Arg Gln Arg Thr Gly Phe Val Phe His Lys Pro Asn Ile Phe Pro Tyr  
145 150 155 160

Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Met His Asp Asn Leu  
165 170 175

Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu Ile Gln Val Ala Gly  
180 185 190

Phe Asp Tyr Ser Cys Ala Ile Asn Ala Pro Ala Asn Ile Gln Gln Phe  
 195 200 205

Glu His Ile Val Gln Leu Arg Arg Ala Leu Thr Thr Ala Thr Ile Thr  
 210 215 220

Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro Arg Val Ile Asn Ser  
 225 230 235 240

Ala Asp Gly Ala Thr Thr Trp Phe Phe Asn Pro Val Ile Leu Arg Pro  
 245 250 255

Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly Gln Ile Ile Asn Thr  
 260 265 270

Tyr Gln Ala Arg Phe Gly Thr Ile Ile Ala Arg Asn Phe Asp Ala Ile  
 275 280 285

Arg Leu Leu Phe Gln Leu Met Arg Pro Pro Asn Met Thr Pro Ala Val  
 290 295 300

Asn Ala Leu Phe Pro Gln Ala Gln Pro Phe Gln His His Ala Thr Val  
 305 310 315 320

Gly Leu Thr Leu Arg Ile Glu Ser Ala Val Cys Glu Ser Val Leu Ala  
 325 330 335

Asp Ala Asn Glu Thr Leu Leu Ala Asn Val Thr Ala Val Arg Gln Glu  
 340 345 350

Tyr Ala Ile Pro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr  
 355 360 365

Glu Leu Ile Thr Asn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg  
 370 375 380

Val Phe Thr Val Ala Ser Ile Arg Ser Met Leu Ile Lys  
 385 390 395

<210> 32

<211> 2934

<212> DNA

<213> Artificial sequence

<220>

<223> Expression cassette number 1714

<400> 32

gtcaacatgg tggagcacga cacacttgct tactccaaaa atatcaaaga tacagtctca 60

gaagacaaa gggcaattga gacttttcaa caaagggtaa tatccgaaa cctcctcgga 120

ttccattgcc cagctatctg tcactttatt gtgaagatag tggaagga aggtggctcc 180

tacaaatgcc atcattgcga taaaggaaag gccatcggtg aagatgcctc tgccgacagt 240



## pctca2013050364-seq1.txt

gggtcccaaag atggaccccc acccacgagg agcatcgtgg aaaaagaaga cggtccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggtgg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc	540
atcgttgaag atgcctctgc cgacagtggc cccaaagatg gacccccacc cacgaggagc	600
atcgtggaag aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgcacaatcc cactatcctt cgcaagacct ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcactctct ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacgtt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgctcta ttcttgctcg tgtggtcttg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtatcttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaa agattgttaa gcttctgtat attctgcca aatttgctcg	1260
gcccattggag gtcctttata gtctctccaa aacgctgaag gacgctaggg acaagatcgt	1320
ggagggatca ctttatagca atgtcagcga cctaatacag cagtttaatc aaatgatcgt	1380
tacaatgaat gggaatgatt tccaaactgg cggatttggg aatctgccc tgaggaactg	1440
gacattcgat ttcggcctgc tgggcacgac tctccttaat ctcgatgcaa attatgtaga	1500
aaacgccaga acgattatcg agtactttat cgatttcatt gataacgttt gtatggatga	1560
gatggccgc gagtcacaac ggaacggagt tgctccacag tccgaggccc ttcggaaact	1620
cgccggcatt aagttcaagc gtattaattt cgacaactcc tccgaatata tagagaactg	1680
gaacttgacg aatcgtcgac agagaaccgg cttcgtgttc cataaaccta atatctttcc	1740
gtatagcgcc tcattcacc tgaataggag tcagcccatg cacgacaacc tcatgggtac	1800
aatgtggctg aatgcgggga gtgaaataca ggtcgccggg ttcgattact cctgtgccat	1860
taatgcacc gcaaacatcc agcagttcga acatatcgtg caactaagac gggctctcac	1920
gaccgcgaca attacactcc tgcccgacgc cgagcgcttc tcctttcccc gcgtaatcaa	1980
ctcagctgat ggcgccacca cttggttctt caaccctgtt atattgcgcc ctaacaacgt	2040
agaggtggag tttctcttaa acggacagat catcaatacc taccaagcca ggttcggcac	2100
gattattgca agaaatttcg acgctatcag gctgctcttc caactgatga ggcccccaa	2160
tatgactccc gctgtgaacg ctttggttcc gcaggctcag cttttccagc accacgccac	2220
cgtcggcttg actcttcgaa tagagagcgc ggtctgcgaa tcagtgtgtg cagacgcaa	2280

pctca2013050364-seq1.txt

cgagacgctg ctggcaaacg ttaccgccgt gcggcaagag tatgccatcc cagtagggcc	2340
tgtgtttcca cccggcatga actggactga actaattact aactatagcc catccagaga	2400
agacaacttg cagcgggtct tctactgtggc ctctatccgg agtatgttga tcaagtagag	2460
gcctattttc tttagtttga atttactgtt attcgggtgtg cttttctatg tttggtgagc	2520
ggttttctgt gctcagagtg tgtttatttt atgtaattta atttctttgt gagtcctgt	2580
ttagcaggtc gtcccttcag caaggacaca aaaagatttt aattttatta aaaaaaaaaa	2640
aaaaaaagac cgggaattcg atatcaagct tatcgacctg cagatcgttc aaacatttgg	2700
caataaagtt tcttaagatt gaatcctgtt gccggtcttg cgatgattat catataattt	2760
ctgttgaatt acgttaagca tgtaataatt aacatgtaat gcatgacgtt atttatgaga	2820
tgggttttta tgattagagt cccgcaatta tacatttaat acgcgataga aaacaaaata	2880
tagcgcgcaa actaggataa attatcgcg gcggtgtcat ctatgttact agat	2934

<210> 33  
 <211> 53  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-Rtx\_VP4(opt).s1+3c

<400> 33	
aaatttgcg ggcccatggc tagcctgatc tacagacaac tcttgaccaa ttc	53

<210> 34  
 <211> 55  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-Rtx\_VP4(opt).s1-4r

<400> 34	
actaaagaaa ataggccttc agagtttaca ttgcaggatt aattgctcaa tccta	55

<210> 35  
 <211> 4068  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Expression cassette number 1731

<400> 35	
gtcaacatgg tggagcacga cacacttgct tactccaaaa atatcaaaga tacagtctca	60
gaagaccaa gggcaattga gacttttcaa caaagggtaa tatccggaaa cctcctcgga	120
ttccattgcc cagctatctg tctctttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcgttg aagatgcctc tgccgacagt	240
ggccccaaag atggaccccc acccacgagg agcatcgtag aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtggg ttgatgtgat aacatggtag agcacgacac acttgtctac	360

## pctca2013050364-seq1.txt

tccaaaaata	tcaaagatac	agtctcagaa	gaccaaaggg	caattgagac	ttttcaacaa	420
agggtaatat	ccggaaacct	cctcggattc	cattgcccag	ctatctgtca	ctttattgtg	480
aagatagtgg	aaaaggaagg	tggctcctac	aaatgccatc	attgcgataa	aggaaaggcc	540
atcgttgaag	atgcctctgc	cgacagtggc	cccaaagatg	gacccccacc	cacgaggagc	600
atcgtggaaa	aagaagacgt	tccaaccacg	tcttcaaagc	aagtggattg	atgtgatatc	660
tccactgacg	taagggatga	cgcacaatcc	cactatcctt	cgcaagaccc	ttcctctata	720
taaggaagtt	catttcattt	ggagaggtat	taaaatctta	ataggttttg	ataaaagcga	780
acgtggggaa	acccgaacca	aaccttcttc	taaactctct	ctcatctctc	ttaaagcaaa	840
cttctctctt	gtctttcttg	cgtgagcgat	cttcaacggt	gtcagatcgt	gcttcggcac	900
cagtacaacg	ttttctttca	ctgaagcgaa	atcaaagatc	tctttgtgga	cacgtagtgc	960
ggcgccatta	aataacgtgt	acttgtccta	ttcttgtcgg	tgtggtcttg	ggaaaagaaa	1020
gcttgctgga	ggctgctggt	cagccccata	cattacttgt	tacgattctg	ctgactttcg	1080
gcgggtgcaa	tatctctact	tctgcttgac	gaggtattgt	tgccgtgact	tctttcttct	1140
tcttcttgct	gattggttct	ataagaaatc	tagtattttc	tttgaaacag	agttttcccg	1200
tggttttcga	acttgagaaa	agattgttaa	gcttctgtat	attctgcca	aatttgctcg	1260
gcccattggc	agcctgatct	acagacaact	cttgaccaat	tcatattctg	tggatcttca	1320
tgacgaaatc	gagcagattg	ggcccgagaa	gaccagaac	gtgaccatca	accctggacc	1380
ttttgctcag	acccgctatg	cccctgtgaa	ttgggatcac	ggagaaatca	acgacagtac	1440
gaccgtcgaa	cccatcttg	acgggccata	ccaaccacc	accttcaccc	cacctaata	1500
ttattggatt	ttaatcaact	ccaacacaaa	cggagtggc	tacgagtcca	ctaataactc	1560
cgatttttgg	accgccgttg	tagccatcga	gccacacgct	aatcctgtcg	atcgccagta	1620
tatgatattc	ggcgagtcca	aacagtttaa	cgtttccaat	gacagcaaca	aatggaagtt	1680
tctggagatg	tttcgcagct	cctctcagaa	cgaattctat	aatagacgga	cccttacctc	1740
cgatacacga	ctcgtgggta	tttttaagta	cggcggcagg	gtgtggacat	ttcacggtga	1800
aacccctcga	gcaaccactg	actccagtag	cactgcaaac	ctgaacaata	tatctattac	1860
catccacagc	gaattctaca	taatcccaag	atctcaggaa	agtaagtgtg	acgaatatat	1920
caacaacgga	ctcccccaa	ttcagaatac	acggaacgtg	gtgcctctcc	cactcagttc	1980
tcggtctatc	cagtataaga	gagcacaagt	gaatgaggac	attattgtga	gcaagactag	2040
cctttggaaa	gaaatgcagt	acaacagaga	cattatcatc	cggtttaagt	ttgggaactc	2100
tatcgtgaag	atgggcggcc	tggggtacaa	atggtcagaa	atctcatata	aagccgcaa	2160
ctatcagtat	aactacttga	gagacggcga	gcaggtaacc	gcccacacaa	catgctctgt	2220
caacggcggt	aataacttta	gctacaacgg	aggcttcctt	cccaccgact	tcggtatcag	2280
ccggtatgaa	gtcatcaagg	aaaattctta	tgtgtacgta	gattactggg	atgatagcaa	2340
agcgttccgc	aacatggtgt	atgttaggag	cctggctgct	aatctcaatt	ctgtgaagtg	2400

pctca2013050364-seq1.txt

tactggtgga tcatattatt tctcaattcc cgtgggggct tggccagtca tgaatggcgg	2460
ggcagttctcc ctccattttg ctggcgtgac gttgagcact cagttttaccg atttcgtgtc	2520
tctgaactcc ctgaggttcc ggttttccct tactgtcgac gagcccccat tcagcattct	2580
gcgtacaaga actgtcaacc tctacgggtt acctgccgcg aatccaaaca acggcaatga	2640
atactatgaa atttcgggcc gcttctcttt gataagtctg gtaccaacta atgacgacta	2700
tcagacaccc atcatgaaca gcgtgactgt cagacaggac ctggaaagac aacttacaga	2760
tctgcgggaa gaattcaatt ctctcagtca ggagattgca atggcccaat tgatagatct	2820
tgccctactg cctctcgata tgttttagtat gttctccggc atcaaataca ctatagatct	2880
gacaaagagc atgggtactt ctgtgatgaa gaagttcagg aaatcaaaac ttgccacgag	2940
catatcagaa atgacgaact ctctgagtga tgcagcatca tcagcgtcac gcaacgtttc	3000
cattcgggtcg aatctcagcg ccacagcaa ctggacaaac gtgtccaacg acgtcagcaa	3060
cgtgaccaac tccttgaacg atatttctac ccagacgtca acgatcagta agaaactccg	3120
cttgaaagaa atgatcacc agactgaggg aatgtctttc gacgacattt ccgccgccgt	3180
gctaaaaacc aaaatcgata tgttactca gatcggaag aacactctgc cggatatcgt	3240
aaccgaagcc tccgaaaagt ttatccctaa gcgcagctac agaataattga aagatgacga	3300
ggtcatggag atcaacacag aagggaagtt cttcgcttat aagatcaaca cttttgacga	3360
ggttccgttt gacgtcaata agtttgaga gctcgtgaca gatagtccag tgattttctgc	3420
catcattgac ttttaagactt tgaagaacct gaacgacaac tatggaataa cacggaccga	3480
agcgttgaac ctcatthaagt ccaatcccaa tatgttgccg aatttcatta accagaacaa	3540
tccaatcata agaaatagga ttgagcaatt aatcctgcaa tgtaaaactct gaaggcctat	3600
tttctttagt ttgaatttac tgttattcgg tgtgcatttc tatgtttggt gagcggtttt	3660
ctgtgctcag agtgtgttta ttttatgtaa ttttaatttct ttgtgagctc ctgttttagca	3720
ggtcgtccct tcagcaagga cacaaaaaga ttttaatttt attaaaaaaa aaaaaaaaaa	3780
agaccgggaa ttcgatatca agcttatcga cctgcagatc gttcaaakat ttggcaataa	3840
agtttcttaa gattgaatcc tgttgccggg cttgcgatga ttatcatata atttctgttg	3900
aattacgtta agcatgtaat aattaacatg taatgcatga cgttatttat gagatgggtt	3960
tttatgatta gagtcccgca attatacatt taatacgca tagaaaacaa aatatagcgc	4020
gcaaactagg ataaattatc gcgcgcggtg tcatctatgt tactagat	4068

<210> 36  
 <211> 775  
 <212> PRT  
 <213> Rotavirus

<400> 36

Met	Ala	Ser	Leu	Ile	Tyr	Arg	Gln	Leu	Leu	Thr	Asn	Ser	Tyr	Ser	Val
1				5					10					15	

pctca2013050364-seq1.txt

Asp Leu His Asp Glu Ile Glu Gln Ile Gly Ser Glu Lys Thr Gln Asn  
 20 25 30  
 Val Thr Ile Asn Pro Gly Pro Phe Ala Gln Thr Arg Tyr Ala Pro Val  
 35 40 45  
 Asn Trp Asp His Gly Glu Ile Asn Asp Ser Thr Thr Val Glu Pro Ile  
 50 55 60  
 Leu Asp Gly Pro Tyr Gln Pro Thr Thr Phe Thr Pro Pro Asn Asp Tyr  
 65 70 75 80  
 Trp Ile Leu Ile Asn Ser Asn Thr Asn Gly Val Val Tyr Glu Ser Thr  
 85 90 95  
 Asn Asn Ser Asp Phe Trp Thr Ala Val Val Ala Ile Glu Pro His Val  
 100 105 110  
 Asn Pro Val Asp Arg Gln Tyr Met Ile Phe Gly Glu Ser Lys Gln Phe  
 115 120 125  
 Asn Val Ser Asn Asp Ser Asn Lys Trp Lys Phe Leu Glu Met Phe Arg  
 130 135 140  
 Ser Ser Ser Gln Asn Glu Phe Tyr Asn Arg Arg Thr Leu Thr Ser Asp  
 145 150 155 160  
 Thr Arg Leu Val Gly Ile Phe Lys Tyr Gly Gly Arg Val Trp Thr Phe  
 165 170 175  
 His Gly Glu Thr Pro Arg Ala Thr Thr Asp Ser Ser Ser Thr Ala Asn  
 180 185 190  
 Leu Asn Asn Ile Ser Ile Thr Ile His Ser Glu Phe Tyr Ile Ile Pro  
 195 200 205  
 Arg Ser Gln Glu Ser Lys Cys Asn Glu Tyr Ile Asn Asn Gly Leu Pro  
 210 215 220  
 Pro Ile Gln Asn Thr Arg Asn Val Val Pro Leu Pro Leu Ser Ser Arg  
 225 230 235 240  
 Ser Ile Gln Tyr Lys Arg Ala Gln Val Asn Glu Asp Ile Ile Val Ser  
 245 250 255  
 Lys Thr Ser Leu Trp Lys Glu Met Gln Tyr Asn Arg Asp Ile Ile Ile  
 260 265 270  
 Arg Phe Lys Phe Gly Asn Ser Ile Val Lys Met Gly Gly Leu Gly Tyr  
 275 280 285

pctca2013050364-seq1.txt

Lys Trp Ser Glu Ile Ser Tyr Lys Ala Ala Asn Tyr Gln Tyr Asn Tyr  
 290 295 300  
 Leu Arg Asp Gly Glu Gln Val Thr Ala His Thr Thr Cys Ser Val Asn  
 305 310 315 320  
 Gly Val Asn Asn Phe Ser Tyr Asn Gly Gly Phe Leu Pro Thr Asp Phe  
 325 330 335  
 Gly Ile Ser Arg Tyr Glu Val Ile Lys Glu Asn Ser Tyr Val Tyr Val  
 340 345 350  
 Asp Tyr Trp Asp Asp Ser Lys Ala Phe Arg Asn Met Val Tyr Val Arg  
 355 360 365  
 Ser Leu Ala Ala Asn Leu Asn Ser Val Lys Cys Thr Gly Gly Ser Tyr  
 370 375 380  
 Tyr Phe Ser Ile Pro Val Gly Ala Trp Pro Val Met Asn Gly Gly Ala  
 385 390 395 400  
 Val Ser Leu His Phe Ala Gly Val Thr Leu Ser Thr Gln Phe Thr Asp  
 405 410 415  
 Phe Val Ser Leu Asn Ser Leu Arg Phe Arg Phe Ser Leu Thr Val Asp  
 420 425 430  
 Glu Pro Pro Phe Ser Ile Leu Arg Thr Arg Thr Val Asn Leu Tyr Gly  
 435 440 445  
 Leu Pro Ala Ala Asn Pro Asn Asn Gly Asn Glu Tyr Tyr Glu Ile Ser  
 450 455 460  
 Gly Arg Phe Ser Leu Ile Ser Leu Val Pro Thr Asn Asp Asp Tyr Gln  
 465 470 475 480  
 Thr Pro Ile Met Asn Ser Val Thr Val Arg Gln Asp Leu Glu Arg Gln  
 485 490 495  
 Leu Thr Asp Leu Arg Glu Glu Phe Asn Ser Leu Ser Gln Glu Ile Ala  
 500 505 510  
 Met Ala Gln Leu Ile Asp Leu Ala Leu Leu Pro Leu Asp Met Phe Ser  
 515 520 525  
 Met Phe Ser Gly Ile Lys Ser Thr Ile Asp Leu Thr Lys Ser Met Ala  
 530 535 540  
 Thr Ser Val Met Lys Lys Phe Arg Lys Ser Lys Leu Ala Thr Ser Ile  
 545 550 555 560

pctca2013050364-seq1.txt

Ser Glu Met Thr Asn Ser Leu Ser Asp Ala Ala Ser Ser Ala Ser Arg  
565 570 575

Asn Val Ser Ile Arg Ser Asn Leu Ser Ala Ile Ser Asn Trp Thr Asn  
580 585 590

Val Ser Asn Asp Val Ser Asn Val Thr Asn Ser Leu Asn Asp Ile Ser  
595 600 605

Thr Gln Thr Ser Thr Ile Ser Lys Lys Leu Arg Leu Lys Glu Met Ile  
610 615 620

Thr Gln Thr Glu Gly Met Ser Phe Asp Asp Ile Ser Ala Ala Val Leu  
625 630 635 640

Lys Thr Lys Ile Asp Met Ser Thr Gln Ile Gly Lys Asn Thr Leu Pro  
645 650 655

Asp Ile Val Thr Glu Ala Ser Glu Lys Phe Ile Pro Lys Arg Ser Tyr  
660 665 670

Arg Ile Leu Lys Asp Asp Glu Val Met Glu Ile Asn Thr Glu Gly Lys  
675 680 685

Phe Phe Ala Tyr Lys Ile Asn Thr Phe Asp Glu Val Pro Phe Asp Val  
690 695 700

Asn Lys Phe Ala Glu Leu Val Thr Asp Ser Pro Val Ile Ser Ala Ile  
705 710 715 720

Ile Asp Phe Lys Thr Leu Lys Asn Leu Asn Asp Asn Tyr Gly Ile Thr  
725 730 735

Arg Thr Glu Ala Leu Asn Leu Ile Lys Ser Asn Pro Asn Met Leu Arg  
740 745 750

Asn Phe Ile Asn Gln Asn Asn Pro Ile Ile Arg Asn Arg Ile Glu Gln  
755 760 765

Leu Ile Leu Gln Cys Lys Leu  
770 775

<210> 37  
<211> 51  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer IF-Rtx\_VP7(opt).s1+3c

<400> 37  
aaatttgctg ggcccatgta cggcatcgag tataacaaca ttttaatttt c

<210> 38  
 <211> 54  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-Rtx\_VP7(opt).s1-4r

<400> 38  
 actaaagaaa ataggcctct aaacgcgata atagaaggct gctgagttca ggga

54

<210> 39  
 <211> 326  
 <212> PRT  
 <213> Rotavirus

<400> 39

Met Tyr Gly Ile Glu Tyr Thr Thr Ile Leu Ile Phe Leu Ile Ser Ile  
 1 5 10 15

Ile Leu Leu Asn Tyr Ile Leu Lys Ser Val Thr Arg Ile Met Asp Tyr  
 20 25 30

Ile Ile Tyr Arg Ser Leu Leu Ile Tyr Val Ala Leu Phe Ala Leu Thr  
 35 40 45

Arg Ala Gln Asn Tyr Gly Leu Asn Leu Pro Ile Thr Gly Ser Met Asp  
 50 55 60

Thr Val Tyr Ala Asn Ser Thr Gln Glu Gly Ile Phe Leu Thr Ser Thr  
 65 70 75 80

Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr Gln Ile Asn Asp Gly  
 85 90 95

Glu Trp Lys Asp Ser Leu Ser Gln Met Phe Leu Thr Lys Gly Trp Pro  
 100 105 110

Thr Gly Ser Val Tyr Phe Lys Glu Tyr Ser Ser Ile Val Asp Phe Ser  
 115 120 125

Val Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Leu Val Leu Met Lys Tyr  
 130 135 140

Asp Gln Asn Leu Glu Leu Asp Met Ser Glu Leu Ala Asp Leu Ile Leu  
 145 150 155 160

Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr Leu Tyr Tyr Tyr Gln  
 165 170 175

Gln Ser Gly Glu Ser Asn Lys Trp Ile Ser Met Gly Ser Ser Cys Thr  
 180 185 190



Val Lys Val Cys Pro Leu Asn Thr Gln Met Leu Gly Ile Gly Cys Gln  
 195 200 205

Thr Thr Asn Val Asp Ser Phe Glu Met Val Ala Glu Asn Glu Lys Leu  
 210 215 220

Ala Ile Val Asp Val Val Asp Gly Ile Asn His Lys Ile Asn Leu Thr  
 225 230 235 240

Thr Thr Thr Cys Thr Ile Arg Asn Cys Lys Lys Leu Gly Pro Arg Glu  
 245 250 255

Asn Val Ala Val Ile Gln Val Gly Gly Ser Asn Val Leu Asp Ile Thr  
 260 265 270

Ala Asp Pro Thr Thr Asn Pro Gln Thr Glu Arg Met Met Arg Val Asn  
 275 280 285

Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Ile Val Asp Tyr Ile Asn  
 290 295 300

Gln Ile Val Gln Val Met Ser Lys Arg Ser Arg Ser Leu Asn Ser Ala  
 305 310 315 320

Ala Phe Tyr Tyr Arg Val  
 325

<210> 40  
 <211> 60  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Primer IF-Rtx\_VP7(opt).s2+4c

<400> 40  
 tctcagatct tcgccagaa ctatggcctg aacttaccaa tcaccggttc aatggatacc 60

<210> 41  
 <211> 4897  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Construct 1192

<400> 41  
 tggcaggata tattgtggtg taaacaaatt gacgcttaga caacttaata acacattgcg 60  
 gacgttttta atgtactgaa ttaacgccga atccggggt ggtatattta tatgttgtca 120  
 aataactcaa aaaccataaa agtttaagtt agcaagtgtg tacattttta cttgaacaaa 180  
 aatattcacc tactactggt ataaatcatt attaaacatt agagtaaaga aatatggatg 240  
 ataagaacaa gagtagtgat attttgacaa caattttggt gcaacatttg agaaaatttt 300  
 gttgttctct cttttcattg gtcaaaaaca atagagagag aaaaaggaag agggagaata 360

## pctca2013050364-seq1.txt

aaaacataat	gtgagtatga	gagagaaagt	tgtacaaaag	ttgtaccaa	atagttgtac	420
aaatatcatt	gaggaatttg	acaaaagcta	cacaaataag	ggttaattgc	tgtaaataaa	480
taaggatgac	gcattagaga	gatgtacat	tagagaat	ttggcaagtc	attaaaaaga	540
aagaataaat	tatttttaaa	attaaaagtt	gagtcatttg	attaaacatg	tgattattta	600
atgaattgat	gaaagagttg	gattaaagtt	gtattagtaa	ttagaatttg	gtgtcaaatt	660
taatttgaca	tttgatcttt	tcctatatat	tgcccatag	agtcagttaa	ctcattttta	720
tatttcatag	atcaaataag	agaaataacg	gtatattaat	ccctccaaaa	aaaaaaaaacg	780
gtatatttac	taaaaaatct	aagccacgta	ggaggataac	aggatccccg	taggaggata	840
acatccaatc	caaccaatca	caacaatcct	gatgagataa	cccactttta	gcccacgcat	900
ctgtggcaca	tctacattat	ctaaatcaca	cattcttcca	cacatctgag	ccacacaaaa	960
accaatccac	atcttttatca	cccattctat	aaaaaatcac	actttgtgag	tctacacttt	1020
gattcccttc	aaacacatac	aaagagaaga	gactaattaa	ttaattaatc	atcttgagag	1080
aaaatggaac	gagctataca	aggaaacgac	gctagggaac	aagctaacag	tgaacgttgg	1140
gatggaggat	caggaggtac	cacttctccc	ttcaaacttc	ctgacgaaag	tccgagttgg	1200
actgagtggc	ggctacataa	cgatgagacg	aattcgaatc	aagataatcc	ccttggtttc	1260
aaggaaagct	ggggtttcgg	gaaagttgta	tttaagagat	atctcagata	cgacaggacg	1320
gaagcttcac	tgcacagagt	ccttggtatct	tggaaggag	attcggttaa	ctatgcagca	1380
tctcgatttt	tcggtttcga	ccagatcgga	tgtacctata	gtattcggtt	tcgaggagtt	1440
agtatcaccg	tttctggagg	gtcgcgaact	cttcagcatc	tctgtgagat	ggcaattcgg	1500
tctaagcaag	aactgctaca	gcttgcccca	atcgaagtgg	aaagtaatgt	atcaagagga	1560
tgccctgaag	gtactcaaac	cttcgaaaaa	gaaagcgagt	aagttaaaat	gcttcttcgt	1620
ctcctattta	taatattggt	tgttattgtt	aattttgttc	ttgtagaaga	gcttaattaa	1680
tcgttgttgt	tatgaaatac	tatttgtatg	agatgaactg	gtgtaatgta	attcattttac	1740
ataagtggag	tcagaatcag	aatgtttcct	ccataactaa	ctagacatga	agacctgccg	1800
cgtacaattg	tcttatattt	gaacaactaa	aattgaacat	cttttgccac	aactttataa	1860
gtggttaata	tagtcaaat	atatggtcaa	gttcaataga	ttaataatgg	aaatatcagt	1920
tatcgaaatt	cattaacaat	caacttaacg	ttattaacta	ctaattttat	atcatccctt	1980
ttgataaatg	atagtacacc	aattaggaag	gagcatgctc	gcctaggaga	ttgtcggttc	2040
ccgccttcag	tttgcaagct	gctctagccg	tgtagccaat	acgcaaaccg	cctctccccg	2100
cgcgttggga	attactagcg	cgtgtcgaca	agcttgcacg	ccggtcaaca	tggtggagca	2160
cgacacactt	gtctactcca	aaaatatcaa	agatacagtc	tcagaagacc	aaagggcaat	2220
tgagactttt	caacaaaggg	taatattccg	aaacctcctc	ggattccatt	gcccagctat	2280
ctgtcacttt	attgtgaaga	tagtggaata	ggaaggtggc	tcctacaaat	gccatcattg	2340
cgataaagga	aaggccatcg	ttgaagatgc	ctctgccgac	agtggtccca	aagatggacc	2400

## pctca2013050364-seq1.txt

cccacccacg	aggagcatcg	tggaaaaaga	agacgttcca	accacgtctt	caaagcaagt	2460
ggattgatgt	gataacatgg	tggagcacga	cacacttgtc	tactccaaaa	atatcaaaga	2520
tacagtctca	gaagaccaaa	gggcaattga	gacttttcaa	caaagggtaa	tatccgga	2580
cctcctcgga	ttccattgcc	cagctatctg	tcactttatt	gtgaagatag	tggaaaagga	2640
aggtggctcc	tacaaatgcc	atcattgcga	taaaggaaag	gccatcgttg	aagatgcctc	2700
tgccgacagt	ggtcccaaag	atggaccccc	accacgagg	agcatcgtgg	aaaaagaaga	2760
cgttccaacc	acgtcttcaa	agcaagtgga	ttgatgtgat	atctccactg	acgtaaggga	2820
tgacgcacaa	tcccactatc	cttcgcaaga	cccttcctct	atataaggaa	gttcattttca	2880
tttggagagg	tattaaaatc	ttaatagggt	ttgataaaag	cgaacgtggg	gaaacccgaa	2940
ccaaaccttc	ttctaaactc	tctctcatct	ctcttaaagc	aaacttctct	cttgtctttc	3000
ttgctgtagc	gatcttcaac	gttgtcagat	cgtgcttcgg	caccagtaca	acgttttctt	3060
tcactgaagc	gaaatcaaag	atctctttgt	ggacacgtag	tgcggcgcca	ttaaataacg	3120
tgtacttgtc	ctattcttgt	cgggtgtggtc	ttgggaaaag	aaagcttgct	ggaggctgct	3180
gttcagcccc	atacattact	tgttacgatt	ctgctgactt	tcggcggtg	caatatctct	3240
acttctgctt	gacgaggtat	tgttgcctgt	acttctttct	tcttcttctt	gctgattggt	3300
tctataagaa	atctagtatt	ttctttgaaa	cagagttttc	ccgtggtttt	cgaacttgga	3360
gaaagattgt	taagcttctg	tatattctgc	ccaaatttgt	cgggcccatg	gcgaaaaacg	3420
ttgcgatttt	cggcttattg	ttttctcttc	ttgtgttggt	tccttctcag	atcttcgccg	3480
cggctcctca	gccaaaacga	cacccccatc	tgtctatcca	ctggcccctg	gatctgctgc	3540
ccaaactaac	tccatggtga	ccctgggatg	cctggtcaag	ggctatttcc	ctgagccagt	3600
gacagtgacc	tggaactctg	gatccctgtc	cagcgggtgtg	cacaccttcc	cagctgtcct	3660
gcagtctgac	ctctacactc	tgagcagctc	agtgactgtc	ccctccagca	cctggcccag	3720
cgagaccgtc	acctgcaacg	ttgcccaccc	ggccagcagc	accaaggtgg	acaagaaaat	3780
tgtgcccagg	gattgtgggt	gtaagccttg	catatgtaca	gtcccagaag	tatcatctgt	3840
cttcatcttc	cccccaaagc	ccaaggatgt	gctcaccatt	actctgactc	ctaaggtcac	3900
gtgtgttggtg	gtagacatca	gcaaggatga	tcccagagtc	cagttcagct	ggttttaga	3960
tgatgtggag	gtgcacacag	ctcagacgca	accccgggag	gagcagttca	acagcacttt	4020
ccgctcagtc	agtgaacttc	ccatcatgca	ccaggactgg	ctcaatggca	aggagcgatc	4080
gctcaccatc	accatcacca	tcaccatcac	cattaaaggc	ctattttctt	tagtttgaat	4140
ttactgttat	tcggtgtgca	tttctatgtt	tggtgagcgg	ttttctgtgc	tcagagtgtg	4200
tttattttat	gtaattta	ttctttgtga	gctcctgttt	agcaggctgt	cccttcagca	4260
aggacacaaa	aagattttaa	ttttattaaa	aaaaaaaaaa	aaaaagaccg	ggaattcgat	4320
atcaagctta	tcgacctgca	gatcgttcaa	acatttggca	ataaagtttc	ttaagattga	4380
atcctgttgc	cggctcttgcg	atgattatca	tataatttct	gttgaattac	gttaagcatg	4440

pctca2013050364-seq1.txt

taataattaa catgtaatgc atgacgttat ttatgagatg ggtttttatg attagagtcc	4500
cgcaattata catttaatac gcgatagaaa acaaaatata ggcgcgaaac taggataaat	4560
tatcgcgcgcg ggtgtcatct atgttactag atctctagag tctcaagctt ggcgcgcccc	4620
cgtgactagt ggcactggcc gtcgttttac aacgtcgtga ctgggaaaac cctggcgтта	4680
cccaacttaa tcgccttgca gcacatcccc ctttcgccag ctggcgtaat agcgaagagg	4740
cccgaccga tcgcccttcc caacagttgc gcagcctgaa tggcgaatgc tagagcagct	4800
tgagcttgga tcagattgtc gtttcccgcc ttcagtttaa actatcagtg tttgacagga	4860
tatattggcg ggtaaacct aagaaaaaga gcgttta	4897

<210> 42

<211> 2643

<212> DNA

<213> Artificial sequence

<220>

<223> Expression cassette number 1735

<400> 42

gtcaacatgg tggagcacga cacacttgtc tactccaaaa atatcaaaga tacagtctca	60
gaagaccaa gggcaattga gacttttcaa caaagggtaa tatccggaaa cctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcgttg aagatgcctc tgccgacagt	240
ggtcccaaag atggaccccc acccacgagg agcatcgtag aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggtag agcacgacac acttgcttac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtag aaaaggaagg tggctcctac aaatgccatc attgagataa aggaaaggcc	540
atcgttgaag atgcctctgc cgacagtggc ccaaagatg gacccccacc cacgaggagc	600
atcgtggaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgacaatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaaagt catttcattt ggagaggtat taaaatctta ataggttttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcattctctc ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacggt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgctcta ttcttgctcg tgtggtcttg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgcctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaaa agattgttaa gcttctgtat attctgcccc aatttgctcg	1260

pctca2013050364-seq1.txt

gcccattggcg aaaaacgttg cgatttttcgg cttattgttt tctcttcttg tgttggttcc 1320  
 ttctcagatc ttcgcccaga actatggcct gaacttacca atcacgggtt caatggatac 1380  
 cgtttacgct aattccactc aagaggggat atttctgaca agtaccctgt gcctgtatta 1440  
 tccaacagaa gcctctaccc agatcaatga tggggagtg gaggatagtc tctcacagat 1500  
 gttcctaacc aagggtctggc ccaccggttc cgtctacttc aaggaatact ctagtattgt 1560  
 cgactttctca gttgaccccc agctttattg cgactacaac ctggtactta tgaaatacga 1620  
 ccagaacctg gagctggata tgtccgagct ggctgacctg atcctcaatg agtggctgtg 1680  
 caaccccatg gacatcacat tatattacta ccagcagtct ggagaatcca acaagtggat 1740  
 cagtatgggc tcaagttgca ccgtgaaggt gtgtcccttg aacacccaaa tgctgggcat 1800  
 tgggtgtcag acaactaatg tggattcggt tgaaatggta gccgaaaacg agaagctggc 1860  
 tatagtggac gtagtcgatg ggattaacca caagatcaat ctgactacca ccacttgtac 1920  
 catcagaaac tgtaaaaagc tcggcccccg ggagaacgtc gccgtgatcc aggtgggggg 1980  
 gagcaatgtg ctcgacatta ctgccgaccc taccaccaat ccacagacgg aacggatgat 2040  
 gagagtcaac tggaagaaat ggtggcaggt cttttatacc attgtggact acattaacca 2100  
 gattgtgcaa gtcattgagta aacgggtccag atccctgaac tcagcagcct tctattatcg 2160  
 cgttttagagg cctattttct ttagtttgaa tttactgtta ttcgggtgtgc atttctatgt 2220  
 ttggtgagcg gttttctgtg ctcagagtgt gtttatttta tgtaatttaa tttctttgtg 2280  
 agtcctgtt tagcaggctg tcccttcagc aaggacacaa aaagatttta attttattaa 2340  
 aaaaaaaaaa aaaaaagacc ggggaattcga tatcaagctt atcgacctgc agatcgttca 2400  
 aacatttggc aataaagttt cttaagattg aatcctgttg ccggtcttgc gatgattatc 2460  
 atataatttc tgttgaatta cgtaagcat gtaataatta acatgtaatg catgacgtta 2520  
 tttatgagat ggggtttttat gattagagtc ccgcaattat acatttaata cgcgatagaa 2580  
 aacaaaatat agcgcgcaaa ctaggataaa ttatcgcgcg cgggtgtcatc tatgttacta 2640  
 gat 2643

<210> 43  
 <211> 300  
 <212> PRT  
 <213> Rotavirus

<400> 43

Met Ala Lys Asn Val Ala Ile Phe Gly Leu Leu Phe Ser Leu Leu Val  
 1 5 10 15

Leu Val Pro Ser Gln Ile Phe Ala Gln Asn Tyr Gly Leu Asn Leu Pro  
 20 25 30

Ile Thr Gly Ser Met Asp Thr Val Tyr Ala Asn Ser Thr Gln Glu Gly  
 35 40 45

pctca2013050364-seql.txt

Ile Phe Leu Thr Ser Thr Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser  
50 55 60

Thr Gln Ile Asn Asp Gly Glu Trp Lys Asp Ser Leu Ser Gln Met Phe  
65 70 75 80

Leu Thr Lys Gly Trp Pro Thr Gly Ser Val Tyr Phe Lys Glu Tyr Ser  
85 90 95

Ser Ile Val Asp Phe Ser Val Asp Pro Gln Leu Tyr Cys Asp Tyr Asn  
100 105 110

Leu Val Leu Met Lys Tyr Asp Gln Asn Leu Glu Leu Asp Met Ser Glu  
115 120 125

Leu Ala Asp Leu Ile Leu Asn Glu Trp Leu Cys Asn Pro Met Asp Ile  
130 135 140

Thr Leu Tyr Tyr Tyr Gln Gln Ser Gly Glu Ser Asn Lys Trp Ile Ser  
145 150 155 160

Met Gly Ser Ser Cys Thr Val Lys Val Cys Pro Leu Asn Thr Gln Met  
165 170 175

Leu Gly Ile Gly Cys Gln Thr Thr Asn Val Asp Ser Phe Glu Met Val  
180 185 190

Ala Glu Asn Glu Lys Leu Ala Ile Val Asp Val Val Asp Gly Ile Asn  
195 200 205

His Lys Ile Asn Leu Thr Thr Thr Thr Cys Thr Ile Arg Asn Cys Lys  
210 215 220

Lys Leu Gly Pro Arg Glu Asn Val Ala Val Ile Gln Val Gly Gly Ser  
225 230 235 240

Asn Val Leu Asp Ile Thr Ala Asp Pro Thr Thr Asn Pro Gln Thr Glu  
245 250 255

Arg Met Met Arg Val Asn Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr  
260 265 270

Ile Val Asp Tyr Ile Asn Gln Ile Val Gln Val Met Ser Lys Arg Ser  
275 280 285

Arg Ser Leu Asn Ser Ala Ala Phe Tyr Tyr Arg Val  
290 295 300

<210> 44  
<211> 4068  
<212> DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt;

Expression cassette number 1730

&lt;400&gt; 44

gtcaacatgg tggagcacga cacacttgct tactccaaaa atatcaaaga tacagtctca	60
gaagacaaa gggcaattga gacttttcaa caaagggtaa tatccgaaa cctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcgctg aagatgcctc tgccgacagt	240
ggccccaaag atggaccccc acccacgagg agcatcgctg aaaaagaaga cggtccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggctg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc	540
atcggtgaag atgcctctgc cgacagtggc cccaaagatg gacccccacc cacgaggagc	600
atcgaggaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgcacaatcc cactatcctt cgcaagacc ttcctctata	720
taaggaagtt catttcattt ggagaggtat taaaatctta atagggtttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcactctctc ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacgtt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgctcta ttcttgctcg tgtggtcttg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaaa agattgttaa gcttctgtat attctgcca aatttgctcg	1260
gcccattggc agcctgatct acagacaact cttgaccaat tcatattctg tggatcttca	1320
tgacgaaatc gagcagattg ggtccgagaa gaccagaac gtgaccatca accctggacc	1380
ttttgctcag acccgctatg cccctgtgaa ttgggatcac ggagaaatca acgacagtac	1440
gaccgtcgaa ccattcttg acgggccata ccaaccacc accttcacc cacctaataga	1500
ttattggatt ttaatcaact ccaacacaaa cggagtggct tacgagtcca ctaataactc	1560
cgatttttgg accgccgttg tagccatcga gccacacgct aatcctgtcg atcgccagta	1620
tatgatattc ggcgagtcca aacagtttaa cgtttccaat gacagcaaca aatggaagtt	1680
tctggagatg tttcgcagct cctctcagaa cgaattctat aatagacgga cccttacctc	1740
cgatacacga ctctgtggta tttttaagta cggcggcagg gtgtggacat ttcacggtga	1800

pctca2013050364-seq1.txt

aacccctcga gcaaccactg actccagtag cactgcaaac ctgaacaata tatctattac	1860
catccacagc gaattctaca taatcccaag atctcaggaa agtaagtgtg acgaatatat	1920
caacaacgga ctccccccaa ttcagaatac acggaacgtg gtgcctctcc cactcagttc	1980
tcggtctatc cagtataaga gagcacaagt gaatgaggac attattgtga gcaagactag	2040
ccttttgaaa gaaatgcagt acaacagaga cattatcatc cggtttaagt ttgggaactc	2100
tatcgtgaag atgggcggcc tggggtacaa atggtcagaa atctcatata aagccgccaa	2160
ctatcagtat aactacttga gagacggcga gcaggtaacc gcccacacaa catgctctgt	2220
caacggcggt aataacttta gctacaacgg aggcttcctt cccaccgact tcggtatcag	2280
ccggtatgaa gtcatcaagg aaaattctta tgtgtacgta gattactggg atgatagcaa	2340
agcgttccgc aacatggtgt atgttaggag cctggctgct aatctcaatt ctgtgaagtg	2400
tactggtgga tcatattatt tctcaattcc cgtgggggct tggccagtca tgaatggcgg	2460
ggcagtctcc ctccattttg ctggcgtgac gttgagcact cagtttaccg atttcgtgtc	2520
tctgaactcc ctgaggttcc ggttttcctt tactgtcgac gagccccat tcagcattct	2580
gcgtaacaaga actgtcaacc tctacgggtt acctgccgcg aatccaaaca acggcaatga	2640
atactatgaa atttcgggcc gcttctcttt gataagtctg gtaccaacta atgacgacta	2700
tcagacaccc atcatgaaca gcgtgactgt cagacaggac ctggaaagac aacttacaga	2760
tctgcgggaa gaattcaatt ctctcagtca ggagattgca atggcccaat tgatagatct	2820
tgccctactg cctctcgata tgtttagtat gttctccggc atcaaataca ctatagatct	2880
gacaaagagc atggctactt ctgtgatgaa gaagttcagg aaatcaaaac ttgccacgag	2940
catatcagaa atgacgaact ctctgagtga tgcagcatca tcagcgtcac gcaacgtttc	3000
cattcggtcg aatctcagcg ccatcagcaa ctggacaaac gtgtccaacg acgtcagcaa	3060
cgtgaccaac tccttgaacg atatttctac ccagacgtca acgatcagta agaaactccg	3120
cttgaaagaa atgatcacc agactgaggg aatgtctttc gacgacattt ccgccgccgt	3180
gctaaaaacc aaaatcgata tgtctactca gatcggcaag aacactctgc cggatatcgt	3240
aaccgaagcc tccgaaaagt ttatccctaa gcgcagctac agaataattga aagatgacga	3300
ggcatgggag atcaacacag aagggaagtt cttcgcttat aagatcaaca cttttgacga	3360
ggttccgttt gacgtcaata agtttgaga gctcgtgaca gatagtccag tgatttctgc	3420
catcattgac ttttaagactt tgaagaacct gaacgacaac tatggaataa cacggaccga	3480
agcgttgaac ctcatthaagt ccaatcccaa tatgttgcg c aatttcatta accagaacaa	3540
tccaatcata agaaatagga ttgagcaatt aatcctgcaa tgtaaactct gaaggcctat	3600
tttctttagt ttgaatttac tgttattcgg tgtgcatttc tatgtttggt gagcggtttt	3660
ctgtgctcag agtgtgttta ttttatgtaa ttttaatttt ttgtgagctc ctgttttagca	3720
ggtcgtccct tcagcaagga cacaaaaaga ttttaatttt attaaaaaaa aaaaaaaaaa	3780
agaccgggaa ttcgatatca agcttatcga cctgcagatc gttcaaacat ttggcaataa	3840



pctca2013050364-seq1.txt

agtttcttaa gattgaatcc tgttgccggt cttgcatga ttatcatata atttctgttg	3900
aattacgtta agcatgtaat aattaacatg taatgcatga cgttatttat gagatgggtt	3960
tttatgatta gagtcccga attatacatt taatacgca tagaaaacaa aatatagcgc	4020
gcaaactagg ataaattatc gcgcgcggtg tcatctatgt tactagat	4068

<210> 45  
 <211> 2673  
 <212> DNA  
 <213> Rotavirus

<400> 45	
atggcatacc ggaagagagg agcaaagcgc gaaaacctgc cgcaacagaa cgagagactg	60
caagaaaaag agatagagaa agatgtcgac gtaacaatgg aaaacaagaa taacaatagg	120
aaacaacagc tgtccgacaa agttctgtcc cagaaggagg aaattatcac tgacgcccag	180
gacgatatta aaattgccgg agaaataaag aagagctcga aagaagaatc taaacagctg	240
ctcgaaattc tgaaaacaaa agaagaccat cagaaagaga ttcaatatga aattttgcaa	300
aaaacaatac ctacatttga gtccaaagaa agtatcctca agaagcttga agacataaga	360
ccggagcagg caaaaaaaca gatgaaactc tttcgcatth tcgagccaaa acagctccct	420
atatatcgcg ccaatggcga gaaggagcta cgcaaccggt ggtactggaa gttgaaaaaa	480
gacaccctgc cagatggaga ttatgacgtc cgggagtatt tcctcaatct ctatgatcag	540
atcctcatcg aaatgccgga ctatctgtc ctcaaggaca tggccgtgga gaacaaaaat	600
agcagagacg ccggcaaagt tgtcgactct gagactgcca atatttgtga tgccatcttc	660
caggatgagg agaccgaggg agtcgtccgt agattcatcg ctgatatgcg gcaacaggctc	720
caggctgatc gtaacattgt caattaccct tccatccttc accctattga tcatgcattc	780
aatgagtatt ttcttaacca ccagttggtg gagccgctga acaatgagat aatcttcaat	840
tacataccag agaggataag gaatgacgtg aattacatcc tgaacatgga tatgaatctg	900
ccatctacag ccaggtatat caggccaaac ttgttgacagg atagactgaa tcttcacgat	960
aattttgagt ccctgtggga taccatcaca acatccaact acattctggc cagggtccgtc	1020
gttcccgatt tgaaggagaa ggagctggtc tccaccgaag cacagatcca gaaaatgagc	1080
caggacctgc agctggaggc cctcactatt cagagcgaga cacagttttt agccgggatt	1140
aacagtcagg ctgccaatga ttgtttcaag accctcatag ccgccatgct gtctcaaaga	1200
accatgtctt tggactttgt gaccacgaac tatatgagcc taatctccgg aatgtggcta	1260
cttacagtga ttcccaacga tatgttcctc cgggagtcac tagtggcctg tgagctggcg	1320
atcatcaaca ccatcgtgta tccagcattc ggaatgcaga gaatgcatta ccggaatggc	1380
gaccctcaga cacccttcca gatcgagaa cagcagatcc agaatttcca ggtggcgaac	1440
tggctccatt ttattaacaa taacagattc aggcaagttg tgattgatgg agttctgaat	1500
cagactctga acgacaatat acggaatgga caggctcatca accagctgat ggaagcattg	1560
atgcaactca gcagacagca gttccccacg atgcctgtgg attacaaacg gagcatccaa	1620

pctca2013050364-seq1.txt

cggggcattc	tgcttctctc	caataggctg	gggcagcttg	tcgacttaac	ccgactggtc	1680
tcctataact	acgagacgct	aatggcttgt	gtgaccatga	acatgcagca	cgtgcaaacc	1740
ctgacaactg	agaagttgca	gctcacttct	gtgacttcgc	tttgtatggt	aattggtaac	1800
acaaccgtga	ttccgtcccc	acagacactg	ttccactact	acaacatcaa	cgtgaatttc	1860
cactccaatt	ataatgagcg	gatcaacgac	gccgtcgcca	taattaccgc	agcaaatagg	1920
ctgaatcttt	atcagaaaaa	aatgaagtcc	atagtggaag	actttctgaa	acggctccag	1980
attttcgacg	taccacgagt	gcctgacgac	caaatgtaca	ggctgaggga	tcgccttcgg	2040
ctcttaccgg	ttgaacggag	acggcttgac	atattcaact	tgatcctgat	gaatatggag	2100
cagatcgaac	gcgcttctga	taagattgct	caggggggta	tcatcgcata	ccgagatatg	2160
cagctggaac	gcgacgagat	gtacggatat	gttaatatgt	cacggaatct	tgatggctac	2220
cagcaaatta	acttgaggga	actcatgctc	accggtgatt	acggacaaat	tacgaacatg	2280
cttctcaaca	atcaaccgtg	tgcccttggt	ggtgcattgc	ccttcgttac	ggactcatcc	2340
gtgatcagtc	taatcgccaa	gctcgacgca	accgtcttcg	ctcagatagt	gaagctcagg	2400
aaagttgaca	cactgaagcc	catactgtac	aaaataaact	cggattccaa	tgacttttac	2460
cttgtggcca	actacgactg	gatccccaca	agtacaacta	aggtctacaa	acaggtgcca	2520
caaccattcg	actttagagc	cagcatgcac	atgctgactt	ctaaccttac	gtttaccgtc	2580
tactctgacc	tactgtcatt	tgtttcagcg	gacacggtag	agcccatata	cgcagtcgca	2640
ttcgacaata	tgcaataat	gaacgagctt	taa			2673

<210> 46  
 <211> 1194  
 <212> DNA  
 <213> Rotavirus

<400> 46	
atggaggtcc	tttatagtct ctccaaaacg ctgaaggacg ctagggacaa gatcgtggag 60
ggtacacttt	atagcaatgt cagcgacctt atacagcagt ttaatcaaat gatcggttaca 120
atgaatggga	atgattttcca aactggcggg attggtaatc tgcccgtgag gaactggaca 180
ttcgatttcg	gcctgctggg cactgactct cttaatctcg atgcaaatta tgtagaaaac 240
gccagaacga	ttatcgagta ctttatcgat ttcatgtgata acgtttgtat ggatgagatg 300
gcccgcgagt	cacaacggaa cggagttgct ccacagtccg aggcccttcg gaaactcgcc 360
ggcattaagt	tcaagcgtat taatttcgac aactcctccg aatatataga gaactggaac 420
ttgcagaatc	gtcgacagag aaccggcttc gtgttccata aacctaatat ctttccgtat 480
agcgcctcat	tcaccctgaa taggagtcag cccatgcacg acaacctcat gggatcaatg 540
tggtggaatg	cggggagtgga aatacaggtc gccgggttcg attactcctg tgccattaat 600
gcacccgcaa	acatccagca gttcgaacat atcgtgcaac taagacgggc tctcacgacc 660
gcgacaatta	cactcctgcc cgacgccgag cgcttctcct ttccccgcgt aatcaactca 720

pctca2013050364-seq1.txt

gctgatggcg ccaccacttg gttcttcaac cctgttatat tgcgccctaa caacgtagag	780
gtggagtttc tcttaaacgg acagatcatc aatacctacc aagccagggtt cggcacgatt	840
attgcaagaa atttcgacgc tatcaggctg ctcttccaac tgatgaggcc cccaatatg	900
actcccgtg tgaacgcttt gtttccgcag gctcagcctt tccagcacca cgccaccgtc	960
ggcttgactc ttcgaataga gagcgcggtc tgcgaatcag tgctggcaga cgccaacgag	1020
acgctgctgg caaacgttac cgccgtgcgg caagagtatg ccatcccagt agggcctgtg	1080
ttccacccg gcatgaactg gactgaacta attactaact atagcccatc cagagaagac	1140
aacttgacgc gggctttcac tgtggcctct atccggagta tgttgatcaa gtag	1194

<210> 47  
 <211> 2328  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Optimized coding sequence of Rotavirus A VP4 from strain  
 RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]

<400> 47 atggctagcc tgatctacag acaactcttg accaattcat attctgtgga tcttcatgac	60
gaaatcgagc agattgggtc cgagaagacc cagaacgtga ccatcaacc tggacctttt	120
gctcagacc gctatgcccc tgtgaattgg gatcacggag aaatcaacga cagtacgacc	180
gtcgaacca ttctggacgg gccataccaa cccaccacct tcacccacc taatgattat	240
tggattttta tcaactcaa cacaaacgga gtggtctacg agtccactaa taactccgat	300
ttttggaccg ccgttgtagc catcgagcca cacgtcaatc ctgtcgatcg ccagtatatg	360
atattcggcg agtccaaaca gtttaacgtt tccaatgaca gcaacaaatg gaagtttctg	420
gagatgtttc gcagctcctc tcagaacgaa ttctataata gacggaccct tacctccgat	480
acacgactcg tgggtatttt taagtacggc ggcagggtgt ggacatttca cggtgaaacc	540
cctcgagcaa cactgactc cagtagcact gcaaacctga acaatatatc tattaccatc	600
cacagcgaat tctacataat cccaagatct caggaaagta agtgtaacga atatatcaac	660
aacggactcc cccaattca gaatacacgg aacgtggtgc ctctccact cagttctcgg	720
tctatccagt ataagagagc acaagtgaat gaggacatta ttgtgagcaa gactagcctt	780
tggaaagaaa tgcagtacaa cagagacatt atcatccggt ttaagtttgg gaactctatc	840
gtgaagatgg gcggcctggg gtacaaatgg tcagaaatct catataaagc cgccaactat	900
cagtataact acttgagaga cggcgagcag gtaaccgccc acacaacatg ctctgtcaac	960
ggcgttaata actttagcta caacggaggc ttctttcca ccgacttcgg tatcagccgg	1020
tatgaagtca tcaaggaaaa ttcttatgtg tacgtagatt actgggatga tagcaaagcg	1080
ttccgcaaca tgggtgatgt taggagcctg gctgctaatc tcaattctgt gaagtgtact	1140
ggtggatcat attatttctc aattcccgtg ggggcttggc cagtcatgaa tggcggggca	1200
gtctccctcc attttgctgg cgtgacgttg agcactcagt ttaccgattt cgtgtctctg	1260

## pctca2013050364-seq1.txt

aactccctga	ggttccggtt	ttcccttact	gtcgacgagc	ccccattcag	cattctgcgt	1320
acaagaactg	tcaacctcta	cgggttacct	gccgcgaatc	caaacaacgg	caatgaatac	1380
tatgaaat	cgggccgctt	ctctttgata	agtctggtac	caactaatga	cgactatcag	1440
acacccatca	tgaacagcgt	gactgtcaga	caggacctgg	aaagacaact	tacagatctg	1500
cggaagaat	tcaattctct	cagtcaggag	attgcaatgg	cccaattgat	agatcttgcc	1560
ctactgcctc	tcgatatggt	tagtatgttc	tccggcatca	aatcaactat	agatctgaca	1620
aagagcatgg	ctacttctgt	gatgaagaag	ttcaggaaat	caaaacttgc	cacgagcata	1680
tcagaaatga	cgaactctct	gagtgatgca	gcatcatcag	cgtcacgcaa	cgtttccatt	1740
cggtcgaatc	tcagcgccat	cagcaactgg	acaaacgtgt	ccaacgacgt	cagcaacgtg	1800
accaactcct	tgaacgatat	ttctaccag	acgtcaacga	tcagtaagaa	actccgcttg	1860
aaagaaatga	tcaccagac	tgagggaatg	tctttcgacg	acatttccgc	cgccgtgcta	1920
aaaacaaaa	tcgatatgtc	tactcagatc	ggcaagaaca	ctctgccgga	tatcgtaacc	1980
gaagcctccg	aaaagtttat	ccctaagcgc	agctacagaa	tattgaaaga	tgacgaggtc	2040
atggagatca	acacagaagg	gaagttcttc	gcttataaga	tcaacacctt	tgacgaggtt	2100
ccgtttgacg	tcaataagtt	tgcagagctc	gtgacagata	gtccagtgat	ttctgccatc	2160
attgacttta	agactttgaa	gaacctgaac	gacaactatg	gaataacacg	gaccgaagcg	2220
ttgaacctca	ttaagtccaa	tcccaatatg	ttgcgcaatt	tcattaacca	gaacaatcca	2280
atcataagaa	ataggattga	gcaattaatc	ctgcaatgta	aactctga		2328

<210> 48  
 <211> 981  
 <212> DNA  
 <213> Rotavirus

<400> 48						
atgtacggca	tcgagtatac	aacaatttta	attttcctga	tttccatcat	tctgttaaac	60
tacatcctta	agtccgtgac	cagaattatg	gattatatta	tctatcgtag	cctcctcatc	120
tacgtggccc	tttttgccct	gaccagggcc	cagaactatg	gcctgaactt	accaatcacc	180
ggttcaatgg	ataccgttta	cgctaattcc	actcaagagg	ggatatttct	gacaagtacc	240
ctgtgcctgt	attatccaac	agaagcctct	accagatca	atgatgggga	gtggaaggat	300
agtctctcac	agatgttcct	aaccaagggc	tggcccaccg	gttccgtcta	cttcaaggaa	360
tactctagta	ttgtcgactt	ctcagttgac	ccccagcttt	attgcgacta	caacctggta	420
cttatgaaat	acgaccagaa	cctggagctg	gatatgtccg	agctggctga	cctgatcctc	480
aatgagtggc	tgtgcaacc	catggacatc	acattatatt	actaccagca	gtctggagaa	540
tccaacaagt	ggatcagtat	gggtcaagt	tgcaccgtga	aggtgtgtcc	cttgaacacc	600
caaatgctgg	gcattggttg	tcagacaact	aatgtggatt	cgtttgaaat	ggtagccgaa	660
aacgagaagc	tggctatagt	ggacgtagtc	gatgggatta	accacaagat	caatctgact	720

pctca2013050364-seq1.txt

accaccactt gtaccatcag aaactgtaaa aagctcggcc cccgggagaa cgtcgccgtg	780
atccagggtg gggggagcaa tgtgctcgac attactgccg accctaccac caatccacag	840
acggaacgga tgatgagagt caactggaag aaatgggtggc aggtctttta taccattgtg	900
gactacatta accagattgt gcaagtcatg agtaaacggt ccagatccct gaactcagca	960
gccttctatt atcgcgttta g	981

<210> 49  
 <211> 903  
 <212> DNA  
 <213> Rotavirus

<400> 49	
atggcgaaaa acgttgcgat tttcggctta ttgttttctc ttcttgtgtt ggttccttct	60
cagatcttcg cccagaacta tggcctgaac ttaccaatca ccggttcaat ggataccgtt	120
tacgctaatt ccactcaaga ggggatattt ctgacaagta ccctgtgcct gtattatcca	180
acagaagcct ctaccagat caatgatggg gagtggaagg atagtctctc acagatgttc	240
ctaaccaagg gctggccac cggttcgct tacttcaagg aatactctag tattgtcgac	300
ttctcagttg acccccagct ttattgacgac tacaacctgg tacttatgaa atacgaccag	360
aacctggagc tggatatgtc cgagctggct gacctgatcc tcaatgagtg gctgtgcaac	420
cccatggaca tcacattata ttactaccag cagtctggag aatccaacaa gtggatcagt	480
atgggctcaa gttgcaccgt gaagggtgtgt cccttgaaca cccaaatgct gggcattggt	540
tgtcagacaa ctaatgtgga ttcgtttgaa atggtagccg aaaacgagaa gctggctata	600
gtggacgtag tcgatgggat taaccacaag atcaatctga ctaccaccac ttgtaccatc	660
agaaactgta aaaagctcgg ccccgaggag aacgtcgccg tgatccaggt gggggggagc	720
aatgtgctcg acattactgc cgaccctacc accaatccac agacggaacg gatgatgaga	780
gtcaactgga agaaatggtg gcaggtcttt tataccattg tggactacat taaccagatt	840
gtgcaagtca tgagtaaacg gtccagatcc ctgaactcag cagccttcta ttatcgcgtt	900
tag	903

<210> 50  
 <211> 2331  
 <212> DNA  
 <213> Rotavirus

<400> 50	
atggcttcgc tcatttatag acaattgctc acgaattctt atacagtaga tttatccgat	60
gagatacaag agattggatc aactaaatca caaaatgtca caattaatcc tggaccattt	120
gcgcaaacag gttatgctcc agttaactgg ggacctggag aaattaatga ttctacgaca	180
gttgaaccat tgctggatgg gccttatcaa ccaacgacat tcaatccacc agtcgattat	240
tggatgttac tggctccaac gacacctggc gtaattgttg aaggtaaaaa taatacagat	300
agatggttag ccacaatttt aatcgagcca aatgttcagt ctgaaaatag aacttacact	360

## pctca2013050364-seq1.txt

atatttggta ttcaagaaca attaacggta tccaatactt cacaagacca gtggaaat	420
attgatgtcg taaaaacaac tgcaaattgga agtataggac aatatggacc attactatcc	480
agtccgaaat tatatgcagt tatgaagcat aatgaaaaat tatatacata tgaaggacag	540
acacctaacg ctaggacagc acattattca acaacgaatt atgattctgt taatatgact	600
gctttttgtg actttttatat aattcctaga tctgaagagt ctaaattgtac ggaatacatt	660
aataatggat taccaccaat acaaaatact agaaatgttg taccattatc gttgactgct	720
agagatgtaa tacactatag agtcaagct aatgaagata ttgtgatatc caagacatca	780
ttgtggaaag aaatgcaata taatagagat ataactatta gatttaaatt tgcaaataca	840
attataaaat caggagggct gggatataag tggtcagaaa tatcatttaa gccagcgaat	900
tatcaataca catatactcg tgatggtgaa gaagttaccg cacatactac ttgttcagtg	960
aatggcggtta atgacttcag ttttaattgga ggatatttac caactgattt tgttgatatc	1020
aaatttgaag taattaaaga gaattcatac gtctatatcg attactggga tgattcacia	1080
gcatttcgta acgtggtgta tgtccgatcg ttagcagcaa acttgaattc agttatgtgt	1140
actggaggca gctataat	1200
gtagtctacca gttggacaat ggctgtttt aactggggga	1260
gcagtttctt tacattcagc tgggtgaaca ctatctactc aatttacaga tttcgtatca	1320
ttaaattcat taagatttag atttagacta gctgtcgaag aaccacactt taaactgact	1380
agaactagat tagatagatt gtatggtctg cctgctgcag atccaaataa tggtaaagaa	1440
tattatgaaa ttgctggacg attttactt atatcattag tgccatcaaa tgatgactat	1500
cagactccta tagcaaaactc agttactgta cgacaagatt tagaaaggca gttaggagaa	1560
ctaagagaag agtttaacgc tttgtctcaa gaaattgcaa tgtcgcagtt aatcgattta	1620
gcgcttctac cattagatat gttctcaatg ttttctggca ttaaaagtac tattgatgct	1680
gcaaaatcaa tggctactaa tgttatgaaa aaattcaaaa agtcaggatt agcgaattca	1740
gtttcaacac tgacagattc tttatcagac gcagcatcat caatatcaag aggttcatct	1800
atacgttcga ttggatcttc agcatcagca tggacggatg tatcaacaca aataactgat	1860
atatcgtcat cagtaagttc agtttcgaca caaacgtcaa ctatcagtag aagattgaga	1920
ctaaaggaaa tggcaacaca aactgagggt atgaattttg atgatatatc agcggctgtt	1980
ttgaagacta agatagataa atcgactcaa atatcaccaa acacaatacc tgacattgtt	2040
actgaagcat cggaataatt catacctaag agggcttacc gtgttataaa caacgatgat	2100
gtgtttgaag ctggaattga tggaaaattt tttgcttata aagtggatac atttgaggaa	2160
ataccatttg atgtacaaa attcgtgac ttagttacag attctccagt aatatccgct	2220
ataattgatt ttaaaacact taaaaatttg aacgataatt acggcattac taagcaacaa	2280
gcatttaatc ttttaagatc tgaccaaga gttttacgtg aattcattaa tcaggacaat	2331
cctataatta gaaatagaat tgaacaactg attatgcaat gcaggttggtg a	

&lt;211&gt; 2331

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

<223> Optimized coding sequence of Rotavirus A VP4 from strain  
RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]

&lt;400&gt; 51

atggcttcat tgatatatcg ccagttgctg actaatagct atactgtgga tttgtcagac	60
gaaatccagg aaataggatc cacaaagagt cagaacgtga ccataaacc cggaccgttc	120
gccagactg ggtatgcccc cgtaaacctg ggccccggcg agattaacga cagcaccacc	180
gtggagccac tgctggatgg accctacca cccactactt ttaatcctcc agtggactac	240
tggatgttgt tggctccac gacacctggt gtaattgtag agggcaccaa caataccgat	300
cgctggctgg cgacaatact gatagaacc aacgtgcagt ccgagaacag aacctatacc	360
attttcggca tccaggaaca gctaaccgtg agcaatacga gccaggacca gtggaagttt	420
atcgatgtag tgaaaactac ggccaatgga tctatcgggc aatacgggcc gctgctgtcc	480
tcacctaagc tctacgccgt gatgaaacat aatgagaaac tgtacactta cgagggccaa	540
acccccaatg ccagaactgc ccactacagt acaaccaact atgactcggg gaacatgaca	600
gcgttctgtg atttttatat tattccaaga tcagaagaat ccaagtgtac tgagtacatc	660
aacaatggac ttccacccat ccagaacact cgaaatgtcg tcccactgtc tctaactgct	720
cgggatgtga tccactatcg cgcccaagct aatgaggata tagtcatttc aaagacgagc	780
ttatggaagg aaatgcagta taacagagac atcacaatca ggttcaagtt cgccaatact	840
attattaagt ccgggggact ggggtacaaa tggagtgaga tcagttttaa gcccgctaac	900
tatcagtaca cctatactcg cgacggcgaa gaggtaaccg cccacacaac ttgctcgggt	960
aatggcgtga acgatttttag cttcaacggg ggctacctgc ctactgattt cgtggtgagc	1020
aagtttgaag tcatcaagga aaattcctac gtgtatattg actactggga tgatagccag	1080
gccttccgaa atgttgtgta tgtagatca ctggccgcaa accttaattc agtcatgtgc	1140
acaggagggt cttacaattt tagtcttccc gtcgggcagt ggccagtgtc cacagggggc	1200
gctgtgagct tgcattccgc cggagtcacc ttgagtactc agttcacaga ctttgtgtct	1260
ctgaatagcc taaggttcag gtttagactt gcagtagaag agcctcactt taagctcact	1320
cgtacgaggc tggatcggct gtacggcctg ccggccgctg atcccaataa cggcaaggaa	1380
tattacgaga tagccgggag attttcgctg atcagtctgg tgccgtcaaa cgatgattac	1440
cagaccccaa ttgccaacag tgtcactgtc aggcaagatc tggagagaca acttggcgag	1500
ctgagagagg agttcaacgc cctgtctcaa gagatcgcaa tgtctcagct cattgacctg	1560
gccctgttac ccctcgacat gttctcaatg ttctccggca taaaatccac tatcgacgct	1620
gcaaagtcca tggccacaaa tgtgatgaag aagtttaaga agagcgggtc ggcaaatagc	1680
gtgtctacgc tgaccgatag tttgtcggat gccgccagtt ccattagccg tggatccagc	1740
attaggtcca ttggctcttc cgcctctgct tggactgacg tgagtacaca gataactgac	1800

pctca2013050364-seq1.txt

atttcctctt ctgtctccag tgtgagcaca caaacttcca cgatatcaag acgactgagg	1860
ctcaaagaga tggcaacgca aacggaaggt atgaattttg atgacatcag cgccgcagtt	1920
ttgaagacaa agatcgataa aagcactcaa attagcccca atacgatccc tgacattgtg	1980
actgaggcat ctgaaaagtt cattcccaac cgtgcttata gggtcattaa caatgatgat	2040
gtcttcgagg ccggcatcga tggcaagttt tttgcttata aagtggatac cttcgaggag	2100
attcctttcg atgtacagaa gtttgctgac ctcgtaacgg atagcccagt gataagcgcc	2160
attatagact tcaaaacatt gaaaaatttg aacgataatt atggtattac caagcagcag	2220
gcttttaact tgtaagatc tgaccctcgc gtgctcagag agttttattaa ccaggacaac	2280
cccatcatca gaaacaggat cgagcagctg attatgcagt gtcgcctgta a	2331

<210> 52  
 <211> 981  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Coding sequence of Rotavirus A VP7 from strain  
 RVA/Simian-tc/ZAF/SA11-H96/1958/G3P5B[2]

<400> 52	
atgtatggtt ttgaatatac cacagttcta acctttctga tatcgattat tctactaaat	60
tacatactta aatcattaac tagaataatg gactttataa ttatagatt tctttttata	120
attgtgatat tgtcaccatt tctcagagca caaaattatg gtattaatct tccaatcaca	180
ggctccatgg aactgcata cgctaattca acgcaagaag aaacattcct cacttctaca	240
ctttgcctat attatccgac tgaggctgag actgaaataa acgataattc atggaaagac	300
acactgtcac aactatttct tacgaaaggg tggccaactg gatccgtata ttttaaagaa	360
tatactaaca ttgcatcggt ttctgttgat ccgcagttgt attgtgatta taacgtagta	420
ctaataaagt atgacgcgac gttgcaattg gatatgtcag aacttgcgga tctaataatta	480
aacgaatggt tgtgtaatcc aatggatatt actctgtatt attatcagca aactgacgaa	540
gcgaataaat ggatatcaat gggctcatca tgtacaatta aagtatgtcc acttaataca	600
caaactcttg gaattggatg cttgacaact gatgctacaa cttttgaaga agttgcgaca	660
gctgaaaagt tggtaattac tgacgtgggt gatggcggtta atcataagct ggatgtcaca	720
acagcaacgt gtactattag aaactgtaag aaattgggac caagagaaaa cgtagccggt	780
atacaagttg gtggttctga catcctcgat ataactgctg atccaactac tgcaccacag	840
acagaacgga tgatgcgaat taactggaaa aaatggtggc aagtttttta tactgtagta	900
gactatgtag atcagataat acaagttatg tccaaaagat caagatcact aaattcagca	960
gcattttatt acagagtgtg g	981

<210> 53  
 <211> 981  
 <212> DNA



&lt;213&gt; Rotavirus

&lt;400&gt; 53

atgtacggaa tcgagtatac caccgttctg acattttctta ttagtattat cctcttgaac	60
tatattctga agtcacttac ccggataatg gattttatta tatatagggt tctgttcac	120
attgtaattc tgagcccttt cctgagggcc cagaattacg gcataaacct accaatcacc	180
ggttctatgg ataccgttta tgctaactct acacaagagg agacattcct cacatcaacc	240
ctatgcctgt actatccgac tgaagcagcc acagagataa acgataactc ttggaaagat	300
acattgagcc agctcttcct gactaaggga tggcccaccg gatcggctta ctttaaggag	360
tacacaaaca tcgcaagttt cagcgtggat cccagctgt attgtgatta taacgttggtg	420
ctgatgaaat acgacgcaac cctccagctt gacatgagcg agttggcaga cctaatactc	480
aatgagtggc tgtgtaacct aatggatata aactgtact attatcagca gaccgatgaa	540
gcaaacaaat ggatttcaat gggaagcagc tgtaccatca aagtttgtcc tctcaacacc	600
caaactctcg gcataggggtg tctgaccaca gacgtacta cttttgaaga agttgcgacc	660
gcggaaaagc tggttatcac agatgtggta gatggcgtta accacaaatt ggacgtaacc	720
acagcaacat gcacaattag gaactgcaag aagctaggac ccagggaaaa cgtagccgtc	780
atccaagtgg gcggcagtga catcctagac atcaccgcag acccaacaac agcaccacaa	840
accgagagga tgatgcgcat taattggaag aaatgggtggc aggtgtttta cactgtcgtt	900
gactatgtgg accagatcat tcaggtgatg agcaagcgga gtcgctcatt gaatagtgt	960
gccttttatt acagagtcta a	981

&lt;210&gt; 54

&lt;211&gt; 981

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;400&gt; 54

atgtacggca tcgagtatac aacaatttta attttctga tttccatcat tctgttaaac	60
tacatcctta agtccgtgac cagaattatg gattatatta tctatcgtag cctcctcatc	120
tacgtggccc tttttgccct gaccagggcc cagaactatg gcctgaactt accaatcacc	180
ggttcaatgg ataccgttta cgctaattcc actcaagagg ggatatttct gacaagtacc	240
ctgtgcctgt attatccaac agaagcctct acccagatca atgatgggga gtggaaggat	300
agtctctcac agatgttcct aaccaagggc tggcccaccg gttccgtcta cttcaaggaa	360
tactctagta ttgtcgactt ctcatgtgac cccagcttt attgcgacta caacctggta	420
cttatgaaat acgaccagaa cctggagctg gatatgtccg agctggctga cctgatcctc	480
aatgagtggc tgtgcaacct catggacatc acattatatt actaccagca gtctggagaa	540
tccaacaagt ggatcagtat gggctcaagt tgcaccgtga aggtgtgtcc cttgaacacc	600
caaatgctgg gcattggttg tcagacaact aatgtggatt cgtttgaaat ggtagccgaa	660
aacgagaagc tggctatagt ggacgtagtc gatgggatta accacaagat caatctgact	720

pctca2013050364-seq1.txt

accaccactt gtaccatcag aaactgtaaa aagctcggcc cccgggagaa cgtcgccgtg 780  
atccagggtg gggggagcaa tgtgctcgac attactgccg accctaccac caatccacag 840  
acggaacgga tgatgagagt caactggaag aaatggtggc aggtctttta taccattgtg 900  
gactacatta accagattgt gcaagtcatt agtaaaccgt ccagatccct gaactcagca 960  
gccttctatt atcgcgttta g 981

<210> 55  
<211> 50  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer IF-TrSP+Rtx\_VP7(opt).s1+3c

<400> 55  
aaatttgtcg ggcccatgga ttatattatc tatcgtagcc tcctcatcta 50

<210> 56  
<211> 54  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer IF-Rtx\_VP7(opt).s1-4r

<400> 56  
actaaagaaa ataggcctct aaacgcgata atagaaggct gctgagttca ggga 54

<210> 57  
<211> 981  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Optimized coding sequence of Rotavirus A VP7 from strain  
RVA/Vaccine/USA/Rotarix-A41CB052A/1988/G1P1A[8]

<400> 57  
atgtacggca tcgagtatac aacaatttta attttcctga tttccatcat tctgttaaac 60  
tacatcctta agtccgtgac cagaattatg gattatatta tctatcgtag cctcctcatc 120  
tacgtggccc tttttgccct gaccagggcc cagaactatg gcctgaactt accaatcacc 180  
ggttcaatgg ataccgttta cgctaattcc actcaagagg ggatatttct gacaagtacc 240  
ctgtgcctgt attatccaac agaagcctct acccagatca atgatgggga gtggaaggat 300  
agtctctcac agatgttcct aaccaagggc tggcccaccg gttccgtcta cttcaaggaa 360  
tactctagta ttgtcgactt ctcaagttgac cccagctttt attgagacta caacctggta 420  
cttatgaaat acgaccagaa cctggagctg gatatgtccg agctggctga cctgatcctc 480  
aatgagtggc tgtgcaacct catggacatc acattatatt actaccagca gtctggagaa 540  
tccaacaagt ggatcagtat gggctcaagt tgcaccgtga aggtgtgtcc cttgaacacc 600  
caaagtctgg gcattggttg tcagacaact aatgtggatt cgtttgaaat ggtagccgaa 660  
aacgagaagc tggctatagt ggacgtagtc gatgggatta accacaagat caatctgact 720

pctca2013050364-seq1.txt

accaccactt gtaccatcag aaactgtaaa aagctcggcc cccgggagaa cgtcgccgtg	780
atccaggtgg gggggagcaa tgtgctcgac attactgccg accctaccac caatccacag	840
acggaacgga tgatgagagt caactggaag aaatggtggc aggtctttta taccattgtg	900
gactacatta accagattgt gcaagtcatg agtaaacggt ccagatccct gaactcagca	960
gccttctatt atcgcgttta g	981

<210> 58  
 <211> 2634  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Expression cassette number 1734

<400> 58 gtcaacatgg tggagcacga cacacttgtc tactccaaaa atatcaaaga tacagtctca	60
gaagaccaa gggcaattga gacttttcaa caaagggtaa tatccggaaa cctcctcgga	120
ttccattgcc cagctatctg tcactttatt gtgaagatag tggaaaagga aggtggctcc	180
tacaaatgcc atcattgcga taaaggaaag gccatcggtg aagatgcctc tgccgacagt	240
ggtcccaaag atggaccccc acccacgagg agcatcggtg aaaaagaaga cgttccaacc	300
acgtcttcaa agcaagtgga ttgatgtgat aacatggtgg agcacgacac acttgtctac	360
tccaaaaata tcaaagatac agtctcagaa gaccaaaggg caattgagac ttttcaacaa	420
agggtaatat ccggaaacct cctcggattc cattgcccag ctatctgtca ctttattgtg	480
aagatagtgg aaaaggaagg tggctcctac aaatgccatc attgcgataa aggaaaggcc	540
atcgttgaag atgcctctgc cgacagtggg cccaaagatg gacccccacc cacgaggagc	600
atcgtggaaa aagaagacgt tccaaccacg tcttcaaagc aagtggattg atgtgatatc	660
tccactgacg taagggatga cgcacaatcc cactatcctt cgcaagaccc ttcctctata	720
taaggaagt catttcattt ggagaggtat taaaatctta atagggtttg ataaaagcga	780
acgtggggaa acccgaacca aaccttcttc taaactctct ctcattctctc ttaaagcaaa	840
cttctctctt gtctttcttg cgtgagcgat cttcaacggt gtcagatcgt gcttcggcac	900
cagtacaacg ttttctttca ctgaagcgaa atcaaagatc tctttgtgga cacgtagtgc	960
ggcgccatta aataacgtgt acttgtccta ttcttgctcg tgtggtcttg ggaaaagaaa	1020
gcttgctgga ggctgctgtt cagccccata cattacttgt tacgattctg ctgactttcg	1080
gcgggtgcaa tatctctact tctgcttgac gaggtattgt tgccctgtact tctttcttct	1140
tcttcttgct gattggttct ataagaaatc tagtattttc tttgaaacag agttttcccg	1200
tggttttcga acttgagaaa agattgttaa gcttctgtat attctgcca aatttgctcg	1260
gccatggat tatattatct atcgtagcct cctcatctac gtggcccttt ttgccctgac	1320
cagggccag aactatggcc tgaacttacc aatcacgggt tcaatggata ccgtttacgc	1380
taattccact caagagggga ttttctgac aagtaccctg tgccctgtatt atccaacaga	1440

pctca2013050364-seq1.txt

```

agcctctacc cagatcaatg atggggagtg gaaggatagt ctctcacaga tgttcctaac 1500
caagggctgg cccaccggtt ccgtctactt caaggaatac tctagtattg tcgactttctc 1560
agttgacccc cagcttttatt gcgactacaa cctgggtactt atgaaatacg accagaacct 1620
ggagctggat atgtccgagc tggctgacct gatcctcaat gagtggctgt gcaaccccat 1680
ggacatcaca ttatattact accagcagtc tggagaatcc aacaagtgga tcagtatggg 1740
ctcaagttgc accgtgaagg tgtgtccctt gaacacccaa atgctgggca ttggttgtca 1800
gacaactaat gtggattcgt ttgaaatggg agccgaaaac gagaagctgg ctatagtgga 1860
cgtagtcgat gggattaacc acaagatcaa tctgactacc accacttgta ccatcagaaa 1920
ctgtaaaaag ctcggccccc gggagaacgt cgccgtgata caggtggggg ggagcaatgt 1980
gctcgacatt actgccgacc ctaccaccaa tccacagacg gaacggatga tgagagtcaa 2040
ctggaagaaa tgggtggcagg tctttttatac cattgtggac tacattaacc agattgtgca 2100
agtcatgagt aaacgggtcca gatccctgaa ctacagagcc ttctattatc gcgttttagag 2160
gcctattttc tttagtttga atttactgtt attcgggtgtg cttttctatg tttggtgagc 2220
ggttttctgt gctcagagtg tgtttatttt atgtaattta atttctttgt gagctcctgt 2280
ttagcagggtc gtcccttcag caaggacaca aaaagatttt aattttatta aaaaaaaaaa 2340
aaaaaaaaagac cgggaattcg atatcaagct tatcgacctg cagatcgttc aaacatttgg 2400
caataaagtt tcttaagatt gaatcctgtt gccggtcttg cgatgattat catataattt 2460
ctgttgaatt acgttaagca tgtaataatt aacatgtaat gcatgacgtt atttatgaga 2520
tgggttttta tgattagagt cccgcaatta tacatttaat acgcgataga aaacaaaata 2580
tagcgcgcaa actaggataa attatcgcg cgggtgtcat ctatgttact agat 2634

```

<210> 59  
 <211> 297  
 <212> PRT  
 <213> Rotavirus

<400> 59

Met Asp Tyr Ile Ile Tyr Arg Ser Leu Leu Ile Tyr Val Ala Leu Phe  
 1 5 10 15

Ala Leu Thr Arg Ala Gln Asn Tyr Gly Leu Asn Leu Pro Ile Thr Gly  
 20 25 30

Ser Met Asp Thr Val Tyr Ala Asn Ser Thr Gln Glu Gly Ile Phe Leu  
 35 40 45

Thr Ser Thr Leu Cys Leu Tyr Tyr Pro Thr Glu Ala Ser Thr Gln Ile  
 50 55 60

Asn Asp Gly Glu Trp Lys Asp Ser Leu Ser Gln Met Phe Leu Thr Lys  
 65 70 75 80

pctca2013050364-seq1.txt

Gly Trp Pro Thr Gly Ser Val Tyr Phe Lys Glu Tyr Ser Ser Ile Val  
85 90 95

Asp Phe Ser Val Asp Pro Gln Leu Tyr Cys Asp Tyr Asn Leu Val Leu  
100 105 110

Met Lys Tyr Asp Gln Asn Leu Glu Leu Asp Met Ser Glu Leu Ala Asp  
115 120 125

Leu Ile Leu Asn Glu Trp Leu Cys Asn Pro Met Asp Ile Thr Leu Tyr  
130 135 140

Tyr Tyr Gln Gln Ser Gly Glu Ser Asn Lys Trp Ile Ser Met Gly Ser  
145 150 155 160

Ser Cys Thr Val Lys Val Cys Pro Leu Asn Thr Gln Met Leu Gly Ile  
165 170 175

Gly Cys Gln Thr Thr Asn Val Asp Ser Phe Glu Met Val Ala Glu Asn  
180 185 190

Glu Lys Leu Ala Ile Val Asp Val Val Asp Gly Ile Asn His Lys Ile  
195 200 205

Asn Leu Thr Thr Thr Thr Cys Thr Ile Arg Asn Cys Lys Lys Leu Gly  
210 215 220

Pro Arg Glu Asn Val Ala Val Ile Gln Val Gly Gly Ser Asn Val Leu  
225 230 235 240

Asp Ile Thr Ala Asp Pro Thr Thr Asn Pro Gln Thr Glu Arg Met Met  
245 250 255

Arg Val Asn Trp Lys Lys Trp Trp Gln Val Phe Tyr Thr Ile Val Asp  
260 265 270

Tyr Ile Asn Gln Ile Val Gln Val Met Ser Lys Arg Ser Arg Ser Leu  
275 280 285

Asn Ser Ala Ala Phe Tyr Tyr Arg Val  
290 295